Id,Name,Applications__c,Brand_Name__c,Chemical_Name__c,Applicants__c,Funding_requested_for__c,Stage__c,Pharmaceutical__c,Community_URL__c,Therapeutic_group__c
a0ROZ000009J5Ev2AK,15-valent pneumococcal conjugate vaccine (PCV15),A-04423,VAXNEUVANCE.,15-valent pneumococcal conjugate vaccine (PCV15),MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,Prevention of invasive pneumococcal disease,Decision,15-valent pneumococcal conjugate vaccine (PCV15) (VAXNEUVANCE.),/apptracker/s/application-public/a102P00000BUmR1,
a0ROZ000004CX2l2AG,Adjuvanted inactivated quadrivalent influenza vaccine,A-03341,FLUAD® QUAD,Adjuvanted inactivated quadrivalent influenza vaccine,Seqirus,influenza vaccination for people aged 65 years and over.,Decision,Adjuvanted inactivated quadrivalent influenza vaccine (FLUAD® QUAD),/apptracker/s/application-public/a102P00000ACGT3,National Immunisation Schedule
a0ROZ00000Cn1xE2AR,Adjuvanted inactivated trivalent influenza vaccine (aTIV),A-00724,Fluad,Adjuvanted inactivated trivalent influenza vaccine (aTIV),Seqirus,Influenza vaccine for people 65 years of age and over,Options Compared,Adjuvanted inactivated trivalent influenza vaccine (aTIV) (Fluad),/apptracker/s/application-public/a10OZ000003tIqb,National Immunisation Schedule
a0R2P000000gVYDUA2,Bevacizumab and Human Papillomavirus (HPV) vaccine,A-00655,,Bevacizumab and Human Papillomavirus (HPV) vaccine,PHARMAC Initiated,Recurrent respiratory papillomatosis,Decision,Bevacizumab and Human Papillomavirus (HPV) vaccine,/apptracker/s/application-public/a102P000008pu1t,Respiratory System and Allergies
a0R2P000000LmcWUAS,Diphtheria and tetanus vaccine,A-00221,,Diphtheria and tetanus vaccine,PHARMAC Initiated,Widening of access,Decision,Diphtheria and tetanus vaccine,/apptracker/s/application-public/a102P000008pu78,National Immunisation Schedule
a0R2P000000TFbbUAG,"Diphtheria, tetanus and pertussis vaccine",A-00319,,"Diphtheria, tetanus and pertussis vaccine",Subcommittee recommendation,Amendments to use after immunosuppression,Decision,"Diphtheria, tetanus and pertussis vaccine",/apptracker/s/application-public/a102P000008puHa,National Immunisation Schedule
a0R2P000000LmYlUAK,"Diphtheria, tetanus and pertussis vaccine (Tdap)",A-01405,,"Diphtheria, tetanus and pertussis vaccine (Tdap)",PHARMAC Initiated,Widening of ages who have access,Decision,"Diphtheria, tetanus and pertussis vaccine (Tdap)",/apptracker/s/application-public/a102P000008puWo,National Immunisation Schedule
a0R2P000000TFULUA4,"Diphtheria, tetanus, and pertussis vaccine",A-00206,Boostrix,"Diphtheria, tetanus, and pertussis vaccine",Clinician,Vaccination of pregnant women regardless of epidemics,Decision,"Diphtheria, tetanus, and pertussis vaccine (Boostrix)",/apptracker/s/application-public/a102P000008ptx8,National Immunisation Schedule
a0ROZ00000DL6Kf2AL,"group B Vaccine (recombinant, adsorbed) 0.5 mL suspension for injection (4CMenB)",A-05455,Bexsero  MenQuadfi,"Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed) 0.5 mL suspension for injection (4CMenB)",Clinician,Booster dose for adolescents on entering a second congregate setting,Seeking Clinical Advice,"Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed) 0.5 mL suspension for injection (4CMenB) (Bexsero  MenQuadfi)",/apptracker/s/application-public/a10OZ000007O7SX,National Immunisation Schedule
a0R2P000000MTXBUA4,Haemophilus B conjugate vaccine with hepatitis B vaccine,A-00020,,Haemophilus B conjugate vaccine with hepatitis B vaccine,PHARMAC Initiated,Hospital listing,Decision,Haemophilus B conjugate vaccine with hepatitis B vaccine,/apptracker/s/application-public/a102P000008puiQ,National Immunisation Schedule
a0R2P000000LmV7UAK,Haemophilus influenzae type B vaccine,A-01408,,Haemophilus influenzae type B vaccine,PHARMAC Initiated,Widening of ages who have access,Decision,Haemophilus influenzae type B vaccine,/apptracker/s/application-public/a102P000008ptxH,National Immunisation Schedule
a0R2P000000TFeLUAW,Haemophilus influenzae type B vaccine,A-00321,,Haemophilus influenzae type B vaccine,Clinician,Amendments to use after immunosuppression,Decision,Haemophilus influenzae type B vaccine,/apptracker/s/application-public/a102P000008puX7,National Immunisation Schedule
a0ROZ000003nsyP2AQ,Hepatitis A vaccine,A-00213,Hbvaxpro,Hepatitis A vaccine,Clinician,Widened access to at-risk groups,Seeking Clinical Advice,Hepatitis A vaccine (Hbvaxpro),/apptracker/s/application-public/a102P000008pu4n,National Immunisation Schedule
a0ROZ000004CTlW2AW,Hepatitis A vaccine,A-00323,,Hepatitis A vaccine,Clinician,Immunisation of HIV patients,Seeking Clinical Advice,Hepatitis A vaccine,/apptracker/s/application-public/a102P000008puOU,National Immunisation Schedule
a0R2P000000MTXGUA4,Hepatitis A vaccine with hepatitis B vaccine,A-00021,,Hepatitis A vaccine with hepatitis B vaccine,PHARMAC Initiated,Hospital listing,Decision,Hepatitis A vaccine with hepatitis B vaccine,/apptracker/s/application-public/a102P000008puJW,National Immunisation Schedule
a0R2P000000TFUfUAO,Hepatitis B recombinant vaccine,A-00379,,Hepatitis B recombinant vaccine,Subcommittee recommendation,Widening access - non-consensual sexual intercourse or needle stick injury,Decision,Hepatitis B recombinant vaccine,/apptracker/s/application-public/a102P000008ptxV,National Immunisation Schedule
a0R2P000000LmaRUAS,Hepatitis B recombinant vaccine - transplant criteria for HSCT,A-00569,,Hepatitis B recombinant vaccine - transplant criteria for HSCT,To be determined,Hepatitis B,Decision,Hepatitis B recombinant vaccine - transplant criteria for HSCT,/apptracker/s/application-public/a102P000008puRF,National Immunisation Schedule
a0R2P000000LmrjUAC,Hepatitis B vaccine,A-01407,,Hepatitis B vaccine,PHARMAC Initiated,Children who have not achieved a positive serology and require additional vaccination,Decision,Hepatitis B vaccine,/apptracker/s/application-public/a102P000008puKJ,National Immunisation Schedule
a0R2P000000LmerUAC,"htheria, tetanus, pertussis, polio, hepatitis B, and haemophillus type B vaccine",A-01409,Infanrix-hexra,"Diphtheria, tetanus, pertussis, polio, hepatitis B, and haemophillus type B vaccine",PHARMAC Initiated,Widening of ages who have access,Decision,"Diphtheria, tetanus, pertussis, polio, hepatitis B, and haemophillus type B vaccine (Infanrix-hexra)",/apptracker/s/application-public/a102P000008ptpK,National Immunisation Schedule
a0ROZ000005ucHV2AY,Human Papillomavirus 9-valent vaccine,A-05223,Gardasil 9,Human Papillomavirus 9-valent vaccine,Consumer,"widen access to people aged 9 to 45 years, who are living with HIV",Seeking Clinical Advice,Human Papillomavirus 9-valent vaccine (Gardasil 9),/apptracker/s/application-public/a10OZ000002rScv,National Immunisation Schedule
a0R2P000000TFfTUAW,Human Papillomavirus Vaccine (HPV),A-00324,,Human Papillomavirus Vaccine (HPV),Clinician,Immunisation post-chemotherapy,Decision,Human Papillomavirus Vaccine (HPV),/apptracker/s/application-public/a102P000008puZT,National Immunisation Schedule
a0R2P000000LmY9UAK,Human Papillomavirus Vaccine (HPV),A-00545,,Human Papillomavirus Vaccine (HPV),Seqirus,Year 7 girls and boys for HPV; naive males and females up to and including 26 years of age,Decision,Human Papillomavirus Vaccine (HPV),/apptracker/s/application-public/a102P000008puXp,National Immunisation Schedule
a0R2P000000LmmhUAC,Human Papillomavirus Vaccine (HPV),A-01447,,Human Papillomavirus Vaccine (HPV),PHARMAC Initiated,Vaccination for HPV in patients who have HIV infection,Decision,Human Papillomavirus Vaccine (HPV),/apptracker/s/application-public/a102P000008pu1a,National Immunisation Schedule
a0R2P000000LmqHUAS,Human Papillomavirus Vaccine (HPV),A-00229,,Human Papillomavirus Vaccine (HPV),PHARMAC Initiated,Universal vaccination (widening access to males),Decision,Human Papillomavirus Vaccine (HPV),/apptracker/s/application-public/a102P000008puCD,National Immunisation Schedule
a0R2P000000TFg7UAG,Human Papillomavirus Vaccine (HPV),A-01273,HPV vaccine,Human Papillomavirus Vaccine (HPV),PHARMAC Initiated,Vaccination for HPV in males at high risk of oncogenic HPV cancers not protected by current criteria,Decision,Human Papillomavirus Vaccine (HPV) (HPV vaccine),/apptracker/s/application-public/a102P000008puck,National Immunisation Schedule
a0ROZ0000029OYE2A2,Human Papillomavirus Vaccine (HPV),A-00220,Gardisil,Human Papillomavirus Vaccine (HPV),Clinician,"Females aged 18 and 19, and HIV patients aged 25",Decision,Human Papillomavirus Vaccine (HPV) (Gardisil),/apptracker/s/application-public/a102P000008pttO,National Immunisation Schedule
a0R2P000000LmXLUA0,Human papillomavirus vaccine 9-valent,A-00475,,Human papillomavirus vaccine 9-valent,Seqirus,Vaccination for HPV,Decision,Human papillomavirus vaccine 9-valent,/apptracker/s/application-public/a102P000008pty0,National Immunisation Schedule
a0R2P000000anUEUAY,"Inactivated influenza vaccine, adjuvanted (Fluad) 2019",A-00724,,"Inactivated influenza vaccine, adjuvanted (Fluad) 2019",Seqirus,Influenza,Decision,"Inactivated influenza vaccine, adjuvanted (Fluad) 2019",/apptracker/s/application-public/a102P000008ptyX,National Immunisation Schedule
a0ROZ000009J5Zt2AK,"Inactivated quadrivalent influenza vaccine, split virion (high dose)",A-04402,Fluzone High-Dose Quadrivalent,"Inactivated quadrivalent influenza vaccine, split virion (high dose)",Sanofi-Aventis New Zealand Limited,"Given the indication will be for 60 plus, it is proposed to replace SD on the Schedule, for people aged 60 plus who meet the criteria",Seeking Clinical Advice,"Inactivated quadrivalent influenza vaccine, split virion (high dose) (Fluzone High-Dose Quadrivalent)",/apptracker/s/application-public/a102P00000BUk3C,
a0ROZ00000Cn1xD2AR,Inactivated trivalent influenza vaccine prepared in cell cultures (TIVc),A-04379,Flucelvax,Inactivated trivalent influenza vaccine prepared in cell cultures (TIVc),Seqirus,Influenza vaccine for people 6 months to under 65 years of age,Options Compared,Inactivated trivalent influenza vaccine prepared in cell cultures (TIVc) (Flucelvax),/apptracker/s/application-public/a10OZ000003tFaz,National Immunisation Schedule
a0ROZ000007hqPL2AY,Influenza vaccine,A-04303,,Influenza vaccine,Clinician,children aged 5 years or younger,Options Compared,Influenza vaccine,/apptracker/s/application-public/a10OZ000001rzeI,
a0R2P000000LmTyUAK,Influenza vaccine,A-00544,,Influenza vaccine,Clinician,Vaccination of inpatients of long term mental health care,Decision,Influenza vaccine,/apptracker/s/application-public/a102P000008puN1,National Immunisation Schedule
a0R2P000000TFa9UAG,Influenza vaccine,A-00318,,Influenza vaccine,Subcommittee recommendation,Additional at-risk groups,Decision,Influenza vaccine,/apptracker/s/application-public/a102P000008puCr,National Immunisation Schedule
a0ROZ00000AQko22AD,Influenza vaccine,A-04292,,Influenza vaccine,Clinician,Options for widened access - Open listing,Options Compared,Influenza vaccine,/apptracker/s/application-public/a102P00000BRGrN,National Immunisation Schedule
a0ROZ000004CbSv2AK,Influenza vaccine,A-00662,,Influenza vaccine,Clinician,ring protection for high risk group,Decision,Influenza vaccine,/apptracker/s/application-public/a102P000008puEx,National Immunisation Schedule
a0R2P000000LmURUA0,Influenza vaccine,A-01272,,Influenza vaccine,PHARMAC Initiated,Access for children four years or less with severe respiratory illness,Decision,Influenza vaccine,/apptracker/s/application-public/a102P000008puNU,National Immunisation Schedule
a0ROZ00000AQko42AD,Influenza vaccine,A-04303,,Influenza vaccine,Clinician,Children up to 18 years of age - widen access,Options Compared,Influenza vaccine,/apptracker/s/application-public/a102P00000BROGR,National Immunisation Schedule
a0ROZ00000AQko32AD,Influenza vaccine,A-04299,,Influenza vaccine,Clinician,People over 50 years of age -widen access,Options Compared,Influenza vaccine,/apptracker/s/application-public/a102P00000BROFJ,National Immunisation Schedule
a0ROZ000000PXiZ2AW,Influenza vaccine,A-04297,,Influenza vaccine,Clinician,"Maori and Pacific people, 50 to 64 years of age",Options Compared,Influenza vaccine,/apptracker/s/application-public/a102P00000BRODX,National Immunisation Schedule
a0R2P000000YfnhUAC,Influenza Vaccine,A-00783,"Influvac, Influvac Tetra, Fluvax, FluQuadri, Vaxigrip",Influenza Vaccine,Clinician,"influenza in people with serious mental health conditions and addiction (schizophrenia/psychotic disorders, major depression, bipolar and people accessing secondary and tertiary mental health and addiction services)",Decision,"Influenza Vaccine (Influvac, Influvac Tetra, Fluvax, FluQuadri, Vaxigrip)",/apptracker/s/application-public/a102P00000BSYZo,
a0R2P000000YfokUAC,Influenza Vaccine,A-00783,"Afluria Quad, Influvac Tetra, FluQuadri, Fluarix Tetra",Influenza Vaccine,Clinician,"influenza in patients with serious mental health conditions and addiction  (schizophrenia/psychotic disorders, major depression and bipolar)",Decision,"Influenza Vaccine (Afluria Quad, Influvac Tetra, FluQuadri, Fluarix Tetra)",/apptracker/s/application-public/a102P000008pu9F,National Immunisation Schedule
a0R2P000000TFXAUA4,"iphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine",A-00320,,"Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine",Subcommittee recommendation,Amendments to use after immunosuppression,Decision,"Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine",/apptracker/s/application-public/a102P000008pu4g,National Immunisation Schedule
a0R2P000000ancmUAA,"iphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine",A-01270,Boostrix,"Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine",PHARMAC Initiated,Changing pertussis component to a two component vaccine,Decision,"Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine (Boostrix)",/apptracker/s/application-public/a102P000008puNb,National Immunisation Schedule
a0R2P000000LmrPUAS,"iphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine",A-00222,,"Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine",Clinician,Widening access - increasing age limit to under 10,Decision,"Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus type B vaccine",/apptracker/s/application-public/a102P000008puJV,National Immunisation Schedule
a0R2P000000LmnuUAC,"Measles, Mumps And Rubella (MMR) Vaccine",A-00380,,"Measles, Mumps And Rubella (MMR) Vaccine",Subcommittee recommendation,Widening access - extra dose for children whose first dose was before 12 months,Decision,"Measles, Mumps And Rubella (MMR) Vaccine",/apptracker/s/application-public/a102P000008ptrZ,National Immunisation Schedule
a0ROZ00000AEHhZ2AX,"Meningococcal  A, C, Y And W-135 Vaccine",A-00769 A-01526,"Menomune,Neisvac-C","Meningococcal  A, C, Y And W-135 Vaccine","Pharmac Initiated, Te Arai Biofarma",Children 1 year of age,Options Compared,"Meningococcal  A, C, Y And W-135 Vaccine (Menomune,Neisvac-C)",/apptracker/s/application-public/a102P000008ptxX,National Immunisation Schedule
a0ROZ00000AqQQZ2A3,"Meningococcal  A, C, Y And W-135 Vaccine",A-00773 A-01526,"Menomune,Neisvac-C","Meningococcal  A, C, Y And W-135 Vaccine","Pharmac Initiated, Te Arai Biofarma","Young people aged 13 to 21 years, ongoing vaccination at 14 years of age",Options Compared,"Meningococcal  A, C, Y And W-135 Vaccine (Menomune,Neisvac-C)",/apptracker/s/application-public/a102P000008puDK,National Immunisation Schedule
a0ROZ00000AqQQY2A3,"Meningococcal  A, C, Y And W-135 Vaccine",A-00770 A-01526,"Menomune,Neisvac-C","Meningococcal  A, C, Y And W-135 Vaccine","Pharmac Initiated, Te Arai Biofarma",Children aged 1 to 4 years,Options Compared,"Meningococcal  A, C, Y And W-135 Vaccine (Menomune,Neisvac-C)",/apptracker/s/application-public/a102P000008pu9d,National Immunisation Schedule
a0ROZ000003doXt2AI,"Meningococcal  A, C, Y And W-135 Vaccine,Meningococcal C Congugated Vaccine",A-00774 A-01526,"Menomune,Neisvac-C","Meningococcal  A, C, Y And W-135 Vaccine,Meningococcal C Congugated Vaccine","Pharmac Initiated, Te Arai Biofarma",Adolescent entrants to close living situations 13 to 25 years (no catchup),Decision,"Meningococcal  A, C, Y And W-135 Vaccine,Meningococcal C Congugated Vaccine (Menomune,Neisvac-C)",/apptracker/s/application-public/a102P000008pttz,National Immunisation Schedule
a0ROZ0000006gW12AI,"Meningococcal  A, C, Y And W-135 Vaccine,Meningococcal C Congugated Vaccine",A-00775 A-01526,"Menomune,Neisvac-C","Meningococcal  A, C, Y And W-135 Vaccine,Meningococcal C Congugated Vaccine","PHARMAC Initiated, Te Arai Biofarma",Entrants & 1-year catchup close living 13 to 25 years,Decision,"Meningococcal  A, C, Y And W-135 Vaccine,Meningococcal C Congugated Vaccine (Menomune,Neisvac-C)",/apptracker/s/application-public/a102P000008ptqm,National Immunisation Schedule
a0R2P000000daLJUAY,"Meningococcal A, C, W and Y conjugate vaccine",A-04258,MenQuadfi®,"Meningococcal A, C, W and Y conjugate vaccine",Sanofi-Aventis New Zealand Limited,"Immunisation against N meningitidis Groups A, C, W and Y (replacement for currently funded Menactra)",Decision,"Meningococcal A, C, W and Y conjugate vaccine (MenQuadfi®)",/apptracker/s/application-public/a102P00000BQGwp,National Immunisation Schedule
a0ROZ00000AqQQW2A3,"Meningococcal A, C, Y And W-135 Vaccine",A-00771 A-01526,"Menomune,Neisvac-C","Meningococcal A, C, Y And W-135 Vaccine","Pharmac Initiated, Te Arai Biofarma",Adolescents at 14 years of age,Options Compared,"Meningococcal A, C, Y And W-135 Vaccine (Menomune,Neisvac-C)",/apptracker/s/application-public/a102P000008ptzk,National Immunisation Schedule
a0ROZ00000AqQQX2A3,"Meningococcal A, C, Y And W-135 Vaccine",A-00772 A-01526,"Menomune,Neisvac-C","Meningococcal A, C, Y And W-135 Vaccine","Pharmac Initiated, Te Arai Biofarma","Young people aged 5 to 21 years, ongoing vaccination at 14 years of age",Options Compared,"Meningococcal A, C, Y And W-135 Vaccine (Menomune,Neisvac-C)",/apptracker/s/application-public/a102P000008pu50,National Immunisation Schedule
a0R2P000000TFU1UAO,Meningococcal C-containing conjugate vaccines,A-00325,Neisvac-C,Meningococcal C-containing conjugate vaccines,Clinician,Dosage amendment for certain patient groups,Decision,Meningococcal C-containing conjugate vaccines (Neisvac-C),/apptracker/s/application-public/a102P000008ptx5,National Immunisation Schedule
a0R2P000000LmhaUAC,Meningococcal conjugate vaccines,A-01269,Meningococcal conjugated vaccine,Meningococcal conjugate vaccines,PHARMAC Initiated,Vaccine against meningitis (for various subgroups),Decision,Meningococcal conjugate vaccines (Meningococcal conjugated vaccine),/apptracker/s/application-public/a102P000008puEE,National Immunisation Schedule
a0ROZ00000CZxxZ2AT,"Meningococcal group A,C,W and Y vaccine",A-00775,,"Meningococcal group A,C,W and Y vaccine",Pharmac Initiated,"Invasive meningococcal disease, widened access to current close living situations for people 13-25 years old",Seeking Clinical Advice,"Meningococcal group A,C,W and Y vaccine",/apptracker/s/application-public/a10OZ000000auoT,
a0ROZ00000CWbC12AL,Meningococcal group B vaccine,A-00766,,Meningococcal group B vaccine,Pharmac Initiated,"Invasive meningococcal disease, widened access to current close living situations for people 13-25 years old",Seeking Clinical Advice,Meningococcal group B vaccine,/apptracker/s/application-public/a10OZ000000aui1,
a0R2P000000T5m6UAC,Meningococcal group B vaccine - Invasive meningococcal disease,A-00767,,Meningococcal group B vaccine - Invasive meningococcal disease,PHARMAC Initiated,High risk immuno-compromised patients,Decision,Meningococcal group B vaccine - Invasive meningococcal disease,/apptracker/s/application-public/a102P000008pttp,National Immunisation Schedule
a0ROZ00000BVkl22AD,Meningococcal group B vaccine - Invasive meningococcal disease,A-04686,Bexsero,Meningococcal group B vaccine - Invasive meningococcal disease,Consumer,All adolescents 13-25 years,Reviewing Consultation Feedback,Meningococcal group B vaccine - Invasive meningococcal disease (Bexsero),/apptracker/s/application-public/a10OZ0000000NB7,
a0R2P000000cHpJUAU,Meningococcal group B vaccine - Invasive meningococcal disease,A-00764,,Meningococcal group B vaccine - Invasive meningococcal disease,PHARMAC Initiated,Entrants to close living situations  (13 to 25 years) - no catchup,Decision,Meningococcal group B vaccine - Invasive meningococcal disease,/apptracker/s/application-public/a102P000008ptpy,National Immunisation Schedule
a0R2P000000da0VUAQ,Meningococcal group B vaccine - Invasive meningococcal disease,A-00766,,Meningococcal group B vaccine - Invasive meningococcal disease,PHARMAC Initiated,Entrants to close living situations and one-year catch-up  (13 to 25 years),Decision,Meningococcal group B vaccine - Invasive meningococcal disease,/apptracker/s/application-public/a102P000008pucI,National Immunisation Schedule
a0R2P000000T5mkUAC,Meningococcal group B vaccine - Invasive meningococcal disease,A-00768,,Meningococcal group B vaccine - Invasive meningococcal disease,PHARMAC Initiated,Contacts of cases,Decision,Meningococcal group B vaccine - Invasive meningococcal disease,/apptracker/s/application-public/a102P000008pu4Q,National Immunisation Schedule
a0R2P000000dZwOUAU,Meningococcal group B vaccine - Invasive meningococcal disease: Infant (2+1),A-00763,,Meningococcal group B vaccine - Invasive meningococcal disease: Infant (2+1),GlaxoSmithKline,Infant Schedule (2+1 dosing),Decision,Meningococcal group B vaccine - Invasive meningococcal disease: Infant (2+1),/apptracker/s/application-public/a102P000008ptux,National Immunisation Schedule
a0R2P000000LmZYUA0,Meningococcal vaccines,A-00218,,Meningococcal vaccines,Clinician,Widening access - HIV; pre-solid organ transplant; severely immunocomp. under 26yrs; complement def.,Decision,Meningococcal vaccines,/apptracker/s/application-public/a102P000008puTY,National Immunisation Schedule
a0R2P000000anRaUAI,MMR vaccine,A-01298,,MMR vaccine,PHARMAC Initiated,"Vaccine against measles, mumps, and rubella, changing age at when vaccine is given",Decision,MMR vaccine,/apptracker/s/application-public/a102P000008ptvA,National Immunisation Schedule
a0R2P000000Lmd8UAC,Pertussis vaccine,A-00543 A-00542,,Pertussis vaccine,"Subcommittee recommendation, Clinician",Parents of infants born at 28 weeks or less or infants admitted to NICU or SCBU for a minimum stay.,Decision,Pertussis vaccine,/apptracker/s/application-public/a102P000008pu7c,National Immunisation Schedule
a0ROZ00000AqQQm2AN,Pertussis-containing vaccine,A-05329,,Pertussis-containing vaccine,Clinician,Additional dose of pertussis-containing vaccine in the second year of life: Widening access ,Options Compared,Pertussis-containing vaccine,/apptracker/s/application-public/a10OZ000003t4vh,National Immunisation Schedule
a0ROZ000006xL4z2AE,Pneumococcal (PCV13) vaccine,A-00390,,Pneumococcal (PCV13) vaccine,Pfizer,Immunisation of adults over 65 years,Decision,Pneumococcal (PCV13) vaccine,/apptracker/s/application-public/a102P000008puBZ,National Immunisation Schedule
a0R2P000000TFe6UAG,Pneumococcal (PCV13) vaccine,A-00326,,Pneumococcal (PCV13) vaccine,Clinician,Immunisation of additional groups,Decision,Pneumococcal (PCV13) vaccine,/apptracker/s/application-public/a102P000008puWY,National Immunisation Schedule
a0ROZ00000DabMX2AZ,Pneumococcal 21-valent conjugate vaccine,A-05374,CAPVAXIVE,Pneumococcal 21-valent conjugate vaccine,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,Prevention of Invasive Pneumococcal Disease in high-risk adults,Under Assessment,Pneumococcal 21-valent conjugate vaccine (CAPVAXIVE),/apptracker/s/application-public/a10OZ000004OFtF,National Immunisation Schedule
a0ROZ00000Dab812AB,Pneumococcal 21-valent conjugate vaccine,A-05374,CAPVAXIVE,Pneumococcal 21-valent conjugate vaccine,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,Prevention of Invasive Pneumococcal Disease in all adults aged 65 years and over,Under Assessment,Pneumococcal 21-valent conjugate vaccine (CAPVAXIVE),/apptracker/s/application-public/a10OZ000005Gy8b,National Immunisation Schedule
a0ROZ0000070OZN2A2,Pneumococcal conjugate vaccine (PCV13),A-05095,,Pneumococcal conjugate vaccine (PCV13),Clinician,"Individuals who have had invasive pneumococcal disease, secondary prophylaxis",Under Assessment,Pneumococcal conjugate vaccine (PCV13),/apptracker/s/application-public/a10OZ000001nwWv,
a0ROZ0000070PLl2AM,Pneumococcal conjugate vaccine (PCV13),A-05089,,Pneumococcal conjugate vaccine (PCV13),Clinician,Non-cystic fibrosis bronchiectasis,Under Assessment,Pneumococcal conjugate vaccine (PCV13),/apptracker/s/application-public/a10OZ000001rCGz,
a0ROZ00000BcrzU2AR,"Pneumococcal polysaccharide conjugate vaccine, 20-valent",A-05408,Prevenar 20,"Pneumococcal polysaccharide conjugate vaccine, 20-valent",PFIZER NEW ZEALAND LIMITED,Prevention of invasive pneumococcal disease,Seeking Clinical Advice,"Pneumococcal polysaccharide conjugate vaccine, 20-valent (Prevenar 20)",/apptracker/s/application-public/a10OZ000004yfM9,
a0ROZ000006xLL72AM,Pneumococcal polysaccharide vaccine,A-01523 A-03030,,Pneumococcal polysaccharide vaccine,"Merck Sharp & Dohme, MERCK SHARP & DOHME (NEW ZEALAND) LIMITED",Immunisation of over-65s,Decision,Pneumococcal polysaccharide vaccine,/apptracker/s/application-public/a102P000008ptpI,National Immunisation Schedule
a0ROZ0000070NAK2A2,Pneumococcal polysaccharide vaccine (PPV23),A-05095,,Pneumococcal polysaccharide vaccine (PPV23),Clinician,"Individuals who have had invasive pneumococcal disease, secondary prophylaxis",Under Assessment,Pneumococcal polysaccharide vaccine (PPV23),/apptracker/s/application-public/a10OZ000001rAiD,
a0ROZ0000070KFg2AM,Pneumococcal polysaccharide vaccine (PPV23),A-05089,,Pneumococcal polysaccharide vaccine (PPV23),Clinician,Non-cystic fibrosis bronchiectasis,Under Assessment,Pneumococcal polysaccharide vaccine (PPV23),/apptracker/s/application-public/a10OZ000001rCFN,
a0R2P000000anVWUAY,Pneumococcal vaccine,A-00518,,Pneumococcal vaccine,To be determined,People with rheumatological conditions on biologic treatments,Decision,Pneumococcal vaccine,/apptracker/s/application-public/a102P000008pu19,National Immunisation Schedule
a0R2P000000anZtUAI,Pneumococcal vaccine,A-00570,,Pneumococcal vaccine,Clinician,Prevention of pneumococcal diseases in individuals with neuromuscular conditions,Decision,Pneumococcal vaccine,/apptracker/s/application-public/a102P000008puIw,National Immunisation Schedule
a0R2P000000ane9UAA,Pneumococcal vaccine - Pneumovax 23,A-00736,,Pneumococcal vaccine - Pneumovax 23,Clinician,Individuals with untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).,Decision,Pneumococcal vaccine - Pneumovax 23,/apptracker/s/application-public/a102P000008puTh,National Immunisation Schedule
a0R2P000000LmZ4UAK,Pneumococcal vaccine (PCV 13),A-01274,Pneumococcal vaccine (PCV 13),Pneumococcal vaccine (PCV 13),PHARMAC Initiated,Prevention of pneumococcal disease vaccine for infants,Decision,Pneumococcal vaccine (PCV 13) (Pneumococcal vaccine (PCV 13)),/apptracker/s/application-public/a102P000008puV6,National Immunisation Schedule
a0ROZ000000B1wr2AC,Pneumococcal vaccine (PCV13),A-01274,Pneumococcal vaccine (PCV 13),Pneumococcal vaccine (PCV13),PHARMAC Initiated,"Prevention of IPD, supplemental dose, individuals aged 12 to 59 months",Options Compared,Pneumococcal vaccine (PCV13) (Pneumococcal vaccine (PCV 13)),/apptracker/s/application-public/a102P00000BZUOn,National Immunisation Schedule
a0R2P000000LmYNUA0,Pneumococcal vaccine (PCV13),A-00217,,Pneumococcal vaccine (PCV13),Clinician,Widening access - patients with HIV,Decision,Pneumococcal vaccine (PCV13),/apptracker/s/application-public/a102P000008puUe,National Immunisation Schedule
a0R2P000000LmV6UAK,Poliomyelitis vaccine,A-00219,,Poliomyelitis vaccine,Clinician,Widening access - partially vaccinated individuals,Decision,Poliomyelitis vaccine,/apptracker/s/application-public/a102P000008ptvk,National Immunisation Schedule
a0ROZ00000882EX2AY,Recombinant Zoster Vaccine,A-04290,SHINGRIX,Recombinant Zoster Vaccine,GLAXOSMITHKLINE NZ LIMITED,Māori and Pacific people aged 60 years and over for the prevention of herpes zoster and post-herpetic neuralgia,Options Compared,Recombinant Zoster Vaccine (SHINGRIX),/apptracker/s/application-public/a102P00000BUKoR,
a0ROZ000003Notp2AC,Recombinant Zoster Vaccine,A-04290,SHINGRIX,Recombinant Zoster Vaccine,GLAXOSMITHKLINE NZ LIMITED,"Prevention of herpes zoster and post-herpetic neuralgia, people at 50 years of age and a catch-up program  for people 51 to 64 years",Options Compared,Recombinant Zoster Vaccine (SHINGRIX),/apptracker/s/application-public/a102P00000BUKrt,National Immunisation Schedule
a0ROZ0000046xHd2AI,Recombinant Zoster Vaccine,A-04290 A-04447 A-04325,SHINGRIX,Recombinant Zoster Vaccine,"GLAXOSMITHKLINE NZ LIMITED, Auckland City Hospital, Clinician",Prevention of herpes zoster in immunocompromised adults,Decision,Recombinant Zoster Vaccine (SHINGRIX),/apptracker/s/application-public/a102P00000BUKrF,
a0ROZ000007hqPH2AY,Recombinant Zoster Vaccine,A-04902,Shingrix,Recombinant Zoster Vaccine,Clinician,Catch-up programme due to COVID-19 pandemic disruption,Options Compared,Recombinant Zoster Vaccine (Shingrix),/apptracker/s/application-public/a10OZ000000UvLp,
a0ROZ000009A8qn2AC,Recombinant Zoster Vaccine,A-04290,SHINGRIX,Recombinant Zoster Vaccine,GLAXOSMITHKLINE NZ LIMITED,"Prevention of herpes zoster in adults aged 66 to 74 years, plus catch up for those aged 75 years and over",Options Compared,Recombinant Zoster Vaccine (SHINGRIX),/apptracker/s/application-public/a10OZ000000ioHF,
a0ROZ000009A8qj2AC,Recombinant Zoster Vaccine,A-04290,SHINGRIX,Recombinant Zoster Vaccine,GLAXOSMITHKLINE NZ LIMITED,People over 65 years of age who require a Shingrix catch-up at least 5 years post Zostavax,Options Compared,Recombinant Zoster Vaccine (SHINGRIX),/apptracker/s/application-public/a102P00000BUKp9,National Immunisation Schedule
a0ROZ00000D1Wj82AF,Recombinant zoster vaccine (Shingles vaccine),A-05271,Shingrix,Recombinant zoster vaccine (Shingles vaccine),Clinician,Prevention of shingles in immunocompromised people - widen access to additional immunocompromised groups,Seeking Clinical Advice,Recombinant zoster vaccine (Shingles vaccine) (Shingrix),/apptracker/s/application-public/a10OZ000003GCQ5,
a0R2P000000fsK4UAI,Recombinant Zoster Vaccine (Shingrix),A-04290,SHINGRIX,Recombinant Zoster Vaccine (Shingrix),GLAXOSMITHKLINE NZ LIMITED,"People at 65 years of age, for the prevention of herpes zoster and post-herpetic neuralgia",Decision,Recombinant Zoster Vaccine (Shingrix) (SHINGRIX),/apptracker/s/application-public/a102P00000BRHo8,National Immunisation Schedule
a0R2P000000LmnNUAS,Rotavirus vaccine,A-01266,Rotavirus vaccine,Rotavirus vaccine,Merck Sharp & Dohme,Vaccine against rotavirus in infants less than 6 months old,Decision,Rotavirus vaccine (Rotavirus vaccine),/apptracker/s/application-public/a102P000008ptsN,National Immunisation Schedule
a0ROZ00000BcrzR2AR,RSVPreF3 Vaccine,A-04909,Arexvy,RSVPreF3 Vaccine,GLAXOSMITHKLINE NZ LIMITED,prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older,Seeking Clinical Advice,RSVPreF3 Vaccine (Arexvy),/apptracker/s/application-public/a10OZ000000aMGX,
a0R2P000000MW0oUAG,Tetanus vaccine,A-01271,,Tetanus vaccine,PHARMAC Initiated,Hospital listing,Decision,Tetanus vaccine,/apptracker/s/application-public/a102P000008puFB,National Immunisation Schedule
a0R2P000000LmTcUAK,Vaccines,A-01410,,Vaccines,PHARMAC Initiated,"Revaccination after HSCT, solid organ transplant, or chemotherapy",Decision,Vaccines,/apptracker/s/application-public/a102P000008puUI,National Immunisation Schedule
a0R2P000000TFTIUA4,Varicella vaccine,A-01268,Varicella vaccine,Varicella vaccine,PHARMAC Initiated,Universal varicella vaccination,Decision,Varicella vaccine (Varicella vaccine),/apptracker/s/application-public/a102P000008ptpq,National Immunisation Schedule
a0R2P000000LmhFUAS,Varicella vaccine,A-00216,,Varicella vaccine,Clinician,"Widening access, including amending cocooning rules",Decision,Varicella vaccine,/apptracker/s/application-public/a102P000008puDy,National Immunisation Schedule
a0R2P000000LmkkUAC,Varicella vaccine,A-01402,,Varicella vaccine,PHARMAC Initiated,Immunisation of high risk patients,Decision,Varicella vaccine,/apptracker/s/application-public/a102P000008puhB,National Immunisation Schedule
a0R2P000000TGQ2UAO,Zoster vaccine live,A-00361,,Zoster vaccine live,Merck Sharp & Dohme,"Vaccination for herpes zoster, catchup program",Decision,Zoster vaccine live,/apptracker/s/application-public/a102P000008pu8G,National Immunisation Schedule
a0R2P000000TGOfUAO,Zoster vaccine live,A-00278,,Zoster vaccine live,Merck Sharp & Dohme,Vaccination for herpes zoster,Decision,Zoster vaccine live,/apptracker/s/application-public/a102P000008ptts,National Immunisation Schedule
a0R2P000000LmniUAC,Pertussis maternal vaccination,A-00696,,Pertussis maternal vaccination,PHARMAC Initiated,Widen Access - all pregnant women,Decision,Pertussis maternal vaccination,/apptracker/s/application-public/a102P000008pu1u,National Immunisation Schedule
a0ROZ00000DL6an2AD,Quadrivalent meningococcal conjugate (MenACWY-T),A-05455,Bexsero  MenQuadfi,Quadrivalent meningococcal conjugate (MenACWY-T),Clinician,Booster dose for adolescents on entering a second congregate setting,Seeking Clinical Advice,Quadrivalent meningococcal conjugate (MenACWY-T) (Bexsero  MenQuadfi),/apptracker/s/application-public/a10OZ000007O83d,National Immunisation Schedule
a0R2P000000MSKmUAO,"1 kcal/ml, 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml - Cubison",A-01513,Cubison,"Enteral feed, 1 kcal/ml, 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml - Cubison",Pharmac Initiated,Hospital listing,Decision,"Enteral feed, 1 kcal/ml, 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml - Cubison (Cubison)",/apptracker/s/application-public/a102P000008puet,Special Foods
a0R2P000000OZ49UAG,Acamprosate Calcium,A-01418,,Acamprosate Calcium,PHARMAC Initiated,Alcohol dependence,Decision,Acamprosate Calcium,/apptracker/s/application-public/a102P000008pu8H,Nervous System
a0R2P000000MwSSUA0,Acetylcysteine eye drops,A-01420,,Acetylcysteine eye drops,PHARMAC Initiated,Hospital listing,Decision,Acetylcysteine eye drops,/apptracker/s/application-public/a102P000008puDI,Sensory Organs
a0R2P000000MW9WUAW,Acetylcysteine tablet eff 600 mg,A-01419,,Acetylcysteine tablet eff 600 mg,PHARMAC Initiated,Antidote,Decision,Acetylcysteine tablet eff 600 mg,/apptracker/s/application-public/a102P000008puTZ,Various
a0R2P000000Lmq1UAC,Acitretin,A-00258,"Neotigason,Novatretin",Acitretin,PHARMAC Initiated,"Widening access, including removal of",Decision,"Acitretin (Neotigason,Novatretin)",/apptracker/s/application-public/a102P000008puCu,Dermatologicals
a0R2P000000LmkdUAC,Adalimumab,A-00782,Humira,Adalimumab,PHARMAC Initiated,Ankylosing spondylitis amended access,Decision,Adalimumab (Humira),/apptracker/s/application-public/a102P000008pugZ,Oncology Agents and Immunosuppressants
a0R2P000000LmpOUAS,Adalimumab,A-01066,,Adalimumab,PHARMAC Initiated,Psoriatic arthritis; widen access,Decision,Adalimumab,/apptracker/s/application-public/a102P000008puB7,Oncology Agents and Immunosuppressants
a0R2P000000LmUCUA0,"Adalimumab, Etanercept",A-01323,"Enbrel,Humira,Humirapen","Adalimumab, Etanercept",PHARMAC Initiated,Pyoderma gangrenosum,Decision,"Adalimumab, Etanercept (Enbrel,Humira,Humirapen)",/apptracker/s/application-public/a102P000008puNE,Dermatologicals
a0ROZ0000006h2H2AQ,"Alendronate sodium, with or without colecalciferol",A-00754,,"Alendronate sodium, with or without colecalciferol",PHARMAC Initiated,Removal of funding restrictions,Decision,"Alendronate sodium, with or without colecalciferol",/apptracker/s/application-public/a102P000008puCM,Musculoskeletal System
a0R2P000000MW0UUAW,Alfacalcidol injection,A-01421,,Alfacalcidol injection,PHARMAC Initiated,Vitamin D supplement,Decision,Alfacalcidol injection,/apptracker/s/application-public/a102P000008ptvC,Alimentary Tract and Metabolism
a0R2P000000OB8jUAG,Almond oil,A-01422,,Almond oil,PHARMAC Initiated,Hospital listing,Decision,Almond oil,/apptracker/s/application-public/a102P000008puax,Extemporaneous Compounds
a0R2P000000MQtoUAG,Amoxycillin paediatric drops,A-01425,"Amoxil Paediatric Drops,Ospamox Paediatric Drops",Amoxycillin paediatric drops,PHARMAC Initiated,Hospital listing,Decision,"Amoxycillin paediatric drops (Amoxil Paediatric Drops,Ospamox Paediatric Drops)",/apptracker/s/application-public/a102P000008puB6,Infections - Agents for Systemic Use
a0R2P000000TW8uUAG,"anti-inflammatory drugs (NSAIDs) - Diclofenac, Ibuprofen, Ketoprofen, Piroxicam",A-00378,,"Topical non-steroidal anti-inflammatory drugs (NSAIDs) - Diclofenac, Ibuprofen, Ketoprofen, Piroxicam",PHARMAC Initiated,Osteoarthritis,Options Compared,"Topical non-steroidal anti-inflammatory drugs (NSAIDs) - Diclofenac, Ibuprofen, Ketoprofen, Piroxicam",/apptracker/s/application-public/a102P000008puNS,Musculoskeletal System
a0R2P000000LmZuUAK,Antiretrovirals,A-01397,,Antiretrovirals,PHARMAC Initiated,Antiretrovirals for HIV prophylaxis (non-occupational exposure),Decision,Antiretrovirals,/apptracker/s/application-public/a102P000008pua4,Infections - Agents for Systemic Use
a0R2P000000LmWxUAK,Antiretrrovirals,A-00826,,Antiretrrovirals,PHARMAC Initiated,HIV - increasing the number subsidised to permit access to optimised background therapy (OBT),Decision,Antiretrrovirals,/apptracker/s/application-public/a102P000008ptx0,Infections - Agents for Systemic Use
a0R2P000000LmdHUAS,"Anxiolytics, Sedatives and hypnotics - Various benzodiazepines and zopiclone",A-00962,,"Anxiolytics, Sedatives and hypnotics - Various benzodiazepines and zopiclone",PHARMAC Initiated,Removing the month restriction,Decision,"Anxiolytics, Sedatives and hypnotics - Various benzodiazepines and zopiclone",/apptracker/s/application-public/a102P000008pubx,Nervous System
a0R2P000000MR1jUAG,Arnica cream,A-01429,,Arnica cream,PHARMAC Initiated,Hospital listing,Decision,Arnica cream,/apptracker/s/application-public/a102P000008pubU,Musculoskeletal System
a0R2P000000MTbmUAG,"Arnicia, Hypericum oil - Anti-Flamme cream",A-00045,,"Arnicia, Hypericum oil - Anti-Flamme cream",PHARMAC Initiated,Hospital listing,Decision,"Arnicia, Hypericum oil - Anti-Flamme cream",/apptracker/s/application-public/a102P000008puc5,Musculoskeletal System
a0R2P000000MW0ZUAW,"Ascorbic acid injections, 500 mg per 5 ml",A-01392,,"Ascorbic acid injections, 500 mg per 5 ml",PHARMAC Initiated,Hospital listing,Decision,"Ascorbic acid injections, 500 mg per 5 ml",/apptracker/s/application-public/a102P000008puL5,Blood and Blood Forming Organs
a0R2P000000MW0PUAW,Ascorbic acid large chewable tablets (500 mg and 1 g),A-01426,,Ascorbic acid large chewable tablets (500 mg and 1 g),PHARMAC Initiated,Hospital listing,Decision,Ascorbic acid large chewable tablets (500 mg and 1 g),/apptracker/s/application-public/a102P000008puca,Alimentary Tract and Metabolism
a0R2P000000LmeRUAS,Atomoxetine,A-00752 A-00753,,Atomoxetine,"PHARMAC Initiated, Generic Partners",Removal of funding restrictions,Decision,Atomoxetine,/apptracker/s/application-public/a102P000008pttw,Nervous System
a0ROZ000004CaLZ2A0,Atropine 0.5% eye drops,A-01054,,Atropine 0.5% eye drops,Pharmac Initiated,Congenital cataract surgery - paediatric patients,Decision,Atropine 0.5% eye drops,/apptracker/s/application-public/a102P000008ptxz,Sensory Organs
a0ROZ0000008ZTd2AM,Bart's Solution - Glucose 4% with sodium chloride 0.18%,A-00018,,Bart's Solution - Glucose 4% with sodium chloride 0.18%,PHARMAC Initiated,Hospital listing,Decision,Bart's Solution - Glucose 4% with sodium chloride 0.18%,/apptracker/s/application-public/a102P000008pu9E,Blood and Blood Forming Organs
a0R2P000000Lmb3UAC,"Beclomethasone dipropionate, extra fine aerosol inhalers",A-01342,"Qvar 100,Qvar 50","Beclomethasone dipropionate, extra fine aerosol inhalers",PHARMAC Initiated,Reversible obstructive airways disease,Decision,"Beclomethasone dipropionate, extra fine aerosol inhalers (Qvar 100,Qvar 50)",/apptracker/s/application-public/a102P000008puRq,Respiratory System and Allergies
a0ROZ0000001M1h2AE,Bee and wasp venom allergy treatment,A-00256,Albay,Bee and wasp venom allergy treatment,PHARMAC Initiated,Removal of Special Authority,Options Compared,Bee and wasp venom allergy treatment (Albay),/apptracker/s/application-public/a102P000008puiG,Respiratory System and Allergies
a0ROZ0000012YUr2AM,Benzoyl peroxide topical preparation 2.5% to 5%,A-01394,,Benzoyl peroxide topical preparation 2.5% to 5%,PHARMAC Initiated,Acne vulgaris,Under Assessment,Benzoyl peroxide topical preparation 2.5% to 5%,/apptracker/s/application-public/a102P000008puCG,Dermatologicals
a0R2P000000LmXiUAK,Benzydamine Hcl,A-01337,Difflam,Benzydamine Hcl,PHARMAC Initiated,Oral mucositis as a result of treatment for cancer,Decision,Benzydamine Hcl (Difflam),/apptracker/s/application-public/a102P000008pu0N,Oncology Agents and Immunosuppressants
a0R2P000000LmolUAC,Bicalutamide,A-00255,Bicalaccord,Bicalutamide,PHARMAC Initiated,Removal of Special Authority,Decision,Bicalutamide (Bicalaccord),/apptracker/s/application-public/a102P000008pu36,Oncology Agents and Immunosuppressants
a0R2P000000LmrfUAC,Bortezomib,A-01030,Velcade,Bortezomib,PHARMAC Initiated,Multiple myeloma-Bridge to transplant,Decision,Bortezomib (Velcade),/apptracker/s/application-public/a102P000008puGe,Oncology Agents and Immunosuppressants
a0R2P000000MwSKUA0,Bromhexine,A-01391,,Bromhexine,PHARMAC Initiated,Respiratory conditions,Decision,Bromhexine,/apptracker/s/application-public/a102P000008puiI,Respiratory System and Allergies
a0R2P000000MQttUAG,Bromocriptine 10 mg tablet,A-01428,,Bromocriptine 10 mg tablet,PHARMAC Initiated,Parkinson's disease,Decision,Bromocriptine 10 mg tablet,/apptracker/s/application-public/a102P000008pu1E,Nervous System
a0R2P000000Lmr6UAC,Budesonide,A-00924 A-00925,Entocort CIR,Budesonide,"PHARMAC Initiated, Clinician",Microscopic colitis,Decision,Budesonide (Entocort CIR),/apptracker/s/application-public/a102P000008puHb,Alimentary Tract and Metabolism
a0ROZ000008FImP2AW,Budesonide and Formoterol Inhalers,A-03669 A-04400,,Budesonide and Formoterol Inhalers,"Pharmac Initiated, Clinician","Asthma, dispensing in greater quantities than one (STAT dispensing) and add to Practitioner's supply order (PSO) list",Decision,Budesonide and Formoterol Inhalers,/apptracker/s/application-public/a102P00000AlhdU,Respiratory System and Allergies
a0R2P000000MR1eUAG,"Bupivacaine hydrochloride with adrenaline, various formulations",A-01451,,"Bupivacaine hydrochloride with adrenaline, various formulations",PHARMAC Initiated,Hospital listing,Decision,"Bupivacaine hydrochloride with adrenaline, various formulations",/apptracker/s/application-public/a102P000008puAs,Nervous System
a0R2P000000OcirUAC,"Bupivacaine hydrochloride, inj 3.75 mg per ml, 20 ml",A-01450,,"Bupivacaine hydrochloride, inj 3.75 mg per ml, 20 ml",PHARMAC Initiated,Hospital listing,Decision,"Bupivacaine hydrochloride, inj 3.75 mg per ml, 20 ml",/apptracker/s/application-public/a102P000008puAv,Nervous System
a0R2P000000MR1oUAG,"Buprenorphine injection (0.3 mg per ml, 1ml ampoule)",A-01453,,"Buprenorphine injection (0.3 mg per ml, 1ml ampoule)",PHARMAC Initiated,Hospital listing,Decision,"Buprenorphine injection (0.3 mg per ml, 1ml ampoule)",/apptracker/s/application-public/a102P000008pu0r,Nervous System
a0R2P000000MW0KUAW,"Calcium folinate injection, 1 mg per ml, 50 ml",A-01454,,"Calcium folinate injection, 1 mg per ml, 50 ml",PHARMAC Initiated,Hospital listing,Decision,"Calcium folinate injection, 1 mg per ml, 50 ml",/apptracker/s/application-public/a102P000008pu2J,Oncology Agents and Immunosuppressants
a0R2P000000Lmm3UAC,Candesartan cilexetil,A-01081,Candestar,Candesartan cilexetil,PHARMAC Initiated,Removal of Special Authority,Decision,Candesartan cilexetil (Candestar),/apptracker/s/application-public/a102P000008puib,Cardiovascular System
a0R2P000000MQfDUAW,Capreomycin Sulphate,A-01455,Capastat,Capreomycin Sulphate,PHARMAC Initiated,Hospital listing,Decision,Capreomycin Sulphate (Capastat),/apptracker/s/application-public/a102P000008puc7,Infections - Agents for Systemic Use
a0R2P000000OURBUA4,Carboxymethyl cellulose with propylene glycol,A-00055,,Carboxymethyl cellulose with propylene glycol,PHARMAC Initiated,Hospital listing,Decision,Carboxymethyl cellulose with propylene glycol,/apptracker/s/application-public/a102P000008pu9w,Extemporaneous Compounds
a0ROZ00000DqVY52AN,Carboxypeptidase G2,A-01411,,Carboxypeptidase G2,Pharmac Initiated,Methotrexate overdose,Options Compared,Carboxypeptidase G2,/apptracker/s/application-public/a102P000008pu4B,Oncology Agents and Immunosuppressants
a0R2P000000OUSdUAO,Carmustine implant,A-01460,,Carmustine implant,PHARMAC Initiated,Glioma,Decision,Carmustine implant,/apptracker/s/application-public/a102P000008puWV,Oncology Agents and Immunosuppressants
a0R2P000000MQfIUAW,Cefamandole nafate,A-01461,,Cefamandole nafate,PHARMAC Initiated,Anti-infection,Decision,Cefamandole nafate,/apptracker/s/application-public/a102P000008puKT,Infections - Agents for Systemic Use
a0R2P000000MQfNUAW,Cefotaxime injection 2 g,A-01462,,Cefotaxime injection 2 g,PHARMAC Initiated,Anti-infection,Decision,Cefotaxime injection 2 g,/apptracker/s/application-public/a102P000008ptsG,Infections - Agents for Systemic Use
a0R2P000000MQfSUAW,Cefpirome Sulfate,A-01463,,Cefpirome Sulfate,PHARMAC Initiated,Anti-infection,Decision,Cefpirome Sulfate,/apptracker/s/application-public/a102P000008pukc,Infections - Agents for Systemic Use
a0R2P000000MQfcUAG,Cefpodoxime proxetil,A-01464,,Cefpodoxime proxetil,PHARMAC Initiated,Anti-infection,Decision,Cefpodoxime proxetil,/apptracker/s/application-public/a102P000008pu6m,Infections - Agents for Systemic Use
a0R2P000000MQsvUAG,Cefradine,A-01465,,Cefradine,PHARMAC Initiated,Anti-infection,Decision,Cefradine,/apptracker/s/application-public/a102P000008ptxn,Infections - Agents for Systemic Use
a0R2P000000MQt0UAG,"Cefuroxime sodium, injection 250 mg",A-01466,,"Cefuroxime sodium, injection 250 mg",PHARMAC Initiated,Anti-infection,Decision,"Cefuroxime sodium, injection 250 mg",/apptracker/s/application-public/a102P000008ptog,Infections - Agents for Systemic Use
a0R2P000000MQtFUAW,Cetomacrogol with paraffin and cetyl alcohol,A-01468,,Cetomacrogol with paraffin and cetyl alcohol,PHARMAC Initiated,Hospital listing,Decision,Cetomacrogol with paraffin and cetyl alcohol,/apptracker/s/application-public/a102P000008ptwL,Dermatologicals
a0ROZ000000VXPV2A4,Cetrimide shampoo,A-01469,,Cetrimide shampoo,PHARMAC Initiated,Psoriasis and eczema,Decision,Cetrimide shampoo,/apptracker/s/application-public/a102P000008pudT,Dermatologicals
a0R2P000000MQtKUAW,Cetylpyridinium chloride,A-01470,,Cetylpyridinium chloride,PHARMAC Initiated,"Mouthwash, lozenge, and mouthwash with benzocaine",Decision,Cetylpyridinium chloride,/apptracker/s/application-public/a102P000008ptwn,Alimentary Tract and Metabolism
a0R2P000000OSpmUAG,Charcoal tablet,A-01471,,Charcoal tablet,PHARMAC Initiated,Hospital listing,Decision,Charcoal tablet,/apptracker/s/application-public/a102P000008puUg,Various
a0R2P000000MQtPUAW,Chlordiazepoxide hydrochloride,A-01472,,Chlordiazepoxide hydrochloride,PHARMAC Initiated,Hospital listing,Decision,Chlordiazepoxide hydrochloride,/apptracker/s/application-public/a102P000008pu5W,Nervous System
a0R2P000000MOw9UAG,Chlorpropamide,A-01390,,Chlorpropamide,PHARMAC Initiated,Diabetes,Decision,Chlorpropamide,/apptracker/s/application-public/a102P000008pud6,Alimentary Tract and Metabolism
a0ROZ0000012YLB2A2,Cinacalcet Hcl,A-00827,,Cinacalcet Hcl,PHARMAC Initiated,"Parathyroid disorders, non-malignant, any cause, without symptomatic hypercalcaemia",Under Assessment,Cinacalcet Hcl,/apptracker/s/application-public/a102P000008puMU,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000eyO0UAI,Cinacalcet Hcl,A-00435,Sensipar,Cinacalcet Hcl,PHARMAC Initiated,Parathyroid carcinoma with symptomatic hypercalcaemia unresponsive to other treatments,Decision,Cinacalcet Hcl (Sensipar),/apptracker/s/application-public/a102P000008puBu,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000en0VUAQ,Cinacalcet Hcl,A-01262,Sensipar,Cinacalcet Hcl,PHARMAC Initiated,"Symptomatic calciphylaxis, after failure of bisphosphonates and sodium thiosulfate",Decision,Cinacalcet Hcl (Sensipar),/apptracker/s/application-public/a102P000008pu6q,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000cuXAUAY,Cinacalcet Hcl,A-00471 A-00472,,Cinacalcet Hcl,"PHARMAC Initiated, Clinician",Tertiary hyperparathyroidism,Decision,Cinacalcet Hcl,/apptracker/s/application-public/a102P000008puPm,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000bo8YUAQ,Cinacalcet Hcl,A-00469 A-00470,,Cinacalcet Hcl,"PHARMAC Initiated, Clinician",Primary hyperparathyroidism,Decision,Cinacalcet Hcl,/apptracker/s/application-public/a102P000008ptsL,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmXzUAK,Cisapride,A-01473,,Cisapride,PHARMAC Initiated,Gastrointestinal motility disorders,Decision,Cisapride,/apptracker/s/application-public/a102P000008puWX,Alimentary Tract and Metabolism
a0R2P000000MQtZUAW,Clobetasone butyrate ointment,A-01474,,Clobetasone butyrate ointment,PHARMAC Initiated,Hospital listing,Decision,Clobetasone butyrate ointment,/apptracker/s/application-public/a102P000008ptom,Dermatologicals
a0R2P000000OUSsUAO,Clofarabine,A-01475,,Clofarabine,PHARMAC Initiated,Hospital listing,Decision,Clofarabine,/apptracker/s/application-public/a102P000008pu6Q,Oncology Agents and Immunosuppressants
a0R2P000000LmjzUAC,"Clonidine injections 1.5 mg per ml: 1 ml, 2 ml, and 20 ml presentations",A-01476,,"Clonidine injections 1.5 mg per ml: 1 ml, 2 ml, and 20 ml presentations",PHARMAC Initiated,Hospital listing,Decision,"Clonidine injections 1.5 mg per ml: 1 ml, 2 ml, and 20 ml presentations",/apptracker/s/application-public/a102P000008pudm,Cardiovascular System
a0R2P000000QcSLUA0,Clopidogrel,A-00926,Plavix,Clopidogrel,PHARMAC Initiated,For Stroke & Transient Ischemic Attack as an alternative to aspirin and dipyridamole combo therapy,Decision,Clopidogrel (Plavix),/apptracker/s/application-public/a102P000008puQD,Blood and Blood Forming Organs
a0R2P000000LmZhUAK,Clopidogrel,A-00913,,Clopidogrel,PHARMAC Initiated,Widening of access to include aspirin intolerant patients,Decision,Clopidogrel,/apptracker/s/application-public/a102P000008puSL,Blood and Blood Forming Organs
a0R2P000000WspyUAC,Clopidogrel,A-00927,,Clopidogrel,PHARMAC Initiated,High risk Transient Ischemic Attack (TIA) patients,Decision,Clopidogrel,/apptracker/s/application-public/a102P000008pu0c,Blood and Blood Forming Organs
a0R2P000000MwSCUA0,"Clotrimazole hydrochloride, vaginal cream 10% and pessaries",A-01477,,"Clotrimazole hydrochloride, vaginal cream 10% and pessaries",PHARMAC Initiated,Hospital listing,Decision,"Clotrimazole hydrochloride, vaginal cream 10% and pessaries",/apptracker/s/application-public/a102P000008ptqf,Genito-Urinary System
a0ROZ000000VX1J2AW,Coal tar shampoo 4%,A-01479,,Coal tar shampoo 4%,PHARMAC Initiated,Psoriasis,Decision,Coal tar shampoo 4%,/apptracker/s/application-public/a102P000008pu8q,Dermatologicals
a0R2P000000MR2IUAW,"Coal tar with allantoin, menthol, phenol and sulphur",A-01480,,"Coal tar with allantoin, menthol, phenol and sulphur",PHARMAC Initiated,Hospital listing,Decision,"Coal tar with allantoin, menthol, phenol and sulphur",/apptracker/s/application-public/a102P000008puCc,Dermatologicals
a0R2P000000MR2NUAW,"Codeine phosphate injection 50 mg per ml, 1 ml",A-01481,,"Codeine phosphate injection 50 mg per ml, 1 ml",PHARMAC Initiated,Hospital listing,Decision,"Codeine phosphate injection 50 mg per ml, 1 ml",/apptracker/s/application-public/a102P000008puMH,Nervous System
a0R2P000000MR2mUAG,Compound electrolytes ice block,A-01482,,Compound electrolytes ice block,PHARMAC Initiated,Hospital listing,Decision,Compound electrolytes ice block,/apptracker/s/application-public/a102P000008puKU,Blood and Blood Forming Organs
a0R2P000000MROjUAO,Compound electrolytes injection - Plasma-Lyte 56 in Glucose,A-01483,Plasma-Lyte 56 in Glucose,Compound electrolytes injection - Plasma-Lyte 56 in Glucose,PHARMAC Initiated,Hospital listing,Decision,Compound electrolytes injection - Plasma-Lyte 56 in Glucose (Plasma-Lyte 56 in Glucose),/apptracker/s/application-public/a102P000008puTn,Blood and Blood Forming Organs
a0R2P000000MwS1UAK,Cortisone acetate,A-01484,,Cortisone acetate,PHARMAC Initiated,Hospital listing,Decision,Cortisone acetate,/apptracker/s/application-public/a102P000008puXn,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MRPSUA4,Cyclopenthiazide,A-01485,,Cyclopenthiazide,PHARMAC Initiated,Diuretic,Decision,Cyclopenthiazide,/apptracker/s/application-public/a102P000008pubY,Cardiovascular System
a0R2P000000MwRzUAK,Cyproterone Acetate injection,A-01486,,Cyproterone Acetate injection,PHARMAC Initiated,Hospital listing,Decision,Cyproterone Acetate injection,/apptracker/s/application-public/a102P000008ptxv,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000OUT2UAO,Daunorubicin Citrate Liposome,A-01487,,Daunorubicin Citrate Liposome,PHARMAC Initiated,Hospital listing,Decision,Daunorubicin Citrate Liposome,/apptracker/s/application-public/a102P000008ptvi,Oncology Agents and Immunosuppressants
a0R2P000000MOUnUAO,"Deep Heat - 2-hydroxybenzoate, Methyl Ester, Pyridinecarboxylic acid",A-00046,,"Deep Heat - 2-hydroxybenzoate, Methyl Ester, Pyridinecarboxylic acid",PHARMAC Initiated,Hospital listing,Decision,"Deep Heat - 2-hydroxybenzoate, Methyl Ester, Pyridinecarboxylic acid",/apptracker/s/application-public/a102P000008puj5,Musculoskeletal System
a0R2P000000MRVDUA4,"Desmopressin nasal spray, 150 mcg",A-01492,,"Desmopressin nasal spray, 150 mcg",PHARMAC Initiated,Hospital listing,Decision,"Desmopressin nasal spray, 150 mcg",/apptracker/s/application-public/a102P000008ptuE,Blood and Blood Forming Organs
a0R2P000000MwSGUA0,Dexchlorpheniramine maleate,A-01494,Dexchlorpheniramine Maleate,Dexchlorpheniramine maleate,PHARMAC Initiated,Hospital listing,Decision,Dexchlorpheniramine maleate (Dexchlorpheniramine Maleate),/apptracker/s/application-public/a102P000008pueZ,Respiratory System and Allergies
a0R2P000000MRPXUA4,Dextran,A-01493,,Dextran,PHARMAC Initiated,Hospital listing,Decision,Dextran,/apptracker/s/application-public/a102P000008ptya,Blood and Blood Forming Organs
a0R2P000000MwSAUA0,Dextromethorphan,A-01389,,Dextromethorphan,PHARMAC Initiated,Cough suppressant,Decision,Dextromethorphan,/apptracker/s/application-public/a102P000008ptpY,Respiratory System and Allergies
a0R2P000000MOvzUAG,Diazepam oral liquid 10 mg per 10 ml,A-01387,,Diazepam oral liquid 10 mg per 10 ml,PHARMAC Initiated,Hospital listing,Decision,Diazepam oral liquid 10 mg per 10 ml,/apptracker/s/application-public/a102P000008puCP,Nervous System
a0R2P000000OZ3jUAG,Diazoxide capsules 50 mg,A-01386,,Diazoxide capsules 50 mg,PHARMAC Initiated,Hyperglycaemic agent,Decision,Diazoxide capsules 50 mg,/apptracker/s/application-public/a102P000008ptym,Alimentary Tract and Metabolism
a0R2P000000MRW5UAO,Dichlorobenzyl alcohol with amylmetacresol and lignocaine,A-01495,,Dichlorobenzyl alcohol with amylmetacresol and lignocaine,PHARMAC Initiated,Hospital listing,Decision,Dichlorobenzyl alcohol with amylmetacresol and lignocaine,/apptracker/s/application-public/a102P000008puDk,Alimentary Tract and Metabolism
a0R2P000000MOd6UAG,Diclofenac gel,A-01385,,Diclofenac gel,PHARMAC Initiated,Pain,Decision,Diclofenac gel,/apptracker/s/application-public/a102P000008puhA,Musculoskeletal System
a0R2P000000MRXsUAO,Diclofenac potassium,A-01496,,Diclofenac potassium,PHARMAC Initiated,Hospital listing,Decision,Diclofenac potassium,/apptracker/s/application-public/a102P000008pubX,Musculoskeletal System
a0R2P000000OUTRUA4,Diethyl ether,A-01497,,Diethyl ether,PHARMAC Initiated,Hospital listing,Decision,Diethyl ether,/apptracker/s/application-public/a102P000008pu4K,Extemporaneous Compounds
a0R2P000000MWAUUA4,"Diltiazem hydrochloride, twice-daily presentations",A-01498,,"Diltiazem hydrochloride, twice-daily presentations",PHARMAC Initiated,Hospital listing,Decision,"Diltiazem hydrochloride, twice-daily presentations",/apptracker/s/application-public/a102P000008ptvm,Cardiovascular System
a0ROZ000001UxBl2AK,Dimercaptosuccinic acid,A-01163,,Dimercaptosuccinic acid,Pharmac Initiated,Lead poisoning,Decision,Dimercaptosuccinic acid,/apptracker/s/application-public/a102P000008ptt7,Various
a0R2P000000Ma0CUAS,Dimethicone cream 10%,A-01499,Psm,Dimethicone cream 10%,PHARMAC Initiated,Hospital listing,Decision,Dimethicone cream 10% (Psm),/apptracker/s/application-public/a102P000008ptrI,Dermatologicals
a0R2P000000MRYjUAO,Dimethicone with calamine and retinol palmitate,A-01501,,Dimethicone with calamine and retinol palmitate,PHARMAC Initiated,Hospital listing,Decision,Dimethicone with calamine and retinol palmitate,/apptracker/s/application-public/a102P000008pu3I,Dermatologicals
a0R2P000000MRcaUAG,Dimethicone with cetyl alcohol and glycerol,A-01502,,Dimethicone with cetyl alcohol and glycerol,PHARMAC Initiated,Hospital listing,Decision,Dimethicone with cetyl alcohol and glycerol,/apptracker/s/application-public/a102P000008ptrG,Dermatologicals
a0R2P000000MS6BUAW,Dinoprost trometamol,A-01503,,Dinoprost trometamol,PHARMAC Initiated,Hospital listing,Decision,Dinoprost trometamol,/apptracker/s/application-public/a102P000008puk9,Genito-Urinary System
a0R2P000000MS6QUAW,Dithranol cream,A-01504,,Dithranol cream,PHARMAC Initiated,Hospital listing,Decision,Dithranol cream,/apptracker/s/application-public/a102P000008ptwU,Dermatologicals
a0R2P000000MUDsUAO,docaine [lignocaine] hydrochloride prefilled syringes 1% in 10 ml and 2% in 5 ml,A-00069,,Lidocaine [lignocaine] hydrochloride prefilled syringes 1% in 10 ml and 2% in 5 ml,PHARMAC Initiated,Hospital listing,Decision,Lidocaine [lignocaine] hydrochloride prefilled syringes 1% in 10 ml and 2% in 5 ml,/apptracker/s/application-public/a102P000008ptxJ,Nervous System
a0R2P000000MS6VUAW,Docusate sodium enema,A-01505,,Docusate sodium enema,PHARMAC Initiated,Hospital listing,Decision,Docusate sodium enema,/apptracker/s/application-public/a102P000008puCI,Alimentary Tract and Metabolism
a0R2P000000LmjPUAS,Domperidone,A-00901,,Domperidone,PHARMAC Initiated,removal of Special Authority and fully funding,Decision,Domperidone,/apptracker/s/application-public/a102P000008pud9,Nervous System
a0R2P000000MS6aUAG,Domperidone suppositories and oral liquid,A-01506,,Domperidone suppositories and oral liquid,PHARMAC Initiated,Hospital listing,Decision,Domperidone suppositories and oral liquid,/apptracker/s/application-public/a102P000008pu4X,Nervous System
a0R2P000000LmoIUAS,Donepezil,A-00902 A-00903,Aricept,Donepezil,"Pfizer, PHARMAC Initiated",Alzheimer's disease (Dementia),Decision,Donepezil (Aricept),/apptracker/s/application-public/a102P000008pu16,Nervous System
a0R2P000000MS6fUAG,Doripenem,A-01507,,Doripenem,PHARMAC Initiated,Hospital listing,Decision,Doripenem,/apptracker/s/application-public/a102P000008ptwT,Infections - Agents for Systemic Use
a0R2P000000TGRPUA4,Dornase alfa,A-00365,Pulmozyme,Dornase alfa,PHARMAC Initiated,Cystic fibrosis - widening access to under 5s with severe symptoms,Decision,Dornase alfa (Pulmozyme),/apptracker/s/application-public/a102P000008puEF,Respiratory System and Allergies
a0R2P000000Lml6UAC,Dornase alfa,A-00476,,Dornase alfa,PHARMAC Initiated,Cystic fibrosis - removal of 6-month test,Decision,Dornase alfa,/apptracker/s/application-public/a102P000008pukA,Respiratory System and Allergies
a0R2P000000N6iZUAS,Dornase alfa,A-01154,Pulmozyme,Dornase alfa,PHARMAC Initiated,Cystic fibrosis - widening access to patients with an FEV1 >65% predicted,Decision,Dornase alfa (Pulmozyme),/apptracker/s/application-public/a102P000008pu1N,Respiratory System and Allergies
a0ROZ000000VTyb2AG,Dronedarone,A-01249,,Dronedarone,PHARMAC Initiated,Atrial fibrillation,Decision,Dronedarone,/apptracker/s/application-public/a102P000008puV3,Cardiovascular System
a0R2P000000MSDfUAO,"Droperidol injection 5 mg per ml, 2 ml ampoule",A-01509,,"Droperidol injection 5 mg per ml, 2 ml ampoule",PHARMAC Initiated,Hospital listing,Decision,"Droperidol injection 5 mg per ml, 2 ml ampoule",/apptracker/s/application-public/a102P000008puAw,Nervous System
a0R2P000000MS6kUAG,Drospirenone with Ethinylestradiol,A-01508,,Drospirenone with Ethinylestradiol,PHARMAC Initiated,Hospital listing,Decision,Drospirenone with Ethinylestradiol,/apptracker/s/application-public/a102P000008puct,Genito-Urinary System
a0R2P000000Ma0HUAS,"droxide oral liq with magnesium hydroxide and simeticone, 400:400:30 mg per 5 ml",A-01393,,"Aluminium hydroxide oral liq with magnesium hydroxide and simeticone, 400:400:30 mg per 5 ml",PHARMAC Initiated,Antacid,Decision,"Aluminium hydroxide oral liq with magnesium hydroxide and simeticone, 400:400:30 mg per 5 ml",/apptracker/s/application-public/a102P000008pty1,Alimentary Tract and Metabolism
a0R2P000000MwSFUA0,Dydrogesterone,A-01510,Duphaston,Dydrogesterone,PHARMAC Initiated,Hospital listing,Decision,Dydrogesterone (Duphaston),/apptracker/s/application-public/a102P000008puFC,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MSDpUAO,Enoxolone with povidone (polyvinylpyrrolidone) and sodium hyaluronate,A-01511,,Enoxolone with povidone (polyvinylpyrrolidone) and sodium hyaluronate,PHARMAC Initiated,Hospital listing,Decision,Enoxolone with povidone (polyvinylpyrrolidone) and sodium hyaluronate,/apptracker/s/application-public/a102P000008pu8r,Alimentary Tract and Metabolism
a0R2P000000MSDuUAO,Entecavir tablet 1 mg,A-01512,Baraclude,Entecavir tablet 1 mg,PHARMAC Initiated,Hospital listing,Decision,Entecavir tablet 1 mg (Baraclude),/apptracker/s/application-public/a102P000008ptzZ,Infections - Agents for Systemic Use
a0R2P000000fV7MUAU,Ergocalciferol,A-01514,,Ergocalciferol,PHARMAC Initiated,Hospital listing,Decision,Ergocalciferol,/apptracker/s/application-public/a102P000008pton,Alimentary Tract and Metabolism
a0R2P000000MSE9UAO,Erythromycin (as lactobionate) - injection 300 mg,A-01515,,Erythromycin (as lactobionate) - injection 300 mg,PHARMAC Initiated,Hospital listing,Decision,Erythromycin (as lactobionate) - injection 300 mg,/apptracker/s/application-public/a102P000008puWg,Infections - Agents for Systemic Use
a0R2P000000MSKwUAO,"Esmolol Hcl injection 250 mg per ml, 10 ml",A-01516,,"Esmolol Hcl injection 250 mg per ml, 10 ml",PHARMAC Initiated,Hospital listing,Decision,"Esmolol Hcl injection 250 mg per ml, 10 ml",/apptracker/s/application-public/a102P000008ptuj,Cardiovascular System
a0R2P000000MSLHUA4,"Ethanol, dehydrated - injection 100%, 20 ml",A-01517,,"Ethanol, dehydrated - injection 100%, 20 ml",PHARMAC Initiated,Hospital listing,Decision,"Ethanol, dehydrated - injection 100%, 20 ml",/apptracker/s/application-public/a102P000008ptwv,Various
a0R2P000000MSNIUA4,Ethanolamine oleate,A-01518,,Ethanolamine oleate,PHARMAC Initiated,Hospital listing,Decision,Ethanolamine oleate,/apptracker/s/application-public/a102P000008puV5,Blood and Blood Forming Organs
a0R2P000000MSSOUA4,Ethinyloestradiol with gestodene,A-01519,,Ethinyloestradiol with gestodene,PHARMAC Initiated,Hospital listing,Decision,Ethinyloestradiol with gestodene,/apptracker/s/application-public/a102P000008pufk,Genito-Urinary System
a0R2P000000MSO3UAO,Ethionamide,A-01520,,Ethionamide,PHARMAC Initiated,Hospital listing,Decision,Ethionamide,/apptracker/s/application-public/a102P000008puAz,Infections - Agents for Systemic Use
a0R2P000000MSSsUAO,Etonogestrel subdermal implant,A-01522,,Etonogestrel subdermal implant,PHARMAC Initiated,Hospital listing,Decision,Etonogestrel subdermal implant,/apptracker/s/application-public/a102P000008puTN,Genito-Urinary System
a0R2P000000MW0eUAG,Eucalyptus oil,A-01384,,Eucalyptus oil,PHARMAC Initiated,Removing sticking plaster residues,Decision,Eucalyptus oil,/apptracker/s/application-public/a102P000008puJw,Extemporaneous Compounds
a0R2P000000SWXEUA4,Famotidine,A-01524,,Famotidine,PHARMAC Initiated,Hospital listing,Decision,Famotidine,/apptracker/s/application-public/a102P000008ptoe,Alimentary Tract and Metabolism
a0R2P000000MVCEUA4,fat  - crm paraffin liquid 12.6% with white soft paraffin 14.5% and wool fat 1%,A-00128,,Paraffin with wool fat  - crm paraffin liquid 12.6% with white soft paraffin 14.5% and wool fat 1%,PHARMAC Initiated,Hospital listing,Decision,Paraffin with wool fat  - crm paraffin liquid 12.6% with white soft paraffin 14.5% and wool fat 1%,/apptracker/s/application-public/a102P000008ptuC,Dermatologicals
a0R2P000000MSSxUAO,Felbamate,A-01528,FELBAMATE,Felbamate,PHARMAC Initiated,Hospital listing,Decision,Felbamate (FELBAMATE),/apptracker/s/application-public/a102P000008puY3,Nervous System
a0R2P000000MSTHUA4,"Fentanyl injection, 50 mcg per ml, 50 ml",A-01529,,"Fentanyl injection, 50 mcg per ml, 50 ml",PHARMAC Initiated,Hospital listing,Decision,"Fentanyl injection, 50 mcg per ml, 50 ml",/apptracker/s/application-public/a102P000008pudl,Nervous System
a0ROZ000009A8qp2AC,Ferric carboxymaltose,A-05318,,Ferric carboxymaltose,Pharmac Initiated,"heart failure, without anaemia, with low serum ferritin",Options Compared,Ferric carboxymaltose,/apptracker/s/application-public/a10OZ000003lVzX,
a0ROZ000008xzpF2AQ,Ferric carboxymaltose,A-05318,,Ferric carboxymaltose,Pharmac Initiated,"heart failure, without anaemia, with low serum ferritin, with reduced or mid-range ejection fraction",Under Assessment,Ferric carboxymaltose,/apptracker/s/application-public/a10OZ000003vSYv,
a0R2P000000LmV3UAK,Ferrous Sulfate 325mg with Ascorbic Acid 500mg,A-00677,Ferrograd C,Ferrous Sulfate 325mg with Ascorbic Acid 500mg,PHARMAC Initiated,Open listing,Options Compared,Ferrous Sulfate 325mg with Ascorbic Acid 500mg (Ferrograd C),/apptracker/s/application-public/a102P000008ptyp,Alimentary Tract and Metabolism
a0R2P000000MSXUUA4,Fibre supplement - Stimulance,A-01530,Stimulance,Fibre supplement - Stimulance,PHARMAC Initiated,Hospital listing,Decision,Fibre supplement - Stimulance (Stimulance),/apptracker/s/application-public/a102P000008puQC,Alimentary Tract and Metabolism
a0R2P000000LmXoUAK,Filgrastim,A-01063,,Filgrastim,PHARMAC Initiated,Neutropenia - autoimmune / congenital / infection-related,Decision,Filgrastim,/apptracker/s/application-public/a102P000008pu0T,Blood and Blood Forming Organs
a0R2P000000LmltUAC,Flavoured condoms,A-01280,,Flavoured condoms,PHARMAC Initiated,Contraception,Decision,Flavoured condoms,/apptracker/s/application-public/a102P000008puiR,Genito-Urinary System
a0R2P000000MSYgUAO,Flucytosine: capsule 100 mg; injections; and infusions,A-01531,Alcobon,Flucytosine: capsule 100 mg; injections; and infusions,PHARMAC Initiated,Hospital listing,Decision,Flucytosine: capsule 100 mg; injections; and infusions (Alcobon),/apptracker/s/application-public/a102P000008pu0h,Infections - Agents for Systemic Use
a0R2P000000MSTMUA4,Flunitrazepam,A-01532,Rohypnol,Flunitrazepam,PHARMAC Initiated,Hospital listing,Decision,Flunitrazepam (Rohypnol),/apptracker/s/application-public/a102P000008ptr3,Nervous System
a0R2P000000MwSDUA0,Fluorescein sodium eye drops 1%,A-01534,,Fluorescein sodium eye drops 1%,PHARMAC Initiated,Hospital listing,Decision,Fluorescein sodium eye drops 1%,/apptracker/s/application-public/a102P000008ptpF,Sensory Organs
a0R2P000000MwS9UAK,Flurbiprofen,A-01535,Ocufen,Flurbiprofen,PHARMAC Initiated,Hospital listing,Decision,Flurbiprofen (Ocufen),/apptracker/s/application-public/a102P000008pttD,Sensory Organs
a0R2P000000MwSPUA0,Follitropin,A-01536,,Follitropin,PHARMAC Initiated,Hospital listing,Decision,Follitropin,/apptracker/s/application-public/a102P000008pu15,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MSkkUAG,Fuller's earth - hydrous aluminum silicates,A-01537,,Fuller's earth - hydrous aluminum silicates,PHARMAC Initiated,Hospital listing,Decision,Fuller's earth - hydrous aluminum silicates,/apptracker/s/application-public/a102P000008puMI,Various
a0R2P000000MSlJUAW,Fusidic acid injection,A-01538,Fucidin,Fusidic acid injection,PHARMAC Initiated,Hospital listing,Decision,Fusidic acid injection (Fucidin),/apptracker/s/application-public/a102P000008pugC,Infections - Agents for Systemic Use
a0R2P000000LmfiUAC,Gabapentin,A-00253,Arrow-Gabapentin,Gabapentin,PHARMAC Initiated,Removal of Special Authority,Decision,Gabapentin (Arrow-Gabapentin),/apptracker/s/application-public/a102P000008ptoh,Nervous System
a0R2P000000MSlTUAW,Ganciclovir capsule,A-01539,Cymevene,Ganciclovir capsule,PHARMAC Initiated,Hospital listing,Decision,Ganciclovir capsule (Cymevene),/apptracker/s/application-public/a102P000008puDr,Infections - Agents for Systemic Use
a0R2P000000MwSQUA0,Ganirelix,A-01540,Orgalutran,Ganirelix,PHARMAC Initiated,Hospital listing,Decision,Ganirelix (Orgalutran),/apptracker/s/application-public/a102P000008pu3N,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MWAoUAO,Gatifloxacin,A-01541,Tequin,Gatifloxacin,PHARMAC Initiated,Hospital listing,Decision,Gatifloxacin (Tequin),/apptracker/s/application-public/a102P000008ptyD,Infections - Agents for Systemic Use
a0R2P000000LmWkUAK,"Gemcitabine hydrochloride, Vinorelbine",A-00914,"Gemcitabine Ebewe,Vinorelbine Ebewe","Gemcitabine hydrochloride, Vinorelbine",PHARMAC Initiated,Relapsed Hodgkin's disease,Decision,"Gemcitabine hydrochloride, Vinorelbine (Gemcitabine Ebewe,Vinorelbine Ebewe)",/apptracker/s/application-public/a102P000008ptzY,Oncology Agents and Immunosuppressants
a0R2P000000LmhtUAC,"Gemcitabine hydrochloride, Vinorelbine",A-00916,"Gemcitabine Ebewe,Vinorelbine Ebewe","Gemcitabine hydrochloride, Vinorelbine",PHARMAC Initiated,Relapsed T-cell lymphoma,Decision,"Gemcitabine hydrochloride, Vinorelbine (Gemcitabine Ebewe,Vinorelbine Ebewe)",/apptracker/s/application-public/a102P000008puEV,Oncology Agents and Immunosuppressants
a0R2P000000gXA9UAM,GLP-1 agonists with proven CV benefit,A-00793,,GLP-1 agonists with proven CV benefit,PHARMAC Initiated,Diabetes with established and/or high risk cardiovascular disease,Decision,GLP-1 agonists with proven CV benefit,/apptracker/s/application-public/a102P000008pu0Y,Alimentary Tract and Metabolism
a0R2P000000MTX1UAO,"Glucose injections: 25%, 1000 ml; and 5%, 10 ml",A-01543,,"Glucose injections: 25%, 1000 ml; and 5%, 10 ml",PHARMAC Initiated,Hospital listing,Decision,"Glucose injections: 25%, 1000 ml; and 5%, 10 ml",/apptracker/s/application-public/a102P000008puDp,Blood and Blood Forming Organs
a0R2P000000MTWwUAO,"Glucose prefilled syringe (50%, 50ml)",A-01542,,"Glucose prefilled syringe (50%, 50ml)",PHARMAC Initiated,Hospital listing,Decision,"Glucose prefilled syringe (50%, 50ml)",/apptracker/s/application-public/a102P000008puH6,Blood and Blood Forming Organs
a0ROZ0000002dzl2AA,Gluten free foods review,A-00837,,Gluten free foods review,PHARMAC Initiated,Coeliac disease,Decision,Gluten free foods review,/apptracker/s/application-public/a102P000008puDz,Special Foods
a0R2P000000LmcUUAS,Glycopyrronium inhaler,A-00446,Seebri Breezhaler,Glycopyrronium inhaler,PHARMAC Initiated,Removal of all restrictions except having COPD diagnosed using spirometry,Decision,Glycopyrronium inhaler (Seebri Breezhaler),/apptracker/s/application-public/a102P000008puc6,Respiratory System and Allergies
a0ROZ000003dp2X2AQ,Granisetron injection,A-00490,Kytril,Granisetron injection,Pharmac Initiated,Post operative and chemotherapy induced nausea and vomiting,Decision,Granisetron injection (Kytril),/apptracker/s/application-public/a102P000008puMG,Nervous System
a0R2P000000MTXLUA4,Guanethidine Sulfate,A-00019,Ismelin,Guanethidine Sulfate,PHARMAC Initiated,Hospital listing,Decision,Guanethidine Sulfate (Ismelin),/apptracker/s/application-public/a102P000008puTO,Cardiovascular System
a0R2P000000WlnnUAC,Heparinoid cream 0.3%,A-01383,,Heparinoid cream 0.3%,PHARMAC Initiated,"Bruising, inflammation and discomfort following arteriovenous fistula surgeries and cannulation",Decision,Heparinoid cream 0.3%,/apptracker/s/application-public/a102P000008pube,Dermatologicals
a0R2P000000LmiZUAS,High Fat low carbohydrate formula - Heparon Junior,A-01281,Heparon Junior,High Fat low carbohydrate formula - Heparon Junior,PHARMAC Initiated,Liver disease,Decision,High Fat low carbohydrate formula - Heparon Junior (Heparon Junior),/apptracker/s/application-public/a102P000008puEp,Special Foods
a0R2P000000MwRyUAK,Homatropine Hydrobromide,A-00023,Isopto Homatropine,Homatropine Hydrobromide,PHARMAC Initiated,Hospital listing,Decision,Homatropine Hydrobromide (Isopto Homatropine),/apptracker/s/application-public/a102P000008ptxa,Sensory Organs
a0R2P000000LmiAUAS,"hydrochloride with fentanyl, inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag",A-01452,,"Bupivacaine hydrochloride with fentanyl, inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag",PHARMAC Initiated,Hospital listing,Decision,"Bupivacaine hydrochloride with fentanyl, inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag",/apptracker/s/application-public/a102P000008puEY,Nervous System
a0R2P000000MTXQUA4,Hydrochlorothiazide tablets,A-00024,,Hydrochlorothiazide tablets,PHARMAC Initiated,Hospital listing,Decision,Hydrochlorothiazide tablets,/apptracker/s/application-public/a102P000008ptpe,Cardiovascular System
a0R2P000000MTXpUAO,Hydrocortisone butyrate with chlorquinaldol,A-00028,,Hydrocortisone butyrate with chlorquinaldol,PHARMAC Initiated,Hospital listing,Decision,Hydrocortisone butyrate with chlorquinaldol,/apptracker/s/application-public/a102P000008puJx,Dermatologicals
a0ROZ00000754F32AI,Hydrocortisone cream 0.5%,A-00026,,Hydrocortisone cream 0.5%,Pharmac Initiated,Facial dermatitis,Decision,Hydrocortisone cream 0.5%,/apptracker/s/application-public/a102P000008pua8,Dermatologicals
a0R2P000000MTXuUAO,"Hydrocortisone with miconazole, cream 0.5% with miconazole nitrate 2%",A-00029,,"Hydrocortisone with miconazole, cream 0.5% with miconazole nitrate 2%",PHARMAC Initiated,Hospital listing,Decision,"Hydrocortisone with miconazole, cream 0.5% with miconazole nitrate 2%",/apptracker/s/application-public/a102P000008ptxd,Dermatologicals
a0R2P000000MTXzUAO,Hydrogen peroxide soln 20 vol (6%),A-00030,,Hydrogen peroxide soln 20 vol (6%),PHARMAC Initiated,Hospital listing,Decision,Hydrogen peroxide soln 20 vol (6%),/apptracker/s/application-public/a102P000008pu2j,Dermatologicals
a0R2P000000MTbwUAG,Hydroxyethyl starch 200/0.5,A-00031,"Starquin 10%,Starquin 200 6%",Hydroxyethyl starch 200/0.5,PHARMAC Initiated,Hospital listing,Decision,"Hydroxyethyl starch 200/0.5 (Starquin 10%,Starquin 200 6%)",/apptracker/s/application-public/a102P000008puYH,Blood and Blood Forming Organs
a0R2P000000MwSNUA0,"Hypromellose eye drops, 0.3% and 2%",A-00032,Tears Naturale,"Hypromellose eye drops, 0.3% and 2%",PHARMAC Initiated,Hospital listing,Decision,"Hypromellose eye drops, 0.3% and 2% (Tears Naturale)",/apptracker/s/application-public/a102P000008pu2F,Sensory Organs
a0R2P000000MTcGUAW,Hypromellose sodium oral gel,A-00033,,Hypromellose sodium oral gel,PHARMAC Initiated,Hospital listing,Decision,Hypromellose sodium oral gel,/apptracker/s/application-public/a102P000008ptol,Alimentary Tract and Metabolism
a0R2P000000MUCuUAO,Ibuprofen 200mg with codeine phosphate 12.8mg,A-00035,Nurofen Plus,Ibuprofen 200mg with codeine phosphate 12.8mg,PHARMAC Initiated,Hospital listing,Decision,Ibuprofen 200mg with codeine phosphate 12.8mg (Nurofen Plus),/apptracker/s/application-public/a102P000008ptxr,Nervous System
a0R2P000000MUCpUAO,Ibuprofen lysine injection,A-00034,Imbun [S.29],Ibuprofen lysine injection,PHARMAC Initiated,Hospital listing,Decision,Ibuprofen lysine injection (Imbun [S.29]),/apptracker/s/application-public/a102P000008puUf,Musculoskeletal System
a0R2P000000LmbGUAS,Imiquimod,A-00251,Aldara,Imiquimod,PHARMAC Initiated,Removal of Special Authority,Decision,Imiquimod (Aldara),/apptracker/s/application-public/a102P000008puSd,Dermatologicals
a0ROZ00000085CF2AY,Insulin glargine,A-00934,Lantus,Insulin glargine,PHARMAC Initiated,Widening access for all type 1 diabetes and cystic fibrosis related patients,Decision,Insulin glargine (Lantus),/apptracker/s/application-public/a102P000008puhD,Alimentary Tract and Metabolism
a0R2P000000LmjgUAC,Insulin pump (including consumables),A-01354,,Insulin pump (including consumables),PHARMAC Initiated,Cystic fibrosis-related diabetes,Decision,Insulin pump (including consumables),/apptracker/s/application-public/a102P000008pufR,Alimentary Tract and Metabolism
a0R2P000000Lmm8UAC,Insulin pump (including consumables),A-01044,"Animas 2020, Comfort Shot, Comfort, Inset II, Inset 30, IR2020, Paradigim Cartridge 1.8, Paradigim Cartridge 3.0",Insulin pump (including consumables),PHARMAC Initiated,"Diabetes - type 1, specific subgroups (incl brittle w severe hypoglycaemia)",Decision,"Insulin pump (including consumables) (Animas 2020, Comfort Shot, Comfort, Inset II, Inset 30, IR2020, Paradigim Cartridge 1.8, Paradigim Cartridge 3.0)",/apptracker/s/application-public/a102P000008puid,Alimentary Tract and Metabolism
a0R2P000000TW8vUAG,Insulin pump (including consumables),A-00043,,Insulin pump (including consumables),PHARMAC Initiated,Diabetes during pregnancy,Options Compared,Insulin pump (including consumables),/apptracker/s/application-public/a102P000008puM6,Alimentary Tract and Metabolism
a0R2P000000MUDEUA4,Ipecacuanha,A-00051,,Ipecacuanha,PHARMAC Initiated,Hospital listing,Decision,Ipecacuanha,/apptracker/s/application-public/a102P000008pu51,Various
a0R2P000000MUDJUA4,Irbesartan,A-00052,Karvea [S.29],Irbesartan,PHARMAC Initiated,Hospital listing,Decision,Irbesartan (Karvea [S.29]),/apptracker/s/application-public/a102P000008pu08,Cardiovascular System
a0R2P000000LmmyUAC,Isotretinoin,A-00257,Oratane,Isotretinoin,PHARMAC Initiated,"Widening of access, including removal of trial of other agents",Decision,Isotretinoin (Oratane),/apptracker/s/application-public/a102P000008pu0d,Dermatologicals
a0ROZ0000007feL2AQ,Isotretinoin,A-00492,"Isotrex,Oratane",Isotretinoin,PHARMAC Initiated,Low dose (5 mg) isotretinoin for treatment of acne,Decision,"Isotretinoin (Isotrex,Oratane)",/apptracker/s/application-public/a102P000008pudk,Dermatologicals
a0R2P000000MUDOUA4,Isotretinoin gel,A-00053,Isotrex,Isotretinoin gel,PHARMAC Initiated,Hospital listing,Decision,Isotretinoin gel (Isotrex),/apptracker/s/application-public/a102P000008ptuf,Dermatologicals
a0R2P000000SQBAUA4,Ivabradine,A-01250 A-04671,,Ivabradine,"Pharmac Initiated, Consumer",Inappropriate sinus tachycardia (IST),Seeking Clinical Advice,Ivabradine,/apptracker/s/application-public/a102P000008ptpB,Cardiovascular System
a0R2P000000MUDdUAO,Ivermectin tablet 6 mg,A-00054,,Ivermectin tablet 6 mg,PHARMAC Initiated,Hospital listing,Decision,Ivermectin tablet 6 mg,/apptracker/s/application-public/a102P000008ptpZ,Infections - Agents for Systemic Use
a0R2P000000MUDiUAO,"Ketamine inj 1 mg per ml, 10 ml syringe",A-00056,,"Ketamine inj 1 mg per ml, 10 ml syringe",PHARMAC Initiated,Hospital listing,Decision,"Ketamine inj 1 mg per ml, 10 ml syringe",/apptracker/s/application-public/a102P000008puP7,Nervous System
a0R2P000000MUDYUA4,Ketoconazole cream,A-00057,,Ketoconazole cream,PHARMAC Initiated,Hospital listing,Decision,Ketoconazole cream,/apptracker/s/application-public/a102P000008ptpd,Dermatologicals
a0R2P000000MUDTUA4,Ketoconazole shampoo 1%,A-00058,,Ketoconazole shampoo 1%,PHARMAC Initiated,Hospital listing,Decision,Ketoconazole shampoo 1%,/apptracker/s/application-public/a102P000008ptsv,Dermatologicals
a0R2P000000PXX2UAO,Labetalol oral liquid,A-00060,,Labetalol oral liquid,PHARMAC Initiated,Hospital listing,Decision,Labetalol oral liquid,/apptracker/s/application-public/a102P000008puiw,Cardiovascular System
a0R2P000000N6iVUAS,Lacosamide,A-00974,Vimpat,Lacosamide,PHARMAC Initiated,Epilepsy (last-line treatment),Decision,Lacosamide (Vimpat),/apptracker/s/application-public/a102P000008ptsu,Nervous System
a0R2P000000MUDnUAO,Lamotrigine tab dispersible 200 mg,A-00061,,Lamotrigine tab dispersible 200 mg,PHARMAC Initiated,Hospital listing,Decision,Lamotrigine tab dispersible 200 mg,/apptracker/s/application-public/a102P000008ptsh,Nervous System
a0ROZ0000006zdZ2AQ,Latex oral dams,A-01347,,Latex oral dams,PHARMAC Initiated,Prevention of sexually transmitted infections,Options Compared,Latex oral dams,/apptracker/s/application-public/a102P000008ptz7,Genito-Urinary System
a0R2P000000MVhcUAG,Lavender oil,A-01382,Home Essentials,Lavender oil,PHARMAC Initiated,Hospital listing,Decision,Lavender oil (Home Essentials),/apptracker/s/application-public/a102P000008pu3y,Extemporaneous Compounds
a0R2P000000LmnnUAC,Leflunomide,A-00561,Arava,Leflunomide,PHARMAC Initiated,Widening of access (removal of Special Authority),Decision,Leflunomide (Arava),/apptracker/s/application-public/a102P000008pu0o,Musculoskeletal System
a0ROZ0000004hZT2AY,Left atrial appendage occlusion for prevention of stroke,A-00633,,Left atrial appendage occlusion for prevention of stroke,PHARMAC Initiated,Stroke prophlaxis,Decision,Left atrial appendage occlusion for prevention of stroke,/apptracker/s/application-public/a102P000008puUk,Cardiovascular System
a0ROZ000004EwjP2AS,Lenalidomide,A-00503,Revlimid,Lenalidomide,Pharmac Initiated,"Multiple myeloma, first line, grade 3 or greater pre-existing neuropathy",Decision,Lenalidomide (Revlimid),/apptracker/s/application-public/a102P000008ptoq,Oncology Agents and Immunosuppressants
a0R2P000000MUekUAG,Lenograstim,A-00062,"Granocyte 13,Granocyte 34",Lenograstim,PHARMAC Initiated,Hospital listing,Decision,"Lenograstim (Granocyte 13,Granocyte 34)",/apptracker/s/application-public/a102P000008puFY,Blood and Blood Forming Organs
a0R2P000000MUepUAG,Lepirudin,A-00063,,Lepirudin,PHARMAC Initiated,Hospital listing,Decision,Lepirudin,/apptracker/s/application-public/a102P000008pufl,Blood and Blood Forming Organs
a0R2P000000LmnzUAC,Letrozole,A-01164,Femara,Letrozole,PHARMAC Initiated,First line treatment for new patients with early breast cancer,Decision,Letrozole (Femara),/apptracker/s/application-public/a102P000008pu12,Oncology Agents and Immunosuppressants
a0R2P000000LmUEUA0,Letrozole,A-01160,Femara,Letrozole,PHARMAC Initiated,Breast cancer in post-menopausal women,Decision,Letrozole (Femara),/apptracker/s/application-public/a102P000008puNG,Oncology Agents and Immunosuppressants
a0R2P000000MwS4UAK,"Leuprorelin inj 5 mg per ml, 2.8 ml",A-00064,Lucrin,"Leuprorelin inj 5 mg per ml, 2.8 ml",PHARMAC Initiated,Hospital listing,Decision,"Leuprorelin inj 5 mg per ml, 2.8 ml (Lucrin)",/apptracker/s/application-public/a102P000008puT8,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ000000W3xJ2AS,Levamisole,A-00065 A-00066,"Ergamisole [S.29],Levamisole 50mg BASE",Levamisole,"PHARMAC Initiated, Clinician","Nephrotic syndrome, frequently relapsing, steroid sensitive",Decision,"Levamisole (Ergamisole [S.29],Levamisole 50mg BASE)",/apptracker/s/application-public/a102P000008ptpG,Oncology Agents and Immunosuppressants
a0R2P000000Ma07UAC,Levetiracetam: tablet 1000 mg,A-00067,Keppra,Levetiracetam: tablet 1000 mg,PHARMAC Initiated,Hospital listing,Decision,Levetiracetam: tablet 1000 mg (Keppra),/apptracker/s/application-public/a102P000008ptrK,Nervous System
a0R2P000000MV1VUAW,Levothyroxine injection,A-00068,,Levothyroxine injection,PHARMAC Initiated,Hospital listing,Decision,Levothyroxine injection,/apptracker/s/application-public/a102P000008pua7,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MUE2UAO,Lidocaine [lignocaine] hydrochloride injections of unusual size,A-00072,,Lidocaine [lignocaine] hydrochloride injections of unusual size,PHARMAC Initiated,Hospital listing,Decision,Lidocaine [lignocaine] hydrochloride injections of unusual size,/apptracker/s/application-public/a102P000008puDG,Nervous System
a0R2P000000MUE7UAO,Lidocaine [lignocaine] hydrochloride ointment,A-00073,,Lidocaine [lignocaine] hydrochloride ointment,PHARMAC Initiated,Hospital listing,Decision,Lidocaine [lignocaine] hydrochloride ointment,/apptracker/s/application-public/a102P000008pubJ,Nervous System
a0R2P000000MUDxUAO,Lidocaine [lignocaine] hydrochloride patches,A-00070,,Lidocaine [lignocaine] hydrochloride patches,PHARMAC Initiated,Hospital listing,Decision,Lidocaine [lignocaine] hydrochloride patches,/apptracker/s/application-public/a102P000008puTV,Nervous System
a0R2P000000MUECUA4,Lidocaine [lignocaine] lozenge with cetrimide,A-00074,,Lidocaine [lignocaine] lozenge with cetrimide,PHARMAC Initiated,Hospital listing,Decision,Lidocaine [lignocaine] lozenge with cetrimide,/apptracker/s/application-public/a102P000008ptsC,Nervous System
a0R2P000000TW91UAG,Lidocaine [lignocaine] with adrenaline and tetracaine (4%; 0.1%; 0.5%),A-00416,,Lidocaine [lignocaine] with adrenaline and tetracaine (4%; 0.1%; 0.5%),PHARMAC Initiated,Wound repair (not restricted by age),Options Compared,Lidocaine [lignocaine] with adrenaline and tetracaine (4%; 0.1%; 0.5%),/apptracker/s/application-public/a102P000008puhU,Nervous System
a0R2P000000MUEHUA4,Lidocaine [lignocaine] with glucose,A-00075,,Lidocaine [lignocaine] with glucose,PHARMAC Initiated,Hospital listing,Decision,Lidocaine [lignocaine] with glucose,/apptracker/s/application-public/a102P000008ptuq,Cardiovascular System
a0R2P000000anY8UAI,Lidocaine [Lignocaine] With Prilocaine,A-00374,Emla,Lidocaine [Lignocaine] With Prilocaine,PHARMAC Initiated,Removal of Special Authority,Decision,Lidocaine [Lignocaine] With Prilocaine (Emla),/apptracker/s/application-public/a102P000008puKL,Nervous System
a0R2P000000MUf9UAG,Linezolid tablet 250 mg,A-00076,Zyvox,Linezolid tablet 250 mg,PHARMAC Initiated,Hospital listing,Decision,Linezolid tablet 250 mg (Zyvox),/apptracker/s/application-public/a102P000008ptsi,Infections - Agents for Systemic Use
a0R2P000000OWQkUAO,Liothyronine tablet 20 mg,A-00077,,Liothyronine tablet 20 mg,PHARMAC Initiated,Hospital listing,Decision,Liothyronine tablet 20 mg,/apptracker/s/application-public/a102P000008puSh,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmfLUAS,Losartan,A-00139,,Losartan,PHARMAC Initiated,"Proteinuria with type 2 diabetes, intolerant of ACE inhibitors",Decision,Losartan,/apptracker/s/application-public/a102P000008pu4M,Cardiovascular System
a0R2P000000MUvcUAG,Low electrolyte oral feed 2 kcal/ml (Renilon 4.0),A-00078,Renilon 4.0,Low electrolyte oral feed 2 kcal/ml (Renilon 4.0),PHARMAC Initiated,Hospital listing,Decision,Low electrolyte oral feed 2 kcal/ml (Renilon 4.0) (Renilon 4.0),/apptracker/s/application-public/a102P000008pttq,Special Foods
a0R2P000000LmUsUAK,Low molecular weight heparin (widening of access),A-00866,CLEXANE,Low molecular weight heparin (widening of access),PHARMAC Initiated,Prevention of venous thrombosis,Decision,Low molecular weight heparin (widening of access) (CLEXANE),/apptracker/s/application-public/a102P000008puOS,Blood and Blood Forming Organs
a0R2P000000MUfEUAW,Lymecycline,A-00079,Tetralysal 300,Lymecycline,PHARMAC Initiated,Hospital listing,Decision,Lymecycline (Tetralysal 300),/apptracker/s/application-public/a102P000008puRH,Infections - Agents for Systemic Use
a0R2P000000OapUUAS,"m bicarbonate 25.32 mg, sodium chloride 22 mg and sodium sulphate 84.81 mg per g",A-00080,,"Glycoprep - Powder for oral soln 856.92 mg with potassium chloride 112.5 mg, sodium bicarbonate 25.32 mg, sodium chloride 22 mg and sodium sulphate 84.81 mg per g",PHARMAC Initiated,Hospital listing,Decision,"Glycoprep - Powder for oral soln 856.92 mg with potassium chloride 112.5 mg, sodium bicarbonate 25.32 mg, sodium chloride 22 mg and sodium sulphate 84.81 mg per g",/apptracker/s/application-public/a102P000008ptve,Alimentary Tract and Metabolism
a0R2P000000OUU0UAO,Magnesium carbonate,A-00081,,Magnesium carbonate,PHARMAC Initiated,Hospital listing,Decision,Magnesium carbonate,/apptracker/s/application-public/a102P000008puj1,Various
a0R2P000000MWAuUAO,"Magnesium chloride infusion - 96 mg per ml, 5 ml",A-00083,,"Magnesium chloride infusion - 96 mg per ml, 5 ml",PHARMAC Initiated,Hospital listing,Decision,"Magnesium chloride infusion - 96 mg per ml, 5 ml",/apptracker/s/application-public/a102P000008pu4C,Blood and Blood Forming Organs
a0R2P000000MOvkUAG,Magnesium sulphate paste,A-01381,,Magnesium sulphate paste,PHARMAC Initiated,Hospital listing,Decision,Magnesium sulphate paste,/apptracker/s/application-public/a102P000008puXo,Dermatologicals
a0R2P000000MUvhUAG,Malathion with permethrin,A-00084,,Malathion with permethrin,PHARMAC Initiated,Hospital listing,Decision,Malathion with permethrin,/apptracker/s/application-public/a102P000008pu0K,Infections - Agents for Systemic Use
a0R2P000000MUvmUAG,Mebendazole chocolate squares,A-00085,Combantrin-1,Mebendazole chocolate squares,PHARMAC Initiated,Hospital listing,Decision,Mebendazole chocolate squares (Combantrin-1),/apptracker/s/application-public/a102P000008puG7,Infections - Agents for Systemic Use
a0R2P000000MUvrUAG,Meclozine hydrochloride,A-00086,Sea Legs,Meclozine hydrochloride,PHARMAC Initiated,Hospital listing,Decision,Meclozine hydrochloride (Sea Legs),/apptracker/s/application-public/a102P000008pttB,Nervous System
a0R2P000000OUYNUA4,Melaleuca oil,A-00087,,Melaleuca oil,PHARMAC Initiated,Hospital listing,Decision,Melaleuca oil,/apptracker/s/application-public/a102P000008puer,Infections - Agents for Systemic Use
a0R2P000000MUvwUAG,Menadiol phosphate,A-00088,,Menadiol phosphate,PHARMAC Initiated,Hospital listing,Decision,Menadiol phosphate,/apptracker/s/application-public/a102P000008pug6,Blood and Blood Forming Organs
a0R2P000000MwS5UAK,Menthol capsules,A-00089,,Menthol capsules,PHARMAC Initiated,Hospital listing,Decision,Menthol capsules,/apptracker/s/application-public/a102P000008puSe,Respiratory System and Allergies
a0R2P000000LmrBUAS,Methotrexate prefilled syringe,A-01162,,Methotrexate prefilled syringe,PHARMAC Initiated,"Antineoplastic chemotherapy, high dose therapy, psoriasis chemotherapy",Decision,Methotrexate prefilled syringe,/apptracker/s/application-public/a102P000008puIW,Oncology Agents and Immunosuppressants
a0R2P000000MUCzUAO,Methyl salicylate cream with menthol,A-00047,,Methyl salicylate cream with menthol,PHARMAC Initiated,Hospital listing,Decision,Methyl salicylate cream with menthol,/apptracker/s/application-public/a102P000008ptxG,Musculoskeletal System
a0R2P000000MUD4UAO,Methyl salicylate cream with menthol and eucalyptus,A-00049,,Methyl salicylate cream with menthol and eucalyptus,PHARMAC Initiated,Hospital listing,Decision,Methyl salicylate cream with menthol and eucalyptus,/apptracker/s/application-public/a102P000008ptpr,Musculoskeletal System
a0R2P000000MUwBUAW,Methylergometrine,A-00090,Hospira,Methylergometrine,PHARMAC Initiated,Hospital listing,Decision,Methylergometrine (Hospira),/apptracker/s/application-public/a102P000008puT6,Genito-Urinary System
a0R2P000000MUwGUAW,Methysergide Dimaleate,A-00091,Deseril,Methysergide Dimaleate,PHARMAC Initiated,Hospital listing,Decision,Methysergide Dimaleate (Deseril),/apptracker/s/application-public/a102P000008puUM,Nervous System
a0R2P000000MUwLUAW,Metoclopramide Hydrochloride suppositories,A-00092,Maxolon,Metoclopramide Hydrochloride suppositories,PHARMAC Initiated,Hospital listing,Decision,Metoclopramide Hydrochloride suppositories (Maxolon),/apptracker/s/application-public/a102P000008puDW,Nervous System
a0R2P000000OapjUAC,Metronidazole topical gel 0.5% and 1 g suppositories,A-00093,Flagyl,Metronidazole topical gel 0.5% and 1 g suppositories,PHARMAC Initiated,Hospital listing,Decision,Metronidazole topical gel 0.5% and 1 g suppositories (Flagyl),/apptracker/s/application-public/a102P000008puHZ,Infections - Agents for Systemic Use
a0R2P000000MV0hUAG,Miconazole nitrate 2% dusting powder and 2% spray powder,A-00094,Daktarin,Miconazole nitrate 2% dusting powder and 2% spray powder,PHARMAC Initiated,Hospital listing,Decision,Miconazole nitrate 2% dusting powder and 2% spray powder (Daktarin),/apptracker/s/application-public/a102P000008puaD,Infections - Agents for Systemic Use
a0R2P000000MV0mUAG,Miconazole nitrate with zinc ointment,A-00095,,Miconazole nitrate with zinc ointment,PHARMAC Initiated,Hospital listing,Decision,Miconazole nitrate with zinc ointment,/apptracker/s/application-public/a102P000008puJy,Infections - Agents for Systemic Use
a0ROZ00000085NV2AY,Midazolam injection,A-00038,,Midazolam injection,PHARMAC Initiated,Removal of Special Authority,Decision,Midazolam injection,/apptracker/s/application-public/a102P000008puQz,Nervous System
a0R2P000000LmpZUAS,Midodrine,A-00248,Gutron,Midodrine,PHARMAC Initiated,Widening access - move to first line,Decision,Midodrine (Gutron),/apptracker/s/application-public/a102P000008puBB,Cardiovascular System
a0R2P000000LmXSUA0,Minoxidil,A-00250,Loniten,Minoxidil,PHARMAC Initiated,Removal of Special Authority,Decision,Minoxidil (Loniten),/apptracker/s/application-public/a102P000008pu07,Cardiovascular System
a0ROZ000000964b2AA,Modafinil,A-00059,,Modafinil,PHARMAC Initiated,Narcolepsy - last-line treatment,Decision,Modafinil,/apptracker/s/application-public/a102P000008puiH,Nervous System
a0R2P000000MV1GUAW,"Morphine sulphate: inj 1 mg per ml, 30 ml syringe; and cap long-acting 200 mg",A-00096,,"Morphine sulphate: inj 1 mg per ml, 30 ml syringe; and cap long-acting 200 mg",PHARMAC Initiated,Hospital listing,Decision,"Morphine sulphate: inj 1 mg per ml, 30 ml syringe; and cap long-acting 200 mg",/apptracker/s/application-public/a102P000008puUF,Nervous System
a0R2P000000MV0wUAG,Mupirocin injection,A-00097,,Mupirocin injection,PHARMAC Initiated,Hospital listing,Decision,Mupirocin injection,/apptracker/s/application-public/a102P000008puUL,Infections - Agents for Systemic Use
a0R2P000000MV11UAG,Muromonab-CD3,A-00098,,Muromonab-CD3,PHARMAC Initiated,Hospital listing,Decision,Muromonab-CD3,/apptracker/s/application-public/a102P000008pty2,Oncology Agents and Immunosuppressants
a0R2P000000Lmm4UAC,Mycophenolate mofetil,A-00254,Cellcept,Mycophenolate mofetil,PHARMAC Initiated,Removal of Special Authority,Decision,Mycophenolate mofetil (Cellcept),/apptracker/s/application-public/a102P000008puic,Oncology Agents and Immunosuppressants
a0R2P000000MUwQUAW,"Naloxone hydrochloride, prefilled syringe, 400 mcg per ml, 2 ml",A-00099,Min-I-Jet,"Naloxone hydrochloride, prefilled syringe, 400 mcg per ml, 2 ml",PHARMAC Initiated,Hospital listing,Decision,"Naloxone hydrochloride, prefilled syringe, 400 mcg per ml, 2 ml (Min-I-Jet)",/apptracker/s/application-public/a102P000008ptx3,Various
a0ROZ000009J4cD2AS,Naltrexone hydrochloride,A-01353,,Naltrexone hydrochloride,Pharmac Initiated,Removal of Special Authority,Decision,Naltrexone hydrochloride,/apptracker/s/application-public/a102P000008puVE,Nervous System
a0ROZ00000AQknt2AD,Naltrexone hydrochloride,A-01395,,Naltrexone hydrochloride,Pharmac Initiated,Opioid-induced constipation and treatment-resistant cholestasis,Options Compared,Naltrexone hydrochloride,/apptracker/s/application-public/a102P000008pu3T,Alimentary Tract and Metabolism
a0R2P000000MwSJUA0,Nandrolone decanoate,A-00100,Deca-Durabolin Orgaject,Nandrolone decanoate,PHARMAC Initiated,Hospital listing,Decision,Nandrolone decanoate (Deca-Durabolin Orgaject),/apptracker/s/application-public/a102P000008pukZ,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MwSTUA0,Naphazoline hydrochloride with antazoline phosphate,A-00101,,Naphazoline hydrochloride with antazoline phosphate,PHARMAC Initiated,Hospital listing,Decision,Naphazoline hydrochloride with antazoline phosphate,/apptracker/s/application-public/a102P000008puJZ,Sensory Organs
a0ROZ000000VsQn2AK,Naproxen oral liquid,A-01057,Naprosyn,Naproxen oral liquid,PHARMAC Initiated,Inflammation and pain,Decision,Naproxen oral liquid (Naprosyn),/apptracker/s/application-public/a102P000008puMg,Musculoskeletal System
a0R2P000000MOd1UAG,Naproxen sodium,A-01380,,Naproxen sodium,PHARMAC Initiated,Hospital listing,Decision,Naproxen sodium,/apptracker/s/application-public/a102P000008ptyG,Musculoskeletal System
a0ROZ00000096pN2AQ,Narrow-width condoms,A-01000,,Narrow-width condoms,PHARMAC Initiated,Contraception,Decision,Narrow-width condoms,/apptracker/s/application-public/a102P000008pu4o,Genito-Urinary System
a0R2P000000MOUxUAO,"nate 250 mg, with sodium bicarbonate 133.5 mg, calcium carbonate 80 mg - tablets",A-01370,,"Sodium alginate 250 mg, with sodium bicarbonate 133.5 mg, calcium carbonate 80 mg - tablets",PHARMAC Initiated,Heartburn and GERD,Decision,"Sodium alginate 250 mg, with sodium bicarbonate 133.5 mg, calcium carbonate 80 mg - tablets",/apptracker/s/application-public/a102P000008puAu,Alimentary Tract and Metabolism
a0R2P000000MV2JUAW,Neomycin,A-00102,Douglas,Neomycin,PHARMAC Initiated,Hospital listing,Decision,Neomycin (Douglas),/apptracker/s/application-public/a102P000008pukW,Infections - Agents for Systemic Use
a0R2P000000MV2YUAW,Netilmicin,A-00104,Netromycin,Netilmicin,PHARMAC Initiated,Hospital listing,Decision,Netilmicin (Netromycin),/apptracker/s/application-public/a102P000008pu1F,Infections - Agents for Systemic Use
a0R2P000000LmqJUAS,Nicardipine hydrochloride,A-00105 A-00106,Any,Nicardipine hydrochloride,"PHARMAC Initiated, Clinician","Hypertensive Intensive Care Unit patients or cardiac surgery with cardiopulmonary bypass, paediatric",Decision,Nicardipine hydrochloride (Any),/apptracker/s/application-public/a102P000008puDA,Cardiovascular System
a0R2P000000LmiPUAS,Nicorandil,A-00249,Ikorel,Nicorandil,PHARMAC Initiated,Removal of Special Authority,Decision,Nicorandil (Ikorel),/apptracker/s/application-public/a102P000008puDg,Cardiovascular System
a0R2P000000MV7nUAG,Nicotine nasal spray,A-00109,,Nicotine nasal spray,PHARMAC Initiated,Hospital listing,Decision,Nicotine nasal spray,/apptracker/s/application-public/a102P000008puUN,Nervous System
a0R2P000000MV7iUAG,"Nicotine patch 16 hours; 5, 10, and 15 mg",A-00107,,"Nicotine patch 16 hours; 5, 10, and 15 mg",PHARMAC Initiated,Hospital listing,Decision,"Nicotine patch 16 hours; 5, 10, and 15 mg",/apptracker/s/application-public/a102P000008ptsP,Nervous System
a0ROZ000007546z2AA,Nicotine sublingual tablet,A-00108,,Nicotine sublingual tablet,Pharmac Initiated,Hospital listing,Decision,Nicotine sublingual tablet,/apptracker/s/application-public/a102P000008pu7Z,Nervous System
a0R2P000000LmeTUAS,Nilotinib,A-01080,Tasigna,Nilotinib,PHARMAC Initiated,Chronic myeloid leukaemia (CML) - intolerant or resistant to imatinib andor dasatinib (2nd/3rd-line),Decision,Nilotinib (Tasigna),/apptracker/s/application-public/a102P000008ptt4,Oncology Agents and Immunosuppressants
a0R2P000000MV7sUAG,Nonoxynol-9,A-00110,Gynol Ii,Nonoxynol-9,PHARMAC Initiated,Hospital listing,Decision,Nonoxynol-9 (Gynol Ii),/apptracker/s/application-public/a102P000008ptrW,Genito-Urinary System
a0R2P000000MV9AUAW,nteral feed 1.5 kcal/ml - Tentrini Energy RTH and Tentrini Energy Multifibre RTH,A-00122,Tentrini Energy RTH and Tentrini Energy Multifibre RTH,Paediatric enteral feed 1.5 kcal/ml - Tentrini Energy RTH and Tentrini Energy Multifibre RTH,PHARMAC Initiated,Hospital listing,Decision,Paediatric enteral feed 1.5 kcal/ml - Tentrini Energy RTH and Tentrini Energy Multifibre RTH (Tentrini Energy RTH and Tentrini Energy Multifibre RTH),/apptracker/s/application-public/a102P000008pu4f,Special Foods
a0R2P000000LmbiUAC,Octreotide,A-00899,,Octreotide,PHARMAC Initiated,Management of nausea and vomiting for malignant bowel obstruction,Decision,Octreotide,/apptracker/s/application-public/a102P000008pu6k,Oncology Agents and Immunosuppressants
a0R2P000000MwS8UAK,Oestradiol pessaries,A-00111,Vagifem,Oestradiol pessaries,PHARMAC Initiated,Hospital listing,Decision,Oestradiol pessaries (Vagifem),/apptracker/s/application-public/a102P000008ptt9,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MV8MUAW,Oily cream,A-00112,,Oily cream,PHARMAC Initiated,Hospital listing,Decision,Oily cream,/apptracker/s/application-public/a102P000008puC5,Dermatologicals
a0R2P000000MV8bUAG,"Ointment base, greasy",A-00113,,"Ointment base, greasy",PHARMAC Initiated,Hospital listing,Decision,"Ointment base, greasy",/apptracker/s/application-public/a102P000008ptsY,Extemporaneous Compounds
a0R2P000000MOcrUAG,"Omeprazole, amoxycillin, and clarithromycin combination pack",A-01379,,"Omeprazole, amoxycillin, and clarithromycin combination pack",PHARMAC Initiated,Hospital listing,Decision,"Omeprazole, amoxycillin, and clarithromycin combination pack",/apptracker/s/application-public/a102P000008pu6u,Alimentary Tract and Metabolism
a0R2P000000MwSBUA0,Opiate squill,A-00114,,Opiate squill,PHARMAC Initiated,Hospital listing,Decision,Opiate squill,/apptracker/s/application-public/a102P000008pu4O,Respiratory System and Allergies
a0R2P000000MV9FUAW,Oral feed - Oral Impact,A-00118,Oral Impact,Oral feed - Oral Impact,PHARMAC Initiated,Hospital listing,Decision,Oral feed - Oral Impact (Oral Impact),/apptracker/s/application-public/a102P000008ptsQ,Special Foods
a0R2P000000MTXVUA4,Oral Feed 1.6kcal/ml with fibre - Forticare,A-00022,Forticare,Oral Feed 1.6kcal/ml with fibre - Forticare,PHARMAC Initiated,Hospital listing,Decision,Oral Feed 1.6kcal/ml with fibre - Forticare (Forticare),/apptracker/s/application-public/a102P000008puZ3,Special Foods
a0R2P000000MV8qUAG,Oral Feed Powder - Generaid Plus,A-00117,Generaid Plus,Oral Feed Powder - Generaid Plus,PHARMAC Initiated,Hospital listing,Decision,Oral Feed Powder - Generaid Plus (Generaid Plus),/apptracker/s/application-public/a102P000008puaG,Special Foods
a0R2P000000OWREUA4,Oral feeds: Resource Arginaid and Resource Arginaid Extra,A-00116,Resource Arginaid and Resource Arginaid Extra,Oral feeds: Resource Arginaid and Resource Arginaid Extra,PHARMAC Initiated,Hospital listing,Decision,Oral feeds: Resource Arginaid and Resource Arginaid Extra (Resource Arginaid and Resource Arginaid Extra),/apptracker/s/application-public/a102P000008ptun,Special Foods
a0R2P000000MOcmUAG,Orlistat,A-01376,Xenical,Orlistat,PHARMAC Initiated,Obesity,Decision,Orlistat (Xenical),/apptracker/s/application-public/a102P000008puCo,Alimentary Tract and Metabolism
a0R2P000000MVBaUAO,Ornipressin,A-00119,Por 8 Ferring,Ornipressin,PHARMAC Initiated,Hospital listing,Decision,Ornipressin (Por 8 Ferring),/apptracker/s/application-public/a102P000008ptqd,Blood and Blood Forming Organs
a0R2P000000MVBfUAO,Orphenadrine citrate injection,A-00120,Norflex,Orphenadrine citrate injection,PHARMAC Initiated,Hospital listing,Decision,Orphenadrine citrate injection (Norflex),/apptracker/s/application-public/a102P000008puFi,Musculoskeletal System
a0ROZ000004CQm12AG,Oseltamivir,A-01325,,Oseltamivir,Pharmac Initiated,Influenza prevention,Decision,Oseltamivir,/apptracker/s/application-public/a102P000008puXU,Infections - Agents for Systemic Use
a0R2P000000LmePUAS,Oseltamivir,A-01349,,Oseltamivir,PHARMAC Initiated,Influenza,Decision,Oseltamivir,/apptracker/s/application-public/a102P000008pttS,Infections - Agents for Systemic Use
a0R2P000000MV95UAG,Paediatric enteral feed 1 kcal/ml - Tentrini RTH,A-00121,Tentrini RTH,Paediatric enteral feed 1 kcal/ml - Tentrini RTH,PHARMAC Initiated,Hospital listing,Decision,Paediatric enteral feed 1 kcal/ml - Tentrini RTH (Tentrini RTH),/apptracker/s/application-public/a102P000008ptwp,Special Foods
a0R2P000000MVBkUAO,"Paracetamol - tab soluble 250 mg, and capsule 500 mg",A-00123,,"Paracetamol - tab soluble 250 mg, and capsule 500 mg",PHARMAC Initiated,Hospital listing,Decision,"Paracetamol - tab soluble 250 mg, and capsule 500 mg",/apptracker/s/application-public/a102P000008ptrx,Nervous System
a0R2P000000MVBzUAO,Paracetamol 500 mg with codeine 15 mg,A-00125,,Paracetamol 500 mg with codeine 15 mg,PHARMAC Initiated,Hospital listing,Decision,Paracetamol 500 mg with codeine 15 mg,/apptracker/s/application-public/a102P000008puJv,Nervous System
a0ROZ00000269Qr2AI,Paracetamol 500mg with codeine 30mg,A-00702,,Paracetamol 500mg with codeine 30mg,Pharmac Initiated,Pain,Decision,Paracetamol 500mg with codeine 30mg,/apptracker/s/application-public/a102P000008puP8,Nervous System
a0R2P000000MVBpUAO,Paracetamol with caffeine,A-00124,,Paracetamol with caffeine,PHARMAC Initiated,Hospital listing,Decision,Paracetamol with caffeine,/apptracker/s/application-public/a102P000008puTH,Nervous System
a0R2P000000MVCJUA4,Paraffin with retinol palmitate,A-00129,,Paraffin with retinol palmitate,PHARMAC Initiated,Hospital listing,Decision,Paraffin with retinol palmitate,/apptracker/s/application-public/a102P000008puRy,Dermatologicals
a0R2P000000LmddUAC,Peg-asparaginase,A-01064,,Peg-asparaginase,PHARMAC Initiated,Acute Lymphoblastic Leukaemia,Decision,Peg-asparaginase,/apptracker/s/application-public/a102P000008pu6g,Oncology Agents and Immunosuppressants
a0R2P000000MwS3UAK,Pegvisomant,A-00130,Somavert,Pegvisomant,PHARMAC Initiated,Hospital listing,Decision,Pegvisomant (Somavert),/apptracker/s/application-public/a102P000008puYG,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MOchUAG,Peppermint oil,A-01375,,Peppermint oil,PHARMAC Initiated,Irritable bowel syndrome,Decision,Peppermint oil,/apptracker/s/application-public/a102P000008pu4x,Alimentary Tract and Metabolism
a0R2P000000MOccUAG,Pergolide 0.05 mg,A-01374,,Pergolide 0.05 mg,PHARMAC Initiated,Parkinson's syndrome,Decision,Pergolide 0.05 mg,/apptracker/s/application-public/a102P000008puSu,Nervous System
a0R2P000000LmiaUAC,Perhexiline maleate,A-00247,Pexsig,Perhexiline maleate,PHARMAC Initiated,Removal of Special Authority,Decision,Perhexiline maleate (Pexsig),/apptracker/s/application-public/a102P000008puEq,Cardiovascular System
a0ROZ00000BQU0v2AH,Pertuzumab,A-00546,Perjeta,Pertuzumab,Pharmac Initiated,"Breast cancer; HER2 positive, metastatic, previously-treated",Decision,Pertuzumab (Perjeta),/apptracker/s/application-public/a102P000008ptr5,Oncology Agents and Immunosuppressants
a0R2P000000MVC4UAO,"Pethidine hydrochloride, inj 50 mg per ml, 1.5 ml ampoule",A-00131,Pethidine,"Pethidine hydrochloride, inj 50 mg per ml, 1.5 ml ampoule",PHARMAC Initiated,Hospital listing,Decision,"Pethidine hydrochloride, inj 50 mg per ml, 1.5 ml ampoule (Pethidine)",/apptracker/s/application-public/a102P000008puMV,Nervous System
a0R2P000000MVC9UAO,Phenobarbitone injection 20 mg in 0.5 ml,A-00132,,Phenobarbitone injection 20 mg in 0.5 ml,PHARMAC Initiated,Hospital listing,Decision,Phenobarbitone injection 20 mg in 0.5 ml,/apptracker/s/application-public/a102P000008puYM,Nervous System
a0R2P000000MwS7UAK,Phenylephrine hydrochloride with zinc sulphate,A-00133,,Phenylephrine hydrochloride with zinc sulphate,PHARMAC Initiated,Hospital listing,Decision,Phenylephrine hydrochloride with zinc sulphate,/apptracker/s/application-public/a102P000008puAt,Sensory Organs
a0R2P000000MwRxUAK,Pholcodine oral liquid 2 or 3 mg per ml,A-00134,Duro-Tuss Forte,Pholcodine oral liquid 2 or 3 mg per ml,PHARMAC Initiated,Hospital listing,Decision,Pholcodine oral liquid 2 or 3 mg per ml (Duro-Tuss Forte),/apptracker/s/application-public/a102P000008puQF,Respiratory System and Allergies
a0R2P000000MVCxUAO,Phytomenadione tablets,A-00135,Konakion,Phytomenadione tablets,PHARMAC Initiated,Hospital listing,Decision,Phytomenadione tablets (Konakion),/apptracker/s/application-public/a102P000008puLb,Blood and Blood Forming Organs
a0ROZ000000W4lF2AS,Pimozide,A-01373,,Pimozide,PHARMAC Initiated,Schizophrenia,Decision,Pimozide,/apptracker/s/application-public/a102P000008pu57,Nervous System
a0R2P000000LmUKUA0,Pioglitazone,A-01177,Actos,Pioglitazone,PHARMAC Initiated,Widening of access to include triple therapy and increasing HbA1c threshold,Decision,Pioglitazone (Actos),/apptracker/s/application-public/a102P000008puNH,Alimentary Tract and Metabolism
a0R2P000000MVCiUAO,Piperacillin,A-00138,Pipril,Piperacillin,PHARMAC Initiated,Hospital listing,Decision,Piperacillin (Pipril),/apptracker/s/application-public/a102P000008pudV,Infections - Agents for Systemic Use
a0R2P000000MVCsUAO,Piracetam,A-00140,Nootropil [S.29],Piracetam,PHARMAC Initiated,Hospital listing,Decision,Piracetam (Nootropil [S.29]),/apptracker/s/application-public/a102P000008ptqA,Nervous System
a0R2P000000MVCnUAO,Piroxicam,A-00141,"Candyl D,Piram-D",Piroxicam,PHARMAC Initiated,Hospital listing,Decision,"Piroxicam (Candyl D,Piram-D)",/apptracker/s/application-public/a102P000008pttM,Musculoskeletal System
a0R2P000000MVUxUAO,Podophyllum resin with salicylic acid,A-00142,,Podophyllum resin with salicylic acid,PHARMAC Initiated,Hospital listing,Decision,Podophyllum resin with salicylic acid,/apptracker/s/application-public/a102P000008pttW,Dermatologicals
a0R2P000000MVV2UAO,"Polidocanol, injection 3%, 2 ml",A-00143,,"Polidocanol, injection 3%, 2 ml",PHARMAC Initiated,Hospital listing,Decision,"Polidocanol, injection 3%, 2 ml",/apptracker/s/application-public/a102P000008puSI,Blood and Blood Forming Organs
a0R2P000000MVV7UAO,Polygeline,A-00144,,Polygeline,PHARMAC Initiated,Hospital listing,Decision,Polygeline,/apptracker/s/application-public/a102P000008puIZ,Blood and Blood Forming Organs
a0R2P000000N6icUAC,Posaconazole,A-01021,Noxafil,Posaconazole,PHARMAC Initiated,Fungal infection in immunocompromised patients - prophylaxis,Decision,Posaconazole (Noxafil),/apptracker/s/application-public/a102P000008pu2n,Infections - Agents for Systemic Use
a0R2P000000MVVCUA4,Potassium acetate,A-00145,Potassium Acetate,Potassium acetate,PHARMAC Initiated,Hospital listing,Decision,Potassium acetate (Potassium Acetate),/apptracker/s/application-public/a102P000008puZ9,Blood and Blood Forming Organs
a0R2P000000MVVHUA4,Potassium bromide,A-00146,Potassium Bromide M&B,Potassium bromide,PHARMAC Initiated,Hospital listing,Decision,Potassium bromide (Potassium Bromide M&B),/apptracker/s/application-public/a102P000008ptrz,Extemporaneous Compounds
a0R2P000000MVVMUA4,"Potassium chloride, inj 150 mg (2 mmol) per ml",A-00147,,"Potassium chloride, inj 150 mg (2 mmol) per ml",PHARMAC Initiated,Hospital listing,Decision,"Potassium chloride, inj 150 mg (2 mmol) per ml",/apptracker/s/application-public/a102P000008puad,Blood and Blood Forming Organs
a0R2P000000MVVRUA4,Praziquantel tab 500 mg,A-00149,Biltricide,Praziquantel tab 500 mg,PHARMAC Initiated,Hospital listing,Decision,Praziquantel tab 500 mg (Biltricide),/apptracker/s/application-public/a102P000008ptxi,Infections - Agents for Systemic Use
a0R2P000000MwSHUA0,Prednisolone tablets,A-00151,Psm,Prednisolone tablets,PHARMAC Initiated,Hospital listing,Decision,Prednisolone tablets (Psm),/apptracker/s/application-public/a102P000008pueu,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MVVbUAO,Procaine hydrochloride,A-00153,,Procaine hydrochloride,PHARMAC Initiated,Hospital listing,Decision,Procaine hydrochloride,/apptracker/s/application-public/a102P000008pu4L,Nervous System
a0R2P000000MVVlUAO,Procaine hydrochloride with adrenaline and atropine sulphate,A-00152,,Procaine hydrochloride with adrenaline and atropine sulphate,PHARMAC Initiated,Hospital listing,Decision,Procaine hydrochloride with adrenaline and atropine sulphate,/apptracker/s/application-public/a102P000008puZb,Nervous System
a0R2P000000MVVqUAO,Prochlorperazine suppository 5 mg,A-00154,Stemetil,Prochlorperazine suppository 5 mg,PHARMAC Initiated,Hospital listing,Decision,Prochlorperazine suppository 5 mg (Stemetil),/apptracker/s/application-public/a102P000008puMi,Nervous System
a0R2P000000MwS0UAK,Progesterone injection,A-00155,Gestone,Progesterone injection,PHARMAC Initiated,Hospital listing,Decision,Progesterone injection (Gestone),/apptracker/s/application-public/a102P000008puWF,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000aeqHUAQ,Propantheline bromide,A-01372 A-03813,,Propantheline bromide,"PHARMAC Initiated, Consumer",Irritable bowel syndrome,Decision,Propantheline bromide,/apptracker/s/application-public/a102P000008ptyO,Alimentary Tract and Metabolism
a0R2P000000MVW0UAO,"Propofol injection, 20 mg per ml",A-00156,,"Propofol injection, 20 mg per ml",PHARMAC Initiated,Hospital listing,Decision,"Propofol injection, 20 mg per ml",/apptracker/s/application-public/a102P000008pu44,Nervous System
a0R2P000000MwSMUA0,Proxymetacaine Hydrochloride,A-00157,Alcaine,Proxymetacaine Hydrochloride,PHARMAC Initiated,Hospital listing,Decision,Proxymetacaine Hydrochloride (Alcaine),/apptracker/s/application-public/a102P000008ptrJ,Sensory Organs
a0R2P000000MVW5UAO,Pyrantel embonate,A-00158,Combantrin,Pyrantel embonate,PHARMAC Initiated,Hospital listing,Decision,Pyrantel embonate (Combantrin),/apptracker/s/application-public/a102P000008puep,Infections - Agents for Systemic Use
a0R2P000000MVWAUA4,Pyridoxine injection 50 mg,A-00159,Pyridoxine Baxter,Pyridoxine injection 50 mg,PHARMAC Initiated,Hospital listing,Decision,Pyridoxine injection 50 mg (Pyridoxine Baxter),/apptracker/s/application-public/a102P000008pu7H,Blood and Blood Forming Organs
a0R2P000000MVWFUA4,Quinupristin with dalfopristin,A-00160,Synercid,Quinupristin with dalfopristin,PHARMAC Initiated,Hospital listing,Decision,Quinupristin with dalfopristin (Synercid),/apptracker/s/application-public/a102P000008ptsx,Infections - Agents for Systemic Use
a0ROZ000004Ca732AC,Ranibizumab,A-00480,,Ranibizumab,Pharmac Initiated,Diabetic macular oedema,Decision,Ranibizumab,/apptracker/s/application-public/a102P000008puDC,Sensory Organs
a0R2P000000OchKUAS,Reboxetine,A-01361,,Reboxetine,PHARMAC Initiated,Depression,Decision,Reboxetine,/apptracker/s/application-public/a102P000008puUJ,Nervous System
a0R2P000000MVWKUA4,Remifentanil hydrochloride injection 5 mg,A-00162,Ultiva,Remifentanil hydrochloride injection 5 mg,PHARMAC Initiated,Hospital listing,Decision,Remifentanil hydrochloride injection 5 mg (Ultiva),/apptracker/s/application-public/a102P000008puPv,Nervous System
a0R2P000000MVWPUA4,Reteplase,A-00163,Rapilysin,Reteplase,PHARMAC Initiated,Hospital listing,Decision,Reteplase (Rapilysin),/apptracker/s/application-public/a102P000008ptuh,Blood and Blood Forming Organs
a0R2P000000MVWUUA4,Retigabine,A-00164,Retigabine [S.29],Retigabine,PHARMAC Initiated,Hospital listing,Decision,Retigabine (Retigabine [S.29]),/apptracker/s/application-public/a102P000008puQ8,Nervous System
a0R2P000000MWAyUAO,"Retinol capsule 9,000 iu",A-00165,,"Retinol capsule 9,000 iu",PHARMAC Initiated,Hospital listing,Decision,"Retinol capsule 9,000 iu",/apptracker/s/application-public/a102P000008puKN,Alimentary Tract and Metabolism
a0R2P000000anYGUAY,Rituximab,A-01291,Mabthera,Rituximab,PHARMAC Initiated,"Chronic lymphocytic leukaemia, 17p del",Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008pu5v,Oncology Agents and Immunosuppressants
a0R2P000000MzKzUAK,Rivastigmine capsules,A-00984 A-00985,Exelon,Rivastigmine capsules,"Novartis, PHARMAC Initiated",Alzheimer's disease,Decision,Rivastigmine capsules (Exelon),/apptracker/s/application-public/a102P000008puSM,Nervous System
a0R2P000000LmeMUAS,Rizatriptan,A-00661,,Rizatriptan,PHARMAC Initiated,Migraine,Decision,Rizatriptan,/apptracker/s/application-public/a102P000008pttt,Nervous System
a0R2P000000MVWtUAO,"Rocuronium bromide inj 10 mg per ml, 10 ml vial",A-00166,Esmeron,"Rocuronium bromide inj 10 mg per ml, 10 ml vial",PHARMAC Initiated,Hospital listing,Decision,"Rocuronium bromide inj 10 mg per ml, 10 ml vial (Esmeron)",/apptracker/s/application-public/a102P000008puJY,Musculoskeletal System
a0R2P000000MVWjUAO,Ropinirole - tablet products containing multiple strengths,A-00167,Requip,Ropinirole - tablet products containing multiple strengths,PHARMAC Initiated,Hospital listing,Decision,Ropinirole - tablet products containing multiple strengths (Requip),/apptracker/s/application-public/a102P000008ptx1,Nervous System
a0R2P000000MwS2UAK,Rose bengal sodium eye drops,A-00168,Minims,Rose bengal sodium eye drops,PHARMAC Initiated,Hospital listing,Decision,Rose bengal sodium eye drops (Minims),/apptracker/s/application-public/a102P000008puWc,Sensory Organs
a0R2P000000MVWoUAO,Salicylic Acid 16.7% with Lactic Acid 16.7%,A-00170,,Salicylic Acid 16.7% with Lactic Acid 16.7%,PHARMAC Initiated,Hospital listing,Decision,Salicylic Acid 16.7% with Lactic Acid 16.7%,/apptracker/s/application-public/a102P000008puTj,Dermatologicals
a0R2P000000MVWeUAO,Salicylic acid gel,A-00169,Duofilm,Salicylic acid gel,PHARMAC Initiated,Hospital listing,Decision,Salicylic acid gel (Duofilm),/apptracker/s/application-public/a102P000008puVG,Dermatologicals
a0R2P000000OUUAUA4,Sargramostim,A-00171,Leukine,Sargramostim,PHARMAC Initiated,Hospital listing,Decision,Sargramostim (Leukine),/apptracker/s/application-public/a102P000008puaB,Blood and Blood Forming Organs
a0R2P000000LmaPUAS,Secukinumab,A-00549,,Secukinumab,PHARMAC Initiated,"Plaque psoriasis, chronic, moderate to severe chronic, 1st line biologic",Decision,Secukinumab,/apptracker/s/application-public/a102P000008puSs,Dermatologicals
a0R2P000000SLvvUAG,SGLT-2 inhibitors with proven CV benefit,A-00792 A-00500,,SGLT-2 inhibitors with proven CV benefit,"PHARMAC Initiated, Boehringer Mannheim (NZ) Ltd",Diabetes with established and/or high risk cardiovascular disease,Decision,SGLT-2 inhibitors with proven CV benefit,/apptracker/s/application-public/a102P000008ptvj,Alimentary Tract and Metabolism
a0R2P000000LmXgUAK,Sildenafil,A-01219,,Sildenafil,PHARMAC Initiated,Raynaud's phenomenon - severe secondary,Decision,Sildenafil,/apptracker/s/application-public/a102P000008puXH,Cardiovascular System
a0R2P000000MVgZUAW,Sildenafil tablet 20 mg,A-00173,Silagra,Sildenafil tablet 20 mg,PHARMAC Initiated,Hospital listing,Decision,Sildenafil tablet 20 mg (Silagra),/apptracker/s/application-public/a102P000008ptth,Cardiovascular System
a0R2P000000NRTuUAO,Simethicone capsules,A-01371,,Simethicone capsules,PHARMAC Initiated,Bloating or excessive gas,Decision,Simethicone capsules,/apptracker/s/application-public/a102P000008pu33,Alimentary Tract and Metabolism
a0R2P000000LmoCUAS,"SNRIs - duloxetine, venlafaxine",A-01362,,"SNRIs - duloxetine, venlafaxine",PHARMAC Initiated,Pain,Decision,"SNRIs - duloxetine, venlafaxine",/apptracker/s/application-public/a102P000008pu1M,Nervous System
a0R2P000000MVgeUAG,"Sodium bicarbonate injection 5%, 500 ml",A-00174,Baxter,"Sodium bicarbonate injection 5%, 500 ml",PHARMAC Initiated,Hospital listing,Decision,"Sodium bicarbonate injection 5%, 500 ml (Baxter)",/apptracker/s/application-public/a102P000008puEr,Blood and Blood Forming Organs
a0R2P000000OUUjUAO,Sodium bicarbonate prefilled syringe,A-00175,Biomed,Sodium bicarbonate prefilled syringe,PHARMAC Initiated,Hospital listing,Decision,Sodium bicarbonate prefilled syringe (Biomed),/apptracker/s/application-public/a102P000008puhE,Blood and Blood Forming Organs
a0R2P000000LmnmUAC,"Sodium chloride, hypertonic (7% solution)",A-00972,,"Sodium chloride, hypertonic (7% solution)",PHARMAC Initiated,Cystic fibrosis,Decision,"Sodium chloride, hypertonic (7% solution)",/apptracker/s/application-public/a102P000008ptsT,Respiratory System and Allergies
a0R2P000000MwSOUA0,"Sodium hyaluronate, inj 16 mg per ml",A-00176,Healon Endocoat,"Sodium hyaluronate, inj 16 mg per ml",PHARMAC Initiated,Hospital listing,Decision,"Sodium hyaluronate, inj 16 mg per ml (Healon Endocoat)",/apptracker/s/application-public/a102P000008pu0e,Sensory Organs
a0R2P000000MVgoUAG,Sodium hydrogen phosphate,A-00177,,Sodium hydrogen phosphate,PHARMAC Initiated,Hospital listing,Decision,Sodium hydrogen phosphate,/apptracker/s/application-public/a102P000008pu2k,Blood and Blood Forming Organs
a0R2P000000MVgtUAG,"Sodium tetradecyl sulphate, injections 0.5% and 1%, 2 ml",A-00178,Fibro-Vein,"Sodium tetradecyl sulphate, injections 0.5% and 1%, 2 ml",PHARMAC Initiated,Hospital listing,Decision,"Sodium tetradecyl sulphate, injections 0.5% and 1%, 2 ml (Fibro-Vein)",/apptracker/s/application-public/a102P000008puXs,Blood and Blood Forming Organs
a0ROZ00000BV8Sn2AL,Sofosbuvir,A-00496,Sovaldi,Sofosbuvir,Pharmac Initiated,"Hepatitis C, direct-acting antiviral",Reviewing Consultation Feedback,Sofosbuvir (Sovaldi),/apptracker/s/application-public/a102P000008pu04,Infections - Agents for Systemic Use
a0ROZ000009A8qV2AS,Somatropin,A-00532 A-04951,Any,Somatropin,"Pharmac Initiated, Consumer","Prader-Willi Syndrome, widened access for adults and adolescents",Options Compared,Somatropin (Any),/apptracker/s/application-public/a102P000008ptyS,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmaoUAC,Somatropin - Growth Hormone,A-00531,Any,Somatropin - Growth Hormone,PHARMAC Initiated,Widening access for patients with Prader-Willi Syndrome under 2 years,Decision,Somatropin - Growth Hormone (Any),/apptracker/s/application-public/a102P000008puZB,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmnMUAS,Somatropin - Growth Hormone,A-00765,Genotropin,Somatropin - Growth Hormone,PHARMAC Initiated,Revised access criteria for patients with Prader-Willi Syndrome,Decision,Somatropin - Growth Hormone (Genotropin),/apptracker/s/application-public/a102P000008ptrS,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MVgyUAG,Stavudine capsule 20 mg,A-00179,Zerit,Stavudine capsule 20 mg,PHARMAC Initiated,Hospital listing,Decision,Stavudine capsule 20 mg (Zerit),/apptracker/s/application-public/a102P000008puiz,Infections - Agents for Systemic Use
a0R2P000000MVh3UAG,Sterculia,A-00180,,Sterculia,PHARMAC Initiated,Hospital listing,Decision,Sterculia,/apptracker/s/application-public/a102P000008ptsW,Alimentary Tract and Metabolism
a0R2P000000anWeUAI,Strontium ranelate,A-00965,Protos,Strontium ranelate,PHARMAC Initiated,Osteoporosis (2nd-line treatment),Decision,Strontium ranelate (Protos),/apptracker/s/application-public/a102P000008puMh,Musculoskeletal System
a0R2P000000LmdTUAS,Sugammadex,A-01437,,Sugammadex,PHARMAC Initiated,Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required,Decision,Sugammadex,/apptracker/s/application-public/a102P000008puaZ,Musculoskeletal System
a0R2P000000anfCUAQ,Tacrolimus,A-00785,,Tacrolimus,PHARMAC Initiated,Neuromyelitis Optica Spectrum Disorders,Decision,Tacrolimus,/apptracker/s/application-public/a102P000008pufm,Oncology Agents and Immunosuppressants
a0ROZ00000753kP2AQ,Tadalafil,A-01459,,Tadalafil,Pharmac Initiated,Hospital listing,Decision,Tadalafil,/apptracker/s/application-public/a102P000008puaF,Genito-Urinary System
a0R2P000000MVh8UAG,Tamsulosin long-acting tablet,A-00181,Flomaxtra,Tamsulosin long-acting tablet,PHARMAC Initiated,Hospital listing,Decision,Tamsulosin long-acting tablet (Flomaxtra),/apptracker/s/application-public/a102P000008puke,Genito-Urinary System
a0R2P000000MVWyUAO,Tar with coal tar and cade oil,A-00182,,Tar with coal tar and cade oil,PHARMAC Initiated,Hospital listing,Decision,Tar with coal tar and cade oil,/apptracker/s/application-public/a102P000008puZV,Dermatologicals
a0R2P000000MOUsUAO,Temocillin sodium injection,A-01369,,Temocillin sodium injection,PHARMAC Initiated,Infections,Decision,Temocillin sodium injection,/apptracker/s/application-public/a102P000008puio,Infections - Agents for Systemic Use
a0R2P000000WlIBUA0,Teniposide,A-00514 A-00515,,Teniposide,"PHARMAC Initiated, Clinician",Multiple myeloma,Decision,Teniposide,/apptracker/s/application-public/a102P000008pu1H,Oncology Agents and Immunosuppressants
a0ROZ0000008Opx2AE,Tenofovir,A-01302,,Tenofovir,PHARMAC Initiated,Hepatitis B - first-line patients with advanced fibrosis/cirrhosis,Decision,Tenofovir,/apptracker/s/application-public/a102P000008ptyM,Infections - Agents for Systemic Use
a0R2P000000LmV2UAK,Tenofovir,A-01322,,Tenofovir,PHARMAC Initiated,"Hepatitis B, with decompensated cirrhosis",Decision,Tenofovir,/apptracker/s/application-public/a102P000008ptyo,Infections - Agents for Systemic Use
a0R2P000000Lmd7UAC,Terbinafine creams and gels,A-00184,,Terbinafine creams and gels,PHARMAC Initiated,Antifungal cream,Options Compared,Terbinafine creams and gels,/apptracker/s/application-public/a102P000008pu7b,Dermatologicals
a0R2P000000MwSEUA0,Testosterone gel,A-00185,,Testosterone gel,PHARMAC Initiated,Hospital listing,Decision,Testosterone gel,/apptracker/s/application-public/a102P000008puE3,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MwSIUA0,Testosterone implant,A-00186,Testosterone Implants,Testosterone implant,PHARMAC Initiated,Hospital listing,Decision,Testosterone implant (Testosterone Implants),/apptracker/s/application-public/a102P000008pukH,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmhxUAC,Thalidomide,A-01109,Thalidomide Pharmion,Thalidomide,PHARMAC Initiated,Relapsed or treatment refractory multiple myeloma (brand change),Decision,Thalidomide (Thalidomide Pharmion),/apptracker/s/application-public/a102P000008pu4k,Oncology Agents and Immunosuppressants
a0R2P000000MVhDUAW,Tinidazole,A-00187,Dyzole,Tinidazole,PHARMAC Initiated,Hospital listing,Decision,Tinidazole (Dyzole),/apptracker/s/application-public/a102P000008ptry,Infections - Agents for Systemic Use
a0R2P000000Lmd4UAC,Tiotropium bromide and glycopyrronium,A-01404,,Tiotropium bromide and glycopyrronium,PHARMAC Initiated,Amending access - removing FEV1 requirement for renewals,Decision,Tiotropium bromide and glycopyrronium,/apptracker/s/application-public/a102P000008pubf,Respiratory System and Allergies
a0R2P000000MW0jUAG,Tirofiban Hydrochloride,A-01368,,Tirofiban Hydrochloride,PHARMAC Initiated,Acute coronary syndromes undergoing percutaneous coronary intervention,Decision,Tirofiban Hydrochloride,/apptracker/s/application-public/a102P000008ptyZ,Blood and Blood Forming Organs
a0R2P000000LmfSUAS,Tolterodine L-Tartrate,A-00825,,Tolterodine L-Tartrate,PHARMAC Initiated,Overactive bladder,Decision,Tolterodine L-Tartrate,/apptracker/s/application-public/a102P000008ptpX,Genito-Urinary System
a0R2P000000MVX8UAO,Topiramate sprinkle cap 50 mg,A-00189,,Topiramate sprinkle cap 50 mg,PHARMAC Initiated,Hospital listing,Decision,Topiramate sprinkle cap 50 mg,/apptracker/s/application-public/a102P000008puYP,Nervous System
a0R2P000000OUYDUA4,Topotecan,A-00190,,Topotecan,PHARMAC Initiated,Hospital listing,Decision,Topotecan,/apptracker/s/application-public/a102P000008puaa,Oncology Agents and Immunosuppressants
a0R2P000000MVhIUAW,"Tramadol tablet, sustained-release 50 mg",A-00191,,"Tramadol tablet, sustained-release 50 mg",PHARMAC Initiated,Hospital listing,Decision,"Tramadol tablet, sustained-release 50 mg",/apptracker/s/application-public/a102P000008puTg,Nervous System
a0ROZ00000085P72AI,Trastuzumab,A-01234,Herceptin,Trastuzumab,PHARMAC Initiated,early HER-2 positive breast cancer - 9 week regimen,Decision,Trastuzumab (Herceptin),/apptracker/s/application-public/a102P000008pu4W,Oncology Agents and Immunosuppressants
a0R2P000000MwSLUA0,"Triamcinolone hexacetonide injection 20 mg per ml, 5 ml",A-00192,Aristopan,"Triamcinolone hexacetonide injection 20 mg per ml, 5 ml",PHARMAC Initiated,Hospital listing,Decision,"Triamcinolone hexacetonide injection 20 mg per ml, 5 ml (Aristopan)",/apptracker/s/application-public/a102P000008ptrH,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000MVhSUAW,Triamterene with hydrochlorothiazide,A-00193,Dyazide,Triamterene with hydrochlorothiazide,PHARMAC Initiated,Hospital listing,Decision,Triamterene with hydrochlorothiazide (Dyazide),/apptracker/s/application-public/a102P000008ptsO,Cardiovascular System
a0R2P000000MVhXUAW,Trichloroethane,A-00195,Dry Cleaner Ipw,Trichloroethane,PHARMAC Initiated,Hospital listing,Decision,Trichloroethane (Dry Cleaner Ipw),/apptracker/s/application-public/a102P000008ptxt,Extemporaneous Compounds
a0R2P000000MVhrUAG,Trifluoperazine hydrochloride oral liquid,A-00196,Stelazine,Trifluoperazine hydrochloride oral liquid,PHARMAC Initiated,Hospital listing,Decision,Trifluoperazine hydrochloride oral liquid (Stelazine),/apptracker/s/application-public/a102P000008puaW,Nervous System
a0R2P000000MR2XUAW,Trimipramine Maleate,A-01365,,Trimipramine Maleate,PHARMAC Initiated,Depression,Decision,Trimipramine Maleate,/apptracker/s/application-public/a102P000008ptpt,Nervous System
a0ROZ00000BHvwP2AT,"Tyrosine kinase inhibitors (eg. sunitinib, pazopanib)",A-01045 A-03507,,"Tyrosine kinase inhibitors (eg. sunitinib, pazopanib)","Pharmac Initiated, Clinician","Renal cell carcinoma (RCC), advanced or metastatic with a good prognosis",Decision,"Tyrosine kinase inhibitors (eg. sunitinib, pazopanib)",/apptracker/s/application-public/a102P000008puY1,Oncology Agents and Immunosuppressants
a0R2P000000MTX6UAO,"um chloride and sodium chloride, inj 2.5% glucose 20 mmol KCl, NaCl 0.45%, 500ml",A-00017,,"Glucose with potassium chloride and sodium chloride, inj 2.5% glucose 20 mmol KCl, NaCl 0.45%, 500ml",PHARMAC Initiated,Hospital listing,Decision,"Glucose with potassium chloride and sodium chloride, inj 2.5% glucose 20 mmol KCl, NaCl 0.45%, 500ml",/apptracker/s/application-public/a102P000008puD7,Blood and Blood Forming Organs
a0R2P000000MVXDUA4,Urea 25% ointment,A-00197,,Urea 25% ointment,PHARMAC Initiated,Hospital listing,Decision,Urea 25% ointment,/apptracker/s/application-public/a102P000008puWb,Dermatologicals
a0R2P000000MVhwUAG,Urea with lactic acid,A-00198,,Urea with lactic acid,PHARMAC Initiated,Hospital listing,Decision,Urea with lactic acid,/apptracker/s/application-public/a102P000008pucl,Dermatologicals
a0R2P000000LmTeUAK,Ursodeoxycholic acid,A-01065,Actigall,Ursodeoxycholic acid,PHARMAC Initiated,"Hepatic complications, veno-occlusive disease - prevention, with high dose conditioning therapy",Decision,Ursodeoxycholic acid (Actigall),/apptracker/s/application-public/a102P000008puP5,Alimentary Tract and Metabolism
a0R2P000000LmaSUAS,Ursodeoxycholic acid,A-01223,Ursodiol,Ursodeoxycholic acid,PHARMAC Initiated,TPN-IC in children; Alagille syndrome; PFIC; chronic drug induced liver injury,Decision,Ursodeoxycholic acid (Ursodiol),/apptracker/s/application-public/a102P000008puYz,Alimentary Tract and Metabolism
a0R2P000000aneEUAQ,Ursodeoxycholic acid,A-01352,,Ursodeoxycholic acid,PHARMAC Initiated,Cystic fibrosis related liver disease,Decision,Ursodeoxycholic acid,/apptracker/s/application-public/a102P000008puUG,Alimentary Tract and Metabolism
a0R2P000000TipoUAC,Ursodeoxycholic acid,A-01351,,Ursodeoxycholic acid,PHARMAC Initiated,TPN-IC in adults; non-alcoholic steatohepatitis; prophylaxis of colon cancer in IBD,Decision,Ursodeoxycholic acid,/apptracker/s/application-public/a102P000008pug2,Alimentary Tract and Metabolism
a0R2P000000MVi1UAG,Ursodeoxycholic acid: oral liquid; and capsule 300 mg,A-00199,Actigall,Ursodeoxycholic acid: oral liquid; and capsule 300 mg,PHARMAC Initiated,Hospital listing,Decision,Ursodeoxycholic acid: oral liquid; and capsule 300 mg (Actigall),/apptracker/s/application-public/a102P000008pu3S,Alimentary Tract and Metabolism
a0R2P000000Lmj3UAC,Valaciclovir,A-00231,,Valaciclovir,PHARMAC Initiated,Removal of Special Authority,Decision,Valaciclovir,/apptracker/s/application-public/a102P000008pu5T,Infections - Agents for Systemic Use
a0R2P000000LmrkUAC,Valganciclovir,A-01060,,Valganciclovir,PHARMAC Initiated,Lung transplant - CMV prophylaxis,Decision,Valganciclovir,/apptracker/s/application-public/a102P000008puKK,Infections - Agents for Systemic Use
a0ROZ00000753qr2AA,Vardenafil,A-00200,Levitra,Vardenafil,Pharmac Initiated,Hospital listing,Decision,Vardenafil (Levitra),/apptracker/s/application-public/a102P000008pua5,Genito-Urinary System
a0ROZ000003H4YY2A0,Vedolizumab,A-04846,Entyvio,Vedolizumab,Pharmac Initiated,"Ulcerative colitis and Crohn's disease, secondary loss of response to vedolizumab (dose escalation)",Under Assessment,Vedolizumab (Entyvio),/apptracker/s/application-public/a10OZ00000162Ef,Alimentary Tract and Metabolism
a0ROZ000003H6KD2A0,Vedolizumab,A-04846,Entyvio,Vedolizumab,Pharmac Initiated,"Ulcerative colitis and Crohn's disease, primary non-response to vedolizumab (dose escalation)",Under Assessment,Vedolizumab (Entyvio),/apptracker/s/application-public/a10OZ000000EevF,Alimentary Tract and Metabolism
a0ROZ000000VUY52AO,Vernakalant,A-01334,,Vernakalant,PHARMAC Initiated,Atrial fibrillation,Decision,Vernakalant,/apptracker/s/application-public/a102P000008pu5e,Cardiovascular System
a0R2P000000MVhmUAG,Vindesine,A-00201,,Vindesine,PHARMAC Initiated,Hospital listing,Decision,Vindesine,/apptracker/s/application-public/a102P000008puGh,Oncology Agents and Immunosuppressants
a0R2P000000MUD9UAO,Vitamin E cream,A-00050,,Vitamin E cream,PHARMAC Initiated,Hospital listing,Decision,Vitamin E cream,/apptracker/s/application-public/a102P000008pu1Q,Dermatologicals
a0R2P000000N6iHUAS,Voriconazole,A-01022,,Voriconazole,PHARMAC Initiated,Invasive fungal infections,Decision,Voriconazole,/apptracker/s/application-public/a102P000008ptt5,Infections - Agents for Systemic Use
a0R2P000000MVhhUAG,Water injection 100 ml,A-00202,Baxter,Water injection 100 ml,PHARMAC Initiated,Hospital listing,Decision,Water injection 100 ml (Baxter),/apptracker/s/application-public/a102P000008pubV,Blood and Blood Forming Organs
a0R2P000000OcfEUAS,"Witch hazel, distilled liquid, topical",A-01366,,"Witch hazel, distilled liquid, topical",PHARMAC Initiated,Hospital listing,Decision,"Witch hazel, distilled liquid, topical",/apptracker/s/application-public/a102P000008ptoi,Dermatologicals
a0ROZ000004CQu52AG,Zanamivir,A-01326,Relenza Rotadisk,Zanamivir,Pharmac Initiated,Influenza (community listing),Decision,Zanamivir (Relenza Rotadisk),/apptracker/s/application-public/a102P000008puBC,Infections - Agents for Systemic Use
a0R2P000000LmhTUAS,Zanamivir,A-01343,,Zanamivir,PHARMAC Initiated,Influenza (hospital listing),Decision,Zanamivir,/apptracker/s/application-public/a102P000008puE2,Infections - Agents for Systemic Use
a0R2P000000OciXUAS,Zinc oxide suppositories,A-01364,,Zinc oxide suppositories,PHARMAC Initiated,Haemorrhoids,Decision,Zinc oxide suppositories,/apptracker/s/application-public/a102P000008puWs,Alimentary Tract and Metabolism
a0R2P000000MVXIUA4,Zinc oxide with glycerol,A-00203,,Zinc oxide with glycerol,PHARMAC Initiated,Hospital listing,Decision,Zinc oxide with glycerol,/apptracker/s/application-public/a102P000008puIY,Dermatologicals
a0R2P000000OUYIUA4,Zinc oxide with peru balsam,A-00204,,Zinc oxide with peru balsam,PHARMAC Initiated,Hospital listing,Decision,Zinc oxide with peru balsam,/apptracker/s/application-public/a102P000008ptrT,Alimentary Tract and Metabolism
a0R2P000000LmjBUAS,Zoledronic acid,A-01416,Zometa,Zoledronic acid,PHARMAC Initiated,"Bone metastases with severe pain or risk of skeletal events, and community listing",Decision,Zoledronic acid (Zometa),/apptracker/s/application-public/a102P000008puDu,Oncology Agents and Immunosuppressants
a0ROZ000000BZwv2AG,Zuclopenthixol hydrochloride,A-00834,,Zuclopenthixol hydrochloride,PHARMAC Initiated,Schizophrenia and related psychoses,Decision,Zuclopenthixol hydrochloride,/apptracker/s/application-public/a102P000008ptpv,Nervous System
a0ROZ000009J4Fd2AK,Aprepitant,A-03563,Emend,Aprepitant,Clinician,Nausea and vomiting associated with moderately emetogenic chemotherapy,Decision,Aprepitant (Emend),/apptracker/s/application-public/a102P00000BOI2z,Nervous System
a0R2P000000LmVDUA0,Aprepitant,A-00421,Emend,Aprepitant,Merck Sharp & Dohme,Nausea associated with emetogenic chemotherapy,Decision,Aprepitant (Emend),/apptracker/s/application-public/a102P000008ptyq,Nervous System
a0ROZ000009J4HF2A0,Aprepitant,A-03563,Emend,Aprepitant,Clinician,"Nausea and vomiting, carboplatin-based chemotherapy, widen access",Decision,Aprepitant (Emend),/apptracker/s/application-public/a102P00000AmySz,Oncology Agents and Immunosuppressants
a0ROZ000009J4fR2AS,Atezolizumab,A-00746,,Atezolizumab,Roche,Advanced NSCLC 1L combination therapy with platinum chemotherapy,Decision,Atezolizumab,/apptracker/s/application-public/a102P000008puFH,Oncology Agents and Immunosuppressants
a0ROZ000009A8qf2AC,Atezolizumab (with chemotherapy),A-03769,Tecentriq,Atezolizumab (with chemotherapy),ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Extensive-stage small cell lung cancer (ES-SCLC), first-line",Options Compared,Atezolizumab (with chemotherapy) (Tecentriq),/apptracker/s/application-public/a102P00000B08F7,Oncology Agents and Immunosuppressants
a0ROZ000009A8qd2AC,Atezolizumab (with chemotherapy),A-03352,Tecentriq,Atezolizumab (with chemotherapy),ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Triple-negative breast cancer (TNBC), advanced or metastatic, PDL1 expression over 1%",Options Compared,Atezolizumab (with chemotherapy) (Tecentriq),/apptracker/s/application-public/a102P00000ANEYB,Oncology Agents and Immunosuppressants
a0R2P000000LmhCUAS,Bortezomib,A-00945,Velcade,Bortezomib,Janssen,"Multiple myeloma - newly diagnosed, ineligible for high dose chemotherapy",Decision,Bortezomib (Velcade),/apptracker/s/application-public/a102P000008pu5X,Oncology Agents and Immunosuppressants
a0ROZ00000BQW9B2AX,Calcium phosphate oral rinse,A-01277 A-01278,Caphasol,Calcium phosphate oral rinse,"NPPA, Clinician",Oral mucositis following chemotherapy or radiation therapy,Decision,Calcium phosphate oral rinse (Caphasol),/apptracker/s/application-public/a102P000008pu4H,Alimentary Tract and Metabolism
a0R2P000000Sk5IUAS,Dexrazoxane,A-00580,,Dexrazoxane,Clinician,Cardioprotection in conjunction with anthracycline chemotherapy in children and young adults,Decision,Dexrazoxane,/apptracker/s/application-public/a102P000008puDD,Oncology Agents and Immunosuppressants
a0R2P000000TEx2UAG,Dexrazoxane,A-01327,,Dexrazoxane,Clinician,Cardioprotection with chemotherapy in paediatric patients participating in a randomised clinical trial,Decision,Dexrazoxane,/apptracker/s/application-public/a102P000008puc3,Oncology Agents and Immunosuppressants
a0ROZ000008vbhN2AQ,Durvalumab,A-05338,IMFINZI®,Durvalumab,ASTRAZENECA LIMITED,"Muscle invasive bladder cancer (MIBC), neoadjuvant and adjuvant, first-line (with neoadjuvant chemotherapy)",Seeking Clinical Advice,Durvalumab (IMFINZI®),/apptracker/s/application-public/a10OZ000004RGft,Oncology Agents and Immunosuppressants
a0ROZ000002jRkT2AU,Durvalumab,A-04551,Imfinzi,Durvalumab,ASTRAZENECA LIMITED,"biliary tract cancer, Locally advanced or metastatic, in combination with chemotherapy",Options Compared,Durvalumab (Imfinzi),/apptracker/s/application-public/a102P00000Bajp3,Oncology Agents and Immunosuppressants
a0ROZ00000DXjTV2A1,Eribulin,A-04168,Halaven,Eribulin,Consumer,Locally advanced or metastatic breast cancer (following progression on chemotherapy),Seeking Clinical Advice,Eribulin (Halaven),/apptracker/s/application-public/a102P00000BVRE2,Oncology Agents and Immunosuppressants
a0ROZ000001H37N2AS,Eribulin,A-04168,Halaven,Eribulin,Consumer,Advanced liposarcoma (following chemotherapy),Seeking Clinical Advice,Eribulin (Halaven),/apptracker/s/application-public/a102P00000BVRxj,Oncology Agents and Immunosuppressants
a0ROZ000009wWS92AM,Nab-paclitaxel,A-01009,Abraxane,Nab-paclitaxel,Specialised Therapeutics Ltd,"Metastatic breast cancer, contraindicated or intolerant to taxane chemotherapy",Options Compared,Nab-paclitaxel (Abraxane),/apptracker/s/application-public/a102P00000BQdRd,
a0ROZ00000AQkoA2AT,Nab-paclitaxel,A-04802,,Nab-paclitaxel,Clinician,"Any cancer, contraindicated or intolerant to taxane chemotherapy",Options Compared,Nab-paclitaxel,/apptracker/s/application-public/a10OZ0000001REH,Oncology Agents and Immunosuppressants
a0ROZ000004u6hx2AA,Nivolumab,A-05059,Opdivo,Nivolumab,BRISTOL-MYERS SQUIBB (NZ) LIMITED,"head and neck squamous cell cancer, recurrent or metastatic, progressed within 6 months of platinum-based chemotherapy",Seeking Clinical Advice,Nivolumab (Opdivo),/apptracker/s/application-public/a10OZ000002EQxZ,
a0ROZ00000BP6Bx2AL,Nivolumab,A-05227,OPDIVO,Nivolumab,Consumer,"Unresectable or metastatic urothelial carcinoma, first line, with cisplatin chemotherapy",Seeking Clinical Advice,Nivolumab (OPDIVO),/apptracker/s/application-public/a10OZ0000038WPB,
a0ROZ00000ApJsX2AV,Nivolumab (with chemotherapy),A-05298,Opdivo®,Nivolumab (with chemotherapy),BRISTOL-MYERS SQUIBB (NZ) LIMITED,"Oesophageal adenocarcinoma and gastric/gastro-oesophageal junction cancers, advanced/metastatic, 1st line",Seeking Clinical Advice,Nivolumab (with chemotherapy) (Opdivo®),/apptracker/s/application-public/a10OZ000004a5zl,Oncology Agents and Immunosuppressants
a0ROZ00000ApJsY2AV,Nivolumab (with chemotherapy),A-05298,Opdivo®,Nivolumab (with chemotherapy),BRISTOL-MYERS SQUIBB (NZ) LIMITED,"Oesophageal squamous cell carcinoma, advanced, 1st line",Seeking Clinical Advice,Nivolumab (with chemotherapy) (Opdivo®),/apptracker/s/application-public/a10OZ000004a7of,Oncology Agents and Immunosuppressants
a0ROZ00000BTW9U2AX,Nivolumab (with chemotherapy),A-05276,Opdivo®,Nivolumab (with chemotherapy),BRISTOL-MYERS SQUIBB (NZ) LIMITED,"Non-small cell lung cancer (NSCLC), stage IB, II, or IIIA, resectable",Seeking Clinical Advice,Nivolumab (with chemotherapy) (Opdivo®),/apptracker/s/application-public/a10OZ000004ZpDR,Oncology Agents and Immunosuppressants
a0ROZ000009J4xB2AS,Nivolumab (with ipilimumab and platinum-based chemotherapy),A-04403,"OPDIVO, YERVOY",Nivolumab (with ipilimumab and platinum-based chemotherapy),BRISTOL-MYERS SQUIBB (NZ) LIMITED,"Advanced non-small cell lung cancer, 1st line combination therapy, irrespective of PDL-1 status",Decision,"Nivolumab (with ipilimumab and platinum-based chemotherapy) (OPDIVO, YERVOY)",/apptracker/s/application-public/a102P00000BUI9R,
a0ROZ000008gKFR2A2,olaparib,A-04698 A-05127 A-05260,Lynparza,olaparib,"ASTRAZENECA LIMITED, Clinician, Consumer","BRCAm HER2-negative breast cancer, early high risk after neoadjuvant/adjuvant chemotherapy",Seeking Clinical Advice,olaparib (Lynparza),/apptracker/s/application-public/a10OZ000001vDnx,
a0R2P000000LmYuUAK,Ondansetron,A-01533,,Ondansetron,Clinician,Nausea with radiation and/or chemotherapy - removal of dispensing limit,Decision,Ondansetron,/apptracker/s/application-public/a102P000008puWp,Nervous System
a0R2P000000andpUAA,Pazopanib,A-00596,,Pazopanib,Clinician,Advanced soft tissue sarcoma after prior chemotherapy,Decision,Pazopanib,/apptracker/s/application-public/a102P000008puNy,Oncology Agents and Immunosuppressants
a0R2P000000Lme6UAC,Pegfilgrastim,A-01350,,Pegfilgrastim,Roche,Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer,Decision,Pegfilgrastim,/apptracker/s/application-public/a102P000008ptuB,Blood and Blood Forming Organs
a0ROZ00000Cn1xB2AR,pembrolizumab,A-04736,Keytruda,pembrolizumab,Clinician,"First line persistent, recurrent or metastatic cervical cancer in addition to chemotherapy, for patients with a PD-L1 combined positive score of 1 or more, with bevacizumab",Options Compared,pembrolizumab (Keytruda),/apptracker/s/application-public/a10OZ000001jcQL,Oncology Agents and Immunosuppressants
a0R2P000000fjrYUAQ,Pembrolizumab,A-00712,Keytruda,Pembrolizumab,Merck Sharp & Dohme,"Non small cell lung cancer, metastatic,  with chemotherapy, 1st line",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008puL2,Oncology Agents and Immunosuppressants
a0ROZ00000AQko02AD,Pembrolizumab,A-03035,KEYTRUDA (for HNSCC),Pembrolizumab,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,Pembrolizumab in combination with chemotherapy for those with recurrent or metastatic head and neck squamous cell carcinoma irrespective of Combined Positive Score (ie. an all-comers population),Options Compared,Pembrolizumab (KEYTRUDA (for HNSCC)),/apptracker/s/application-public/a102P00000BQMFj,
a0R2P000000ZwaFUAS,Pembrolizumab,A-03934,KEYTRUDA,Pembrolizumab,Clinician,"Classical Hodgkin lymphoma, relapsed or refractory to a second or subsequent line of chemotherapy, or that has relapsed after at least three lines of therapy (bridge to transplant)",Decision,Pembrolizumab (KEYTRUDA),/apptracker/s/application-public/a102P00000BKugI,Oncology Agents and Immunosuppressants
a0ROZ00000BQVxt2AH,Pembrolizumab,A-00615,Keytruda,Pembrolizumab,Merck Sharp & Dohme,"Hodgkin's lymphoma, relapsed or refractory after two or more lines of chemotherapy,  ineligible for or relapsed following an autologous stem cell transplant",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008pu3x,Oncology Agents and Immunosuppressants
a0ROZ0000077hiZ2AQ,Pembrolizumab,A-04736 A-04982,Keytruda,Pembrolizumab,"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Clinician","First line persistent, recurrent or metastatic cervical cancer in addition to chemotherapy, for patients with a PD-L1 combined positive score of 1 or more.",Under Assessment,Pembrolizumab (Keytruda),/apptracker/s/application-public/a10OZ00000010ij,Oncology Agents and Immunosuppressants
a0ROZ000004obGc2AI,Pembrolizumab (with chemotherapy),A-03035,KEYTRUDA,Pembrolizumab (with chemotherapy),MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,"Head and neck squamous cell carcinoma (HNSCC), Combined Positive Score (CPS) >1, first-line",Decision,Pembrolizumab (with chemotherapy) (KEYTRUDA),/apptracker/s/application-public/a102P00000AHK7u,Oncology Agents and Immunosuppressants
a0ROZ000004ocXd2AI,Pembrolizumab (with or without chemotherapy),A-03035,KEYTRUDA (for HNSCC),Pembrolizumab (with or without chemotherapy),MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,"Head and neck squamous cell carcinoma (HNSCC), Combined Positive Score (CPS) >1, 1st line",Decision,Pembrolizumab (with or without chemotherapy) (KEYTRUDA (for HNSCC)),/apptracker/s/application-public/a102P00000BQmYU,Oncology Agents and Immunosuppressants
a0ROZ00000DaaS52AJ,Pembrolizumab (with pemetrexed and chemotherapy),A-05379,KEYTRUDA,Pembrolizumab (with pemetrexed and chemotherapy),MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,"Malignant pleural mesothelioma, all histological subtypes, unresectable advanced, 1st line",Seeking Clinical Advice,Pembrolizumab (with pemetrexed and chemotherapy) (KEYTRUDA),/apptracker/s/application-public/a10OZ000006KWoH,
a0ROZ00000DabJJ2AZ,Pembrolizumab (with pemetrexed and chemotherapy),A-05379,KEYTRUDA,Pembrolizumab (with pemetrexed and chemotherapy),MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,"Malignant pleural mesothelioma, non-epithelioid histological subtypes, unresectable advanced, 1st line",Under Assessment,Pembrolizumab (with pemetrexed and chemotherapy) (KEYTRUDA),/apptracker/s/application-public/a10OZ000004iMLt,Oncology Agents and Immunosuppressants
a0ROZ00000AsPWj2AN,Pertuzumab and trastuzumab,A-04334,PHESGO,Pertuzumab and trastuzumab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Adjuvant treatment of individuals with HER2-positive early breast cancer at high risk of recurrence in combination with chemotherapy,Seeking Clinical Advice,Pertuzumab and trastuzumab (PHESGO),/apptracker/s/application-public/a102P00000BZPBQ,Oncology Agents and Immunosuppressants
a0ROZ000009J50P2AS,Tislelizumab (with platinum-based chemotherapy),A-04346,Tevimbra,Tislelizumab (with platinum-based chemotherapy),BEIGENE NZ UNLIMITED,"Advanced non-small cell lung cancer, 1st line combination therapy, irrespective of PDL-1 status",Decision,Tislelizumab (with platinum-based chemotherapy) (Tevimbra),/apptracker/s/application-public/a102P00000BTxb5,
a0ROZ000008BWpZ2AW,Venetoclax (w current access azacitidine or low dose cytarabine),A-03627,Venclexta,Venetoclax (w current access azacitidine or low dose cytarabine),ABBVIE LIMITED,"AML, newly diagnosed,  ineligible for intensive chemotherapy",Decision,Venetoclax (w current access azacitidine or low dose cytarabine) (Venclexta),/apptracker/s/application-public/a102P00000AmyhI,Oncology Agents and Immunosuppressants
a0ROZ000008BV5X2AW,Venetoclax (with widened access to azacitidine),A-03627,Venclexta,Venetoclax (with widened access to azacitidine),ABBVIE LIMITED,"Acute myeloid leukaemia, newly diagnosed, ineligible for intensive induction chemotherapy",Decision,Venetoclax (with widened access to azacitidine) (Venclexta),/apptracker/s/application-public/a102P00000BIsBP,Oncology Agents and Immunosuppressants
a0R2P000000LmTdUAK,Teriflunomide,A-00295,,Teriflunomide,Sanofi,Multiple sclerosis (MS),Decision,Teriflunomide,/apptracker/s/application-public/a102P000008puP4,Nervous System
a0ROZ000000W2WY2A0,"Amifampridine (3,4-diaminopyridine)",A-01403,,"Amifampridine (3,4-diaminopyridine)",NPPA,Lambert Eaton Myasthenic Syndrome,Decision,"Amifampridine (3,4-diaminopyridine)",/apptracker/s/application-public/a102P000008puXm,Nervous System
a0R2P000000LmhjUAC,Amisulpride,A-00433,Solian,Amisulpride,Sanofi-Aventis,Schizophrenia and related psychoses,Decision,Amisulpride (Solian),/apptracker/s/application-public/a102P000008puEI,Nervous System
a0R2P000000anaWUAQ,"an, frovatriptan, naratriptan, rizatriptan, sumatriptan succinate, zolmitrioptan",A-01442,,"Triptans - almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan succinate, zolmitrioptan",Clinician,Listing of additional triptans,Decision,"Triptans - almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan succinate, zolmitrioptan",/apptracker/s/application-public/a102P000008puH3,Nervous System
a0ROZ00000ChnPx2AJ,Aprepitant 40 mg,A-00207 A-04819,,Aprepitant 40 mg,Clinician,People at high risk of post-operative nausea and vomiting,Seeking Clinical Advice,Aprepitant 40 mg,/apptracker/s/application-public/a102P000008ptty,Nervous System
a0R2P000000LmkyUAC,Aripiprazole,A-00302,Abilify,Aripiprazole,Clinician,Severe irritability associated with autism spectrum disorder,Decision,Aripiprazole (Abilify),/apptracker/s/application-public/a102P000008puif,Nervous System
a0R2P000000LmZPUA0,Aripiprazole,A-00413,Abilify,Aripiprazole,Bristol-Myers Squibb,Schizophrenia,Decision,Aripiprazole (Abilify),/apptracker/s/application-public/a102P000008puW5,Nervous System
a0ROZ000004u9Kr2AI,Aripiprazole long acting injection,A-00411,,Aripiprazole long acting injection,Lundbeck,"People with or at high risk of metabolic syndrome or other serious side effects from currently funded atypical antipsychotic depot injections, or for people with schizophrenia with adherence challenges to oral atypical antipsychotics",Decision,Aripiprazole long acting injection,/apptracker/s/application-public/a102P000008puBE,Nervous System
a0R2P000000OcgWUAS,Asenapine,A-01253,Saphris,Asenapine,Lundbeck,Bipolar 1 disorder or schizophrenia,Decision,Asenapine (Saphris),/apptracker/s/application-public/a102P000008pu40,Nervous System
a0ROZ00000BGaUL2A1,Atogepant,A-04773,AQUIPTA,Atogepant,ABBVIE LIMITED,Chronic migraine prevention,Options Compared,Atogepant (AQUIPTA),/apptracker/s/application-public/a10OZ00000019Fl,Nervous System
a0R2P000000LmliUAC,Atomoxetine,A-00334,Strattera,Atomoxetine,Eli Lilly,2nd line ADHD   (methylphenidate intolerant patients),Decision,Atomoxetine (Strattera),/apptracker/s/application-public/a102P000008puj2,Nervous System
a0R2P000000LmrJUAS,Atomoxetine,A-01301,,Atomoxetine,Clinician,ADHD: first line for patients at significant risk of psychosis on methylphenidate or dexamphetamine,Decision,Atomoxetine,/apptracker/s/application-public/a102P000008puIx,Nervous System
a0R2P000000LmTvUAK,Atomoxetine,A-00865,Strattera,Atomoxetine,Clinician,ADHD (Attention Deficit Hyperactivity Disorder) - First-line and/or in combination with a stimulant,Decision,Atomoxetine (Strattera),/apptracker/s/application-public/a102P000008puLc,Nervous System
a0R2P000000NyAxUAK,"Benzocaine 18%, tetracaine hydrochloride 2% (Zap gel) topical anaesthetic",A-00758,Zap gel,"Benzocaine 18%, tetracaine hydrochloride 2% (Zap gel) topical anaesthetic",Clinician,topical anaesthetic for dental use,Decision,"Benzocaine 18%, tetracaine hydrochloride 2% (Zap gel) topical anaesthetic (Zap gel)",/apptracker/s/application-public/a102P000008ptuF,Nervous System
a0ROZ0000084s6r2AA,Buprenorphine injection (Buvidal),A-03883,Buvidal Weekly & Buvidal Monthly,Buprenorphine injection (Buvidal),Camurus AB,"Opioid dependence, maintenance treatment",Options Compared,Buprenorphine injection (Buvidal) (Buvidal Weekly & Buvidal Monthly),/apptracker/s/application-public/a102P00000BHRv4,Nervous System
a0ROZ000002BrKr2AK,Buprenorphine modified release solution for injection (Sublocade),A-03106,SUBLOCADE®,Buprenorphine modified release solution for injection (Sublocade),PHARMACY RETAILING (NZ) LIMITED,"Opioid dependence, maintenance treatment",Options Compared,Buprenorphine modified release solution for injection (Sublocade) (SUBLOCADE®),/apptracker/s/application-public/a102P00000Al9Ir,Nervous System
a0R2P000000fAU8UAM,Buprenorphine patches,A-00859 A-04380,Norspan,Buprenorphine patches,"Mundipharma, Clinician","Pain, persistent moderate/severe",Under Assessment,Buprenorphine patches (Norspan),/apptracker/s/application-public/a102P000008ptrY,Nervous System
a0R2P000000anV3UAI,Buprenorphine sublingual tablets,A-01359,,Buprenorphine sublingual tablets,Clinician,Opioid dependence during pregnancy and breastfeeding,Decision,Buprenorphine sublingual tablets,/apptracker/s/application-public/a102P000008puF8,Nervous System
a0ROZ000009J4M52AK,Buprenorphine sublingual tablets,A-00370,Temgesic,Buprenorphine sublingual tablets,Clinician,Acute pain,Decision,Buprenorphine sublingual tablets (Temgesic),/apptracker/s/application-public/a102P000008ptoz,Nervous System
a0R2P000000LmkuUAC,Buprenorphine/naloxone,A-01521,Suboxone,Buprenorphine/naloxone,Reckitt Benckiser,Opioid dependence - detoxification and maintenance treatment,Decision,Buprenorphine/naloxone (Suboxone),/apptracker/s/application-public/a102P000008pucv,Nervous System
a0R2P000000LmlXUAS,Bupropion,A-01438,,Bupropion,Clinician,Depression,Decision,Bupropion,/apptracker/s/application-public/a102P000008puix,Nervous System
a0R2P000000Lmj7UAC,Bupropion Hydrochloride,A-00183,Zyban,Bupropion Hydrochloride,GlaxoSmithKline,Smoking cessation,Decision,Bupropion Hydrochloride (Zyban),/apptracker/s/application-public/a102P000008puFA,Nervous System
a0ROZ00000AqQQe2AN,Cannabidiol,A-04183,Epidyolex oral solution,Cannabidiol,Clinician,"Dravet Syndrome, adjunctive therapy",Options Compared,Cannabidiol (Epidyolex oral solution),/apptracker/s/application-public/a102P00000BTLIN,Nervous System
a0ROZ00000Cn1wv2AB,Cannabidiol with tetrahydrocannabinol,A-00385,Sativex,Cannabidiol with tetrahydrocannabinol,To be determined,"Multiple sclerosis spasticity, epilepsy, pain and spasticity",Options Compared,Cannabidiol with tetrahydrocannabinol (Sativex),/apptracker/s/application-public/a102P000008ptyj,Nervous System
a0ROZ000004CLBG2A4,Capsaicin 0.075% cream,A-00706,,Capsaicin 0.075% cream,Clinician,Cannabinoid hyperemesis syndrome,Decision,Capsaicin 0.075% cream,/apptracker/s/application-public/a102P000008puaE,Nervous System
a0ROZ000003Notf2AC,Cladribine,A-00685 A-04772,,Cladribine,"Merck Serono, Merck Healthcare Pty Ltd",relapsing-remitting multiple sclerosis,Options Compared,Cladribine,/apptracker/s/application-public/a102P000008puCH,Nervous System
a0ROZ00000DilgT2AR,Clozapine intramuscular,A-05226,Clozapine,Clozapine intramuscular,Clinician,"Treatment-refractory psychotic disorder, refusing oral clozapine",Seeking Clinical Advice,Clozapine intramuscular (Clozapine),/apptracker/s/application-public/a10OZ000007jbH7,Nervous System
a0R2P000000LmW5UAK,Dimethyl fumarate,A-00315,,Dimethyl fumarate,Biogen,"Multiple sclerosis, relapse remitting",Decision,Dimethyl fumarate,/apptracker/s/application-public/a102P000008ptyN,Nervous System
a0ROZ0000000QYn2AM,Duloxetine hydrochloride,A-00841 A-04689,Cymbalta,Duloxetine hydrochloride,"Eli Lilly, Clinician",Depression - treatment-resistant major depressive disorder,Decision,Duloxetine hydrochloride (Cymbalta),/apptracker/s/application-public/a102P000008puGi,Nervous System
a0ROZ00000BGaUG2A1,Erenumab,A-03753 A-03152 A-04113,Aimovig,Erenumab,"Clinician, Consumer",Chronic migraine prevention,Options Compared,Erenumab (Aimovig),/apptracker/s/application-public/a102P00000BIw0I,Nervous System
a0R2P000000LmWGUA0,Escitalopram,A-01083,Loxalate,Escitalopram,Lundbeck,Major/severe depression,Decision,Escitalopram (Loxalate),/apptracker/s/application-public/a102P000008ptyQ,Nervous System
a0R2P000000LmitUAC,Escitalopram,A-00812,Lexapro,Escitalopram,Lundbeck,Treatment-resistant depression (alternative to venlafaxine),Decision,Escitalopram (Lexapro),/apptracker/s/application-public/a102P000008puF1,Nervous System
a0R2P000000LmVSUA0,Escitalopram,A-00820,Lexapro,Escitalopram,Lundbeck,Obsessive compulsive disorder,Decision,Escitalopram (Lexapro),/apptracker/s/application-public/a102P000008ptxW,Nervous System
a0ROZ000004CRa12AG,Esketamine,A-03087,SPRAVATO,Esketamine,JANSSEN NZ LIMITED,Treatment-resistant depression,Decision,Esketamine (SPRAVATO),/apptracker/s/application-public/a102P000009Loyo,Nervous System
a0ROZ000004CKbx2AG,Esketamine hydrochloride.,A-03443,SPRAVATO®,Esketamine hydrochloride.,JANSSEN NZ LIMITED,Major depressive disorder with active suicidal ideation with intent (MDSI).,Decision,Esketamine hydrochloride. (SPRAVATO®),/apptracker/s/application-public/a102P00000AUOmP,Nervous System
a0R2P000000WkjaUAC,Fentanyl citrate sublingual tablets,A-00612,,Fentanyl citrate sublingual tablets,A Menarini,Pain management for oncology patients,Decision,Fentanyl citrate sublingual tablets,/apptracker/s/application-public/a102P000008ptyv,Nervous System
a0R2P000000LmaLUAS,Fentanyl patches,A-01478,Durogesic,Fentanyl patches,Janssen,Widen access for chronic pain of malignant origin and renal failure,Decision,Fentanyl patches (Durogesic),/apptracker/s/application-public/a102P000008puYO,Nervous System
a0R2P000000LmgHUAS,"Fentanyl patches, low-dose",A-01489,Durogesic,"Fentanyl patches, low-dose",Janssen,Pain,Decision,"Fentanyl patches, low-dose (Durogesic)",/apptracker/s/application-public/a102P000008ptpl,Nervous System
a0R2P000000TEsiUAG,Fingolimod,A-01161,Gilenya,Fingolimod,Novartis,Multiple sclerosis,Decision,Fingolimod (Gilenya),/apptracker/s/application-public/a102P000008puZQ,Nervous System
a0ROZ00000Dabb32AB,Foslevodopa foscarbidopa,A-05259,VYALEV,Foslevodopa foscarbidopa,ABBVIE LIMITED,Advanced Parkinson’s Disease (aPD) with severe motor fluctuations despite optimised alternative pharmacological treatment,Under Assessment,Foslevodopa foscarbidopa (VYALEV),/apptracker/s/application-public/a10OZ000003vpNR,Nervous System
a0ROZ00000CpJmT2AV,Fremanezumab,A-05285,Ajovy,Fremanezumab,TEVA PHARMA (NEW ZEALAND) LIMITED,Episodic migraine prevention,Seeking Clinical Advice,Fremanezumab (Ajovy),/apptracker/s/application-public/a10OZ000004REhJ,Nervous System
a0ROZ00000Cpc8P2AR,Fremanezumab,A-05285,Ajovy,Fremanezumab,TEVA PHARMA (NEW ZEALAND) LIMITED,Chronic migraine prevention,Seeking Clinical Advice,Fremanezumab (Ajovy),/apptracker/s/application-public/a10OZ000004REnl,Nervous System
a0ROZ0000007fOD2AY,Gabapentin,A-01198,Neurontin,Gabapentin,Pfizer,Neuropathic pain,Decision,Gabapentin (Neurontin),/apptracker/s/application-public/a102P000008puFh,Nervous System
a0R2P000000LmZTUA0,Gabapentin,A-00235,Arrow-Gabapentin,Gabapentin,Clinician,Uraemic pruritus,Decision,Gabapentin (Arrow-Gabapentin),/apptracker/s/application-public/a102P000008puZS,Nervous System
a0R2P000000TSeZUAW,Gabapentin,A-01441,Nupentin,Gabapentin,Clinician,"Headache, chronic, daily",Decision,Gabapentin (Nupentin),/apptracker/s/application-public/a102P000008puih,Nervous System
a0R2P000000LmjmUAC,Gabapentin,A-01197,Neurontin,Gabapentin,Parke Davis,Partial seizures in patients who have not achieved adequate control with other anti-epileptic drugs,Decision,Gabapentin (Neurontin),/apptracker/s/application-public/a102P000008pufT,Nervous System
a0R2P000000OcgqUAC,Galantamine,A-00986,Reminyl,Galantamine,Janssen,Alzheimer's disease (Dementia),Decision,Galantamine (Reminyl),/apptracker/s/application-public/a102P000008puPi,Nervous System
a0ROZ00000Cn1x12AB,Galcanezumab,A-04467 A-04893 A-04758,Emgality,Galcanezumab,Consumer,Episodic migraine prevention,Options Compared,Galcanezumab (Emgality),/apptracker/s/application-public/a102P00000BYQiM,Nervous System
a0ROZ00000BOqrx2AD,Galcanezumab,A-04467 A-04893 A-04758 A-05532,Emgality,Galcanezumab,Consumer,Chronic migraine prevention,Options Compared,Galcanezumab (Emgality),/apptracker/s/application-public/a102P00000BXRxH,Nervous System
a0R2P000000LmlTUAS,Glatiramer acetate,A-01181,Copaxone,Glatiramer acetate,Clinician,Multiple sclerosis,Decision,Glatiramer acetate (Copaxone),/apptracker/s/application-public/a102P000008puiv,Nervous System
a0ROZ00000DU91Z2AT,Guanfacine,A-03629 A-04528 A-04684 A-05346 A-04866 A-04949,Intuniv,Guanfacine,"TAKEDA NEW ZEALAND LIMITED, Clinician, Consumer",Attention deficit hyperactivity disorder (ADHD),Seeking Clinical Advice,Guanfacine (Intuniv),/apptracker/s/application-public/a102P00000B55Zn,Nervous System
a0R2P000000LmjiUAC,Hyoscine,A-01251,Scopoderm Tts,Hyoscine,Clinician,Clozapine-induced hypersalivation (CIH),Decision,Hyoscine (Scopoderm Tts),/apptracker/s/application-public/a102P000008puhr,Nervous System
a0R2P000000TGP4UAO,Infliximab,A-00461,Remicade,Infliximab,Subcommittee recommendation,Neurosarcoidosis,Decision,Infliximab (Remicade),/apptracker/s/application-public/a102P000008ptwS,Nervous System
a0R2P000000Lmq2UAC,Interferon beta-1-alpha,A-01185,Avonex,Interferon beta-1-alpha,CSL,Relapsing remitting multiple sclerosis,Decision,Interferon beta-1-alpha (Avonex),/apptracker/s/application-public/a102P000008puC3,Nervous System
a0R2P000000Lmo2UAC,Interferon beta-1-beta,A-01183,Betaferon,Interferon beta-1-beta,Bayer,Relapsing remitting multiple sclerosis,Decision,Interferon beta-1-beta (Betaferon),/apptracker/s/application-public/a102P000008ptra,Nervous System
a0R2P000000MburUAC,Ketamine,A-00578,,Ketamine,Clinician,Emergency use for primary care,Reviewing Consultation Feedback,Ketamine,/apptracker/s/application-public/a102P000008puUd,Nervous System
a0ROZ00000DhPjf2AF,Ketamine (community use),A-00900,Biomed,Ketamine (community use),Clinician,"Intractable pain, palliative care patients, not adequately controlled with opioids",Reviewing Consultation Feedback,Ketamine (community use) (Biomed),/apptracker/s/application-public/a102P000008puSc,Nervous System
a0R2P000000LmVjUAK,Lacosamide,A-01035,,Lacosamide,UCB Pharma,Epilepsy (third-line treatment),Decision,Lacosamide,/apptracker/s/application-public/a102P000008ptwI,Nervous System
a0R2P000000TW90UAG,Lacosamide,A-00460,Vimpat,Lacosamide,Clinician,"Epilepsy, move up to 5th line",Options Compared,Lacosamide (Vimpat),/apptracker/s/application-public/a102P000008pu5w,Nervous System
a0ROZ00000128XB2AY,Lacosamide syrup,A-04263,Te Arai,Lacosamide syrup,TE ARAI BIOFARMA LIMITED,"Epilepsy,  same line as current special authority criteria",Options Compared,Lacosamide syrup (Te Arai),/apptracker/s/application-public/a102P00000BVtwY,Nervous System
a0R2P000000LmbdUAC,Lamotrigine,A-01147,"Lamictal, Arrow-Lamotrigine, Lamotrigine-DP",Lamotrigine,GlaxoSmithKline,Bipolar disorder,Decision,"Lamotrigine (Lamictal, Arrow-Lamotrigine, Lamotrigine-DP)",/apptracker/s/application-public/a102P000008pu6j,Nervous System
a0R2P000000LmkJUAS,Levetiracetam,A-00027,Keppra,Levetiracetam,UCB Pharma,Epilepsy,Decision,Levetiracetam (Keppra),/apptracker/s/application-public/a102P000008pucY,Nervous System
a0ROZ000003PB9p2AG,Levetiracetam (subcutaneous),A-03277,Levetiracetam AFT,Levetiracetam (subcutaneous),Clinician,"Seizure control ,palliative care",Decision,Levetiracetam (subcutaneous) (Levetiracetam AFT),/apptracker/s/application-public/a102P000009utiT,Nervous System
a0ROZ000009SEaj2AG,Levodopa / Carbidopa intestinal gel,A-00539,Duodopa,Levodopa / Carbidopa intestinal gel,AbbVie,Advanced Parkinson's with severe motor fluctuations despite optimised alternative treatment,Under Assessment,Levodopa / Carbidopa intestinal gel (Duodopa),/apptracker/s/application-public/a102P000008puND,Nervous System
a0ROZ000000W3sQ2AS,Levomilnacipran,A-00796,,Levomilnacipran,Consumer,major depressive disorder,Decision,Levomilnacipran,/apptracker/s/application-public/a102P000008pu4T,Nervous System
a0R2P000000LmjSUAS,Lidocaine [lignocaine] cream 4%,A-00236,LMX4,Lidocaine [lignocaine] cream 4%,Orion,"Anaesthetic: topical, local",Decision,Lidocaine [lignocaine] cream 4% (LMX4),/apptracker/s/application-public/a102P000008pufC,Nervous System
a0R2P000000OcgvUAC,Lidocaine [lignocaine] gel 2% (community listing),A-01320,,Lidocaine [lignocaine] gel 2% (community listing),NPPA,Pain,Decision,Lidocaine [lignocaine] gel 2% (community listing),/apptracker/s/application-public/a102P000008puBw,Nervous System
a0R2P000000NNE0UAO,"Lidocaine [lignocaine] Gel 2%, 10 ml urethral syringe",A-00760,,"Lidocaine [lignocaine] Gel 2%, 10 ml urethral syringe",Clinician,Intractable rectal pain/tenesmus in palliative care,Decision,"Lidocaine [lignocaine] Gel 2%, 10 ml urethral syringe",/apptracker/s/application-public/a102P000008puYK,Nervous System
a0R2P000000TW92UAG,Lidocaine [lignocaine] with adrenaline and tetracaine (4%; 0.1%; 0.5%),A-00276,,Lidocaine [lignocaine] with adrenaline and tetracaine (4%; 0.1%; 0.5%),Subcommittee recommendation,Wound repair for children,Options Compared,Lidocaine [lignocaine] with adrenaline and tetracaine (4%; 0.1%; 0.5%),/apptracker/s/application-public/a102P000008pufj,Nervous System
a0R2P000000cT2KUAU,Lidocaine [Lignocaine] With Prilocaine,A-01345 A-03240,Emla,Lidocaine [Lignocaine] With Prilocaine,"NPPA, Consumer",Widening community access for adults,Options Compared,Lidocaine [Lignocaine] With Prilocaine (Emla),/apptracker/s/application-public/a102P000008puWa,Nervous System
a0R2P000000anbAUAQ,Lidocaine [Lignocaine] With Prilocaine,A-00275,Emla,Lidocaine [Lignocaine] With Prilocaine,Subcommittee recommendation,Pain,Decision,Lidocaine [Lignocaine] With Prilocaine (Emla),/apptracker/s/application-public/a102P000008puMy,Nervous System
a0ROZ000001kWU92AM,Lidocaine 10%,A-03630,Xylocard 500,Lidocaine 10%,Clinician,"Pain, terminally ill patients,  intravenous route is not appropriate",Decision,Lidocaine 10% (Xylocard 500),/apptracker/s/application-public/a102P00000BCCcR,Nervous System
a0R2P000000anJfUAI,"Lidocaine 2.5%, prilocaine 2.5% (Oraqix) dental cartridges",A-00759,Oraqix,"Lidocaine 2.5%, prilocaine 2.5% (Oraqix) dental cartridges",Clinician,Topical local anaesthetic for dental use,Decision,"Lidocaine 2.5%, prilocaine 2.5% (Oraqix) dental cartridges (Oraqix)",/apptracker/s/application-public/a102P000008ptsI,Nervous System
a0ROZ000005pbYv2AI,Lisdexamfetamine dimesilate,A-03211 A-03096 A-04828,VYVANSE®,Lisdexamfetamine dimesilate,"TAKEDA NEW ZEALAND LIMITED, Consumer",Attention Deficit Hyperactivity Disorder (ADHD),Decision,Lisdexamfetamine dimesilate (VYVANSE®),/apptracker/s/application-public/a102P00000BHRok,Nervous System
a0R2P000000SNPbUAO,Melatonin,A-01490,Circadin,Melatonin,Clinician,Insomnia - secondary to dementia,Decision,Melatonin (Circadin),/apptracker/s/application-public/a102P000008pu1r,Nervous System
a0R2P000000SNPvUAO,Melatonin,A-01443,Circadin,Melatonin,Aspen,"Insomnia - primary, patients aged >55 years",Decision,Melatonin (Circadin),/apptracker/s/application-public/a102P000008pubG,Nervous System
a0R2P000000TEzIUAW,Melatonin,A-01288,Circadin,Melatonin,Clinician,"Insomnia - Children and adolescents, secondary to neurodevelopmental disorders",Decision,Melatonin (Circadin),/apptracker/s/application-public/a102P000008pukf,Nervous System
a0R2P000000LmlrUAC,Meloxicam,A-00918,,Meloxicam,Clinician,Haemophilia with arthropathy,Decision,Meloxicam,/apptracker/s/application-public/a102P000008puj6,Nervous System
a0R2P000000Lmk5UAC,Memantine,A-01108,Exiba,Memantine,Clinician,Severe behavioural disturbance in patients with moderate-severe dementia,Decision,Memantine (Exiba),/apptracker/s/application-public/a102P000008pucP,Nervous System
a0R2P000000LmaBUAS,Memantine,A-00082,Exiba,Memantine,Lundbeck,Moderate to Severe Alzheimer's Disease,Decision,Memantine (Exiba),/apptracker/s/application-public/a102P000008puQB,Nervous System
a0ROZ00000BVWIE2A5,Memantine hydrochloride,A-04333,EBIXA,Memantine hydrochloride,Consumer,"Dementia, 1st line",Reviewing Consultation Feedback,Memantine hydrochloride (EBIXA),/apptracker/s/application-public/a102P00000BVtzr,Nervous System
a0ROZ00000BVlvZ2AT,Memantine hydrochloride,A-04013,Ebixa,Memantine hydrochloride,Clinician,"Dementia, moderate, cholinesterases not tolerable",Reviewing Consultation Feedback,Memantine hydrochloride (Ebixa),/apptracker/s/application-public/a102P00000BVu0Q,Nervous System
a0R2P000000LmkaUAC,Metclopramide,A-00892,,Metclopramide,Clinician,Nausea and vomiting,Decision,Metclopramide,/apptracker/s/application-public/a102P000008pueb,Nervous System
a0R2P000000LmqeUAC,Methoxyflurane,A-01225,Penthrox,Methoxyflurane,Medical Developments International,Pain,Decision,Methoxyflurane (Penthrox),/apptracker/s/application-public/a102P000008puCO,Nervous System
a0R2P000000TW8yUAG,Methoxyflurane,A-00240,Penthrox,Methoxyflurane,Medical Developments International,Pain relief,Options Compared,Methoxyflurane (Penthrox),/apptracker/s/application-public/a102P000008puQf,Nervous System
a0R2P000000LmhVUAS,Methylphenidate ER,A-00233,Concerta,Methylphenidate ER,Janssen,ADHD - second line,Decision,Methylphenidate ER (Concerta),/apptracker/s/application-public/a102P000008puFL,Nervous System
a0R2P000000LmVEUA0,Methylphenidate hydrochloride,A-01491,,Methylphenidate hydrochloride,Clinician,"Depression, treatment resistant",Decision,Methylphenidate hydrochloride,/apptracker/s/application-public/a102P000008ptyr,Nervous System
a0R2P000000LmYfUAK,Methylphenidate hydrochloride,A-00127,Ritalin LA,Methylphenidate hydrochloride,Novartis,Second line for ADHD,Decision,Methylphenidate hydrochloride (Ritalin LA),/apptracker/s/application-public/a102P000008puUi,Nervous System
a0R2P000000TGO6UAO,Methylphenidate hydrochloride,A-01396,,Methylphenidate hydrochloride,Clinician,Traumatic brain injury and acquired brain injury,Decision,Methylphenidate hydrochloride,/apptracker/s/application-public/a102P000008ptqg,Nervous System
a0R2P000000LmjeUAC,Methylphenidate Hydrochloride,A-01360,,Methylphenidate Hydrochloride,Clinician,Depression in terminally ill patients,Decision,Methylphenidate Hydrochloride,/apptracker/s/application-public/a102P000008pudU,Nervous System
a0ROZ00000096UP2AY,Mianserin Hydrochloride,A-00982,Tolvon,Mianserin Hydrochloride,Clinician,Widening access to include treatment-resistant depression,Decision,Mianserin Hydrochloride (Tolvon),/apptracker/s/application-public/a102P000008pu9H,Nervous System
a0ROZ00000BV7Of2AL,Micronutrient formulas,A-00454 A-04278,,Micronutrient formulas,Clinician,ADHD and or mood dysregulation,Reviewing Consultation Feedback,Micronutrient formulas,/apptracker/s/application-public/a102P000008puPl,Nervous System
a0R2P000000LmUIUA0,Midazolam - available on a PSO,A-00567,,Midazolam - available on a PSO,To be determined,Status epilepticus,Decision,Midazolam - available on a PSO,/apptracker/s/application-public/a102P000008puLy,Nervous System
a0R2P000000LmnRUAS,Mirtazapine,A-00720,,Mirtazapine,Clinician,Depression,Decision,Mirtazapine,/apptracker/s/application-public/a102P000008pu0l,Nervous System
a0R2P000000WlNLUA0,Modafinil,A-00300,Modavigil,Modafinil,Clinician,"Mood disorders, psychoses, attention deficit disorders, drug dependency and shift workers",Decision,Modafinil (Modavigil),/apptracker/s/application-public/a102P000008puDM,Nervous System
a0R2P000000fSvnUAE,Modafinil,A-03150,Modavigil,Modafinil,Consumer,Excessive Daytime Sleepiness in Obstructive Sleep Apnoea,Decision,Modafinil (Modavigil),/apptracker/s/application-public/a102P000009qt5x,Nervous System
a0ROZ0000003pu12AA,Modafinil,A-01028,Modavigil,Modafinil,CSL,Narcolepsy - first-line,Options Compared,Modafinil (Modavigil),/apptracker/s/application-public/a102P000008pu2H,Nervous System
a0R2P000000bp8jUAA,Multiple Sclerosis (MS) Treatments,A-03701,,Multiple Sclerosis (MS) Treatments,Clinician,Widen access to include patients who meet the 2017 McDonald criteria,Decision,Multiple Sclerosis (MS) Treatments,/apptracker/s/application-public/a102P00000Ano3u,Nervous System
a0ROZ000004CPmm2AG,Multiple Sclerosis (MS) treatments,A-00636,,Multiple Sclerosis (MS) treatments,Clinician,Amending definition of Significant Relapse to 24 hr duration,Decision,Multiple Sclerosis (MS) treatments,/apptracker/s/application-public/a102P000008puhC,Nervous System
a0ROZ000004CX2j2AG,Multiple Sclerosis (MS) treatments,A-00637,,Multiple Sclerosis (MS) treatments,Clinician,Amending access criteria to include an additional measurement scale,Decision,Multiple Sclerosis (MS) treatments,/apptracker/s/application-public/a102P000008puD8,Nervous System
a0R2P000000SQAMUA4,Multiple Sclerosis (MS) treatments,A-00675,"Aubagio,avonex,Betaferon,Copaxone,Gilenya,Tecfidera,Tysabri",Multiple Sclerosis (MS) treatments,Clinician,Amending stopping criteria to EDSS 6.5 (note recommendation for funding was amending stopping criteria to EDSS 6.0),Decision,"Multiple Sclerosis (MS) treatments (Aubagio,avonex,Betaferon,Copaxone,Gilenya,Tecfidera,Tysabri)",/apptracker/s/application-public/a102P000008pu52,Nervous System
a0ROZ000004CXFd2AO,Multiple Sclerosis (MS) treatments,A-00635,,Multiple Sclerosis (MS) treatments,Clinician,Amending entry criteria to include CIS,Decision,Multiple Sclerosis (MS) treatments,/apptracker/s/application-public/a102P000008puTK,Nervous System
a0R2P000000LmWNUA0,Naltrexone hydrochloride,A-00822 A-00823,ReVia,Naltrexone hydrochloride,"Clinician, Consumer",Alcohol dependence - amending access criteria,Decision,Naltrexone hydrochloride (ReVia),/apptracker/s/application-public/a102P000008ptxk,Nervous System
a0ROZ0000006KQf2AM,Naltrexone hydrochloride,A-01179,ReVia,Naltrexone hydrochloride,Baxter,Alcohol dependence,Decision,Naltrexone hydrochloride (ReVia),/apptracker/s/application-public/a102P000008puZD,Nervous System
a0R2P000000LmpWUAS,Naltrexone hydrochloride,A-00993,ReVia,Naltrexone hydrochloride,Clinician,Changes to criterion requiring applicant to work in a CADS,Decision,Naltrexone hydrochloride (ReVia),/apptracker/s/application-public/a102P000008puCU,Nervous System
a0R2P000000OciNUAS,Naratriptan,A-00851,,Naratriptan,GlaxoSmithKline,Migraine,Decision,Naratriptan,/apptracker/s/application-public/a102P000008ptph,Nervous System
a0R2P000000TEl3UAG,Natalizumab,A-01214,Tysabri,Natalizumab,Biogen,Multiple sclerosis,Decision,Natalizumab (Tysabri),/apptracker/s/application-public/a102P000008ptwK,Nervous System
a0ROZ00000129JZ2AY,Natalizumab (subcutaneous administration),A-04477,TYSABRI®,Natalizumab (subcutaneous administration),BIOGEN NZ BIOPHARMA LIMITED,Relapsing-remitting multiple sclerosis (RRMS),Options Compared,Natalizumab (subcutaneous administration) (TYSABRI®),/apptracker/s/application-public/a102P00000BYlWI,Nervous System
a0ROZ000004CWuf2AG,"ngolimod,Glatiramer Acetate, Interferon Beta 1A, Interferon Beta 1B, Natalizumab",A-00528,"Any,Avonex,Betaferon,Gilenya,Tysabri","Multiple Sclerosis (MS) treatments - Fingolimod,Glatiramer Acetate, Interferon Beta 1A, Interferon Beta 1B, Natalizumab",Subcommittee recommendation,clinically isolated syndrome fulfilling the McDonald 2010 diagnostic criteria,Decision,"Multiple Sclerosis (MS) treatments - Fingolimod,Glatiramer Acetate, Interferon Beta 1A, Interferon Beta 1B, Natalizumab (Any,Avonex,Betaferon,Gilenya,Tysabri)",/apptracker/s/application-public/a102P000008puiO,Nervous System
a0R2P000000TEyFUAW,Nicotine inhaler,A-01329,Nicorette,Nicotine inhaler,Johnson & Johnson Medical,Smoking cessation,Decision,Nicotine inhaler (Nicorette),/apptracker/s/application-public/a102P000008puiE,Nervous System
a0R2P000000W3sfUAC,Nicotine oral spray,A-01439,Nicorette QuickMist,Nicotine oral spray,Johnson & Johnson Medical,Nicotine addiction management in high need hospital patients,Decision,Nicotine oral spray (Nicorette QuickMist),/apptracker/s/application-public/a102P000008puLe,Nervous System
a0R2P000000LmasUAC,Nicotine replacement therapy sample packs,A-00282,,Nicotine replacement therapy sample packs,Clinician,"Smoking cessation, increasing attempts",Decision,Nicotine replacement therapy sample packs,/apptracker/s/application-public/a102P000008puTG,Nervous System
a0R2P000000cI4xUAE,Nusinersen,A-00755,Spinraza,Nusinersen,Biogen,"Spinal muscular atrophy Type I, II and III",Decision,Nusinersen (Spinraza),/apptracker/s/application-public/a102P000008puSr,Nervous System
a0R2P000000cI4sUAE,Nusinersen (Spinraza),A-00714 A-00755,,Nusinersen (Spinraza),"Biogen, Biogen",Presymptomatic individuals with spinal muscular atrophy,Decision,Nusinersen (Spinraza),/apptracker/s/application-public/a102P000009QXCv,Nervous System
a0R2P000000YbV5UAK,Ocrelizumab,A-00563,,Ocrelizumab,Roche,Relapse (remitting) multiple sclerosis,Decision,Ocrelizumab,/apptracker/s/application-public/a102P000008puFI,Nervous System
a0ROZ0000006HRB2A2,Ocrelizumab,A-00599 A-03502,,Ocrelizumab,"Roche, ROCHE PRODUCTS (NEW ZEALAND) LIMITED",Primary Progressive Multiple Sclerosis,Decision,Ocrelizumab,/apptracker/s/application-public/a102P000008puUE,Nervous System
a0ROZ00000CHiAb2AL,Ocrelizumab subcutaneous formulation,A-05146,OCREVUS SC,Ocrelizumab subcutaneous formulation,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Same indications as the intravenous formulation (relapsing remitting multiple sclerosis, and primary progressive multiple sclerosis)",Decision,Ocrelizumab subcutaneous formulation (OCREVUS SC),/apptracker/s/application-public/a10OZ0000024MK9,Nervous System
a0ROZ000000PXic2AG,Ofatumumab,A-04341,KESIMPTA,Ofatumumab,NOVARTIS NEW ZEALAND LIMITED,Relapsing Remitting Multiple Sclerosis (MS),Options Compared,Ofatumumab (KESIMPTA),/apptracker/s/application-public/a102P00000BXRxM,Nervous System
a0ROZ0000007fG92AI,Olanzapine,A-01125,Zyprexa,Olanzapine,Eli Lilly,Second line treatment of acute manic or mixed episodes in bipolar disorder,Decision,Olanzapine (Zyprexa),/apptracker/s/application-public/a102P000008puTJ,Nervous System
a0R2P000000LmiKUAS,Olanzapine,A-01123,Zyprexa,Olanzapine,Eli Lilly,Second line treatment for schizophrenia and related psychoses,Decision,Olanzapine (Zyprexa),/apptracker/s/application-public/a102P000008puEa,Nervous System
a0R2P000000LmdIUAS,Olanzapine depot,A-00964,,Olanzapine depot,Eli Lilly,Schizophrenia - for patients who are non-compliant with oral treatments,Decision,Olanzapine depot,/apptracker/s/application-public/a102P000008pu7d,Nervous System
a0R2P000000LmZlUAK,Olanzapine depot injection,A-00898,Zyprexa Relprevv,Olanzapine depot injection,Eli Lilly,Schizophrenia,Decision,Olanzapine depot injection (Zyprexa Relprevv),/apptracker/s/application-public/a102P000008puTp,Nervous System
a0R2P000000M873UAC,Omega-3 fatty acids,A-01252,Fish Oils,Omega-3 fatty acids,Clinician,Schizophrenia - augmentation of antipsychotics,Decision,Omega-3 fatty acids (Fish Oils),/apptracker/s/application-public/a102P000008puV4,Nervous System
a0ROZ00000D1R572AF,Onasemnogene abeparvovec,A-04397,ZOLGENSMA,Onasemnogene abeparvovec,NOVARTIS NEW ZEALAND LIMITED,"Spinal muscular atrophy (SMA), pre-symptomatic or type 1",Options Compared,Onasemnogene abeparvovec (ZOLGENSMA),/apptracker/s/application-public/a102P00000BY8r2,Nervous System
a0ROZ000000AP3Z2AW,Oxcarbazepine,A-01544,,Oxcarbazepine,Novartis,Epilepsy - second line (after carbamazepine),Under Assessment,Oxcarbazepine,/apptracker/s/application-public/a102P000008ptss,Nervous System
a0ROZ0000007fPp2AI,Oxycodone hydrochloride,A-01118,OxyContin,Oxycodone hydrochloride,Mundipharma,Pain,Decision,Oxycodone hydrochloride (OxyContin),/apptracker/s/application-public/a102P000008puDX,Nervous System
a0ROZ000003nol72AA,Paliperidone  (three monthly depot),A-04505,Invega Trinza,Paliperidone  (three monthly depot),Consumer,Schizoaffective Disorder,Seeking Clinical Advice,Paliperidone  (three monthly depot) (Invega Trinza),/apptracker/s/application-public/a102P00000Baahe,Nervous System
a0R2P000000bslZUAQ,Paliperidone 3 monthly depot injection,A-00507,INVEGA TRINZA,Paliperidone 3 monthly depot injection,Janssen,Schizophrenia,Decision,Paliperidone 3 monthly depot injection (INVEGA TRINZA),/apptracker/s/application-public/a102P000008ptup,Nervous System
a0R2P000000LmdjUAC,Paliperidone Palmitate depot injection,A-00971,Invega Sustenna,Paliperidone Palmitate depot injection,Janssen,Schizophrenia,Decision,Paliperidone Palmitate depot injection (Invega Sustenna),/apptracker/s/application-public/a102P000008puaf,Nervous System
a0R2P000000Och5UAC,Paliperidone tablets,A-00897,Invega,Paliperidone tablets,Janssen,Schizophrenia second-line to risperidone or quetiapine,Decision,Paliperidone tablets (Invega),/apptracker/s/application-public/a102P000008puM8,Nervous System
a0R2P000000anY1UAI,"Paliperidone, risperidone, olanzapine depot injections",A-00383,,"Paliperidone, risperidone, olanzapine depot injections",Clinician,Amending access criteria,Decision,"Paliperidone, risperidone, olanzapine depot injections",/apptracker/s/application-public/a102P000008pu54,Nervous System
a0ROZ000000AP8P2AW,Paracetamol 1000 mg with ibuprofen 300 mg in 100 mL solution for infusion,A-03337,Maxigesic IV,Paracetamol 1000 mg with ibuprofen 300 mg in 100 mL solution for infusion,Clinician,Acute pain (hospital use),Options Compared,Paracetamol 1000 mg with ibuprofen 300 mg in 100 mL solution for infusion (Maxigesic IV),/apptracker/s/application-public/a102P00000A9y1G,Nervous System
a0R2P000000anfqUAA,Paracetamol 500 mg with ibuprofen 150 mg,A-01003,Maxigesic,Paracetamol 500 mg with ibuprofen 150 mg,AFT Pharmaceuticals,Analgesia,Decision,Paracetamol 500 mg with ibuprofen 150 mg (Maxigesic),/apptracker/s/application-public/a102P000008puhX,Nervous System
a0R2P000000LmVFUA0,Paracetamol sustained release,A-01336,Panadol Osteo,Paracetamol sustained release,GlaxoSmithKline,Pain,Decision,Paracetamol sustained release (Panadol Osteo),/apptracker/s/application-public/a102P000008ptvl,Nervous System
a0R2P000000Sk4jUAC,Peginterferon beta-1a (rch),A-00610,,Peginterferon beta-1a (rch),Biogen,Relapsing forms of multiple sclerosis,Decision,Peginterferon beta-1a (rch),/apptracker/s/application-public/a102P000008pu5g,Nervous System
a0ROZ00000Db3vV2AR,Perampanel,A-03631,FYCOMPA®,Perampanel,EISAI NEW ZEALAND LIMITED,Generalised epilepsy,Under Assessment,Perampanel (FYCOMPA®),/apptracker/s/application-public/a102P00000AlVIh,Nervous System
a0ROZ00000721da2AA,Perampanel,A-03638,FYCOMPA®,Perampanel,EISAI NEW ZEALAND LIMITED,Focal epilepsy,Options Compared,Perampanel (FYCOMPA®),/apptracker/s/application-public/a102P00000AlVHF,Nervous System
a0R2P000000LmiDUAS,Pramipexole,A-00048,,Pramipexole,Boehringer Ingelheim,Parkinson's disease,Decision,Pramipexole,/apptracker/s/application-public/a102P000008pucM,Nervous System
a0R2P000000LmYEUA0,Pregabalin,A-01061,Lyrica,Pregabalin,Pfizer,Neuropathic pain,Decision,Pregabalin (Lyrica),/apptracker/s/application-public/a102P000008pu0a,Nervous System
a0R2P000000Lmn2UAC,Pregabalin,A-00349,Lyrica,Pregabalin,Clinician,Generalised anxiety disorder,Decision,Pregabalin (Lyrica),/apptracker/s/application-public/a102P000008ptrN,Nervous System
a0R2P000000LmZvUAK,Quetiapine,A-01134,"Dr Reddy's Quetiapine,Quetapel,Seroquel",Quetiapine,AstraZeneca,Schizophrenia,Decision,"Quetiapine (Dr Reddy's Quetiapine,Quetapel,Seroquel)",/apptracker/s/application-public/a102P000008puTi,Nervous System
a0ROZ0000006LBR2A2,Quetiapine,A-01137,Seroquel,Quetiapine,AstraZeneca,Mania associated with Bipolar disorder,Decision,Quetiapine (Seroquel),/apptracker/s/application-public/a102P000008pu75,Nervous System
a0R2P000000OchFUAS,Quetiapine extended-release tablets,A-00975,Seroquel XR,Quetiapine extended-release tablets,AstraZeneca,Schizophrenia and bipolar disorder,Decision,Quetiapine extended-release tablets (Seroquel XR),/apptracker/s/application-public/a102P000008ptsb,Nervous System
a0R2P000000WlmzUAC,Riluzole,A-01415,Rilutek,Riluzole,Clinician,Amending access for amyotrophic lateral sclerosis,Decision,Riluzole (Rilutek),/apptracker/s/application-public/a102P000008puXD,Nervous System
a0R2P000000LmohUAC,Riluzole,A-00909,Rilutek,Riluzole,Sanofi-Aventis,Amyotrophic lateral sclerosis,Decision,Riluzole (Rilutek),/apptracker/s/application-public/a102P000008pu32,Nervous System
a0ROZ00000039LJ2AY,Risdiplam,A-03717,Evrysdi,Risdiplam,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Pre-symptomatic spinal muscular atrophy (SMA),Decision,Risdiplam (Evrysdi),/apptracker/s/application-public/a102P00000BURRd,Nervous System
a0R2P000000fFB2UAM,Risdiplam,A-03717,Evrysdi,Risdiplam,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Spinal muscular atrophy (SMA), Types 1-3",Decision,Risdiplam (Evrysdi),/apptracker/s/application-public/a102P00000BB5pi,Nervous System
a0R2P000000Lma0UAC,Risperidone depot injection,A-01128,Risperdal Consta,Risperidone depot injection,Janssen,Patients with schizophrenia with a history of relapse due to non-compliance,Decision,Risperidone depot injection (Risperdal Consta),/apptracker/s/application-public/a102P000008puYI,Nervous System
a0R2P000000LmcfUAC,Risperidone orally disintegrating tablets,A-01129,Risperdal Quicklet,Risperidone orally disintegrating tablets,Janssen,Second-line treatment of schizophrenia & related psychoses,Decision,Risperidone orally disintegrating tablets (Risperdal Quicklet),/apptracker/s/application-public/a102P000008pu79,Nervous System
a0R2P000000LmkWUAS,Risperidone tablets,A-01127,Risperdal,Risperidone tablets,Janssen,Schizophrenia,Decision,Risperidone tablets (Risperdal),/apptracker/s/application-public/a102P000008pugY,Nervous System
a0R2P000000gVXoUAM,Rituximab,A-00593,,Rituximab,Clinician,Neuromyelitis optica spectrum disorder (NMOSD),Decision,Rituximab,/apptracker/s/application-public/a102P000008pttn,Nervous System
a0R2P000000N6iGUAS,Rivastigmine patches,A-00811,Exelon,Rivastigmine patches,Novartis,"Alzheimer's disease, donepezil intolerant",Decision,Rivastigmine patches (Exelon),/apptracker/s/application-public/a102P000008pubw,Nervous System
a0ROZ00000DqVYA2A3,Rotigotine,A-04502,Neupro,Rotigotine,Clinician,Restless leg syndrome,Options Compared,Rotigotine (Neupro),/apptracker/s/application-public/a102P00000BXb9h,Nervous System
a0R2P000000anedUAA,Rotigotine,A-00314,,Rotigotine,UCB Pharma,Parkinson's disease,Decision,Rotigotine,/apptracker/s/application-public/a102P000008puXF,Nervous System
a0ROZ00000128aP2AQ,Rotigotine,A-04502,Neupro,Rotigotine,Clinician,Parkinson's disease,Options Compared,Rotigotine (Neupro),/apptracker/s/application-public/a102P00000BXb9N,Nervous System
a0ROZ00000AQknx2AD,Rufinamide,A-03931,INOVELON®,Rufinamide,EISAI NEW ZEALAND LIMITED,Developmental and epileptic encephalopathies,Options Compared,Rufinamide (INOVELON®),/apptracker/s/application-public/a102P00000BHRQO,Nervous System
a0R2P000000LmgWUAS,Sertraline,A-00833,,Sertraline,Clinician,Depression,Decision,Sertraline,/apptracker/s/application-public/a102P000008ptus,Nervous System
a0ROZ000000xTPP2A2,Siponimod,A-03996,MAYZENT,Siponimod,NOVARTIS NEW ZEALAND LIMITED,Secondary Progressive Multiple Sclerosis (SPMS),Under Assessment,Siponimod (MAYZENT),/apptracker/s/application-public/a102P00000BOsXf,Nervous System
a0ROZ00000CqzLR2AZ,SMA treatments,A-04568 A-03717 A-00755,nusinersen (Spinraza) and risdiplam (Evrysdi),SMA treatments,"ROCHE PRODUCTS (NEW ZEALAND) LIMITED, Biogen, Clinician",People with SMA type II and III who are aged 19 years and over,Options Compared,SMA treatments (nusinersen (Spinraza) and risdiplam (Evrysdi)),/apptracker/s/application-public/a102P00000BYT2Q,Nervous System
a0R2P000000Lmh9UAC,Sugammadex,A-01335,Bridion,Sugammadex,Merck Sharp & Dohme,Anaesthetic procedures - reversal of neuromuscular blockade,Decision,Sugammadex (Bridion),/apptracker/s/application-public/a102P000008ptul,Nervous System
a0R2P000000anImUAI,Tetracaine (amethocaine) gel 4% (community listing),A-01344,Ametop Gel,Tetracaine (amethocaine) gel 4% (community listing),NPPA,Pain,Decision,Tetracaine (amethocaine) gel 4% (community listing) (Ametop Gel),/apptracker/s/application-public/a102P000008ptqj,Nervous System
a0R2P000000LmmeUAC,Topiramate,A-00071,Topamax,Topiramate,Janssen,Migraine prophylaxis,Decision,Topiramate (Topamax),/apptracker/s/application-public/a102P000008ptsw,Nervous System
a0ROZ00000096kX2AQ,Tramadol,A-01500,Tramal,Tramadol,CSL,Pain,Decision,Tramadol (Tramal),/apptracker/s/application-public/a102P000008puiF,Nervous System
a0R2P000000LmdFUAS,"treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate",A-00857 A-00858,"Avonex, Betaferon, Copaxone","Multiple Sclerosis (MS) treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate","Multiple Sclerosis Treatment Assessments Committee, Clinician",Amending criteria to permit treatment switching,Decision,"Multiple Sclerosis (MS) treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate (Avonex, Betaferon, Copaxone)",/apptracker/s/application-public/a102P000008pubv,Nervous System
a0ROZ000004CRyG2AW,"treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate",A-00855 A-00856,"Avonex, Betaferon, Copaxone","Multiple Sclerosis treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate","Multiple Sclerosis Treatment Assessments Committee, Clinician",Multiple sclerosis (MS) - amending entry criteria,Decision,"Multiple Sclerosis treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate (Avonex, Betaferon, Copaxone)",/apptracker/s/application-public/a102P000008puX6,Nervous System
a0R2P000000LmgLUAS,"treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate",A-00873 A-00874,"Avonex, Betaferon, Copaxone","Multiple Sclerosis (MS) treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate","Multiple Sclerosis Treatment Assessments Committee, Clinician",Amending exit criteria,Decision,"Multiple Sclerosis (MS) treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate (Avonex, Betaferon, Copaxone)",/apptracker/s/application-public/a102P000008ptuo,Nervous System
a0ROZ000004CX9B2AW,"treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate",A-01011 A-01012,"Avonex, Betaferon, Copaxone","Multiple Sclerosis (MS) treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate","Multiple Sclerosis Treatment Assessments Committee, Clinician",Removal of exit criteria,Decision,"Multiple Sclerosis (MS) treatments - interferon beta-1-alpha, interferon beta-1-beta, glatiramer acetate (Avonex, Betaferon, Copaxone)",/apptracker/s/application-public/a102P000008pujf,Nervous System
a0R2P000000N6iTUAS,Varenicline,A-00172,,Varenicline,Pfizer,Smoking cessation,Decision,Varenicline,/apptracker/s/application-public/a102P000008pukY,Nervous System
a0R2P000000anWtUAI,Varenicline Tartrate,A-00428,Champix,Varenicline Tartrate,Pfizer,Adjustment to treatment periods,Decision,Varenicline Tartrate (Champix),/apptracker/s/application-public/a102P000008pu3V,Nervous System
a0R2P000000TGUJUA4,Varenicline Tartrate,A-00498,Champix,Varenicline Tartrate,Pfizer,Smoking cessation - Reducing re-treatment period from 12 months to 6 months,Decision,Varenicline Tartrate (Champix),/apptracker/s/application-public/a102P000008puje,Nervous System
a0ROZ000006Ejmc2AC,Varenicline Tartrate,A-00717,Champix,Varenicline Tartrate,Pfizer,"Smoking cessation, open-listing",Options Compared,Varenicline Tartrate (Champix),/apptracker/s/application-public/a102P000008ptwz,Nervous System
a0R2P000000Lmc9UAC,Varenicline Tartrate,A-00487,Champix,Varenicline Tartrate,Pfizer,Increasing size of starter pack to 4 weeks,Decision,Varenicline Tartrate (Champix),/apptracker/s/application-public/a102P000008puAr,Nervous System
a0R2P000000LmbPUAS,Venlafaxine 37.5 mg extended-release,A-00721,Efexor XR,Venlafaxine 37.5 mg extended-release,Clinician,Treatment resistant depression,Decision,Venlafaxine 37.5 mg extended-release (Efexor XR),/apptracker/s/application-public/a102P000008puSf,Nervous System
a0R2P000000LmgSUAS,Vigabatrin,A-00849,Sabril,Vigabatrin,Clinician,Infantile spasms,Decision,Vigabatrin (Sabril),/apptracker/s/application-public/a102P000008ptpn,Nervous System
a0R2P000000LmYFUA0,Ziprasidone,A-00205,Zeldox,Ziprasidone,Pfizer,Schizophrenia,Decision,Ziprasidone (Zeldox),/apptracker/s/application-public/a102P000008pu0b,Nervous System
a0ROZ000004CXQv2AO,Zolmitriptan,A-00432,Zomig,Zolmitriptan,AstraZeneca,Migraine - acute migraine with or without aura,Seeking Clinical Advice,Zolmitriptan (Zomig),/apptracker/s/application-public/a102P000008ptsZ,Nervous System
a0ROZ000004IavZ2AS,Zonisamide,A-03205,"Zonegran, Zonicane",Zonisamide,Clinician,Developmental and epileptic encephalopathies,Reviewing Consultation Feedback,"Zonisamide (Zonegran, Zonicane)",/apptracker/s/application-public/a102P000009qscT,Nervous System
a0ROZ000004IVW52AO,Zonisamide,A-03205,"Zonegran, Zonicane",Zonisamide,Clinician,"Focal epilepsy, treatment refractory",Reviewing Consultation Feedback,"Zonisamide (Zonegran, Zonicane)",/apptracker/s/application-public/a102P00000AiIAH,Nervous System
a0R2P000000LmeOUAS,"Zuclopenthixol decanoate, 500 ml per ml, 1 ml injection",A-00382,Clopixol,"Zuclopenthixol decanoate, 500 ml per ml, 1 ml injection",Clinician,Open listing (schizophrenia),Decision,"Zuclopenthixol decanoate, 500 ml per ml, 1 ml injection (Clopixol)",/apptracker/s/application-public/a102P000008pttR,Nervous System
a0R2P000000MTXfUAO,Zuclopenthixol hydrochloride Tablet 25 mg,A-00025,,Zuclopenthixol hydrochloride Tablet 25 mg,Lundbeck,Hospital listing,Decision,Zuclopenthixol hydrochloride Tablet 25 mg,/apptracker/s/application-public/a102P000008puE0,Nervous System
a0ROZ0000093lZt2AI,Agalsidase beta,A-00887 A-04944,Fabrazyme,Agalsidase beta,"Sanofi-Aventis New Zealand Limited, Clinician",Fabry disease (a-galactosidase deficiency) by enzyme replacment therapy,Options Compared,Agalsidase beta (Fabrazyme),/apptracker/s/application-public/a102P000008ptsH,Alimentary Tract and Metabolism
a0ROZ000004CR3n2AG,Alglucosidase alfa,A-00527,Myozyme,Alglucosidase alfa,Sanofi Genzyme,Late onset Pompe disease,Decision,Alglucosidase alfa (Myozyme),/apptracker/s/application-public/a102P000008puPu,Alimentary Tract and Metabolism
a0ROZ000009J1cl2AC,Alirocumab,A-00799 A-00625,,Alirocumab,"Sanofi, Sanofi",hypercholesterolaemia in people with diabetes and acute coronary syndrome (ACS),Decision,Alirocumab,/apptracker/s/application-public/a102P000008puS0,Cardiovascular System
a0ROZ000009J1w52AC,Alirocumab,A-00797,,Alirocumab,Sanofi,"Heterozygous familial hypercholesterolaemia (HeFH), prevention of CV events",Decision,Alirocumab,/apptracker/s/application-public/a102P000008puNX,Cardiovascular System
a0ROZ0000076Lk52AE,Avalglucosidase alfa,A-04926,NEXVIAZYME,Avalglucosidase alfa,Sanofi-Aventis New Zealand Limited,"Pompe disease, infantile onset (IOPD)",Under Assessment,Avalglucosidase alfa (NEXVIAZYME),/apptracker/s/application-public/a10OZ000001A6Zp,
a0ROZ0000076KuW2AU,Avalglucosidase alfa,A-04926,NEXVIAZYME,Avalglucosidase alfa,Sanofi-Aventis New Zealand Limited,"Pompe disease, late onset (LOPD)",Under Assessment,Avalglucosidase alfa (NEXVIAZYME),/apptracker/s/application-public/a10OZ000001rvu2,
a0R2P000000LmhDUAS,Clopidogrel,A-00963,Plavix,Clopidogrel,Sanofi-Aventis,Aspirin-allergic; event while on aspirin; awaiting revascularisation; post-stenting,Decision,Clopidogrel (Plavix),/apptracker/s/application-public/a102P000008pu5d,Blood and Blood Forming Organs
a0ROZ000005gKyj2AE,Eliglustat,A-04924,Cerdelga,Eliglustat,Sanofi-Aventis New Zealand Limited,type 1 or type 3 Gaucher disease,Under Assessment,Eliglustat (Cerdelga),/apptracker/s/application-public/a10OZ0000011wKj,
a0R2P000000LmdsUAC,Enoxaparin Sodium,A-00538,Clexane,Enoxaparin Sodium,Sanofi,Widening access for community dialysis patients,Decision,Enoxaparin Sodium (Clexane),/apptracker/s/application-public/a102P000008pttL,Blood and Blood Forming Organs
a0R2P000000LmeQUAS,Insulin glargine,A-00821,Lantus,Insulin glargine,Sanofi-Aventis,Widening of access to include type II diabetes,Decision,Insulin glargine (Lantus),/apptracker/s/application-public/a102P000008pttv,Alimentary Tract and Metabolism
a0ROZ00000081q92AA,Insulin glargine,A-00652,Lantus,Insulin glargine,Sanofi-Aventis,Type 1 diabetes mellitus (second line treatment),Decision,Insulin glargine (Lantus),/apptracker/s/application-public/a102P000008puRI,Alimentary Tract and Metabolism
a0R2P000000LtcTUAS,Insulin Glargine - Long Acting,A-00630,,Insulin Glargine - Long Acting,Sanofi,Diabetes,Options Compared,Insulin Glargine - Long Acting,/apptracker/s/application-public/a102P000008ptpm,Alimentary Tract and Metabolism
a0R2P000000LmgaUAC,Insulin Glargine - Long Acting,A-00671,,Insulin Glargine - Long Acting,Sanofi,Type 1 diabetes,Options Compared,Insulin Glargine - Long Acting,/apptracker/s/application-public/a102P000008ptpp,Alimentary Tract and Metabolism
a0R2P000000LmarUAC,Insulin glulisine,A-00912,Apidra,Insulin glulisine,Sanofi-Aventis,Type I and Type II Diabetes,Decision,Insulin glulisine (Apidra),/apptracker/s/application-public/a102P000008puTA,Alimentary Tract and Metabolism
a0ROZ000004CJbf2AG,Lixisenatide,A-00238,Lyxumia,Lixisenatide,Sanofi,"Type 2 diabetes, with established cardiovascular disease",Decision,Lixisenatide (Lyxumia),/apptracker/s/application-public/a102P000008pu8J,Alimentary Tract and Metabolism
a0ROZ00000BcrzV2AR,Nirsevimab,A-05044 A-05481,BEYFORTUS®,Nirsevimab,"Sanofi-Aventis New Zealand Limited, Clinician",Infant RSV protection,Seeking Clinical Advice,Nirsevimab (BEYFORTUS®),/apptracker/s/application-public/a10OZ000005Gq1O,
a0ROZ00000096qz2AA,Oxaliplatin,A-01248,Eloxatin,Oxaliplatin,Sanofi-Aventis,Adjuvant colorectal cancer,Decision,Oxaliplatin (Eloxatin),/apptracker/s/application-public/a102P000008puig,Oncology Agents and Immunosuppressants
a0ROZ000002ox2E2AQ,Sevelamer carbonate,A-00656 A-00657,,Sevelamer carbonate,"Sanofi, Te Arai Biofarma",Chronic kidney disease,Under Assessment,Sevelamer carbonate,/apptracker/s/application-public/a102P000008ptrP,Genito-Urinary System
a0ROZ000009J3mb2AC,Sevelamer hydrochloride,A-01309,Renagel,Sevelamer hydrochloride,Sanofi,Hyperphosphataemia in people with chronic kidney disease on dialysis,Decision,Sevelamer hydrochloride (Renagel),/apptracker/s/application-public/a102P000008ptpJ,Genito-Urinary System
a0R2P000000OcdlUAC,", Sodium Chloride 350.7Mg, Sodium Bicarbonate 178.5Mg, Potassium Chloride 46.6Mg",A-00347,Movicol,"Macrogol with electrolytes, half strenght - Macrogol 3350 13.125G, Sodium Chloride 350.7Mg, Sodium Bicarbonate 178.5Mg, Potassium Chloride 46.6Mg",Subcommittee recommendation,Paediatric constipation,Decision,"Macrogol with electrolytes, half strenght - Macrogol 3350 13.125G, Sodium Chloride 350.7Mg, Sodium Bicarbonate 178.5Mg, Potassium Chloride 46.6Mg (Movicol)",/apptracker/s/application-public/a102P000008pubI,Alimentary Tract and Metabolism
a0R2P000000LmkTUAS,Adalimumab,A-01073,"Humira,Humirapen",Adalimumab,Abbott,Crohn's disease - fistulising,Decision,"Adalimumab (Humira,Humirapen)",/apptracker/s/application-public/a102P000008puea,Alimentary Tract and Metabolism
a0ROZ000001eLzd2AE,Adalimumab,A-04149,,Adalimumab,Clinician,"Crohn's disease, CDAI score of 220 or greater, widening access",Under Assessment,Adalimumab,/apptracker/s/application-public/a102P00000BNlWu,Alimentary Tract and Metabolism
a0R2P000000Uw3mUAC,Adalimumab,A-00211,Humira,Adalimumab,Clinician,Inflammatory bowel disease-associated arthritis,Decision,Adalimumab (Humira),/apptracker/s/application-public/a102P00000ADwOL,Alimentary Tract and Metabolism
a0ROZ000003Notj2AC,Agalsidase alfa,A-00888,,Agalsidase alfa,Takeda (Shire),Fabry disease (a-galactosidase A deficiency),Options Compared,Agalsidase alfa,/apptracker/s/application-public/a102P000008puS1,Alimentary Tract and Metabolism
a0ROZ00000Cn1wx2AB,Alglucosidase alfa,A-00813,Myozyme,Alglucosidase alfa,Clinician,Pompe's disease,Options Compared,Alglucosidase alfa (Myozyme),/apptracker/s/application-public/a102P000008pujd,Alimentary Tract and Metabolism
a0R2P000000anSXUAY,Benefibre,A-00335,,Benefibre,Clinician,Fibre supplement for constipation,Decision,Benefibre,/apptracker/s/application-public/a102P000008ptwl,Alimentary Tract and Metabolism
a0R2P000000LmehUAC,Betaine,A-00488,,Betaine,Emerge Health,Homocystinuria,Decision,Betaine,/apptracker/s/application-public/a102P000008pttI,Alimentary Tract and Metabolism
a0R2P000000LmdqUAC,Blood Glucose test strip - 5 second Optium G3c,A-00824,,Blood Glucose test strip - 5 second Optium G3c,Medica Pacifica,Blood glucose testing for patients with diabetes,Decision,Blood Glucose test strip - 5 second Optium G3c,/apptracker/s/application-public/a102P000008pu3W,Alimentary Tract and Metabolism
a0R2P000000LmbXUAS,Blood ketone test strips,A-00489,Optium,Blood ketone test strips,Abbot Diagnostics,Diabetes mellitus (insulin dependent),Decision,Blood ketone test strips (Optium),/apptracker/s/application-public/a102P000008puSg,Alimentary Tract and Metabolism
a0R2P000000LmoeUAC,Budesonide,A-00923,Entocort CIR,Budesonide,Clinician,Crohn's disease - patients with psychiatric problems and patients with relapse during pregnancy,Decision,Budesonide (Entocort CIR),/apptracker/s/application-public/a102P000008ptr4,Alimentary Tract and Metabolism
a0R2P000000LmamUAC,Budesonide,A-00933,Entocort Cir,Budesonide,Clinician,Crohn's disease ( longer SA period); and gut Graft vs Host disease.,Decision,Budesonide (Entocort Cir),/apptracker/s/application-public/a102P000008puRW,Alimentary Tract and Metabolism
a0ROZ0000006XJ32AM,Budesonide capsules,A-00660,Entocort Cir,Budesonide capsules,Clinician,Non-cirrhotic autoimmune hepatitis,Decision,Budesonide capsules (Entocort Cir),/apptracker/s/application-public/a102P000008puTz,Alimentary Tract and Metabolism
a0R2P000000TBrbUAG,Budesonide controlled-release,A-00711,,Budesonide controlled-release,Pharmaco (NZ) Ltd,"Ulcerative colitis, mild to moderately active",Options Compared,Budesonide controlled-release,/apptracker/s/application-public/a102P000008pu9g,Alimentary Tract and Metabolism
a0R2P000000gIviUAE,Budesonide orodispersible tablets,A-04536 A-04527 A-04573,,Budesonide orodispersible tablets,"DR FALK PHARMA NEW ZEALAND LIMITED, Clinician, Consumer","Eosinophilic oesophagitis, 2nd line after fluticasone",Options Compared,Budesonide orodispersible tablets,/apptracker/s/application-public/a102P00000BY17Q,Alimentary Tract and Metabolism
a0ROZ000009J13F2AS,"Budesonide, oral viscous nebules",A-00676,,"Budesonide, oral viscous nebules",Clinician,Eosinophilic oesophagitis unresponsive to fluticasone in  children,Decision,"Budesonide, oral viscous nebules",/apptracker/s/application-public/a102P000008puVO,Alimentary Tract and Metabolism
a0ROZ000009J14r2AC,"Budesonide, oral viscous nebules",A-00537,,"Budesonide, oral viscous nebules",Clinician,Eosinophilic oesophagitis unresponsive to fluticasone in adults,Decision,"Budesonide, oral viscous nebules",/apptracker/s/application-public/a102P000008pu5t,Alimentary Tract and Metabolism
a0ROZ000000MEHF2A4,Calcitriol liquid,A-00609,,Calcitriol liquid,Clinician,Chronic kidney disease,Decision,Calcitriol liquid,/apptracker/s/application-public/a102P000008pu4V,Alimentary Tract and Metabolism
a0ROZ000000MG692AG,Calcium acetate,A-00356,,Calcium acetate,Clinician,Phosphate binder,Decision,Calcium acetate,/apptracker/s/application-public/a102P000008puka,Alimentary Tract and Metabolism
a0ROZ000004CPUz2AO,Canagliflozin,A-00294,Invokana,Canagliflozin,Janssen,Diabetes - type 2,Decision,Canagliflozin (Invokana),/apptracker/s/application-public/a102P000008puDt,Alimentary Tract and Metabolism
a0R2P000000SoqDUAS,Carglumic acid,A-00699 A-00698 A-00700,,Carglumic acid,"Max Health, Te Arai Biofarma, Clinician",Hyperammonaemia resulting from CPS1 and NAGs deficiencies of urea cycle.,Options Compared,Carglumic acid,/apptracker/s/application-public/a102P000008pu8I,Alimentary Tract and Metabolism
a0R2P000000UjnCUAS,Carglumic acid,A-00777 A-00776 A-00778,,Carglumic acid,"Max Health, Te Arai Biofarma, Clinician","Hyperammonaemia resulting from isovaleric, methylmalonic and propionic organic acidaemias",Options Compared,Carglumic acid,/apptracker/s/application-public/a102P000008pubu,Alimentary Tract and Metabolism
a0R2P000000LmrGUAS,Carnitine,A-01240,,Carnitine,NPPA,Multiple indications,Decision,Carnitine,/apptracker/s/application-public/a102P000008puIa,Alimentary Tract and Metabolism
a0ROZ000004nOoZ2AU,Cholecalciferol (Vitamin D) 1000 IU tablets,A-00955,OsteoVit-D,Cholecalciferol (Vitamin D) 1000 IU tablets,Wilson Consumer Products,Vitamin D deficiency,Options Compared,Cholecalciferol (Vitamin D) 1000 IU tablets (OsteoVit-D),/apptracker/s/application-public/a102P000008pueX,Alimentary Tract and Metabolism
a0R2P000000OcdgUAC,Cholecalciferol (vitamin D) and calcium carbonate,A-00954,OsteoVit-D and Calcium,Cholecalciferol (vitamin D) and calcium carbonate,Wilson Consumer Products,Vitamin D deficiency and osteoporosis,Decision,Cholecalciferol (vitamin D) and calcium carbonate (OsteoVit-D and Calcium),/apptracker/s/application-public/a102P000008puCn,Alimentary Tract and Metabolism
a0R2P000000LmdhUAC,Cholic acid,A-00501,,Cholic acid,Max Health,Errors in bile acid synthesis in infants with liver disease,Decision,Cholic acid,/apptracker/s/application-public/a102P000008pu9h,Alimentary Tract and Metabolism
a0R2P000000anTpUAI,Citrulline,A-00541,,Citrulline,Orpharma NZ Ltd,Nutritional product for use in urea cycle disorders,Decision,Citrulline,/apptracker/s/application-public/a102P000008ptyV,Alimentary Tract and Metabolism
a0R2P000000Uf84UAC,Coenzyme Q10,A-00703,,Coenzyme Q10,Clinician,Mitochondrial disease,Decision,Coenzyme Q10,/apptracker/s/application-public/a102P000008ptyb,Alimentary Tract and Metabolism
a0ROZ00000AQkoH2AT,Cyanocobalamin (1mg sub-lingual),A-04821,unknown,Cyanocobalamin (1mg sub-lingual),Clinician,Vitamin B12 deficiency,Options Compared,Cyanocobalamin (1mg sub-lingual) (unknown),/apptracker/s/application-public/a10OZ000000witV,Alimentary Tract and Metabolism
a0ROZ000004CKn72AG,Dapagliflozin,A-01436,Forxiga,Dapagliflozin,AstraZeneca,Diabetes - type 2,Decision,Dapagliflozin (Forxiga),/apptracker/s/application-public/a102P000008pukV,Alimentary Tract and Metabolism
a0R2P000000anWPUAY,Dapagliflozin with Metformin Hcl,A-00457,,Dapagliflozin with Metformin Hcl,AstraZeneca,Diabetes - type 2,Decision,Dapagliflozin with Metformin Hcl,/apptracker/s/application-public/a102P000008pu3K,Alimentary Tract and Metabolism
a0ROZ000006Ejmi2AC,Dexcom G5 Continuous Glucose Monitors,A-03871,Dexcom,Dexcom G5 Continuous Glucose Monitors,Consumer,Type 2 diabetes,Options Compared,Dexcom G5 Continuous Glucose Monitors (Dexcom),/apptracker/s/application-public/a102P00000BBg62,Alimentary Tract and Metabolism
a0R2P000000LmnSUAS,Diazoxide,A-01231,,Diazoxide,NPPA,Hypoglycaemia caused by hyperinsulinism,Decision,Diazoxide,/apptracker/s/application-public/a102P000008pu1y,Alimentary Tract and Metabolism
a0ROZ00000128CD2AY,Elosulfase alfa,A-00728,,Elosulfase alfa,BioMarin Pharmaceutical Australia Ltd,MPS IVA for individuals aged 2 years and over,Under Assessment,Elosulfase alfa,/apptracker/s/application-public/a102P000008ptxy,Alimentary Tract and Metabolism
a0R2P000000atpFUAQ,Empagliflozin,A-00500 A-03700,Jardiance,Empagliflozin,"Boehringer Mannheim (NZ) Ltd, Consumer",Type 2 diabetes with established high CVD risk,Decision,Empagliflozin (Jardiance),/apptracker/s/application-public/a102P000008pudZ,Alimentary Tract and Metabolism
a0ROZ000001jrSb2AI,Empagliflozin,A-04658,Jardiance,Empagliflozin,Clinician,"Diabetes mellitus type 2, remove the HbA1c threshold",Under Assessment,Empagliflozin (Jardiance),/apptracker/s/application-public/a102P00000BagLJ,Alimentary Tract and Metabolism
a0ROZ000004CPd32AG,Exenatide,A-00232,Byetta,Exenatide,AstraZeneca,"Type 2 diabetes, with established cardiovascular disease",Decision,Exenatide (Byetta),/apptracker/s/application-public/a102P000008ptuy,Alimentary Tract and Metabolism
a0R2P000000LmaZUAS,Ferric carboxymaltose,A-01287,Ferinject,Ferric carboxymaltose,Vifor Pharma,Iron deficiency,Decision,Ferric carboxymaltose (Ferinject),/apptracker/s/application-public/a102P000008puZ1,Alimentary Tract and Metabolism
a0ROZ000004u9MT2AY,Ferric carboxymaltose,A-03467,Ferinject,Ferric carboxymaltose,Clinician,"Iron deficiency anaemia, patients with an inflammatory response, serum ferritin of 20mcg/L to 50mcg/L and CRP >5",Decision,Ferric carboxymaltose (Ferinject),/apptracker/s/application-public/a102P00000ATC4R,Alimentary Tract and Metabolism
a0R2P000000TFbXUAW,Ferric carboxymaltose,A-00286,Ferinject,Ferric carboxymaltose,Vifor Pharma,Iron deficiency (community),Decision,Ferric carboxymaltose (Ferinject),/apptracker/s/application-public/a102P000008puH7,Alimentary Tract and Metabolism
a0ROZ000009J0NK2A0,Freestyle Libre Flash Glucose Monitoring System,A-00649 A-00648 A-00650 A-03089 A-03294 A-03297 A-03306 A-03460 A-03628 A-04100 A-03848 A-03748 A-05018,,Freestyle Libre Flash Glucose Monitoring System,"Abbott, Clinician, Consumer",Type 1 diabetes,Decision,Freestyle Libre Flash Glucose Monitoring System,/apptracker/s/application-public/a102P000008pucQ,Alimentary Tract and Metabolism
a0ROZ000004h8ks2AA,G6 continuous glucose monitoring device,A-03844 A-03871,Dexcom,G6 continuous glucose monitoring device,"New Zealand Medical and Scientific, Consumer",Type 1 Diabetes,Decision,G6 continuous glucose monitoring device (Dexcom),/apptracker/s/application-public/a102P00000BB9Fr,Alimentary Tract and Metabolism
a0R2P000000LmkKUAS,Galsulfase,A-00327,,Galsulfase,BioMarin Pharmaceutical Australia Ltd,Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome),Decision,Galsulfase,/apptracker/s/application-public/a102P000008pucZ,Alimentary Tract and Metabolism
a0ROZ000004C8Ir2AK,Glucose solution with complex carbohydrate biscuit,A-00594,,Glucose solution with complex carbohydrate biscuit,AJW Enterprises Ltd,Hypoglycemia,Under Assessment,Glucose solution with complex carbohydrate biscuit,/apptracker/s/application-public/a102P000008puGg,Alimentary Tract and Metabolism
a0R2P000000LmguUAC,Glyceryl trinitrate 0.2%,A-01227,Rectogesic,Glyceryl trinitrate 0.2%,Care Pharmaceuticals Australia,Anal fissure,Decision,Glyceryl trinitrate 0.2% (Rectogesic),/apptracker/s/application-public/a102P000008ptpu,Alimentary Tract and Metabolism
a0R2P000000TEnJUAW,Glycopyrronium bromide injection,A-01398,,Glycopyrronium bromide injection,NPPA,Open listing (palliative care),Decision,Glycopyrronium bromide injection,/apptracker/s/application-public/a102P000008pu4E,Alimentary Tract and Metabolism
a0R2P000000anZTUAY,Golimumab,A-00519,,Golimumab,Janssen,"Ulcerative colitis, moderate to severe",Decision,Golimumab,/apptracker/s/application-public/a102P000008puDx,Alimentary Tract and Metabolism
a0ROZ0000052sCj2AI,Idursulfase,A-00890,Elaprase,Idursulfase,Clinician,Hunter syndrome - patients with mucopolysaccharidosis II (MPS II),Seeking Clinical Advice,Idursulfase (Elaprase),/apptracker/s/application-public/a102P000008puWU,Alimentary Tract and Metabolism
a0R2P000000N6iLUAS,Imiglucerase,A-01005,Cerezyme,Imiglucerase,Clinician,"Gaucher disease - type 1, children with 2+ systems",Decision,Imiglucerase (Cerezyme),/apptracker/s/application-public/a102P000008ptpw,Alimentary Tract and Metabolism
a0R2P000000N6iRUAS,Imiglucerase,A-01075,Cerezyme,Imiglucerase,Clinician,Gaucher disease - type 3,Decision,Imiglucerase (Cerezyme),/apptracker/s/application-public/a102P000008pugF,Alimentary Tract and Metabolism
a0R2P000000ePXfUAM,Infliximab,A-00643,,Infliximab,Clinician,Crohn's disease and ulcerative colitis - widening access (dose escalation),Under Assessment,Infliximab,/apptracker/s/application-public/a102P00000AlWG7,Alimentary Tract and Metabolism
a0ROZ000009J1fx2AC,Insujet,A-00367,,Insujet,Pharmaco (NZ) Ltd,Insulin administration,Decision,Insujet,/apptracker/s/application-public/a102P000008ptwy,Alimentary Tract and Metabolism
a0R2P000000LmUcUAK,Insulin aspart,A-01180,NovoRapid,Insulin aspart,Novo Nordisk,Type I diabetes mellitus,Decision,Insulin aspart (NovoRapid),/apptracker/s/application-public/a102P000008puNY,Alimentary Tract and Metabolism
a0R2P000000LmoEUAS,Insulin aspart 30/70,A-00835,Novomix,Insulin aspart 30/70,Novo Nordisk,Diabetes mellitus - insulin dependent,Decision,Insulin aspart 30/70 (Novomix),/apptracker/s/application-public/a102P000008ptre,Alimentary Tract and Metabolism
a0R2P000000LmVCUA0,Insulin detemir,A-00936,,Insulin detemir,Clinician,Multiple daily injections where compliance may be an issue,Options Compared,Insulin detemir,/apptracker/s/application-public/a102P000008pty5,Alimentary Tract and Metabolism
a0R2P000000SHakUAG,Insulin detemir,A-00906,Levemir Flexpen,Insulin detemir,Novo Nordisk,Diabetes - type 1 (2nd-line LA insulin treatment),Options Compared,Insulin detemir (Levemir Flexpen),/apptracker/s/application-public/a102P000008pu4m,Alimentary Tract and Metabolism
a0R2P000000Lme5UAC,Insulin detemir,A-00935,Levemir,Insulin detemir,Clinician,"Diabetes: cystic fibrosis; insulinopaenic type 2 ;or type 2, multiple injections & hypoglycaemia",Options Compared,Insulin detemir (Levemir),/apptracker/s/application-public/a102P000008ptu0,Alimentary Tract and Metabolism
a0R2P000000LmY4UAK,Insulin lispro,A-00478,Humalog,Insulin lispro,Eli Lilly,Diabetes mellitus (Type I and  II),Decision,Insulin lispro (Humalog),/apptracker/s/application-public/a102P000008puUK,Alimentary Tract and Metabolism
a0R2P000000gVXUUA2,Insulin needle repeats,A-00560,,Insulin needle repeats,Subcommittee recommendation,Diabetes,Decision,Insulin needle repeats,/apptracker/s/application-public/a102P000008puFa,Alimentary Tract and Metabolism
a0ROZ000009J1Uf2AK,INSULIN PUMP,A-04175,DANA-i,INSULIN PUMP,INTUITIVE THERAPEUTICS LIMITED,"Diabetes, DANA insulin pumps",Decision,INSULIN PUMP (DANA-i),/apptracker/s/application-public/a10OZ000000dKoT,Alimentary Tract and Metabolism
a0ROZ000009IyWo2AK,INSULIN PUMP INFUSION SET (STEEL CANNULA),A-04034,DANA Easy Release I 29G,INSULIN PUMP INFUSION SET (STEEL CANNULA),INTUITIVE THERAPEUTICS LIMITED,"Diabetes,  DANA insulin pumps",Decision,INSULIN PUMP INFUSION SET (STEEL CANNULA) (DANA Easy Release I 29G),/apptracker/s/application-public/a10OZ000000dKYL,Alimentary Tract and Metabolism
a0ROZ000009J03y2AC,INSULIN PUMP INFUSION SET (TEFLON CANNULA),A-04124,DANA Inset ii,INSULIN PUMP INFUSION SET (TEFLON CANNULA),INTUITIVE THERAPEUTICS LIMITED,"Diabetes, DANA insulin pumps",Decision,INSULIN PUMP INFUSION SET (TEFLON CANNULA) (DANA Inset ii),/apptracker/s/application-public/a10OZ000000dKjd,Alimentary Tract and Metabolism
a0ROZ000009J1EY2A0,INSULIN PUMP RESERVOIR,A-04125,DANA 3cc Syringe,INSULIN PUMP RESERVOIR,INTUITIVE THERAPEUTICS LIMITED,"Diabetes, DANA insulin pumps",Decision,INSULIN PUMP RESERVOIR (DANA 3cc Syringe),/apptracker/s/application-public/a10OZ000000dKmr,Alimentary Tract and Metabolism
a0R2P000000d7i4UAA,iPort  - insulin injection port / cannula,A-00801,,iPort  - insulin injection port / cannula,Clinician,Diabetes (requiring treatment with insulin),Seeking Clinical Advice,iPort  - insulin injection port / cannula,/apptracker/s/application-public/a102P000008puDL,Alimentary Tract and Metabolism
a0ROZ000003LsVF2A0,Lanthanum carbonate,A-04006,Fosrenol®,Lanthanum carbonate,TAKEDA NEW ZEALAND LIMITED,"Hyperphosphataemia, CKD patients on dialysis, 2nd line after calcium",Seeking Clinical Advice,Lanthanum carbonate (Fosrenol®),/apptracker/s/application-public/a102P00000BLf1R,Alimentary Tract and Metabolism
a0ROZ000004CWY52AO,Laronidase,A-00889,,Laronidase,Clinician,Hurlers disease (Mucopolysaccharidosis 1 or MPS 1),Decision,Laronidase,/apptracker/s/application-public/a102P000008puis,Alimentary Tract and Metabolism
a0R2P000000WsqIUAS,Levocarnitine,A-00659,,Levocarnitine,Clinician,Carnitine deficiency,Decision,Levocarnitine,/apptracker/s/application-public/a102P000008pttU,Alimentary Tract and Metabolism
a0R2P000000QUbaUAG,levocarnitine,A-03190 A-00659,,levocarnitine,"PHARMACEUTICAL MANAGEMENT AGENCY LIMITED, Clinician",for inborn errors of metabolism,Decision,levocarnitine,/apptracker/s/application-public/a102P000009g8un,Alimentary Tract and Metabolism
a0ROZ00000BV8B32AL,Levofloxacin,A-00958,,Levofloxacin,Clinician,Helicobacter pylori - second line use,Reviewing Consultation Feedback,Levofloxacin,/apptracker/s/application-public/a102P000008ptpQ,Alimentary Tract and Metabolism
a0ROZ000004CPMv2AO,Linagliptin,A-01226,Trajenta,Linagliptin,Boehringer Ingelheim,Diabetes - type 2,Decision,Linagliptin (Trajenta),/apptracker/s/application-public/a102P000008puci,Alimentary Tract and Metabolism
a0ROZ00000Cn1x22AB,Liraglutide,A-04522,Saxenda,Liraglutide,Consumer,"PCOS, weight loss due to insulin resistance",Options Compared,Liraglutide (Saxenda),/apptracker/s/application-public/a102P00000BZ6Xf,Alimentary Tract and Metabolism
a0R2P000000URRLUA4,Liraglutide,A-01215,Victoza,Liraglutide,Novo Nordisk,Diabetes - type 2,Options Compared,Liraglutide (Victoza),/apptracker/s/application-public/a102P000008pu13,Alimentary Tract and Metabolism
a0ROZ00000096ML2AY,Macrogol,A-01124,Movicol,Macrogol,Norgine,Refractory constipation and faecal impaction,Decision,Macrogol (Movicol),/apptracker/s/application-public/a102P000008pueo,Alimentary Tract and Metabolism
a0R2P000000er6EUAQ,Macrogol (electrolyte-free),A-00679,,Macrogol (electrolyte-free),Subcommittee recommendation,Paediatric constipation,Under Assessment,Macrogol (electrolyte-free),/apptracker/s/application-public/a102P000008puDm,Alimentary Tract and Metabolism
a0R2P000000MgI0UAK,Magnesium sulfate 5 g in 50 ml premixed bags,A-00780,,Magnesium sulfate 5 g in 50 ml premixed bags,Clinician,seizure prophylaxis in pre-eclamptic toxaemia of pregnancy,Decision,Magnesium sulfate 5 g in 50 ml premixed bags,/apptracker/s/application-public/a102P000008puH5,Alimentary Tract and Metabolism
a0ROZ000009J1Mb2AK,Medtronic Guardian 3 and Guardian Connect continuous glucose monitoring system,A-00756,Guardian,Medtronic Guardian 3 and Guardian Connect continuous glucose monitoring system,Intermed Scientific Ltd,Type 1 diabetes,Decision,Medtronic Guardian 3 and Guardian Connect continuous glucose monitoring system (Guardian),/apptracker/s/application-public/a102P000008pueD,Alimentary Tract and Metabolism
a0ROZ00000096m92AA,Mesalazine 1g suppositories,A-01145,Pentasa,Mesalazine 1g suppositories,Pharmaco (NZ) Ltd,Ulcerative proctitis,Decision,Mesalazine 1g suppositories (Pentasa),/apptracker/s/application-public/a102P000008pua6,Alimentary Tract and Metabolism
a0R2P000000LmXMUA0,"Mesalazine, granules, 2 g sachets",A-00341 A-00340,"Asacor,Pentasa","Mesalazine, granules, 2 g sachets","Baxter, Pharmaco (NZ) Ltd",Inflammatory bowel disease and similar,Options Compared,"Mesalazine, granules, 2 g sachets (Asacor,Pentasa)",/apptracker/s/application-public/a102P000008ptyl,Alimentary Tract and Metabolism
a0R2P000000LmUBUA0,"Mesalazine, tablet, 800 mg",A-00663,,"Mesalazine, tablet, 800 mg",Pharmaco (NZ) Ltd,Open listing,Decision,"Mesalazine, tablet, 800 mg",/apptracker/s/application-public/a102P000008puLw,Alimentary Tract and Metabolism
a0ROZ000004CbzB2AS,Methylnaltrexone bromide (subcutaneous injection),A-00735,Relistor,Methylnaltrexone bromide (subcutaneous injection),Clinician,Opioid-induced constipation in hospitalised patients outside of palliative care,Decision,Methylnaltrexone bromide (subcutaneous injection) (Relistor),/apptracker/s/application-public/a102P000008puSK,Alimentary Tract and Metabolism
a0R2P000000gPF5UAM,"Methylnaltrexone, subcutaneous injection",A-00400,,"Methylnaltrexone, subcutaneous injection",Link Pharmaceuticals,Opioid-induced constipation in patients receiving palliative care,Decision,"Methylnaltrexone, subcutaneous injection",/apptracker/s/application-public/a102P000008pu6i,Alimentary Tract and Metabolism
a0ROZ0000012TQL2A2,Migalastat,A-00730,,Migalastat,Amicus,Fabry disease,Options Compared,Migalastat,/apptracker/s/application-public/a102P000008pu0n,Alimentary Tract and Metabolism
a0ROZ000004CWOP2A4,Miglustat,A-00511,,Miglustat,Te Arai Biofarma,Gaucher disease,Decision,Miglustat,/apptracker/s/application-public/a102P000008ptxw,Alimentary Tract and Metabolism
a0ROZ000004CWGL2A4,Miglustat,A-01006,Zavesca,Miglustat,Actelion,Gaucher disease - type 1 (mild to moderate),Decision,Miglustat (Zavesca),/apptracker/s/application-public/a102P000008puLv,Alimentary Tract and Metabolism
a0ROZ00000D1RBZ2A3,Miglustat,A-00729,,Miglustat,Te Arai Biofarma,Niemann Pick Type C,Options Compared,Miglustat,/apptracker/s/application-public/a102P000008ptzs,Alimentary Tract and Metabolism
a0ROZ000001rE132AE,Multivitamin and mineral boost,A-00274,,Multivitamin and mineral boost,Clinician,Burns patients (community),Decision,Multivitamin and mineral boost,/apptracker/s/application-public/a102P000008puDv,Alimentary Tract and Metabolism
a0R2P000000LmWrUAK,Multivitamin and mineral boost,A-00237,,Multivitamin and mineral boost,Clinician,Burns patients (hospital),Decision,Multivitamin and mineral boost,/apptracker/s/application-public/a102P000008ptxs,Alimentary Tract and Metabolism
a0R2P000000LmbHUAS,Multivitamin preparations,A-00621,,Multivitamin preparations,Clinician,Children with epilepsy on ketogenic diets and vitamin/mineral deficient,Decision,Multivitamin preparations,/apptracker/s/application-public/a102P000008puZO,Alimentary Tract and Metabolism
a0ROZ0000063iyk2AA,Multivitamin with trace elements,A-00639,,Multivitamin with trace elements,Clinician,"Bariatric surgery, prevention of micronutrient deficiencies",Options Compared,Multivitamin with trace elements,/apptracker/s/application-public/a102P000008puae,Alimentary Tract and Metabolism
a0R2P000000LmfYUAS,Multivitamins renal,A-01307 A-01306,Clinicians Renal Vit,Multivitamins renal,"Douglas Pharmaceuticals Ltd, Natural Health Laboratories Ltd",Chronic kidney disease stage 5 and dialysis patients,Decision,Multivitamins renal (Clinicians Renal Vit),/apptracker/s/application-public/a102P000008pu41,Alimentary Tract and Metabolism
a0R2P000000MTcQUAW,Naltrexone hydrochloride (low-dose),A-00992,,Naltrexone hydrochloride (low-dose),Consumer,Henoch-Schonlein purpura,Decision,Naltrexone hydrochloride (low-dose),/apptracker/s/application-public/a102P000008puM7,Alimentary Tract and Metabolism
a0R2P000000LmlFUAS,Nateglinide,A-01193,Starlix,Nateglinide,Novartis,Diabetes - type 2,Decision,Nateglinide (Starlix),/apptracker/s/application-public/a102P000008pukJ,Alimentary Tract and Metabolism
a0ROZ00000CZwlN2AT,Nitisinone,A-00732 A-00731,,Nitisinone,"Te Arai Biofarma, Max Health",Tyrosinaemia Type 1,Decision,Nitisinone,/apptracker/s/application-public/a102P000008ptrM,Alimentary Tract and Metabolism
a0ROZ000009J1jB2AS,Octreotide LAR,A-04332,Octreotide Depot Teva,Octreotide LAR,Clinician,"polycystic liver disease, symptomatic relief",Decision,Octreotide LAR (Octreotide Depot Teva),/apptracker/s/application-public/a102P00000BZ6SQ,Alimentary Tract and Metabolism
a0ROZ0000006gHV2AY,"Pancreatic enzymes, pediatric formulation",A-00704,Creon Micro,"Pancreatic enzymes, pediatric formulation",Mylan New Zealand Ltd,Cystic fibrosis,Decision,"Pancreatic enzymes, pediatric formulation (Creon Micro)",/apptracker/s/application-public/a102P000008ptyW,Alimentary Tract and Metabolism
a0R2P000000LmpBUAS,Partially hydrolysed guar gum,A-01196,Benefiber Clear,Partially hydrolysed guar gum,Novartis,Constipation (bulk laxative),Decision,Partially hydrolysed guar gum (Benefiber Clear),/apptracker/s/application-public/a102P000008puAy,Alimentary Tract and Metabolism
a0ROZ000000MElt2AG,Phentermine Hydrochloride (37.5mg immediate-release tab),A-01377,,Phentermine Hydrochloride (37.5mg immediate-release tab),Clinician,Obesity,Decision,Phentermine Hydrochloride (37.5mg immediate-release tab),/apptracker/s/application-public/a102P000008puKV,Alimentary Tract and Metabolism
a0R2P000000LmYtUAK,Pioglitazone,A-01175,Actos,Pioglitazone,Eli Lilly,Diabetes patients intolerant to metformin,Decision,Pioglitazone (Actos),/apptracker/s/application-public/a102P000008puVQ,Alimentary Tract and Metabolism
a0R2P000000LmcjUAC,Pioglitazone,A-01176,Actos,Pioglitazone,Eli Lilly,Diabetes combination therapy with either metformin or a sulphonylurea,Decision,Pioglitazone (Actos),/apptracker/s/application-public/a102P000008pu8c,Alimentary Tract and Metabolism
a0ROZ00000AQknr2AD,Prucalopride succinate,A-00629,,Prucalopride succinate,Clinician,Chronic slow transit constipation,Options Compared,Prucalopride succinate,/apptracker/s/application-public/a102P000008ptz8,Alimentary Tract and Metabolism
a0R2P000000Lmh1UAC,Rifaximin,A-01264,XIFAXAN,Rifaximin,NPPA,Hepatic encephalopathy - 2nd line,Decision,Rifaximin (XIFAXAN),/apptracker/s/application-public/a102P000008ptpH,Alimentary Tract and Metabolism
a0ROZ000004CWhl2AG,Sapropterin,A-00590,,Sapropterin,Te Arai Biofarma,Hyperphenylalaninaemia due to PKU in non-pregnant PKU patients,Decision,Sapropterin,/apptracker/s/application-public/a102P000008ptwR,Alimentary Tract and Metabolism
a0ROZ000003znq52AA,Sapropterin,A-00701,,Sapropterin,Te Arai Biofarma,Phenylketonuria (PKU),Options Compared,Sapropterin,/apptracker/s/application-public/a102P000008puXt,Alimentary Tract and Metabolism
a0R2P000000aneYUAQ,Saxagliptin,A-01072,Onglyza,Saxagliptin,AstraZeneca,Diabetes - type 2,Decision,Saxagliptin (Onglyza),/apptracker/s/application-public/a102P000008puXE,Alimentary Tract and Metabolism
a0ROZ00000Crzfy2AB,Semaglutide,A-05499,Wegovy,Semaglutide,NOVO NORDISK PHARMACEUTICALS LIMITED,"Chronic weight management, Body Mass Index (BMI) ≥30 kg/m2, with at least one weight-related comorbidity",Seeking Clinical Advice,Semaglutide (Wegovy),/apptracker/s/application-public/a10OZ000006OUj3,Alimentary Tract and Metabolism
a0R2P000000Lmf7UAC,Sibutramine,A-01135,Reductil,Sibutramine,Abbott,Obesity,Decision,Sibutramine (Reductil),/apptracker/s/application-public/a102P000008ptvB,Alimentary Tract and Metabolism
a0R2P000000anWAUAY,Sitagliptin,A-00818,Januvia,Sitagliptin,Merck Sharp & Dohme,Diabetes - type 2,Decision,Sitagliptin (Januvia),/apptracker/s/application-public/a102P000008pu1W,Alimentary Tract and Metabolism
a0R2P000000anWoUAI,Sitagliptin and metformin,A-00991,Janumet,Sitagliptin and metformin,Merck Sharp & Dohme,Diabetes - Type 2,Decision,Sitagliptin and metformin (Janumet),/apptracker/s/application-public/a102P000008pu3L,Alimentary Tract and Metabolism
a0R2P000000LmYPUA0,Sodium benzoate,A-01340,,Sodium benzoate,NPPA,Urea cycle disorder,Decision,Sodium benzoate,/apptracker/s/application-public/a102P000008puQe,Alimentary Tract and Metabolism
a0R2P000000Lmr9UAC,Sodium phenylbutyrate,A-00502,,Sodium phenylbutyrate,Max Health,Urea cycle disorders,Decision,Sodium phenylbutyrate,/apptracker/s/application-public/a102P000008puL4,Alimentary Tract and Metabolism
a0R2P000000SBk4UAG,Sodium picosulfate liquid,A-01449,Ducolax Pico Liquid,Sodium picosulfate liquid,Clinician,Constipation in children,Decision,Sodium picosulfate liquid (Ducolax Pico Liquid),/apptracker/s/application-public/a102P000008pttV,Alimentary Tract and Metabolism
a0ROZ000001Uvpt2AC,Tacrolimus suppository,A-00603,,Tacrolimus suppository,Clinician,Rectal inflammation due to inflammatory bowel disease,Decision,Tacrolimus suppository,/apptracker/s/application-public/a102P000008ptpC,Alimentary Tract and Metabolism
a0ROZ0000007YBR2A2,Taliglucerase alfa,A-00526,,Taliglucerase alfa,Pfizer,Gaucher disease,Decision,Taliglucerase alfa,/apptracker/s/application-public/a102P000008puav,Alimentary Tract and Metabolism
a0ROZ000007jPEL2A2,Teduglutide,A-00733 A-04531,,Teduglutide,"Takeda (Shire), Clinician",Short bowel syndrome intestinal failure for adults,Options Compared,Teduglutide,/apptracker/s/application-public/a102P000008puRo,Alimentary Tract and Metabolism
a0ROZ00000DXZ7Z2AX,Tirzepatide (with diet and exercise),A-05340,MOUNJARO®,Tirzepatide (with diet and exercise),ELI LILLY AND COMPANY (NZ) LIMITED,"Diabetes mellitus, type 2, insufficiently controlled",Under Assessment,Tirzepatide (with diet and exercise) (MOUNJARO®),/apptracker/s/application-public/a10OZ000004jPHh,Alimentary Tract and Metabolism
a0ROZ000003dstF2AQ,Trientine Dihydrochloride,A-01258,,Trientine Dihydrochloride,NPPA,Wilson disease (hospital use),Decision,Trientine Dihydrochloride,/apptracker/s/application-public/a102P000008ptsq,Alimentary Tract and Metabolism
a0ROZ000008BTbZ2AW,Upadacitinib,A-04329 A-04450,RINVOQ®,Upadacitinib,"ABBVIE LIMITED, Clinician",Second line treatment of moderate to severe ulcerative colitis,Decision,Upadacitinib (RINVOQ®),/apptracker/s/application-public/a102P00000BTnki,Alimentary Tract and Metabolism
a0ROZ00000DKzRG2A1,Upadacitinib,A-04484 A-05206,RINVOQ®,Upadacitinib,"ABBVIE LIMITED, Clinician",Second line treatment of severe Crohn disease,Decision,Upadacitinib (RINVOQ®),/apptracker/s/application-public/a102P00000BZ6Rw,Alimentary Tract and Metabolism
a0ROZ00000DL1bA2AT,Upadacitinib,A-04484 A-05206,RINVOQ,Upadacitinib,"ABBVIE LIMITED, Clinician","Crohn's disease, severe, 1st line biologic",Options Compared,Upadacitinib (RINVOQ),/apptracker/s/application-public/a10OZ000000ul13,Alimentary Tract and Metabolism
a0R2P000000g58oUAA,Ustekinumab,A-03232,STELARA®,Ustekinumab,JANSSEN NZ LIMITED,"Ulcerative colitis, moderate to severe, 2nd line after infliximab",Decision,Ustekinumab (STELARA®),/apptracker/s/application-public/a102P000009nuvf,Alimentary Tract and Metabolism
a0ROZ000003RQeE2AW,Ustekinumab,A-04504,STELARA,Ustekinumab,JANSSEN NZ LIMITED,"Crohn's disease and ulcerative colitis, moderate to severe, 1st line",Under Assessment,Ustekinumab (STELARA),/apptracker/s/application-public/a102P00000BXdHw,Alimentary Tract and Metabolism
a0ROZ0000007tW12AI,Ustekinumab,A-00565,Stelara,Ustekinumab,Janssen,"Crohn's disease, severe, 3rd line after infliximab and adalimumab",Decision,Ustekinumab (Stelara),/apptracker/s/application-public/a102P000009NExW,Alimentary Tract and Metabolism
a0R2P000000gAbQUAU,Vedolizumab,A-00741,,Vedolizumab,Clinician application,"Crohn's disease, severe, 2nd line after infliximab and/or adalimumab",Decision,Vedolizumab,/apptracker/s/application-public/a102P000008puSt,Alimentary Tract and Metabolism
a0ROZ00000BP6C32AL,Vedolizumab SC,A-05280,ENTYVIO®,Vedolizumab SC,TAKEDA NEW ZEALAND LIMITED,"Ulcerative colitis and Crohn's disease, Maintenance therapy",Seeking Clinical Advice,Vedolizumab SC (ENTYVIO®),/apptracker/s/application-public/a10OZ000005XBTF,Alimentary Tract and Metabolism
a0R2P000000TGSDUA4,Velaglucerase alfa,A-00424,,Velaglucerase alfa,Takeda (Shire),Gaucher disease,Decision,Velaglucerase alfa,/apptracker/s/application-public/a102P000008puP6,Alimentary Tract and Metabolism
a0R2P000000LmVqUAK,Vildagliptin,A-00907,Galvus,Vildagliptin,Novartis,Diabetes - type 2,Decision,Vildagliptin (Galvus),/apptracker/s/application-public/a102P000008ptwJ,Alimentary Tract and Metabolism
a0R2P000000LmrSUAS,Vitamin D-only preparation,A-01413,,Vitamin D-only preparation,Clinician,"Rickets, treatment in infants",Decision,Vitamin D-only preparation,/apptracker/s/application-public/a102P000008puFk,Alimentary Tract and Metabolism
a0R2P000000LmbhUAC,Vitamin D-only preparation,A-01446,,Vitamin D-only preparation,Clinician,"Rickets, prophylaxis - administration to pregnant women or infants",Decision,Vitamin D-only preparation,/apptracker/s/application-public/a102P000008puaz,Alimentary Tract and Metabolism
a0ROZ0000006gz32AA,Vitamin D-only preparation,A-01355,,Vitamin D-only preparation,Clinician,"Rickets, prophylaxis for high-risk infants - administration to pregnant women and/or infants",Decision,Vitamin D-only preparation,/apptracker/s/application-public/a102P000008puST,Alimentary Tract and Metabolism
a0R2P000000LmXUUA0,"Vitamins, fat soluble vitamins",A-00337,Vitabdeck,"Vitamins, fat soluble vitamins",Subcommittee recommendation,"Malabsorption syndrome, severe",Decision,"Vitamins, fat soluble vitamins (Vitabdeck)",/apptracker/s/application-public/a102P000008puW7,Alimentary Tract and Metabolism
a0R2P000000LmX4UAK,Sacubitril with valsartan,A-00540,,Sacubitril with valsartan,Novartis,Heart failure with reduced ejection fraction NYHA III-IV,Decision,Sacubitril with valsartan,/apptracker/s/application-public/a102P000008ptyi,Cardiovascular System
a0R2P000000LmfaUAC,Sacubitril with valsartan,A-00632,,Sacubitril with valsartan,Novartis,Heart failure with reduced ejection fraction NYHA II-IV,Decision,Sacubitril with valsartan,/apptracker/s/application-public/a102P000008ptof,Cardiovascular System
a0R2P000000LmTgUAK,Valsartan,A-00882,Diovan,Valsartan,Novartis,Hypertension and CHF,Decision,Valsartan (Diovan),/apptracker/s/application-public/a102P000008puMY,Cardiovascular System
a0R2P000000LmbnUAC,Valsartan with hydrochlorothiazide,A-00883,Co-Diovan,Valsartan with hydrochlorothiazide,Novartis,Hypertension and CHF,Decision,Valsartan with hydrochlorothiazide (Co-Diovan),/apptracker/s/application-public/a102P000008pubF,Cardiovascular System
a0R2P000000MTd9UAG,Aliskiren,A-00911,Rasilez,Aliskiren,Novartis,Hypertension,Decision,Aliskiren (Rasilez),/apptracker/s/application-public/a102P000008puWr,Cardiovascular System
a0ROZ000000Ahjd2AC,"Alprostadil, 10 mcg or 20 mcg injections",A-01423,,"Alprostadil, 10 mcg or 20 mcg injections",Clinician,Penile Doppler exam,Decision,"Alprostadil, 10 mcg or 20 mcg injections",/apptracker/s/application-public/a102P000008puC4,Cardiovascular System
a0R2P000000LmUXUA0,Ambrisentan,A-00910,Volibris,Ambrisentan,GlaxoSmithKline,Pulmonary arterial hypertension,Decision,Ambrisentan (Volibris),/apptracker/s/application-public/a102P000008puNW,Cardiovascular System
a0R2P000000LmluUAC,Amiloride tablets,A-01229,,Amiloride tablets,NPPA,Re-listing,Decision,Amiloride tablets,/apptracker/s/application-public/a102P000008puiS,Cardiovascular System
a0ROZ0000024ZJ12AM,"Aspirin, atorvastatin, and ramipril combination pill",A-00420,Trinomia FDC polypill,"Aspirin, atorvastatin, and ramipril combination pill",Te Arai Biofarma,Secondary prevention of cardiovascular events,Options Compared,"Aspirin, atorvastatin, and ramipril combination pill (Trinomia FDC polypill)",/apptracker/s/application-public/a102P000008puCm,Cardiovascular System
a0R2P000000LmomUAC,Atenolol oral liquid,A-01275,,Atenolol oral liquid,NPPA,Patients unable to take oral tablets,Decision,Atenolol oral liquid,/apptracker/s/application-public/a102P000008pu37,Cardiovascular System
a0R2P000000LmiIUAS,Bosentan,A-01312,Tracleer,Bosentan,Clinician,Pulmonary artery hypertension - paediatric patients,Decision,Bosentan (Tracleer),/apptracker/s/application-public/a102P000008puDZ,Cardiovascular System
a0R2P000000LmXmUAK,Bosentan,A-00867,Tracleer,Bosentan,Actelion,Pulmonary Arterial Hypertension,Decision,Bosentan (Tracleer),/apptracker/s/application-public/a102P000008puXT,Cardiovascular System
a0R2P000000anRUUAY,Bumetanide oral suspension,A-01304,,Bumetanide oral suspension,NPPA,Complex congenital heart disease,Decision,Bumetanide oral suspension,/apptracker/s/application-public/a102P000008ptum,Cardiovascular System
a0R2P000000Lmm5UAC,Candesartan cilexetil,A-00126,Atacand,Candesartan cilexetil,AstraZeneca,Heart failure - widening access to allow combination with an ACE,Decision,Candesartan cilexetil (Atacand),/apptracker/s/application-public/a102P000008pujx,Cardiovascular System
a0R2P000000LmYRUA0,Candesartan cilexetil,A-01167,Atacand,Candesartan cilexetil,AstraZeneca,Hypertension,Decision,Candesartan cilexetil (Atacand),/apptracker/s/application-public/a102P000008puWe,Cardiovascular System
a0ROZ0000007j6r2AA,Candesartan cilexetil,A-00353,Candestar,Candesartan cilexetil,Subcommittee recommendation,Use in patients with ACE inhibitor intolerance,Decision,Candesartan cilexetil (Candestar),/apptracker/s/application-public/a102P000008pucj,Cardiovascular System
a0R2P000000OceaUAC,Candesartan with hydrochlorothiazide,A-00268,,Candesartan with hydrochlorothiazide,Clinician,Cardiovascular,Decision,Candesartan with hydrochlorothiazide,/apptracker/s/application-public/a102P000008puVh,Cardiovascular System
a0ROZ00000Daagb2AB,Captopril,A-04731,Captopril,Captopril,Clinician,Requesting for use to control high blood pressure during Autonomic dysreflexia in patients with spinal cord injury.,Seeking Clinical Advice,Captopril (Captopril),/apptracker/s/application-public/a10OZ0000001HBh,Cardiovascular System
a0R2P000000LmbeUAC,Carvedilol,A-00103,Dilatrend,Carvedilol,Roche,Heart failure (first line access),Decision,Carvedilol (Dilatrend),/apptracker/s/application-public/a102P000008pu9s,Cardiovascular System
a0R2P000000LmcFUAS,Carvedilol,A-01207,Dilatrend,Carvedilol,Roche,Heart failure (as an adjunct to conventional treatments),Decision,Carvedilol (Dilatrend),/apptracker/s/application-public/a102P000008pu7w,Cardiovascular System
a0ROZ000006i97N2AQ,Empagliflozin,A-04118,Jardiance®,Empagliflozin,Boehringer Ingelheim,"Chronic heart failure, NYHA II-IV and LVEF ≤40%",Decision,Empagliflozin (Jardiance®),/apptracker/s/application-public/a102P00000BNybx,Cardiovascular System
a0ROZ00000DabzG2AR,Empagliflozin,A-04541,Jardiance®,Empagliflozin,Boehringer Ingelheim,"Chronic heart failure, NYHA II-IV and LVEF >40%",Under Assessment,Empagliflozin (Jardiance®),/apptracker/s/application-public/a102P00000BY4ly,Cardiovascular System
a0ROZ000000PXiO2AW,Eplerenone,A-00738,Inspra,Eplerenone,Clinician,"Hypertension, treatment refractory, intolerant to spironolactone",Options Compared,Eplerenone (Inspra),/apptracker/s/application-public/a102P000008puD9,Cardiovascular System
a0ROZ0000008Zjl2AE,Eplerenone,A-00436,Inspra,Eplerenone,Te Arai Biofarma,"Heart failure: ejection fraction <40%, and intolerant to optimal dosing of spironolactone",Decision,Eplerenone (Inspra),/apptracker/s/application-public/a102P000008pu0j,Cardiovascular System
a0R2P000000anI8UAI,Eplerenone,A-00403,,Eplerenone,Te Arai Biofarma,"Heart failure: ejection fraction <=40%, and diabetes or a risk of diabetes",Decision,Eplerenone,/apptracker/s/application-public/a102P000008ptpa,Cardiovascular System
a0ROZ000003FUKD2A4,Eplerenone,A-00800 A-04942,Inspra,Eplerenone,Clinician,Primary aldosteronism; intolerant to spironolactone,Options Compared,Eplerenone (Inspra),/apptracker/s/application-public/a102P000008puaw,Cardiovascular System
a0R2P000000Lmb0UAC,Epoprostenol,A-00310,Veletri,Epoprostenol,Actelion,Pulmonary arterial hypertension,Decision,Epoprostenol (Veletri),/apptracker/s/application-public/a102P000008puTI,Cardiovascular System
a0ROZ0000009XeH2AU,"Epoprostenol, intravenous",A-00441,Veletri,"Epoprostenol, intravenous",Clinician,"Pulmonary arterial hypertension, widening access",Decision,"Epoprostenol, intravenous (Veletri)",/apptracker/s/application-public/a102P000008pufB,Cardiovascular System
a0R2P000000anVlUAI,Evolocumab,A-00719,,Evolocumab,Amgen,Familial hypercholesterolaemia,Decision,Evolocumab,/apptracker/s/application-public/a102P000008pu1G,Cardiovascular System
a0ROZ0000007fEX2AY,Ezetimibe,A-00828,Ezetrol,Ezetimibe,Merck Sharp & Dohme,Hyperlipidemia,Decision,Ezetimibe (Ezetrol),/apptracker/s/application-public/a102P000008ptyh,Cardiovascular System
a0R2P000000MTdOUAW,Fenofibrate,A-01046,,Fenofibrate,Clinician,Hyperlipidemia,Decision,Fenofibrate,/apptracker/s/application-public/a102P000008puie,Cardiovascular System
a0ROZ00000Dhhmz2AB,Furosemide 20mg tablets,A-00653,,Furosemide 20mg tablets,Clinician,Paediatric congenital heart disease,Reviewing Consultation Feedback,Furosemide 20mg tablets,/apptracker/s/application-public/a102P000008puk8,Cardiovascular System
a0R2P000000LmVLUA0,Glyceryl trinitrate spray,A-01199,Glytrin,Glyceryl trinitrate spray,AFT Pharmaceuticals,Angina,Decision,Glyceryl trinitrate spray (Glytrin),/apptracker/s/application-public/a102P000008ptys,Cardiovascular System
a0R2P000000LmqSUAS,Iloprost,A-00848,Ilomedin,Iloprost,Schering,Pulmonary Arterial Hypertension (PAH),Decision,Iloprost (Ilomedin),/apptracker/s/application-public/a102P000008puDE,Cardiovascular System
a0ROZ00000DKzXi2AL,International Normalized Ratio (INR) point-of-care coagulometers and test strips,A-04330 A-04780,Roche CoaguChek® XS system,International Normalized Ratio (INR) point-of-care coagulometers and test strips,"Clinician, Consumer","Rheumatic heart disease, implanted mechanical heart valve, long-term anticoagulation management with warfarin",Seeking Clinical Advice,International Normalized Ratio (INR) point-of-care coagulometers and test strips (Roche CoaguChek® XS system),/apptracker/s/application-public/a102P00000BYAWY,Cardiovascular System
a0R2P000000anb0UAA,Ivabradine,A-00571 A-00572,,Ivabradine,"Te Arai Biofarma, Clinician",Chronic heart failure,Decision,Ivabradine,/apptracker/s/application-public/a102P000008puMW,Cardiovascular System
a0R2P000000LmfPUAS,Ivabradine,A-00453,,Ivabradine,Clinician,Dose prior to computed tomography coronary angiography,Decision,Ivabradine,/apptracker/s/application-public/a102P000008ptoc,Cardiovascular System
a0R2P000000LmWeUAK,Losartan,A-00959,,Losartan,Clinician,Gout,Decision,Losartan,/apptracker/s/application-public/a102P000008ptxo,Cardiovascular System
a0ROZ000004nOoW2AU,Macitentan,A-00312 A-05000,Opsumit,Macitentan,"Actelion, JANSSEN NZ LIMITED",Pulmonary arterial hypertension,Options Compared,Macitentan (Opsumit),/apptracker/s/application-public/a102P000008puIy,Cardiovascular System
a0ROZ000008veQj2AI,Mavacamten,A-05315 A-05264,Camzyos®,Mavacamten,"BRISTOL-MYERS SQUIBB (NZ) LIMITED, Clinician","Obstructive hypertrophic cardiomyopathy, symptomatic, 2nd line. ",Seeking Clinical Advice,Mavacamten (Camzyos®),/apptracker/s/application-public/a10OZ000004RHLp,Cardiovascular System
a0R2P000000LmcDUAS,Metolazone,A-00354,"Metolazone,Zaroxolyn",Metolazone,Subcommittee recommendation,Paediatrics with loop diversion and refractory nephrotic oedema,Decision,"Metolazone (Metolazone,Zaroxolyn)",/apptracker/s/application-public/a102P000008pu6t,Cardiovascular System
a0R2P000000LmiyUAC,Mexiletine Hydrochloride,A-01237,,Mexiletine Hydrochloride,NPPA,Open listing,Decision,Mexiletine Hydrochloride,/apptracker/s/application-public/a102P000008puDq,Cardiovascular System
a0R2P000000LmiJUAS,Multiple PAH therapies,A-00440,,Multiple PAH therapies,Clinician,"Pulmonary arterial hypertension, widening access",Decision,Multiple PAH therapies,/apptracker/s/application-public/a102P000008puDf,Cardiovascular System
a0R2P000000Lpv5UAC,Nicardipine hydrochloride,A-00666,Any,Nicardipine hydrochloride,Clinician,Perioperative use as antihypertensive / vasodilator for adults,Decision,Nicardipine hydrochloride (Any),/apptracker/s/application-public/a102P000008puU2,Cardiovascular System
a0R2P000000LmUyUAK,Nicorandil,A-01232,,Nicorandil,NPPA,Angina - refractory,Decision,Nicorandil,/apptracker/s/application-public/a102P000008ptxF,Cardiovascular System
a0R2P000000LmmWUAS,"PDE5 inhibitors  - Alprostadil, Sildenafil, Tadalafil",A-00234,,"PDE5 inhibitors  - Alprostadil, Sildenafil, Tadalafil",Clinician,Erectile dysfunction in spinal cord injury patients,Decision,"PDE5 inhibitors  - Alprostadil, Sildenafil, Tadalafil",/apptracker/s/application-public/a102P000008pu1X,Cardiovascular System
a0ROZ00000AqQQV2A3,Quinidine Bisulphate,A-00464,Kinidin Durules,Quinidine Bisulphate,Subcommittee recommendation,Brugada syndrome,Options Compared,Quinidine Bisulphate (Kinidin Durules),/apptracker/s/application-public/a102P000008ptxp,Cardiovascular System
a0R2P000000bnF9UAI,Ramipril,A-00664,,Ramipril,Subcommittee recommendation,Open listing (ACE inhibitor),Decision,Ramipril,/apptracker/s/application-public/a102P000008puSl,Cardiovascular System
a0R2P000000aneJUAQ,Ranolazine,A-00287,,Ranolazine,Clinician,"Angina, where nicorandil or perhexiline has failed",Decision,Ranolazine,/apptracker/s/application-public/a102P000008puWG,Cardiovascular System
a0R2P000000OcefUAC,Ranolazine,A-01247,,Ranolazine,Clinician,"Angina, first-line",Decision,Ranolazine,/apptracker/s/application-public/a102P000008puU3,Cardiovascular System
a0R2P000000ezAEUAY,Rivaroxaban,A-03283,XARELTO®,Rivaroxaban,BAYER NEW ZEALAND LIMITED,Prevention of major cardiovascular events,Under Assessment,Rivaroxaban (XARELTO®),/apptracker/s/application-public/a102P00000AEKCR,Cardiovascular System
a0R2P000000aXFOUA2,Rosuvastatin,A-00252 A-03882 A-03904,Crestor,Rosuvastatin,"AstraZeneca, Consumer",Hypercholesterolemia / cardiovascular risk (3rd-line statin treatment),Decision,Rosuvastatin (Crestor),/apptracker/s/application-public/a102P000008ptvc,Cardiovascular System
a0ROZ0000077fjx2AA,Selexipag,A-00683 A-04905 A-05001,,Selexipag,"Actelion, JANSSEN NZ LIMITED, Consumer",Pulmonary arterial hypertension - triple therapy,Under Assessment,Selexipag,/apptracker/s/application-public/a102P000008puAq,Cardiovascular System
a0ROZ000004PMW52AO,Selexipag,A-00682 A-04905 A-05001,,Selexipag,"Actelion, JANSSEN NZ LIMITED, Consumer",Pulmonary arterial hypertension - monotherapy,Under Assessment,Selexipag,/apptracker/s/application-public/a102P000008puLz,Cardiovascular System
a0ROZ000004PMSr2AO,Selexipag,A-00458 A-04905 A-05001,,Selexipag,"Actelion, JANSSEN NZ LIMITED, Consumer",Pulmonary arterial hypertension - dual therapy,Under Assessment,Selexipag,/apptracker/s/application-public/a102P000008ptpc,Cardiovascular System
a0R2P000000LmlUUAS,Sildenafil,A-00980,Viagra,Sildenafil,Clinician,Pulmonary arterial hypertension (PAH) secondary to other lung disease,Decision,Sildenafil (Viagra),/apptracker/s/application-public/a102P000008pukb,Cardiovascular System
a0R2P000000LmjVUAS,Sildenafil,A-00979,,Sildenafil,Clinician,Pulmonary arterial hypertension (PAH) secondary to chronic lung disease (CLD) in neonates/infants,Decision,Sildenafil,/apptracker/s/application-public/a102P000008puhY,Cardiovascular System
a0R2P000000LmjIUAS,Sildenafil,A-00957,,Sildenafil,Clinician,Pulmonary arterial hypertension (PAH) secondary to congenital diaphragmatic hernia (CDH) in neonates,Decision,Sildenafil,/apptracker/s/application-public/a102P000008pud7,Cardiovascular System
a0R2P000000Lmh6UAC,Sildenafil,A-00860,Revatio,Sildenafil,Pfizer,Pulmonary Arterial Hypertension,Decision,Sildenafil (Revatio),/apptracker/s/application-public/a102P000008ptuP,Cardiovascular System
a0R2P000000Lmg5UAC,Sildenafil,A-01290,,Sildenafil,Clinician,Perioperative cardiac surgery,Decision,Sildenafil,/apptracker/s/application-public/a102P000008ptoo,Cardiovascular System
a0R2P000000LmpAUAS,Sildenafil,A-00988,,Sildenafil,Clinician,Post-Fontan Repair in neonates/infants,Decision,Sildenafil,/apptracker/s/application-public/a102P000008pu31,Cardiovascular System
a0R2P000000LmnlUAC,"Sildenafil, intravenous",A-00431,,"Sildenafil, intravenous",Clinician,Pulmonary hypertension pre/post cardiac surgery,Decision,"Sildenafil, intravenous",/apptracker/s/application-public/a102P000008ptsS,Cardiovascular System
a0ROZ000002nZec2AE,"Sildenafil, Tadalafil",A-04815,Various,"Sildenafil, Tadalafil",Consumer,"PDE5 inhibitors ,Erectile dysfunction, following prostate cancer treatment",Under Assessment,"Sildenafil, Tadalafil (Various)",/apptracker/s/application-public/a10OZ000000AjBx,Cardiovascular System
a0R2P000000LmjXUAS,Simvastatin and ezetimibe,A-00987,"Arrow-Simva,Ezetrol",Simvastatin and ezetimibe,Merck Sharp & Dohme,"Hyperlipidemia (widen access, combination therapy)",Decision,"Simvastatin and ezetimibe (Arrow-Simva,Ezetrol)",/apptracker/s/application-public/a102P000008pudR,Cardiovascular System
a0ROZ00000DKzXh2AL,Tadalafil,A-03183,"Cialis, Adcirca, Tadalafil Mylan",Tadalafil,Clinician,Peri operative use in patients with pulmonary hypertension undergoing cardiac surgery ,Seeking Clinical Advice,"Tadalafil (Cialis, Adcirca, Tadalafil Mylan)",/apptracker/s/application-public/a102P000009fETx,Cardiovascular System
a0ROZ000000VUrS2AW,Tafamidis,A-00727,,Tafamidis,Clinician,Cardiac amyloidosis,Under Assessment,Tafamidis,/apptracker/s/application-public/a102P000008puVW,Cardiovascular System
a0R2P000000OcekUAC,Telmisartan,A-00115,Micardis,Telmisartan,Boehringer Ingelheim,Hypertension,Decision,Telmisartan (Micardis),/apptracker/s/application-public/a102P000008pu4J,Cardiovascular System
a0ROZ000008Nz2z2AC,Asciminib,A-04626,SCEMBLIX,Asciminib,NOVARTIS NEW ZEALAND LIMITED,"Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors",Under Assessment,Asciminib (SCEMBLIX),/apptracker/s/application-public/a10OZ000000szzN,
a0ROZ00000BV7mr2AD,Dabrafenib,A-00281,,Dabrafenib,NOVARTIS NEW ZEALAND LIMITED,"Melanoma, stage III/IV with BRAF V600 mutation",Reviewing Consultation Feedback,Dabrafenib,/apptracker/s/application-public/a102P000008pu2y,Oncology Agents and Immunosuppressants
a0ROZ0000094ezN2AQ,Dabrafenib and trametinib,A-00405 A-04762,"Mekinist,Tafinlar",Dabrafenib and trametinib,"NOVARTIS NEW ZEALAND LIMITED, Clinician","Melanoma, stage III/IV with BRAF V600 mutation",Decision,"Dabrafenib and trametinib (Mekinist,Tafinlar)",/apptracker/s/application-public/a102P000008pu5U,Oncology Agents and Immunosuppressants
a0R2P000000Lml4UAC,Deferasirox,A-01545,Exjade,Deferasirox,Novartis,Chronic iron overload in congenital anaemia - intolerant to deferiprone,Decision,Deferasirox (Exjade),/apptracker/s/application-public/a102P000008puij,Blood and Blood Forming Organs
a0R2P000000LmY8UAK,Deferasirox,A-00838,Exjade,Deferasirox,Novartis,Chronic iron overload in congenital anaemia - contraindicated to deferiprone,Decision,Deferasirox (Exjade),/apptracker/s/application-public/a102P000008puWZ,Blood and Blood Forming Organs
a0R2P000000LmisUAC,Eformoterol,A-01205,Foradil,Eformoterol,Novartis,Chronic obstructive pulmonary disease (COPD),Decision,Eformoterol (Foradil),/apptracker/s/application-public/a102P000008puF0,Respiratory System and Allergies
a0R2P000000ane0UAA,Everolimus,A-01303,Certican,Everolimus,Novartis,Rejection of renal/cardiac transplants - preventative,Decision,Everolimus (Certican),/apptracker/s/application-public/a102P000008puWW,Oncology Agents and Immunosuppressants
a0R2P000000MTgzUAG,Everolimus,A-01070,Afinitor,Everolimus,Novartis,Metastatic renal cell carcinoma - second line therapy,Decision,Everolimus (Afinitor),/apptracker/s/application-public/a102P000008puKM,Oncology Agents and Immunosuppressants
a0R2P000000TEqxUAG,Glycopyrronium bromide inhaler,A-01527,Seebri Breezhaler,Glycopyrronium bromide inhaler,Novartis,Chronic obstructive pulmonary disease,Decision,Glycopyrronium bromide inhaler (Seebri Breezhaler),/apptracker/s/application-public/a102P000008puMF,Respiratory System and Allergies
a0R2P000000LmiWUAS,Glycopyrronium with indacaterol,A-00377,Ultibro,Glycopyrronium with indacaterol,Novartis,Chronic obstructive pulmonary disease,Decision,Glycopyrronium with indacaterol (Ultibro),/apptracker/s/application-public/a102P000008puDi,Respiratory System and Allergies
a0R2P000000LmfwUAC,Imatinib,A-01346,Glivec,Imatinib,Novartis,Chronic myeloid leukemia (CML) - allow doses higher than 400mg (600mg max),Decision,Imatinib (Glivec),/apptracker/s/application-public/a102P000008ptpf,Oncology Agents and Immunosuppressants
a0R2P000000LmlmUAC,Imatinib Mesylate,A-01168,Glivec,Imatinib Mesylate,Novartis,"Chronic myeloid leukaemia in blast crisis, accelerated phase, or in chronic phase",Decision,Imatinib Mesylate (Glivec),/apptracker/s/application-public/a102P000008puj3,Oncology Agents and Immunosuppressants
a0ROZ000004JKgh2AG,Inclisiran,A-05097,LEQVIO,Inclisiran,NOVARTIS NEW ZEALAND LIMITED,"ASCVD, high-risk, adjunct to diet, exercise, statin and or ezetimibe",Seeking Clinical Advice,Inclisiran (LEQVIO),/apptracker/s/application-public/a10OZ000001xTyH,
a0ROZ00000DabhV2AR,Inclisiran,A-04999,LEQVIO,Inclisiran,NOVARTIS NEW ZEALAND LIMITED,heterozygous familial hypercholesterolemia.,Under Assessment,Inclisiran (LEQVIO),/apptracker/s/application-public/a10OZ000001vDb3,
a0R2P000000LmpQUAS,Indacaterol,A-01071,Onbrez,Indacaterol,Novartis,Chronic obstructive pulmonary disease,Decision,Indacaterol (Onbrez),/apptracker/s/application-public/a102P000008puCS,Respiratory System and Allergies
a0ROZ00000DabRN2AZ,Iptacopan,A-05317,FABHALTA,Iptacopan,NOVARTIS NEW ZEALAND LIMITED,Paroxysmal nocturnal haemoglobinuria (PNH),Under Assessment,Iptacopan (FABHALTA),/apptracker/s/application-public/a10OZ000004AYis,
a0ROZ000004CUOE2A4,Ketotifen fumarate,A-00817,Zaditen,Ketotifen fumarate,Novartis,Ocular allergy,Decision,Ketotifen fumarate (Zaditen),/apptracker/s/application-public/a102P000008pu7J,Sensory Organs
a0ROZ0000007fHl2AI,Letrozole,A-01166,Femara,Letrozole,Novartis,First line treatment of advanced breast cancer,Decision,Letrozole (Femara),/apptracker/s/application-public/a102P000008puDh,Oncology Agents and Immunosuppressants
a0R2P000000LmeSUAS,Letrozole,A-01159,Femara,Letrozole,Novartis,"Third line treatment of advanced, tamoxifen refractory, breast cancer",Decision,Letrozole (Femara),/apptracker/s/application-public/a102P000008ptt3,Oncology Agents and Immunosuppressants
a0ROZ000001jUar2AE,Midostaurin,A-00808 A-03077 A-03048 A-03279,,Midostaurin,"NOVARTIS NEW ZEALAND LIMITED, Clinician","Acute myeloid leukaemia (AML), FLT3-mutation positive",Decision,Midostaurin,/apptracker/s/application-public/a102P000008ptwH,Oncology Agents and Immunosuppressants
a0R2P000000WlMcUAK,Mycophenolate sodium,A-00798,Myfortic,Mycophenolate sodium,Novartis,Acute transplant rejection prophylaxis in patients receiving allogeneic renal transplants,Decision,Mycophenolate sodium (Myfortic),/apptracker/s/application-public/a102P000008puCQ,Oncology Agents and Immunosuppressants
a0R2P000000LmZbUAK,Nilotinib,A-00819,Tasigna,Nilotinib,Novartis,Chronic myeloid leukaemia (CML),Decision,Nilotinib (Tasigna),/apptracker/s/application-public/a102P000008puTl,Oncology Agents and Immunosuppressants
a0R2P000000LmXFUA0,Octreotide - short acting preparation,A-01220,Sandostatin,Octreotide - short acting preparation,Novartis,Removal of Special Authority,Decision,Octreotide - short acting preparation (Sandostatin),/apptracker/s/application-public/a102P000008ptvf,Oncology Agents and Immunosuppressants
a0R2P000000Lmr0UAC,Omalizumab,A-00895,Xolair,Omalizumab,Novartis,Severe allergic asthma,Decision,Omalizumab (Xolair),/apptracker/s/application-public/a102P000008puKW,Respiratory System and Allergies
a0ROZ0000007fKz2AI,Oral Impact,A-01131,Impact,Oral Impact,Novartis,Pre-operative oral supplement,Decision,Oral Impact (Impact),/apptracker/s/application-public/a102P000008pu1z,Special Foods
a0R2P000000UwFRUA0,Ranibizumab,A-00242,Lucentis,Ranibizumab,Novartis,Wet age-related macular degeneration,Decision,Ranibizumab (Lucentis),/apptracker/s/application-public/a102P000008pueG,Sensory Organs
a0ROZ000001jS9H2AU,Ribociclib,A-03246,Kisqali,Ribociclib,NOVARTIS NEW ZEALAND LIMITED,"Breast cancer, locally advanced/metastatic, HER2negative, HRpositive, second-line endocrine treatment",Decision,Ribociclib (Kisqali),/apptracker/s/application-public/a102P000009mmLY,Oncology Agents and Immunosuppressants
a0ROZ00000BTW9T2AX,Ribociclib,A-05151,KISQALI,Ribociclib,NOVARTIS NEW ZEALAND LIMITED,"Early breast cancer, adjuvant treatment, HR-positive, HER2-negative, high risk of recurrence.",Seeking Clinical Advice,Ribociclib (KISQALI),/apptracker/s/application-public/a10OZ0000035OBF,
a0ROZ000001jJ672AE,Ribociclib,A-00781,Kisqali,Ribociclib,Novartis,"Breast cancer, locally advanced/metastatic, HER2negative, HRpositive, first-line endocrine treatment",Decision,Ribociclib (Kisqali),/apptracker/s/application-public/a102P000008puj0,Oncology Agents and Immunosuppressants
a0R2P000000TgRTUA0,Ruxolitinib,A-00552,,Ruxolitinib,Novartis,"Myelofibrosis, lower-risk (Intermediate-1)",Decision,Ruxolitinib,/apptracker/s/application-public/a102P000008ptsD,Blood and Blood Forming Organs
a0R2P000000LmqLUAS,Ruxolitinib,A-00505,Jakavi,Ruxolitinib,Novartis,"Myelofibrosis, higher-risk (High-risk and Intermediate-2)",Decision,Ruxolitinib (Jakavi),/apptracker/s/application-public/a102P000008puCF,Blood and Blood Forming Organs
a0ROZ000009FoYp2AK,Ruxolitinib,A-05240,JAKAVI,Ruxolitinib,NOVARTIS NEW ZEALAND LIMITED,"Polycythaemia vera, intolerant or resistant to hydroxycarbamide (hydroxyurea)",Seeking Clinical Advice,Ruxolitinib (JAKAVI),/apptracker/s/application-public/a10OZ000004aCht,Oncology Agents and Immunosuppressants
a0R2P000000LmmCUAS,Secukinumab,A-00602,,Secukinumab,Novartis,"Plaque psoriasis, chronic, moderate to severe chronic, 2nd line biologic",Decision,Secukinumab,/apptracker/s/application-public/a102P000008pu1D,Dermatologicals
a0R2P000000Q18TUAS,Secukinumab,A-00673 A-03063,,Secukinumab,"Novartis, Clinician","Psoriatic arthritis, 2nd biologic line",Decision,Secukinumab,/apptracker/s/application-public/a102P000008pttN,Musculoskeletal System
a0ROZ00000DabeH2AR,Secukinumab,A-04711,COSENTYX,Secukinumab,NOVARTIS NEW ZEALAND LIMITED,"Moderate to severe hidradenitis suppurativa, second-line biologic treatment",Under Assessment,Secukinumab (COSENTYX),/apptracker/s/application-public/a10OZ000002qLiL,Dermatologicals
a0R2P000000PdjbUAC,Secukinumab,A-00672 A-03063,,Secukinumab,"Novartis, Clinician","Ankylosing spondylitis, 2nd biologic line",Decision,Secukinumab,/apptracker/s/application-public/a102P000008ptuN,Musculoskeletal System
a0R2P000000PdjMUAS,Secukinumab,A-00674 A-03063,,Secukinumab,"Novartis, Clinician","Psoriatic arthritis, 1st biologic line",Decision,Secukinumab,/apptracker/s/application-public/a102P000008pu5V,Musculoskeletal System
a0ROZ00000BVYS52AP,Secukinumab,A-00626 A-03063,,Secukinumab,"Novartis, Clinician","Ankylosing spondylitis, 1st biologic line",Reviewing Consultation Feedback,Secukinumab,/apptracker/s/application-public/a102P000008puMJ,Musculoskeletal System
a0ROZ00000BGaUO2A1,Secukinumab,A-04711,COSENTYX,Secukinumab,NOVARTIS NEW ZEALAND LIMITED,"moderate to severe hidradenitis suppurativa, first-line biologic treatment",Options Compared,Secukinumab (COSENTYX),/apptracker/s/application-public/a10OZ000002qLdW,Dermatologicals
a0R2P000000LmUqUAK,Tobramycin solution for inhalation,A-00188,Tobi,Tobramycin solution for inhalation,Novartis,Cystic fibrosis with Pseudomonas aeruginosa infection,Decision,Tobramycin solution for inhalation (Tobi),/apptracker/s/application-public/a102P000008puOQ,Respiratory System and Allergies
a0R2P000000LmihUAC,Tobramycin solution for inhalation,A-00246,Tobi,Tobramycin solution for inhalation,Novartis,Cystic fibrosis with Pseudomonas aeruginosa infection: patient has a reaction to IV tobramycin,Decision,Tobramycin solution for inhalation (Tobi),/apptracker/s/application-public/a102P000008puEy,Respiratory System and Allergies
a0ROZ000004CPYH2A4,Verteporfin,A-01136,Visudyne,Verteporfin,Novartis,Small subfoveal choroidal neovascularisation due to age-related macular degeneration,Decision,Verteporfin (Visudyne),/apptracker/s/application-public/a102P000008ptqD,Sensory Organs
a0ROZ00000Cn1x02AB,Voretigene neparvovec,A-04307,LUXTURNA,Voretigene neparvovec,NOVARTIS NEW ZEALAND LIMITED,"inherited retinal dystrophy, biallelic RPE65 mutations",Options Compared,Voretigene neparvovec (LUXTURNA),/apptracker/s/application-public/a102P00000BXTtD,Sensory Organs
a0R2P000000Lmk0UAC,Zoledronic acid,A-01153,Zometa,Zoledronic acid,Novartis,"Bone metastases associated with prostate cancer, breast cancer and multiple myeloma",Decision,Zoledronic acid (Zometa),/apptracker/s/application-public/a102P000008pudn,Oncology Agents and Immunosuppressants
a0R2P000000LmWdUAK,Zoledronic acid,A-00839,Aclasta,Zoledronic acid,Novartis,Paget's disease,Decision,Zoledronic acid (Aclasta),/apptracker/s/application-public/a102P000008ptww,Musculoskeletal System
a0R2P000000LmedUAC,Zoledronic acid,A-01367,Zometa,Zoledronic acid,Novartis,Hypercalcemia of malignancy,Decision,Zoledronic acid (Zometa),/apptracker/s/application-public/a102P000008pttE,Oncology Agents and Immunosuppressants
a0R2P000000LmbMUAS,Zoledronic acid,A-00840,Aclasta,Zoledronic acid,Novartis,Osteoporosis,Decision,Zoledronic acid (Aclasta),/apptracker/s/application-public/a102P000008puRz,Musculoskeletal System
a0R2P000000LmThUAK,Somatropin - Growth Hormone,A-01165,Genotropin,Somatropin - Growth Hormone,Clinician,Adult  and adolescent  patients with growth hormone deficiency,Decision,Somatropin - Growth Hormone (Genotropin),/apptracker/s/application-public/a102P000008puMe,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ00000082Xh2AI,Somatropin - Growth Hormone,A-01121,Genotropin,Somatropin - Growth Hormone,New Zealand Growth Hormone Committee,Children with Prader-Willi Syndrome (PWS),Decision,Somatropin - Growth Hormone (Genotropin),/apptracker/s/application-public/a102P000008puaX,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ000009A8qa2AC,Somatropin Growth Hormone,A-01120,Genotropin,Somatropin Growth Hormone,Consumer,Short children born small for gestational age,Options Compared,Somatropin Growth Hormone (Genotropin),/apptracker/s/application-public/a102P000008puY5,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000eo5vUAA,Cinacalcet,A-00529,,Cinacalcet,Te Arai Biofarma,Secondary hyperparathyroidism in patients taking sevelamer,Decision,Cinacalcet,/apptracker/s/application-public/a102P000008puch,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000eox5UAA,Cinacalcet,A-00510,,Cinacalcet,Te Arai Biofarma,Patients with haemodialysis with secondary hyperparathyroidism and symptomatic hypercalcaemia,Decision,Cinacalcet,/apptracker/s/application-public/a102P000008pu4j,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000eyg4UAA,Cinacalcet,A-00642,Sensipar,Cinacalcet,Subcommittee recommendation,"Calciphylaxis, widening access",Under Assessment,Cinacalcet (Sensipar),/apptracker/s/application-public/a102P000008pu8a,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000bo8dUAA,Cinacalcet Hcl,A-00466 A-00467 A-00468,,Cinacalcet Hcl,"Amgen, Te Arai Biofarma, Clinician",Secondary hyperparathyroidism,Decision,Cinacalcet Hcl,/apptracker/s/application-public/a102P000008puCp,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ000009J3pp2AC,Cyproterone Acetate 10mg tablets,A-00705,,Cyproterone Acetate 10mg tablets,Clinician,Testosterone Supression,Decision,Cyproterone Acetate 10mg tablets,/apptracker/s/application-public/a102P000008ptod,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmWYUA0,Desmopressin - tablets,A-01233,,Desmopressin - tablets,NPPA,Diabetes insipidus and primary nocturnal enuresis where nasal form contraindicated,Decision,Desmopressin - tablets,/apptracker/s/application-public/a102P000008ptyU,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmpdUAC,Finasteride,A-00299,Fintral,Finasteride,Clinician,Benign Prostatic Hyperplasia,Decision,Finasteride (Fintral),/apptracker/s/application-public/a102P000008puBD,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmeNUAS,Goserelin acetate,A-00613,Zoladex,Goserelin acetate,AstraZeneca,Uterine Fibroids,Decision,Goserelin acetate (Zoladex),/apptracker/s/application-public/a102P000008pttu,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ00000085If2AI,Leuprorelin acetate,A-01093,Eligard,Leuprorelin acetate,Mayne Pharma Pty Ltd,"Prostate cancer, endometriosis, and precocious puberty.",Decision,Leuprorelin acetate (Eligard),/apptracker/s/application-public/a102P000008puMX,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000Sk5SUAS,Levonorgestrel intrauterine system,A-00533,Mirena,Levonorgestrel intrauterine system,Clinician,Endometriosis,Decision,Levonorgestrel intrauterine system (Mirena),/apptracker/s/application-public/a102P000008ptvt,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000fSymUAE,Levonorgestrel intrauterine system,A-00536,Mirena,Levonorgestrel intrauterine system,Clinician,heavy menstrual bleeding - widened access,Decision,Levonorgestrel intrauterine system (Mirena),/apptracker/s/application-public/a102P000008pu7a,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ000004CC7z2AG,Levothyroxine oral liquid,A-04020,100mcg/5ml Osoln 100 ml,Levothyroxine oral liquid,Clinician,Congenital hypothyroidism,Decision,Levothyroxine oral liquid (100mcg/5ml Osoln 100 ml),/apptracker/s/application-public/a102P00000BLTjd,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ00000125sf2AA,Oestradiol Patches,A-04219,,Oestradiol Patches,Consumer,"Gender dysphoria among male to female transgender people, unlimited number of patches, oral alternative unsuitable",Seeking Clinical Advice,Oestradiol Patches,/apptracker/s/application-public/a102P00000BPUxo,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmVaUAK,Oestradiol patches,A-00459,"Climara 100,Climara 50,Estradot,Estradot 50 Mcg",Oestradiol patches,Subcommittee recommendation,Hormone replacement therapy - systemic,Decision,"Oestradiol patches (Climara 100,Climara 50,Estradot,Estradot 50 Mcg)",/apptracker/s/application-public/a102P000008ptvw,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000QNOiUAO,Prednisolone oral liquid,A-00291,Redipred,Prednisolone oral liquid,Subcommittee recommendation,Removal of restrictions,Options Compared,Prednisolone oral liquid (Redipred),/apptracker/s/application-public/a102P000008ptqh,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000d7nRUAQ,Progesterone,A-03504,,Progesterone,Clinician,Recurring early pregnancy loss (3 or more) with pre-vaginal bleeding,Decision,Progesterone,/apptracker/s/application-public/a102P00000Au6qf,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000aVixUAE,Progesterone,A-01256,,Progesterone,Pharmaco (NZ) Ltd,Open-listing,Decision,Progesterone,/apptracker/s/application-public/a102P00000BPAvz,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000daDAUAY,Progesterone,A-01256,,Progesterone,Pharmaco (NZ) Ltd,Menopause,Decision,Progesterone,/apptracker/s/application-public/a102P000008puLd,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ000009A8qg2AC,Somatropin,A-04249,Omnitrope,Somatropin,Clinician,"Short stature due to chronic renal insufficiency, amending GFR to 60ml/min/1.73m2",Options Compared,Somatropin (Omnitrope),/apptracker/s/application-public/a102P00000BPnSy,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ000001PfvR2AS,Testosterone gel,A-03198,Testogel,Testosterone gel,Consumer,Transdermal hormone replacement,Decision,Testosterone gel (Testogel),/apptracker/s/application-public/a102P00000Au6oj,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000Lml7UAC,Testosterone patches,A-01194,Androderm,Testosterone patches,Mayne Pharma Pty Ltd,Hypogonadism,Decision,Testosterone patches (Androderm),/apptracker/s/application-public/a102P000008pukG,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000LmoZUAS,Testosterone undecanoate injection,A-00345,Reandron,Testosterone undecanoate injection,Bayer,Testosterone Deficiency,Decision,Testosterone undecanoate injection (Reandron),/apptracker/s/application-public/a102P000008pu1A,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000bjFbUAI,Tolvaptan,A-00447,,Tolvaptan,Clinician,Polycystic chronic kidney disease,Decision,Tolvaptan,/apptracker/s/application-public/a102P000008puBx,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ000004CBlS2AW,"Whole Thyroid Extract, Normal Release T3 and Extended Release T3",A-00644,,"Whole Thyroid Extract, Normal Release T3 and Extended Release T3",Clinician,Hypothyroidism,Decision,"Whole Thyroid Extract, Normal Release T3 and Extended Release T3",/apptracker/s/application-public/a102P000008ptvN,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000birZUAQ,Zoledronic acid,A-04021,,Zoledronic acid,Clinician,Open-listing,Decision,Zoledronic acid,/apptracker/s/application-public/a102P00000BLTj4,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0R2P000000d7c6UAA,Zoledronic acid,A-03342,,Zoledronic acid,Clinician,Moderate to severe hypercalcaemia,Decision,Zoledronic acid,/apptracker/s/application-public/a102P00000AG0tG,Hormone Preparations - Systemic Excluding Contraceptive Hormones
a0ROZ000000MG6A2AW,"1%, Ether liquid 16%, magnesium carbonate light powder 1%, boric acid powder 82%",A-00668,,"Iodine crystals 1%, Ether liquid 16%, magnesium carbonate light powder 1%, boric acid powder 82%",Clinician,otitis externa,Decision,"Iodine crystals 1%, Ether liquid 16%, magnesium carbonate light powder 1%, boric acid powder 82%",/apptracker/s/application-public/a102P000008pu6l,Sensory Organs
a0R2P000000av7tUAA,10% sodium hydroxide,A-04181,10% sodium hydroxide solution,10% sodium hydroxide,Clinician,Nail matrixectomy ablation in Diabetic high risk patients.,Decision,10% sodium hydroxide (10% sodium hydroxide solution),/apptracker/s/application-public/a102P00000BRbIF,Dermatologicals
a0ROZ000005F6Ws2AK,"7% hypertonic saline solution, 4mL single-use vial",A-05090,,"7% hypertonic saline solution, 4mL single-use vial",Clinician,Nebulisation for adjunctive therapy in cystic fibrosis and non-CF bronchiectasis,Seeking Clinical Advice,"7% hypertonic saline solution, 4mL single-use vial",/apptracker/s/application-public/a10OZ000002Q317,Respiratory System and Allergies
a0ROZ00000BTW9R2AX,Abemaciclib,A-05011 A-04989 A-05356,VERZENIO®,Abemaciclib,"ELI LILLY AND COMPANY (NZ) LIMITED, Clinician, Consumer","early breast cancer, in combination with endocrine therapy, adjuvant treatment of HR+/HER2-",Seeking Clinical Advice,Abemaciclib (VERZENIO®),/apptracker/s/application-public/a10OZ000001F0NK,
a0R2P000000Uw3KUAS,Adalimumab,A-00329,"Humira,Humirapen",Adalimumab,Clinician,"Behcet's disease, first line biologic",Decision,"Adalimumab (Humira,Humirapen)",/apptracker/s/application-public/a102P000008puiP,Oncology Agents and Immunosuppressants
a0R2P000000Uw3JUAS,Adalimumab,A-00223,,Adalimumab,Clinician,"Undifferentiated spondyloarthritis, 2nd line (after etanercept)",Decision,Adalimumab,/apptracker/s/application-public/a102P00000B0kHq,Oncology Agents and Immunosuppressants
a0ROZ000003Vk6T2AS,Adalimumab,A-04160,,Adalimumab,Clinician,"Crohn’s disease, children, widening access to people who require a course of EEN",Seeking Clinical Advice,Adalimumab,/apptracker/s/application-public/a102P00000BNlaD,Oncology Agents and Immunosuppressants
a0R2P000000UTvNUAW,Adalimumab,A-00223,Humira,Adalimumab,Clinician,"Undifferentiated spondyloarthritis, 1st line",Decision,Adalimumab (Humira),/apptracker/s/application-public/a102P000008puc4,Oncology Agents and Immunosuppressants
a0R2P000000LmZSUA0,Adalimumab,A-01276,"Humira,Humirapen",Adalimumab,Clinician,"Behcet's disease, second line after infliximab",Decision,"Adalimumab (Humira,Humirapen)",/apptracker/s/application-public/a102P000008puSk,Oncology Agents and Immunosuppressants
a0R2P000000Uw3SUAS,Adalimumab,A-00643,"Humira,Humirapen,Remicade",Adalimumab,Clinician,Crohn's disease - widening access (dose escalation),Decision,"Adalimumab (Humira,Humirapen,Remicade)",/apptracker/s/application-public/a102P000008ptuL,Oncology Agents and Immunosuppressants
a0R2P000000PXYtUAO,Adalimumab,A-00795,,Adalimumab,Clinician,juvenile idiopathic arthritis (access widening),Decision,Adalimumab,/apptracker/s/application-public/a102P000009nuG2,
a0ROZ00000721de2AA,"Adalimumab, etanercept and secukinumab",A-04135,,"Adalimumab, etanercept and secukinumab",Clinician,"Psoriatic arthritis, SA review of number of csDMARDs previously trialled",Options Compared,"Adalimumab, etanercept and secukinumab",/apptracker/s/application-public/a102P00000BaHCo,Oncology Agents and Immunosuppressants
a0ROZ00000721dc2AA,"Adalimumab, etanercept and secukinumab",A-04135,,"Adalimumab, etanercept and secukinumab",Clinician,"Psoriatic arthritis, remove SA criteria relating to CRP",Options Compared,"Adalimumab, etanercept and secukinumab",/apptracker/s/application-public/a102P00000BNlQr,Oncology Agents and Immunosuppressants
a0R2P000000LmaJUAS,"Adalimumab, Etanercept, Tocilizumab",A-01348,"Actemra,Enbrel,Humira,Humirapen","Adalimumab, Etanercept, Tocilizumab",Clinician,"Adult-onset Still's disease, 3rd line",Decision,"Adalimumab, Etanercept, Tocilizumab (Actemra,Enbrel,Humira,Humirapen)",/apptracker/s/application-public/a102P000008puQx,Musculoskeletal System
a0R2P000000gNJZUA2,Adenosine,A-03489,,Adenosine,Clinician,Antiarrhythmics,Decision,Adenosine,/apptracker/s/application-public/a102P00000AV87g,
a0R2P000000d88RUAQ,Adrenaline auto-injector,A-00930 A-00929 A-00241,,Adrenaline auto-injector,"CSL, Clinician","Anaphylaxis, previous anaphylactic reaction or are at high risk of reaction",Decision,Adrenaline auto-injector,/apptracker/s/application-public/a102P000008pu6s,Respiratory System and Allergies
a0ROZ00000BVmA52AL,Aflibercept,A-00317 A-00316,Eylea,Aflibercept,"Bayer, Clinician","Wet age-related macular degeneration, 3rd-line",Reviewing Consultation Feedback,Aflibercept (Eylea),/apptracker/s/application-public/a102P000008pudS,Sensory Organs
a0R2P000000TFVnUAO,Aflibercept,A-00373 A-00372,Eylea,Aflibercept,"Bayer, Clinician","Wet age-related macular degeneration, 2nd line",Decision,Aflibercept (Eylea),/apptracker/s/application-public/a102P000008pu29,Sensory Organs
a0ROZ000004CXU92AO,Amifostine,A-00344,Ethyol,Amifostine,Clinician,Cisplatin-related ototoxicity,Decision,Amifostine (Ethyol),/apptracker/s/application-public/a102P000008ptvY,Oncology Agents and Immunosuppressants
a0ROZ0000002lCX2AY,Amino acid formula (without phenylalinine) with minerals,A-03490,,Amino acid formula (without phenylalinine) with minerals,Clinician,special food,Decision,Amino acid formula (without phenylalinine) with minerals,/apptracker/s/application-public/a102P00000AV8A6,
a0R2P000000LmfqUAC,Aminolevulinic acid hydrochloride,A-00307,Gliolan,Aminolevulinic acid hydrochloride,Clinician,Neurosurgery for malignant glioma,Decision,Aminolevulinic acid hydrochloride (Gliolan),/apptracker/s/application-public/a102P000008pu4U,Oncology Agents and Immunosuppressants
a0ROZ00000004gL2AQ,Aminophylline tablets,A-03491,,Aminophylline tablets,Clinician,Bronchodilator,Decision,Aminophylline tablets,/apptracker/s/application-public/a102P00000AV8B4,Respiratory System and Allergies
a0ROZ0000084s6t2AA,Amphotericin B,A-04794,Fungilin,Amphotericin B,Clinician,"Prophylaxis of invasive fungal infections in people with high risk malignancies, lung and liver transplant recipients",Options Compared,Amphotericin B (Fungilin),/apptracker/s/application-public/a10OZ0000001Qzl,
a0ROZ00000004gM2AQ,Amylobarbitone,A-03492,,Amylobarbitone,Clinician,Hospital listing,Decision,Amylobarbitone,/apptracker/s/application-public/a102P00000AV8BU,Special Foods
a0ROZ00000CqzLS2AZ,Apixaban,A-01399 A-05423,,Apixaban,"Pfizer, Clinician",Anticoagulation therapy - open listing,Options Compared,Apixaban,/apptracker/s/application-public/a10OZ0000000WuL,Blood and Blood Forming Organs
a0R2P000000Z4pgUAC,Arginine,A-03862,Various,Arginine,Clinician,For the treatment of in born errors of metabolism responsive to taurine supplementation,Decision,Arginine (Various),/apptracker/s/application-public/a102P00000BAUMD,
a0R2P000000LmblUAC,Aromatase Inhibitors,A-01242,,Aromatase Inhibitors,Clinician,include stage IIIc for breast cancer,Decision,Aromatase Inhibitors,/apptracker/s/application-public/a102P000008pu9v,Oncology Agents and Immunosuppressants
a0R2P000000LmdVUAS,"Aromatase inhibitors - Anastrozole, Letrozole",A-00554,,"Aromatase inhibitors - Anastrozole, Letrozole",Clinician,Breast cancer (removal of special authority),Decision,"Aromatase inhibitors - Anastrozole, Letrozole",/apptracker/s/application-public/a102P000008puab,Oncology Agents and Immunosuppressants
a0ROZ00000006VF2AY,"Aspirin (75mg tab, 150mg tab, powder for compounding)",A-03493,,"Aspirin (75mg tab, 150mg tab, powder for compounding)",Clinician,Hospital Listing,Decision,"Aspirin (75mg tab, 150mg tab, powder for compounding)",/apptracker/s/application-public/a102P00000AV8Ij,
a0R2P000000gVYrUAM,"Aspirin, intravenous",A-00695,,"Aspirin, intravenous",Clinician,Use during interventional neuroradiology procedures,Decision,"Aspirin, intravenous",/apptracker/s/application-public/a102P000008pu42,Blood and Blood Forming Organs
a0ROZ0000078hdF2AQ,Atezolizumab and bevacizumab,A-03542 A-03919,Tecentriq,Atezolizumab and bevacizumab,"ROCHE PRODUCTS (NEW ZEALAND) LIMITED, Clinician","Hepatocellular carcinoma, unresectable, 1st line",Decision,Atezolizumab and bevacizumab (Tecentriq),/apptracker/s/application-public/a102P00000AlzxU,Oncology Agents and Immunosuppressants
a0ROZ000004CDNN2A4,Atropine .01%,A-00725 A-04563,,Atropine .01%,Clinician,myopia,Under Assessment,Atropine .01%,/apptracker/s/application-public/a102P000008pukd,Sensory Organs
a0ROZ00000005Kf2AI,Atropine prefilled syringes,A-03494,,Atropine prefilled syringes,Clinician,Hospital listing,Decision,Atropine prefilled syringes,/apptracker/s/application-public/a102P00000AV8GT,
a0ROZ00000Dabkj2AB,Avacopan,A-05030 A-05328,Tavneos,Avacopan,"Seqirus, Clinician",ANCA-associated vasculitis,Under Assessment,Avacopan (Tavneos),/apptracker/s/application-public/a10OZ000001CBGs,Musculoskeletal System
a0ROZ00000DaaiD2AR,Avacopan,A-05030 A-05328,Tavneos,Avacopan,"Seqirus, Clinician","ANCA-associated vasculitis, high risk of adverse outcomes from high-dose steroid use",Under Assessment,Avacopan (Tavneos),/apptracker/s/application-public/a10OZ000006ApPB,
a0ROZ00000BwnOb2AJ,Azacitidine,A-03785,,Azacitidine,Clinician,"AML, blast count above 30% -widened access",Decision,Azacitidine,/apptracker/s/application-public/a102P00000B0gUX,Oncology Agents and Immunosuppressants
a0ROZ00000Chvwz2AB,Azacitidine,A-05342,,Azacitidine,Clinician,VEXAS syndrome,Under Assessment,Azacitidine,/apptracker/s/application-public/a10OZ000003vxjB,Oncology Agents and Immunosuppressants
a0ROZ00000BwnGX2AZ,Azacitidine,A-03785,,Azacitidine,Clinician,widened access therapy related MDS/AML,Decision,Azacitidine,/apptracker/s/application-public/a102P00000B0fZJ,Oncology Agents and Immunosuppressants
a0ROZ0000093kh32AA,Azelastine hydrochloride with fluticasone propionate,A-04878,Dymista,Azelastine hydrochloride with fluticasone propionate,Clinician,Adenoid hypertrophy,Options Compared,Azelastine hydrochloride with fluticasone propionate (Dymista),/apptracker/s/application-public/a10OZ000003Nbd3,Respiratory System and Allergies
a0ROZ00000Cn1x72AB,Azelastine hydrochloride with fluticasone propionate,A-04878 A-05144,Dymista,Azelastine hydrochloride with fluticasone propionate,"VIATRIS LIMITED, Clinician",Rhinitis or rhinoconjunctivitis not adequately responding to standard treatments,Options Compared,Azelastine hydrochloride with fluticasone propionate (Dymista),/apptracker/s/application-public/a10OZ000000Um41,Respiratory System and Allergies
a0ROZ000005c2XN2AY,Azithromycin,A-01333 A-05088,,Azithromycin,Clinician,Bronchiectasis - prevention of exacerbations in non-cystic fibrosis in adults,Seeking Clinical Advice,Azithromycin,/apptracker/s/application-public/a102P000008pukK,Infections - Agents for Systemic Use
a0R2P000000LmnqUAC,Azithromycin,A-01238,,Azithromycin,Clinician,Neonatal conjunctivitis and pneumonia due to chlamydia,Decision,Azithromycin,/apptracker/s/application-public/a102P000008pu27,Infections - Agents for Systemic Use
a0R2P000000LmhdUAC,Azithromycin,A-01456,Zithromax,Azithromycin,Clinician,Widen access for Cystic Fibrosis,Decision,Azithromycin (Zithromax),/apptracker/s/application-public/a102P000008puFO,Infections - Agents for Systemic Use
a0R2P000000LmcHUAS,Azithromycin,A-00484,"Apo-Azithromycin,Zithromax",Azithromycin,Clinician,"Post transplant (bone marrow transplant, stem cell transplant) bronchiolitis obliterans",Decision,"Azithromycin (Apo-Azithromycin,Zithromax)",/apptracker/s/application-public/a102P000008pu8F,Infections - Agents for Systemic Use
a0R2P000000LmZIUA0,Azithromycin,A-01209,,Azithromycin,Clinician,Pertussis,Decision,Azithromycin,/apptracker/s/application-public/a102P000008puVj,Infections - Agents for Systemic Use
a0R2P000000TEqXUAW,Baclofen intrathecal injection,A-00226,Lioresal Intrathecal,Baclofen intrathecal injection,Clinician,Muscle relaxant,Decision,Baclofen intrathecal injection (Lioresal Intrathecal),/apptracker/s/application-public/a102P000008puCT,Musculoskeletal System
a0ROZ000009J47Z2AS,Baclofen oral liquid,A-00667,,Baclofen oral liquid,Clinician,Muscle relaxant,Decision,Baclofen oral liquid,/apptracker/s/application-public/a102P000008pudA,Musculoskeletal System
a0R2P000000PjPkUAK,Bendamustine,A-03402,Ribomustin,Bendamustine,Clinician,Bendamustine for relapsed/refractory hodgkin's lymphoma,Decision,Bendamustine (Ribomustin),/apptracker/s/application-public/a102P00000AFSmv,Oncology Agents and Immunosuppressants
a0ROZ00000Dk7lN2AR,Benralizumab and mepolizumab,A-05008,Fasenra and Nucala,Benralizumab and mepolizumab,Clinician,"Severe eosinophilic asthma, second biologic line",Options Compared,Benralizumab and mepolizumab (Fasenra and Nucala),/apptracker/s/application-public/a10OZ000002Be2c,Respiratory System and Allergies
a0ROZ00000006rp2AA,Benzalkonium chloride with panthenol,A-03495,,Benzalkonium chloride with panthenol,Clinician,Dermatology,Decision,Benzalkonium chloride with panthenol,/apptracker/s/application-public/a102P00000AV8KQ,Dermatologicals
a0R2P000000N6iJUAS,Benzbromarone,A-01020,Benzbromaron [S.29],Benzbromarone,Clinician,Gout,Decision,Benzbromarone (Benzbromaron [S.29]),/apptracker/s/application-public/a102P000008ptqC,Musculoskeletal System
a0R2P000000grZSUAY,Benzocaine and Phenazone ear drops,A-04609,Auralgan,Benzocaine and Phenazone ear drops,Clinician,Otitis media or otalgia,Seeking Clinical Advice,Benzocaine and Phenazone ear drops (Auralgan),/apptracker/s/application-public/a102P00000BauiC,Sensory Organs
a0R2P000000OcezUAC,Bepanthen cream,A-00036,,Bepanthen cream,Clinician,Excoriated buttocks,Decision,Bepanthen cream,/apptracker/s/application-public/a102P000008puIv,Dermatologicals
a0ROZ00000BP6By2AL,Bevacizumab,A-05384 A-05389,Vegzelma,Bevacizumab,"Clinician, Consumer","Hereditary Haemorrhagic Telangiectasia (HHT), severe",Seeking Clinical Advice,Bevacizumab (Vegzelma),/apptracker/s/application-public/a10OZ000004UUsp,Oncology Agents and Immunosuppressants
a0ROZ00000721dV2AQ,Bevacizumab,A-00387,,Bevacizumab,Clinician,"Cervical cancer, advanced",Options Compared,Bevacizumab,/apptracker/s/application-public/a102P000008ptxU,Oncology Agents and Immunosuppressants
a0ROZ00000007JF2AY,Bifonazole,A-03496,,Bifonazole,Clinician,antifungal cream,Decision,Bifonazole,/apptracker/s/application-public/a102P00000AV8L4,
a0ROZ000004u9Sv2AI,Biologics currently funded for psoriasis,A-04158,,Biologics currently funded for psoriasis,Clinician,"Widening access to severe, localised flexural or genital psoriasis",Decision,Biologics currently funded for psoriasis,/apptracker/s/application-public/a102P00000BNmFH,Dermatologicals
a0ROZ000008NygP2AS,Blinatumomab,A-04913,Blinctyo,Blinatumomab,Clinician,Measurable residual disease in B cell lineage acute lymphoblastic leukaemia,Under Assessment,Blinatumomab (Blinctyo),/apptracker/s/application-public/a10OZ000000e52b,Oncology Agents and Immunosuppressants
a0ROZ00000DL6Sj2AL,Blinatumomab,A-05485,Blinctyo,Blinatumomab,Clinician,"B cell lineage acute lymphoblastic leukaemia (ALL), measurable residual disease (MRD)-negative",Seeking Clinical Advice,Blinatumomab (Blinctyo),/apptracker/s/application-public/a10OZ000007O2Ss,Oncology Agents and Immunosuppressants
a0R2P000000N6iDUAS,Bortezomib,A-01004,Velcade,Bortezomib,Clinician,AL amyloidosis,Decision,Bortezomib (Velcade),/apptracker/s/application-public/a102P000008puT7,Oncology Agents and Immunosuppressants
a0R2P000000LmavUAC,Bortezomib,A-00976,Velcade,Bortezomib,Clinician,Induction t4:14 Multiple Myeloma,Decision,Bortezomib (Velcade),/apptracker/s/application-public/a102P000008puSS,Oncology Agents and Immunosuppressants
a0ROZ00000DgyY92AJ,Bortezomib,A-04207,Velcade,Bortezomib,Clinician,Waldenström macroglobulinemia,Decision,Bortezomib (Velcade),/apptracker/s/application-public/a102P00000BPPQA,
a0ROZ00000BQXV32AP,Brentuximab vedotin,A-00449,Adcetris,Brentuximab vedotin,Clinician,Brentuximab vedotin - CD30-positive systemic anaplastic large-cell lymphoma,Decision,Brentuximab vedotin (Adcetris),/apptracker/s/application-public/a102P00000BEvHl,Oncology Agents and Immunosuppressants
a0R2P000000bqjMUAQ,Brentuximab vedotin,A-00449,Adcetris,Brentuximab vedotin,Clinician,Relapsed or refractory Hodgkin's lymphoma and anaplastic large cell lymphoma,Decision,Brentuximab vedotin (Adcetris),/apptracker/s/application-public/a102P00000BHli7,Oncology Agents and Immunosuppressants
a0ROZ00000BQWCP2A5,Brentuximab vedotin,A-00786,,Brentuximab vedotin,Clinician,"Relapsed or refractory Hodgkin's lymphoma, ASCT ineligible patients",Decision,Brentuximab vedotin,/apptracker/s/application-public/a102P000008pu9I,Oncology Agents and Immunosuppressants
a0ROZ00000BQXI92AP,Brentuximab vedotin,A-00530,Adcetris,Brentuximab vedotin,Clinician,Relapsed or refractory Hodgkin's lymphoma after auto transplantation,Decision,Brentuximab vedotin (Adcetris),/apptracker/s/application-public/a102P000008puiq,Oncology Agents and Immunosuppressants
a0ROZ000009A8qk2AC,Cabozantanib Nivolumab,A-04694,"Cabometyx,cometriq Opdivo",Cabozantanib Nivolumab,Clinician,First line treatment for metastatic IMDC score intermediate and poor prognosis kidney cancer with a clear cell component.,Options Compared,"Cabozantanib Nivolumab (Cabometyx,cometriq Opdivo)",/apptracker/s/application-public/a102P00000BarHT,Oncology Agents and Immunosuppressants
a0ROZ000003ZaJp2AK,Cabozantinib,A-05037,Cabmetryx,Cabozantinib,Clinician,"advanced clear cell renal cancer, second line therapy",Seeking Clinical Advice,Cabozantinib (Cabmetryx),/apptracker/s/application-public/a10OZ000001XFHS,
a0ROZ00000DyqkD2AR,Canakinumab,A-05078,Ilaris,Canakinumab,Clinician,"Still’s disease, 1st line biologic",Seeking Clinical Advice,Canakinumab (Ilaris),/apptracker/s/application-public/a10OZ000007O3om,
a0R2P000000LmnKUAS,Capecitabine,A-00463,Xeloda,Capecitabine,Clinician,Neoadjuvant rectal cancer,Decision,Capecitabine (Xeloda),/apptracker/s/application-public/a102P000008pu26,Oncology Agents and Immunosuppressants
a0ROZ00000082hN2AQ,Capecitabine,A-01294,Xeloda,Capecitabine,Clinician,Adjuvant colorectal cancer,Decision,Capecitabine (Xeloda),/apptracker/s/application-public/a102P000008ptpW,Oncology Agents and Immunosuppressants
a0R2P000000LmVxUAK,Capecitabine,A-00832,Xeloda,Capecitabine,Clinician,Adjuvant high risk stage II colorectal cancer,Decision,Capecitabine (Xeloda),/apptracker/s/application-public/a102P000008ptyL,Oncology Agents and Immunosuppressants
a0R2P000000VC8EUAW,Carglumic acid,A-03864,Various,Carglumic acid,Clinician,For acute inpatient treatment of hyperammonaemia arising from severe organic acidaemia as an alternative to haemofiltration,Decision,Carglumic acid (Various),/apptracker/s/application-public/a102P00000BAf5s,
a0ROZ0000084s6s2AA,Caspofungin,A-04795,,Caspofungin,Clinician,"Prophylaxis of invasive fungal infections in people with high risk malignancies, lung and liver transplant recipients",Options Compared,Caspofungin,/apptracker/s/application-public/a10OZ0000001Qy9,
a0ROZ0000004hrB2AQ,Cefazolin,A-04096,Cefazolin-AFT,Cefazolin,Clinician,Surgical antibacterial prophylaxis,Decision,Cefazolin (Cefazolin-AFT),/apptracker/s/application-public/a102P00000BRhTJ,Infections - Agents for Systemic Use
a0ROZ0000012XP92AM,Ceftazidime with avibactam,A-00709,,Ceftazidime with avibactam,Clinician,Salvage therapy for infections caused by carbapenem resistant Enterobacteriaceae (CPEs),Decision,Ceftazidime with avibactam,/apptracker/s/application-public/a102P000008pu7I,Infections - Agents for Systemic Use
a0ROZ000005ws1x2AA,Ceftolozane with tazobactam,A-00708,,Ceftolozane with tazobactam,Clinician,Significant infections due to multi-resistant aerobic Gram-negative organisms,Under Assessment,Ceftolozane with tazobactam,/apptracker/s/application-public/a102P000008puSW,Infections - Agents for Systemic Use
a0ROZ00000BVjnJ2AT,Cefuroxime,A-00607 A-04856,,Cefuroxime,Clinician,"Endophthalmitis prophylaxis, post-cataract surgery",Reviewing Consultation Feedback,Cefuroxime,/apptracker/s/application-public/a102P000008puk7,Sensory Organs
a0ROZ000009JC0H2AW,Cemiplimab,A-03458 A-05202,Libtayo,Cemiplimab,"MEDISON PHARMA NEW ZEALAND LIMITED, Clinician","Cutaneous squamous cell carcinoma, metastatic or locally advanced, not eligible for curative surgery or radiation",Seeking Clinical Advice,Cemiplimab (Libtayo),/apptracker/s/application-public/a102P00000AnCMe,Oncology Agents and Immunosuppressants
a0R2P000000anP9UAI,Cetuximab,A-01448,Erbitux,Cetuximab,Clinician,"Colorectal cancer, K-RAS wild-type metastatic, refractory to irinotecan and oxaloplatin",Decision,Cetuximab (Erbitux),/apptracker/s/application-public/a102P000008pttC,Oncology Agents and Immunosuppressants
a0ROZ000000MFV32AO,Cevimeline,A-01058,Evoxac,Cevimeline,Clinician,Dry mouth incl. Sjogren's syndrome,Decision,Cevimeline (Evoxac),/apptracker/s/application-public/a102P000008pu1s,Sensory Organs
a0R2P000000MTl5UAG,Ciprofloxacin and hydrocortisone ear drops,A-00631,,Ciprofloxacin and hydrocortisone ear drops,Clinician,Chronic suppurative otitis media,Decision,Ciprofloxacin and hydrocortisone ear drops,/apptracker/s/application-public/a102P000008ptx6,Sensory Organs
a0R2P000000LmVwUAK,Ciprofloxacin eye drops,A-01430,,Ciprofloxacin eye drops,Clinician,Otitis media (second line treatment of bacterial infections),Decision,Ciprofloxacin eye drops,/apptracker/s/application-public/a102P000008ptyK,Sensory Organs
a0R2P000000ana7UAA,Clarithromycin,A-00270,"Apo-Clarithromycin,Klacid",Clarithromycin,Clinician,Group A beta-hemolytic Streptococcus for beta lactam allergic patients,Decision,"Clarithromycin (Apo-Clarithromycin,Klacid)",/apptracker/s/application-public/a102P000008puFN,Infections - Agents for Systemic Use
a0R2P000000LmkcUAC,Clarithromycin injection,A-00272,Klacid,Clarithromycin injection,Clinician,"Community-acquired pneumonia, first-line",Decision,Clarithromycin injection (Klacid),/apptracker/s/application-public/a102P000008puen,Infections - Agents for Systemic Use
a0R2P000000MTdTUAW,Clindamycin,A-01158,Dalacin C,Clindamycin,Clinician,Prophylaxis of haematogenous infection of prosthetic joints during dental interventions,Decision,Clindamycin (Dalacin C),/apptracker/s/application-public/a102P000008puVY,Infections - Agents for Systemic Use
a0ROZ000009KHyo2AG,Clindamycin vaginal cream,A-01156 A-01157 A-00557,Dalacin V,Clindamycin vaginal cream,"Pfizer, Clinician",Bacterial vaginosis and desquamative inflammatory vaginitis,Under Assessment,Clindamycin vaginal cream (Dalacin V),/apptracker/s/application-public/a102P000008ptyF,Genito-Urinary System
a0ROZ000009J4An2AK,Clodronate,A-01029,,Clodronate,Clinician,Osteoradionecrosis,Decision,Clodronate,/apptracker/s/application-public/a102P000008ptrX,Musculoskeletal System
a0R2P000000QUtyUAG,Clopidogrel,A-00311,,Clopidogrel,Clinician,Widening access to 12 months (from 6 months) for Drug-Eluting Stents (DES),Decision,Clopidogrel,/apptracker/s/application-public/a102P000008puBA,Blood and Blood Forming Organs
a0R2P000000LmpSUAS,Clopidogrel,A-00598,,Clopidogrel,Clinician,Widening access to 12 months (from 3 months) for Acute Coronary Syndrome (ACS),Decision,Clopidogrel,/apptracker/s/application-public/a102P000008puDO,Blood and Blood Forming Organs
a0R2P000000hE0MUAU,Compression hosiery (below knee only),A-01296,Compression hosiery,Compression hosiery (below knee only),Clinician,"Ulcers - chronic, leg - management of venous leg ulceration",Decision,Compression hosiery (below knee only) (Compression hosiery),/apptracker/s/application-public/a102P000008puk0,Dermatologicals
a0ROZ00000CIOrO2AX,Continuous Glucose Monitor,A-05354,Dexcom 1+ Freestyle libre 2 +,Continuous Glucose Monitor,Clinician,"Type 2 diabetes mellitus, youth-onset",Seeking Clinical Advice,Continuous Glucose Monitor (Dexcom 1+ Freestyle libre 2 +),/apptracker/s/application-public/a10OZ000006PxMP,
a0ROZ000003NpXx2AK,Crizotinib,A-03082,Xalkori,Crizotinib,Clinician,"Non-small cell lung cancer, locally advanced or metastatic, ROS1 gene translocation",Decision,Crizotinib (Xalkori),/apptracker/s/application-public/a102P000009rnDX,Oncology Agents and Immunosuppressants
a0R2P000000LmemUAC,Custodiol (cardioplegia solution),A-00369,Custodiol,Custodiol (cardioplegia solution),Clinician,Open listing (perfusion and flushing of donor organs),Decision,Custodiol (cardioplegia solution) (Custodiol),/apptracker/s/application-public/a102P000008ptug,Various
a0R2P000000LmX5UAK,Cyclosporin A,A-00878,Neoral,Cyclosporin A,Clinician,Steriod resistant nephrotic syndrome,Decision,Cyclosporin A (Neoral),/apptracker/s/application-public/a102P000008ptvb,Oncology Agents and Immunosuppressants
a0ROZ000008fbNC2AY,Dabrafenib and trametinib,A-05196,,Dabrafenib and trametinib,Clinician,"Melanoma, Resected Stage III with BRAF V600 mutation, Adjuvant treatment",Decision,Dabrafenib and trametinib,/apptracker/s/application-public/a10OZ000002iTJh,
a0ROZ000007jPav2AE,Daratumumab,A-04790,,Daratumumab,Clinician,2L SC + 4L IV - Multiple Myeloma relapsed or refractory,Options Compared,Daratumumab,/apptracker/s/application-public/a10OZ0000001LOz,
a0R2P000000LmqdUAC,Dasatinib,A-00581,,Dasatinib,Clinician,Philadelphia chromosome-positive acute lymphoblasic leukaemia,Decision,Dasatinib,/apptracker/s/application-public/a102P000008puCN,Oncology Agents and Immunosuppressants
a0R2P000000LmUQUA0,Deferiprone,A-01037,"Exjade,Ferriprox",Deferiprone,Clinician,Acquired red cell aplasia,Decision,"Deferiprone (Exjade,Ferriprox)",/apptracker/s/application-public/a102P000008puNT,Blood and Blood Forming Organs
a0ROZ00000BV5YA2A1,Deflazacort,A-00482,"Calcort,ZAMENE",Deflazacort,Clinician,Duchenne muscular dystrophy,Reviewing Consultation Feedback,"Deflazacort (Calcort,ZAMENE)",/apptracker/s/application-public/a102P000008pujy,Musculoskeletal System
a0R2P000000ftr9UAA,del Nido Cardioplegia solution,A-04084,del-Nido Cardioplegia,del Nido Cardioplegia solution,Clinician,To induce cardiac stasis and to protect the myocardium during open-heart surgery,Under Assessment,del Nido Cardioplegia solution (del-Nido Cardioplegia),/apptracker/s/application-public/a102P00000BMrxB,
a0ROZ000004CYMz2AO,Denosumab,A-00718,,Denosumab,Clinician,"Hypercalcemia (associated with malignant bone disease) in patients with renal impairment, first line",Decision,Denosumab,/apptracker/s/application-public/a102P000008puCE,Oncology Agents and Immunosuppressants
a0ROZ0000074INM2A2,Denosumab,A-00718,,Denosumab,Clinician,"Hypercalcemia in people with malignant bone disease and renal impairment, second line",Decision,Denosumab,/apptracker/s/application-public/a102P00000BIKVx,
a0ROZ000003Nmv32AC,Desmopressin,A-04947,Minirin Melt,Desmopressin,Clinician,"Arginine vasopressin deficiency (previously central diabetes insipidus), 60mcg and 240mcg desmopressin wafers for dose titration",Options Compared,Desmopressin (Minirin Melt),/apptracker/s/application-public/a10OZ000000qI8v,
a0ROZ0000012ZKT2A2,Desmopressin Acetate DDAVP,A-04268,Octostim,Desmopressin Acetate DDAVP,Clinician,"To increase the FVIII concentration in people with Haemophilia A, von Willebrand disease or inherited platelet disorders.",Under Assessment,Desmopressin Acetate DDAVP (Octostim),/apptracker/s/application-public/a102P00000BRdUc,
a0ROZ000008y5DC2AY,Dexamethasone implant,A-04553,Ozurdex,Dexamethasone implant,Clinician,non-infectious uveitis and for macular oedema due to non-infectious uveitis,Under Assessment,Dexamethasone implant (Ozurdex),/apptracker/s/application-public/a102P00000BYOcQ,Sensory Organs
a0ROZ000009KiED2A0,Dimethyl ether and propane,A-00039,,Dimethyl ether and propane,Clinician,Warts,Decision,Dimethyl ether and propane,/apptracker/s/application-public/a102P000008ptro,Dermatologicals
a0R2P000000LmZNUA0,Docetaxel,A-01114,Taxotere,Docetaxel,Clinician,Relapsed gynaecological malignancies,Decision,Docetaxel (Taxotere),/apptracker/s/application-public/a102P000008pu05,Oncology Agents and Immunosuppressants
a0R2P000000Lmc7UAC,Docetaxel,A-00944,Docetaxel Ebewe,Docetaxel,Clinician,Early breast cancer,Decision,Docetaxel (Docetaxel Ebewe),/apptracker/s/application-public/a102P000008pu7v,Oncology Agents and Immunosuppressants
a0R2P000000LmfxUAC,Docetaxel,A-01034,Docetaxel Ebewe,Docetaxel,Clinician,Prostate Cancer- metastatic castration resistant,Decision,Docetaxel (Docetaxel Ebewe),/apptracker/s/application-public/a102P000008ptpg,Oncology Agents and Immunosuppressants
a0R2P000000N6iYUAS,Docetaxel,A-01047,,Docetaxel,Clinician,Early breast cancer- contraindicated to anthracycline treatment,Decision,Docetaxel,/apptracker/s/application-public/a102P000008pu1q,Oncology Agents and Immunosuppressants
a0R2P000000anVCUAY,Doxylamine,A-00761,,Doxylamine,Clinician,use in nausea and vomiting of pregnancy,Decision,Doxylamine,/apptracker/s/application-public/a102P000008pu0Z,Respiratory System and Allergies
a0ROZ00000DHDfh2AH,Dupilumab,A-04064 A-04580 A-04817,Dupixent,Dupilumab,"Clinician, Consumer","Moderate to severe atopic dermatitis, following 2nd line treatment(s)",Options Compared,Dupilumab (Dupixent),/apptracker/s/application-public/a102P00000BMJQf,Dermatologicals
a0ROZ00000DabuP2AR,Eculizumab,A-05320,Soliris,Eculizumab,Clinician,Paroxysmal nocturnal haemoglobinuria (PNH),Under Assessment,Eculizumab (Soliris),/apptracker/s/application-public/a10OZ000004AhB3,
a0ROZ000009PWtx2AG,Eltrombopag,A-05407,Revolade,Eltrombopag,Clinician,"Aplastic anaemia, severe, 1st line, in combination with CSA and hATG immunosuppressive therapy",Seeking Clinical Advice,Eltrombopag (Revolade),/apptracker/s/application-public/a10OZ000004fv9h,Blood and Blood Forming Organs
a0ROZ00000DoZ9Z2AV,Emicizumab,A-05466,Hemlibra,Emicizumab,Clinician,"Haemophilia A, moderate severity, severe bleeding phenotype",Seeking Clinical Advice,Emicizumab (Hemlibra),/apptracker/s/application-public/a10OZ000007owj7,
a0ROZ000007acAn2AI,Empagliflozin,A-04658 A-04751,Jardiance,Empagliflozin,Clinician,"Chronic kidney disease (CKD), non-diabetic",Options Compared,Empagliflozin (Jardiance),/apptracker/s/application-public/a102P00000BaVPW,Genito-Urinary System
a0R2P000000gYklUAE,Emtricitabine with tenofovir disoproxil - HIV Post-Exposure Prophylaxis (nPEP),A-00737,,Emtricitabine with tenofovir disoproxil - HIV Post-Exposure Prophylaxis (nPEP),Clinician,Widening Access,Decision,Emtricitabine with tenofovir disoproxil - HIV Post-Exposure Prophylaxis (nPEP),/apptracker/s/application-public/a102P000008ptvJ,Infections - Agents for Systemic Use
a0ROZ0000009Xsn2AE,Emtricitabine with Tenofovir Disoproxil Fumarate,A-00605,,Emtricitabine with Tenofovir Disoproxil Fumarate,Clinician,HIV pre-exposure prophylaxis (PrEP),Decision,Emtricitabine with Tenofovir Disoproxil Fumarate,/apptracker/s/application-public/a102P000008pu43,Infections - Agents for Systemic Use
a0ROZ0000045ek52AA,Enoxaparin,A-00784,,Enoxaparin,Clinician,patients with lower leg immobilisation,Decision,Enoxaparin,/apptracker/s/application-public/a102P000008pugD,Blood and Blood Forming Organs
a0R2P000000LmoJUAS,Enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre),A-00392 A-00393,,Enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre),"Nutricia, Clinician",Enteral feed for patients with low energy and/or low fluid requirements,Decision,Enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre),/apptracker/s/application-public/a102P000008pu17,Special Foods
a0R2P000000LmkpUAC,Erythropoietin,A-01218,,Erythropoietin,Clinician,Myelodysplasia,Decision,Erythropoietin,/apptracker/s/application-public/a102P000008pueq,Blood and Blood Forming Organs
a0R2P000000LmZkUAK,Erythropoietin beta,A-00852,,Erythropoietin beta,Clinician,Chronic renal failure - widening access from haemoglobin 100 to 110 g/L,Application Received,Erythropoietin beta,/apptracker/s/application-public/a102P000008puTo,Blood and Blood Forming Organs
a0R2P000000anVHUAY,Etanercept,A-00330,Enbrel,Etanercept,Clinician,Behcet's disease,Decision,Etanercept (Enbrel),/apptracker/s/application-public/a102P000008pu0k,Oncology Agents and Immunosuppressants
a0R2P000000PXZ8UAO,Etanercept,A-00795,,Etanercept,Clinician,juvenile idiopathic arthritis (access widening),Decision,Etanercept,/apptracker/s/application-public/a102P000009nuGC,
a0R2P000000Lmb8UAC,Etanercept,A-01067,Enbrel,Etanercept,Clinician,Psoriatic arthritis- changes in access criteria,Decision,Etanercept (Enbrel),/apptracker/s/application-public/a102P000008puZI,Oncology Agents and Immunosuppressants
a0ROZ000004CQE92AO,Everolimus,A-00734,,Everolimus,Clinician,Angiomyolipoma associated with tuberous sclerosis complex,Decision,Everolimus,/apptracker/s/application-public/a102P000008puD6,Oncology Agents and Immunosuppressants
a0ROZ000004CCCo2AO,Everolimus,A-03065,Afinitor,Everolimus,Clinician,Tuberous sclerosis (TSC) 2 years & older with refractory epilepsy,Decision,Everolimus (Afinitor),/apptracker/s/application-public/a102P0000094ozS,Oncology Agents and Immunosuppressants
a0R2P000000TEkoUAG,Everolimus,A-01314,Afinitor [S.29],Everolimus,Clinician,Sub-ependymal giant cell astrocytomas not amenable to neurosurgical resection,Decision,Everolimus (Afinitor [S.29]),/apptracker/s/application-public/a102P000008ptva,Oncology Agents and Immunosuppressants
a0R2P000000P95mUAC,Febuxostat,A-03166,Adenuric,Febuxostat,Clinician,Prevention of tumour lysis syndrome (TLS) in allopurinol-intolerant patients scheduled to receive a cancer therapy that carries an intermediate or high TLS risk,Decision,Febuxostat (Adenuric),/apptracker/s/application-public/a102P000009sDba,Musculoskeletal System
a0ROZ000007hqPK2AY,Ferric Carboxymaltose,A-05054 A-04986,Ferinject,Ferric Carboxymaltose,"Clinician, Consumer","Hereditary Haemorrhagic Telangiectasia (HHT), serum ferritin 50 mcg/L or less or transferrin saturation is 20% or less, widening access",Options Compared,Ferric Carboxymaltose (Ferinject),/apptracker/s/application-public/a10OZ000001SFLJ,Blood and Blood Forming Organs
a0ROZ000009SC982AG,Ferric derisomaltose,A-05201 A-05251,Monofer,Ferric derisomaltose,"Clinician, Consumer","Hereditary Haemorrhagic Telangiectasia (HHT), to prevent iron deficiency/anaemia",Under Assessment,Ferric derisomaltose (Monofer),/apptracker/s/application-public/a10OZ000002nxKM,Blood and Blood Forming Organs
a0ROZ0000006zds2AA,Fexofenadine hydrochloride,A-03506,Telfast,Fexofenadine hydrochloride,Clinician,"Urticaria, children aged 6 months to 2 years",Options Compared,Fexofenadine hydrochloride (Telfast),/apptracker/s/application-public/a102P00000AX1tz,
a0ROZ000003Nou42AC,Fixed duration ibrutinib plus venetoclax,A-04872,,Fixed duration ibrutinib plus venetoclax,Clinician,previously untreated chronic lymphocytic leaukaemia (CLL) with TP53 mutation,Options Compared,Fixed duration ibrutinib plus venetoclax,/apptracker/s/application-public/a10OZ000000Ltb0,
a0ROZ000000MG4X2AW,Folic Acid 0.4 mg tablets,A-00640,,Folic Acid 0.4 mg tablets,Clinician,Folic acid supplementation in pregnancy,Decision,Folic Acid 0.4 mg tablets,/apptracker/s/application-public/a102P000008puZF,Blood and Blood Forming Organs
a0ROZ0000012YD72AM,Food thickeners,A-00836,,Food thickeners,Clinician,Review of community products,Seeking Clinical Advice,Food thickeners,/apptracker/s/application-public/a102P000008pu1x,Special Foods
a0ROZ000009J3rR2AS,Fosfomycin IV,A-00751,,Fosfomycin IV,Clinician,Salvage therapy for infections caused by carbapenem resistant Enterobacteriaceae (CREs) in adults,Decision,Fosfomycin IV,/apptracker/s/application-public/a102P000008puC6,Infections - Agents for Systemic Use
a0R2P000000LmhzUAC,Gefitinib,A-01076 A-01077,Iressa,Gefitinib,"AstraZeneca, Clinician",Non-small cell lung cancer (NSCLC) - first line EGFR +ve mutation,Decision,Gefitinib (Iressa),/apptracker/s/application-public/a102P000008pu6A,Oncology Agents and Immunosuppressants
a0R2P000000N6iBUAS,Gemcitabine,A-00877,,Gemcitabine,Clinician,Adjuvant pancreatic cancer,Decision,Gemcitabine,/apptracker/s/application-public/a102P000008puZX,Oncology Agents and Immunosuppressants
a0R2P000000LmqbUAC,Gemcitabine Hydrochloride,A-01213,,Gemcitabine Hydrochloride,Clinician,Metastatic breast cancer,Decision,Gemcitabine Hydrochloride,/apptracker/s/application-public/a102P000008puAx,Oncology Agents and Immunosuppressants
a0R2P000000LmobUAC,Gemcitabine Hydrochloride,A-00967,,Gemcitabine Hydrochloride,Clinician,Locally advanced or metastatic cholangiocarcinoma,Decision,Gemcitabine Hydrochloride,/apptracker/s/application-public/a102P000008pu1C,Oncology Agents and Immunosuppressants
a0ROZ000009J4lt2AC,Gemtuzumab ozogamicin,A-00371,,Gemtuzumab ozogamicin,Clinician,"Acute myeloid leukaemia, favourable and intermediate-risk (AML-19 trial)",Decision,Gemtuzumab ozogamicin,/apptracker/s/application-public/a102P000008puZc,Oncology Agents and Immunosuppressants
a0R2P000000f07QUAQ,Gemtuzumab ozogamicin,A-03064 A-03351,Mylotarg,Gemtuzumab ozogamicin,"PFIZER NEW ZEALAND LIMITED, Clinician",For use in combination with daunorubicin and cytarabine for treatment of de novo acute myeloid leukaemia,Decision,Gemtuzumab ozogamicin (Mylotarg),/apptracker/s/application-public/a102P00000A613f,Oncology Agents and Immunosuppressants
a0R2P000000LmmbUAC,Gluten free foods,A-00876,,Gluten free foods,Clinician,Coeliac disease - amendment to Special Authority  regarding biopsy being a requirement,Decision,Gluten free foods,/apptracker/s/application-public/a102P000008ptsB,Special Foods
a0ROZ00000007Kr2AI,guaifenesin,A-03486,,guaifenesin,Clinician,respiratory conditions,Decision,guaifenesin,/apptracker/s/application-public/a102P00000AV7z8,
a0ROZ00000CiG0X2AV,Ibrutinib,A-00686 A-05542,Imbruvica,Ibrutinib,"Janssen, Clinician","Waldenström macroglobulinemia, first line",Under Assessment,Ibrutinib (Imbruvica),/apptracker/s/application-public/a102P00000BEpYC,Oncology Agents and Immunosuppressants
a0ROZ00000DKigo2AD,Ibrutinib,A-05536,Imbruvica,Ibrutinib,Clinician,"Mantle cell lymphoma, upfront therapy as alternative to ASCT",Seeking Clinical Advice,Ibrutinib (Imbruvica),/apptracker/s/application-public/a10OZ000007O4JO,Oncology Agents and Immunosuppressants
a0ROZ000009J4qj2AC,Ibrutinib,A-04597,Imbruvica,Ibrutinib,Clinician,"Waldenstroms Macroglobulinaemia, relapsed within 5 years of treatment,  under 55 years",Decision,Ibrutinib (Imbruvica),/apptracker/s/application-public/a102P00000Baabl,Oncology Agents and Immunosuppressants
a0R2P000000QTDdUAO,Imatinib,A-00517,Glivec,Imatinib,Clinician,Gastrointestinal Stromal Tumour (GIST) - c-kit negative,Decision,Imatinib (Glivec),/apptracker/s/application-public/a102P000008ptvK,Oncology Agents and Immunosuppressants
a0ROZ000002BmY22AK,Infanrix-hexa,A-03852,Infanrix-hexa,Infanrix-hexa,Clinician,"Post haematopoietic stem cell transplantation, widen access to up to age 18",Under Assessment,Infanrix-hexa (Infanrix-hexa),/apptracker/s/application-public/a102P00000BZ6Rc,
a0R2P000000ang0UAA,"Infant formula, standard",A-00283,,"Infant formula, standard",Clinician,Infants whose mothers cannot breastfeed,Decision,"Infant formula, standard",/apptracker/s/application-public/a102P000008puhs,Special Foods
a0R2P000000g6aEUAQ,Infliximab,A-00211,Remicade,Infliximab,Clinician,Inflammatory bowel disease-associated arthritis (IBD-A),Decision,Infliximab (Remicade),/apptracker/s/application-public/a102P000008pu6r,Oncology Agents and Immunosuppressants
a0R2P000000LmojUAC,Infliximab,A-00331,Remicade,Infliximab,Clinician,"Behcet's disease, first line",Decision,Infliximab (Remicade),/apptracker/s/application-public/a102P000008pu34,Musculoskeletal System
a0ROZ00000DaaK12AJ,Infliximab,A-04162,,Infliximab,Clinician,"Crohn’s disease, paediatric patients, require exclusive enteral nutrition (EEN), widening access",Seeking Clinical Advice,Infliximab,/apptracker/s/application-public/a102P00000BNlc9,Oncology Agents and Immunosuppressants
a0ROZ000009HGWD2A4,Infliximab and tocilizumab,A-04727 A-05149,Remicade,Infliximab and tocilizumab,Clinician,"Immunotherapy-related adverse events, steroid-refractory, and immune-related colitis, high-risk",Decision,Infliximab and tocilizumab (Remicade),/apptracker/s/application-public/a10OZ0000001LYf,Oncology Agents and Immunosuppressants
a0ROZ00000DL5wT2AT,Infliximab SC,A-04222 A-05200,REMSIMA SC,Infliximab SC,"Celltrion Healthcare New Zealand Limited, Clinician",All currently funded indications (adults >18years),Options Compared,Infliximab SC (REMSIMA SC),/apptracker/s/application-public/a102P00000BQBeV,
a0ROZ000007h1mQ2AQ,Inotuzumab,A-03985 A-04085,Besponsa,Inotuzumab,"PFIZER NEW ZEALAND LIMITED, Clinician","Acute lymphoblastic leukaemia (ALL), eligible and ineligible for transplant, relapsed/refractory CD22-positive, adults",Decision,Inotuzumab (Besponsa),/apptracker/s/application-public/a102P00000BK0rY,Oncology Agents and Immunosuppressants
a0ROZ000008IIjR2AW,Inotuzumab,A-03985,Besponsa,Inotuzumab,Clinician,"Acute lymphoblastic leukaemia (ALL), bridge to transplant, relapsed/refractory CD22-positive, adults",Decision,Inotuzumab (Besponsa),/apptracker/s/application-public/a102P00000BQ7JF,
a0R2P000000QTJ9UAO,Iodine,A-00847,,Iodine,Clinician,Supplementation for pregnancy and breast feeding,Decision,Iodine,/apptracker/s/application-public/a102P000008pu9G,Various
a0ROZ0000094euX2AQ,Ipilimumab and nivolumab,A-04693,Yervoy and Opdivo,Ipilimumab and nivolumab,Clinician,"Renal cell carcinoma, metastatic, clear-cell, 1st line, intermediate and poor prognosis",Decision,Ipilimumab and nivolumab (Yervoy and Opdivo),/apptracker/s/application-public/a102P00000BarIR,Oncology Agents and Immunosuppressants
a0ROZ000007h1Mg2AI,Ipilimumab in combination with nivolumab,A-04693,Yervoy and Opdivo,Ipilimumab in combination with nivolumab,Clinician,"metastatic kidney cancer with a clear cell component, with poor, intermediate and favourable  IMDC risk prognoses, first-line therapy,",Under Assessment,Ipilimumab in combination with nivolumab (Yervoy and Opdivo),/apptracker/s/application-public/a10OZ000000FBET,Oncology Agents and Immunosuppressants
a0R2P000000LmXkUAK,"Irinotecan, Oxaliplatin",A-01292,,"Irinotecan, Oxaliplatin",Clinician,Pancreatic cancer,Decision,"Irinotecan, Oxaliplatin",/apptracker/s/application-public/a102P000008puWI,Oncology Agents and Immunosuppressants
a0R2P000000LmoYUAS,Ivermectin,A-01026,Stromectol,Ivermectin,Clinician,Scabies - institutional encrusted,Decision,Ivermectin (Stromectol),/apptracker/s/application-public/a102P000008ptsp,Dermatologicals
a0R2P000000TGT6UAO,Lamivudine,A-00465,Zeffix,Lamivudine,Clinician,Hepatitis B: prophylaxis in  HBsAg - /anti-HBc + patients,Decision,Lamivudine (Zeffix),/apptracker/s/application-public/a102P000008puUl,Infections - Agents for Systemic Use
a0ROZ00000BHpJC2A1,Lanreotide acetate,A-01310,Somatuline autogel,Lanreotide acetate,Clinician,Acromegaly and Neuroendocrine tumours,Decision,Lanreotide acetate (Somatuline autogel),/apptracker/s/application-public/a102P000008puW6,Oncology Agents and Immunosuppressants
a0R2P000000Wki8UAC,Lapatinib ditosylate,A-00452,,Lapatinib ditosylate,Clinician,Breast cancer - Second line metastatic HER2 positive breast cancer,Decision,Lapatinib ditosylate,/apptracker/s/application-public/a102P000008ptx7,Oncology Agents and Immunosuppressants
a0ROZ0000006XCb2AM,Lenalidomide,A-00614,,Lenalidomide,Clinician,"Multiple myeloma, maintenance following frontline autologous SCT",Decision,Lenalidomide,/apptracker/s/application-public/a102P000008puL6,Oncology Agents and Immunosuppressants
a0ROZ000008O2dZ2AS,Lenalidomide,A-00710 A-00499,,Lenalidomide,"Celgene, Clinician","Multiple myeloma, ASCT-eligible (induction) and ASCT-ineligible, 1st line",Decision,Lenalidomide,/apptracker/s/application-public/a102P00000BVL9Y,
a0ROZ000002dRFJ2A2,Lenalidomide,A-00710,,Lenalidomide,Clinician,in combination with bortezomib and dexamethasone for the first-line treatment of transplant eligible patients with multiple myeloma,Decision,Lenalidomide,/apptracker/s/application-public/a102P000008ptqe,Oncology Agents and Immunosuppressants
a0ROZ000004CYoP2AW,Lenalidomide,A-00710,,Lenalidomide,Clinician,in combination with dexamethasone for the first-line treatment of transplant eligible patients with multiple myeloma,Decision,Lenalidomide,/apptracker/s/application-public/a102P00000BIsC3,
a0R2P000000Lo4NUAS,Levonorgestrel Implants,A-00831 A-00830,Jadelle,Levonorgestrel Implants,"Bayer, Clinician",Long acting reversible contraception,Decision,Levonorgestrel Implants (Jadelle),/apptracker/s/application-public/a102P000008ptxZ,Genito-Urinary System
a0R2P000000Sk6aUAC,Levonorgestrel intrauterine system,A-00665,,Levonorgestrel intrauterine system,Clinician,endometrial hyperplasia without atypia,Decision,Levonorgestrel intrauterine system,/apptracker/s/application-public/a102P000008ptto,Genito-Urinary System
a0R2P000000fSzGUAU,Levonorgestrel intrauterine system,A-00534,,Levonorgestrel intrauterine system,Clinician,contraception,Decision,Levonorgestrel intrauterine system,/apptracker/s/application-public/a102P000008pu0i,Genito-Urinary System
a0R2P000000PZEBUA4,Levonorgestrel intrauterine system,A-00932 A-00534,Mirena,Levonorgestrel intrauterine system,"Bayer, Clinician",Contraception - long acting reversible contraception,Decision,Levonorgestrel intrauterine system (Mirena),/apptracker/s/application-public/a102P000008puk6,Genito-Urinary System
a0ROZ00000Af12P2AR,Lidocaine with prilocaine,A-04227,Emla,Lidocaine with prilocaine,Clinician,Intrauterine device insertion,Under Assessment,Lidocaine with prilocaine (Emla),/apptracker/s/application-public/a102P00000BP9zA,Genito-Urinary System
a0ROZ0000007XYj2AM,Linezolid and bedaquiline,A-03108,Situro,Linezolid and bedaquiline,Clinician,MDR tuberculosis,Decision,Linezolid and bedaquiline (Situro),/apptracker/s/application-public/a102P00000AABsA,Infections - Agents for Systemic Use
a0ROZ000000MGuI2AW,Loteprednol,A-00579,,Loteprednol,Clinician,Eye inflammation in those with intraocular pressure rise,Decision,Loteprednol,/apptracker/s/application-public/a102P000008ptrR,Sensory Organs
a0ROZ0000007VyN2AU,"Lubricant, non-irritant, water-based, single use packets",A-00296,,"Lubricant, non-irritant, water-based, single use packets",Clinician,Sexual health,Options Compared,"Lubricant, non-irritant, water-based, single use packets",/apptracker/s/application-public/a102P000008puQw,Genito-Urinary System
a0R2P000000LmgkUAC,Mannitol,A-00245,Aridol,Mannitol,Clinician,Open listing (diagnosis of asthma),Decision,Mannitol (Aridol),/apptracker/s/application-public/a102P000008ptpD,Respiratory System and Allergies
a0ROZ000002Z6HW2A0,Mepolizumab,A-03801,Nucala,Mepolizumab,Clinician,"Eosinophilic granulomatosis with polyangiitis (EGPA), relapsed or refractory",Decision,Mepolizumab (Nucala),/apptracker/s/application-public/a102P00000BNnj8,Respiratory System and Allergies
a0ROZ000003e9u62AA,Methylphenidate long-acting,A-05006,Ritalin LA,Methylphenidate long-acting,Clinician,Widening access - first line treatment option for Attention Deficit and Hyperactivity Disorder (ADHD),Seeking Clinical Advice,Methylphenidate long-acting (Ritalin LA),/apptracker/s/application-public/a10OZ000001Zasr,
a0ROZ00000DqVY72AN,Mirabegron,A-00762 A-04248 A-04338,,Mirabegron,"Clinician, Consumer","Overactive bladder, 2nd line",Options Compared,Mirabegron,/apptracker/s/application-public/a102P000008pudo,Genito-Urinary System
a0ROZ00000DqVY82AN,Mirabegron,A-00762 A-04248 A-04338,,Mirabegron,"Clinician, Consumer",Open listing,Options Compared,Mirabegron,/apptracker/s/application-public/a102P00000BOI18,Genito-Urinary System
a0R2P000000Lmo8UAC,Montelukast,A-00574,,Montelukast,Clinician,Bronchiolitis obliterans post allogeneic transplantation,Decision,Montelukast,/apptracker/s/application-public/a102P000008pu14,Infections - Agents for Systemic Use
a0ROZ000009J4Qv2AK,Morphine sulphate (5 mg / 5 mL pre-filled syringes),A-03311,,Morphine sulphate (5 mg / 5 mL pre-filled syringes),Clinician,Acute Pain,Decision,Morphine sulphate (5 mg / 5 mL pre-filled syringes),/apptracker/s/application-public/a102P00000A0EJ7,Various
a0R2P000000LmefUAC,Moxifloxacin,A-00595,,Moxifloxacin,Clinician,Mycoplasma genitalium for azithromycin resistance,Decision,Moxifloxacin,/apptracker/s/application-public/a102P000008pttG,Infections - Agents for Systemic Use
a0ROZ000009J5DJ2A0,Moxifloxacin ophthalmic (0.5% USP),A-03320,Vigamox,Moxifloxacin ophthalmic (0.5% USP),Clinician,Prophylaxisis of post-operative endophthalmitis (POE) following intra-ocular surgery.,Decision,Moxifloxacin ophthalmic (0.5% USP) (Vigamox),/apptracker/s/application-public/a102P00000AvPBI,
a0ROZ000004CY6s2AG,Multivitamins (Fruit-Vits and Phlexy-Vits),A-00592 A-00592 A-03369,,Multivitamins (Fruit-Vits and Phlexy-Vits),"NUTRICIA LIMITED, Clinician",Ketogenic dietary treatment for children with epilepsy,Decision,Multivitamins (Fruit-Vits and Phlexy-Vits),/apptracker/s/application-public/a102P000008ptqB,Special Foods
a0R2P000000LmdkUAC,Mycophenolate mofetil,A-01033,Myaccord,Mycophenolate mofetil,Clinician,Lupus nephritis - induction treatment,Decision,Mycophenolate mofetil (Myaccord),/apptracker/s/application-public/a102P000008pu3w,Oncology Agents and Immunosuppressants
a0R2P000000LmhRUAS,Mycophenolate mofetil,A-01056,,Mycophenolate mofetil,Clinician,Vasculitis - induction treatment,Decision,Mycophenolate mofetil,/apptracker/s/application-public/a102P000008pu5h,Oncology Agents and Immunosuppressants
a0R2P000000Lmk3UAC,Mycophenolate mofetil,A-00588,,Mycophenolate mofetil,Clinician,Widening of access for liver transplant patients,Decision,Mycophenolate mofetil,/apptracker/s/application-public/a102P000008pucN,Oncology Agents and Immunosuppressants
a0R2P000000LmdrUAC,Mycophenolate mofetil,A-01078,Myaccord,Mycophenolate mofetil,Clinician,Lupus nephritis - maintenance therapy,Decision,Mycophenolate mofetil (Myaccord),/apptracker/s/application-public/a102P000008pttK,Oncology Agents and Immunosuppressants
a0R2P000000LmrRUAS,Mycophenolate mofetil,A-01079,,Mycophenolate mofetil,Clinician,Vasculitis - maintenance therapy,Decision,Mycophenolate mofetil,/apptracker/s/application-public/a102P000008puFj,Oncology Agents and Immunosuppressants
a0ROZ00000AQkoB2AT,Nab-paclitaxel,A-04802,,Nab-paclitaxel,Clinician,"Any cancer, following grade 3+ hypersensitivity reaction on paclitaxel",Options Compared,Nab-paclitaxel,/apptracker/s/application-public/a10OZ0000001RFt,Oncology Agents and Immunosuppressants
a0ROZ000009wW2L2AU,Nab-paclitaxel,A-01009 A-01008 A-01010,Abraxane,Nab-paclitaxel,"Specialised Therapeutics Ltd, Clinician, Consumer",Metastatic breast cancer,Options Compared,Nab-paclitaxel (Abraxane),/apptracker/s/application-public/a102P000008ptow,Oncology Agents and Immunosuppressants
a0ROZ0000000QXB2A2,Naltrexone hydrochloride,A-04681,Naltraccord,Naltrexone hydrochloride,Clinician,Amend Special Authority criteria to include primary healthcare providers,Seeking Clinical Advice,Naltrexone hydrochloride (Naltraccord),/apptracker/s/application-public/a10OZ0000000OAP,
a0ROZ00000Cn1xJ2AR,Neoadjuvant nivolumab in combination with ipilimumab,A-05473,Opdivo Yervoy,Neoadjuvant nivolumab in combination with ipilimumab,Clinician,for the treatment of resectable cutaneous melanoma (Stage III),Options Compared,Neoadjuvant nivolumab in combination with ipilimumab (Opdivo Yervoy),/apptracker/s/application-public/a10OZ00000599Ar,Oncology Agents and Immunosuppressants
a0R2P000000df0BUAQ,Nintedanib,A-03966,Ofev,Nintedanib,Clinician,Progressive fibrosing interstitial lung diseases,Under Assessment,Nintedanib (Ofev),/apptracker/s/application-public/a102P00000BIZnY,Respiratory System and Allergies
a0ROZ000006sXd32AE,Nivolumab,A-00573,Opdivo,Nivolumab,Clinician,"Renal cell carcinoma, metastatic, clear-cell, 2nd line",Decision,Nivolumab (Opdivo),/apptracker/s/application-public/a102P000008puZW,Oncology Agents and Immunosuppressants
a0R2P000000LmVmUAK,Octreotide,A-01317,,Octreotide,Clinician,Acromegaly (presurgery),Decision,Octreotide,/apptracker/s/application-public/a102P000008ptyI,Oncology Agents and Immunosuppressants
a0R2P000000LmgYUAS,Octreotide,A-00947,,Octreotide,Clinician,Acromegaly - patients for whom surgery is contraindicated or those awaiting effects of radiotherapy,Decision,Octreotide,/apptracker/s/application-public/a102P000008ptp0,Oncology Agents and Immunosuppressants
a0R2P000000LmeJUAS,Octreotide,A-00535,,Octreotide,Clinician,Thyrotropin (TSH)-secreting pituitary adenomas,Decision,Octreotide,/apptracker/s/application-public/a102P000008pttP,Oncology Agents and Immunosuppressants
a0R2P000000MTljUAG,Octreotide - long-acting,A-01315,,Octreotide - long-acting,Clinician,"SI-NETs, metastatic or unresectable",Decision,Octreotide - long-acting,/apptracker/s/application-public/a102P000008puBb,Oncology Agents and Immunosuppressants
a0ROZ0000050yXZ2AY,olaparib,A-04698 A-05127,Lynparza,olaparib,"Clinician, Consumer","BRCAm HER2-negative breast cancer, metastatic after neoadj, adjuv or metastatic chemo",Seeking Clinical Advice,olaparib (Lynparza),/apptracker/s/application-public/a10OZ000001vD6Q,
a0ROZ00000DqVYC2A3,Olaparib,A-05127,Lynparza,Olaparib,Clinician,"breast cancer, metastatic, germline PALB2 pathogenic variant HER2-negative",Options Compared,Olaparib (Lynparza),/apptracker/s/application-public/a10OZ000002C9Kv,
a0R2P000000anQHUAY,Olmesartan,A-00228,,Olmesartan,Clinician,Sarcoidosis,Decision,Olmesartan,/apptracker/s/application-public/a102P000008ptti,Oncology Agents and Immunosuppressants
a0R2P000000LmbuUAC,Omalizumab,A-00412,Xolair,Omalizumab,Clinician,Chronic idiopathic urticaria,Decision,Omalizumab (Xolair),/apptracker/s/application-public/a102P000008puAX,Dermatologicals
a0ROZ000003dpH32AI,Oral feed 1.5k cal/ml liquid,A-00483,,Oral feed 1.5k cal/ml liquid,Clinician,Cystic fibrosis patients > 10 years old,Options Compared,Oral feed 1.5k cal/ml liquid,/apptracker/s/application-public/a102P000008pu3M,Special Foods
a0R2P000000Z1R2UAK,Oral feed 1.5k cal/ml liquid ONS,A-00681,,Oral feed 1.5k cal/ml liquid ONS,Clinician,Head and Neck Cancer,Options Compared,Oral feed 1.5k cal/ml liquid ONS,/apptracker/s/application-public/a102P000008ptz6,Special Foods
a0ROZ00000AvRVZ2A3,Oral feed 1.5kcal/mL,A-03928,Ensure Plus or Fortisip,Oral feed 1.5kcal/mL,Clinician,"Exclusive enteral nutrition, adults with Crohn's disease",Decision,Oral feed 1.5kcal/mL (Ensure Plus or Fortisip),/apptracker/s/application-public/a102P00000BVgFr,
a0ROZ000002yO7x2AE,Oral feed 2.4kcal/mL (Fortisip Compact Protein),A-04963,Fortisip Compact Protein,Oral feed 2.4kcal/mL (Fortisip Compact Protein),Clinician,for oral nutrition support,Under Assessment,Oral feed 2.4kcal/mL (Fortisip Compact Protein) (Fortisip Compact Protein),/apptracker/s/application-public/a10OZ000000wbgj,
a0ROZ000002yNwf2AE,Oral feed liquid,A-04814,Ensure and Fortisp liquid,Oral feed liquid,Clinician,Amendment of criteria for people with COPD,Under Assessment,Oral feed liquid (Ensure and Fortisp liquid),/apptracker/s/application-public/a10OZ0000001pzl,
a0R2P000000anfbUAA,"Oral Iron Chelators - Deferasirox, Deferiprone",A-01038,"Exjade,Ferriprox","Oral Iron Chelators - Deferasirox, Deferiprone",Clinician,Transfusional iron overload secondary to stem cell transplants and myelodysplasia,Decision,"Oral Iron Chelators - Deferasirox, Deferiprone (Exjade,Ferriprox)",/apptracker/s/application-public/a102P000008pug3,Blood and Blood Forming Organs
a0ROZ000004CQvj2AG,Oseltamivir,A-00749,,Oseltamivir,Clinician,treatment and prophylaxis of influenza during influenza outbreaks in long-term care facilities,Decision,Oseltamivir,/apptracker/s/application-public/a102P000008pu0M,Infections - Agents for Systemic Use
a0R2P000000LmhpUAC,Oxaliplatin,A-01293,,Oxaliplatin,Clinician,Oesophagal and gastric cancer,Decision,Oxaliplatin,/apptracker/s/application-public/a102P000008pu68,Oncology Agents and Immunosuppressants
a0ROZ00000096HV2AY,Paclitaxel,A-01357,,Paclitaxel,Clinician,Germ cell cancer of the testis,Decision,Paclitaxel,/apptracker/s/application-public/a102P000008pu4y,Oncology Agents and Immunosuppressants
a0R2P000000LmWRUA0,Paclitaxel,A-01112,,Paclitaxel,Clinician,Relapsed gynaecological malignancies,Decision,Paclitaxel,/apptracker/s/application-public/a102P000008ptzA,Oncology Agents and Immunosuppressants
a0ROZ000006JP452AG,Palivizumab,A-04612,Synagis,Palivizumab,Clinician,Extension of funding for RSV,Decision,Palivizumab (Synagis),/apptracker/s/application-public/a102P00000BZCTE,Respiratory System and Allergies
a0R2P000000Y35IUAS,Palivizumab,A-04000,Synagis,Palivizumab,Clinician,Respiratory syncytial virus (RSV) - (treatment may be initiated in hospital at discharge or in outpatient clinics however predominantly for use in community),Decision,Palivizumab (Synagis),/apptracker/s/application-public/a102P00000BJoA9,Respiratory System and Allergies
a0R2P000000Shu6UAC,Paraffin (liquid) plus laureth-3 and isopropyl myristate bath oil,A-00794,,Paraffin (liquid) plus laureth-3 and isopropyl myristate bath oil,Clinician,xerotic skin,Decision,Paraffin (liquid) plus laureth-3 and isopropyl myristate bath oil,/apptracker/s/application-public/a102P000008puCv,Dermatologicals
a0ROZ00000AqfUL2AZ,Pazopanib,A-05406,Pazopanib Teva,Pazopanib,Clinician,"soft tissue sarcoma (all subtypes), 2nd line +",Application Received,Pazopanib (Pazopanib Teva),/apptracker/s/application-public/a10OZ000005N04T,
a0ROZ0000045es92AA,Peginterferon alfa-2a,A-03373,Pegasys,Peginterferon alfa-2a,Clinician,myeloproliferative neoplasms,Decision,Peginterferon alfa-2a (Pegasys),/apptracker/s/application-public/a102P00000ABujl,Musculoskeletal System
a0R2P000000LmrcUAC,Peginterferon with ribavirin,A-01388,Pegatron Combination Therapy,Peginterferon with ribavirin,Clinician,Hepatitis C genotypes 2 and 3 without cirrhosis,Decision,Peginterferon with ribavirin (Pegatron Combination Therapy),/apptracker/s/application-public/a102P000008puG9,Infections - Agents for Systemic Use
a0ROZ0000007fUf2AI,Pegylated interferon alpha-2a,A-01096,Pegasys,Pegylated interferon alpha-2a,Clinician,Non-cirrhotic genotype 2/3 HCV plus HIV co infected patients,Decision,Pegylated interferon alpha-2a (Pegasys),/apptracker/s/application-public/a102P000008puCK,Infections - Agents for Systemic Use
a0ROZ00000AqQQU2A3,Pegylated liposomal doxorubicin,A-01186,Caelyx,Pegylated liposomal doxorubicin,Clinician,"Ovarian cancer, advanced, epithelial, platinum sensitive/ partially sensitive/ intolerant, third line",Options Compared,Pegylated liposomal doxorubicin (Caelyx),/apptracker/s/application-public/a102P000008ptxf,Oncology Agents and Immunosuppressants
a0ROZ000002ueMb2AI,Pembrolizumab,A-04251 A-04269 A-04437,KEYTRUDA,Pembrolizumab,"Clinician, Consumer",1st line systemic treatment for recurrent locally advanced (not amendable to definitive treatment) or metastatic merkel cell carcinoma,Under Assessment,Pembrolizumab (KEYTRUDA),/apptracker/s/application-public/a102P00000BYyXy,
a0ROZ000004oaVp2AI,Pembrolizumab,A-04465 A-04695 A-04722,Keytruda,Pembrolizumab,"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Clinician, Consumer","Breast cancer, triple negative, locally recurrent unresectable or metastatic, CPS >10",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P00000BYrw6,Oncology Agents and Immunosuppressants
a0ROZ00000BGaUJ2A1,Pembrolizumab,A-04462 A-04722 A-04465,Keytruda,Pembrolizumab,"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Clinician, Consumer","Breast cancer, triple negative, early Stage II or III, neoadjuvant treatment followed by adjuvant monotherapy",Options Compared,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P00000BYrky,Oncology Agents and Immunosuppressants
a0ROZ000009A8ql2AC,Pembrolizumab Axitinib,A-04781 A-04983,Keytruda Inlyta,Pembrolizumab Axitinib,"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Clinician","Pembrolizumab and axitinib, first line treatment of advanced clear cell renal cell carcinoma",Options Compared,Pembrolizumab Axitinib (Keytruda Inlyta),/apptracker/s/application-public/a10OZ000000APQ9,Oncology Agents and Immunosuppressants
a0R2P000000Lmc1UAC,Pemetrexed Disodium,A-00843 A-00842,Alimta,Pemetrexed Disodium,"Eli Lilly, Clinician","Non-small cell lung cancer, advanced, non-squamous, first-line",Decision,Pemetrexed Disodium (Alimta),/apptracker/s/application-public/a102P000008puAa,Oncology Agents and Immunosuppressants
a0R2P000000LmhuUAC,Pemetrexed Disodium,A-01222 A-01221,Alimta,Pemetrexed Disodium,"Eli Lilly, Clinician","Non-small cell lung cancer, advanced, non-squamous, second line",Decision,Pemetrexed Disodium (Alimta),/apptracker/s/application-public/a102P000008puFX,Oncology Agents and Immunosuppressants
a0R2P000000LmirUAC,Pemetrexed Disodium,A-00417,Alimta,Pemetrexed Disodium,Clinician,"Non-small cell lung cancer, advanced, non-squamous, maintenance treatment",Decision,Pemetrexed Disodium (Alimta),/apptracker/s/application-public/a102P000008puEz,Oncology Agents and Immunosuppressants
a0R2P000000Ocf9UAC,Peppermint lip treatment,A-00040,,Peppermint lip treatment,Clinician,Dry lips and dryness of the mouth,Decision,Peppermint lip treatment,/apptracker/s/application-public/a102P000008pty6,Dermatologicals
a0ROZ000004CZR72AO,Peptide Receptor Radionuclide Therapy,A-00641,,Peptide Receptor Radionuclide Therapy,Clinician,neuroendocrine tumours,Decision,Peptide Receptor Radionuclide Therapy,/apptracker/s/application-public/a102P000008puCs,Oncology Agents and Immunosuppressants
a0ROZ000000H5Cz2AK,Perampanel,A-03439,Fycompa,Perampanel,Clinician,"Generalised epilepsy, with complex myoclonic seizures",Under Assessment,Perampanel (Fycompa),/apptracker/s/application-public/a102P00000AeZru,
a0ROZ00000DLDqn2AH,Permethrin,A-05469,A-Scabies,Permethrin,Clinician,for the treatment of scabies,Seeking Clinical Advice,Permethrin (A-Scabies),/apptracker/s/application-public/a10OZ000007ODph,Dermatologicals
a0ROZ000002yNLZ2A2,Phlexy-Vits,A-03369 A-00592,PHLEXY-VITS,Phlexy-Vits,"NUTRICIA LIMITED, Clinician","Intractable epilepsy, pyruvate dehydrogenase, glucose transporter Type 1 deficiency, people with other inborn errors of metabolism, requiring a ketogenic diet or taking a protein supplement without micronutrients",Under Assessment,Phlexy-Vits (PHLEXY-VITS),/apptracker/s/application-public/a102P00000ATdvF,Special Foods
a0R2P000000ftrJUAQ,Physostigmine,A-03903,Akorn,Physostigmine,Clinician,Moderate to severe simultaneous central and peripheral anticholinergic toxicity when the toxicity is only due to anticholinergic poisoning,Under Assessment,Physostigmine (Akorn),/apptracker/s/application-public/a102P00000BUk5r,Various
a0ROZ00000BVlif2AD,Pipobroman,A-00977,,Pipobroman,Clinician,Polycythaemia and essential thrombocythaemia,Reviewing Consultation Feedback,Pipobroman,/apptracker/s/application-public/a102P000008puVi,Oncology Agents and Immunosuppressants
a0R2P000000df0uUAA,Pirfenidone,A-04285,Esbriet,Pirfenidone,Clinician,"Progressive fibrosing interstitial lung diseases, intolerance to nintedanib (if access to nintedanib widened)",Under Assessment,Pirfenidone (Esbriet),/apptracker/s/application-public/a102P00000BUlWu,Respiratory System and Allergies
a0R2P000000dey0UAA,Pirfenidone,A-04285,Esbriet,Pirfenidone,Clinician,Progressive fibrosing interstitial lung diseases,Under Assessment,Pirfenidone (Esbriet),/apptracker/s/application-public/a102P00000BR3bl,Respiratory System and Allergies
a0R2P000000LmdAUAS,Pirfenidone,A-00351,Pirfenex,Pirfenidone,Clinician,Idiopathic pulmonary fibrosis,Decision,Pirfenidone (Pirfenex),/apptracker/s/application-public/a102P000008pu8t,Respiratory System and Allergies
a0ROZ00000DTVDp2AP,Plerixafor,A-04438,MOBOZIL,Plerixafor,Clinician,"Allogeneic stem cell transplant, donor, unsuccessful mobilisation",Decision,Plerixafor (MOBOZIL),/apptracker/s/application-public/a102P00000BVxKl,
a0R2P000000TGOVUA4,Plerixafor,A-01401,Mozobil,Plerixafor,Clinician,Stem cell mobilisation,Decision,Plerixafor (Mozobil),/apptracker/s/application-public/a102P000008ptsX,Blood and Blood Forming Organs
a0ROZ000005Q2Cz2AK,Posaconazole,A-04709 A-01319 A-01283,,Posaconazole,Clinician,"Prophylaxis of invasive fungal infections in people with high risk malignancies, lung and liver transplant recipients",Decision,Posaconazole,/apptracker/s/application-public/a102P00000BbAZ7,
a0ROZ000009J45x2AC,Posaconazole,A-01283,,Posaconazole,Clinician,Prophylaxis of fungal infection in patients with aplastic anaemia,Decision,Posaconazole,/apptracker/s/application-public/a102P000008puiu,Infections - Agents for Systemic Use
a0ROZ000009J44L2AS,Posaconazole,A-01319,Noxafil,Posaconazole,Clinician,Prophylaxis of fungal infection in patients with acute lymphoblastic leukemia,Decision,Posaconazole (Noxafil),/apptracker/s/application-public/a102P000008pu8d,Infections - Agents for Systemic Use
a0R2P000000LmrZUAS,Potassium citrate,A-00850,,Potassium citrate,Clinician,Recurrent calcium oxalate urolithiasis,Decision,Potassium citrate,/apptracker/s/application-public/a102P000008puJu,Genito-Urinary System
a0ROZ0000029hCh2AI,Potassium citrate liquid,A-04953,,Potassium citrate liquid,Clinician,"Hypercalciuria, secondary to therapeutic ketogenic diet for epilepsy",Seeking Clinical Advice,Potassium citrate liquid,/apptracker/s/application-public/a10OZ000000wiNF,Genito-Urinary System
a0ROZ0000012CUL2A2,Potassium citrate tablets,A-00148 A-04857,,Potassium citrate tablets,"Subcommittee recommendation, Clinician",Recurrent calcium oxalate urolithiasis,Seeking Clinical Advice,Potassium citrate tablets,/apptracker/s/application-public/a102P000008ptv9,Genito-Urinary System
a0ROZ000004nOoc2AE,Prasugrel,A-03704,,Prasugrel,Clinician,"Acute coronary syndrome, STEMI or non-STEMI",Options Compared,Prasugrel,/apptracker/s/application-public/a102P00000AnpIO,
a0R2P000000gVWgUAM,"Prasugrel, Ticagrelor",A-00577,,"Prasugrel, Ticagrelor",Clinician,Prevention of thrombosis post-neurological stenting,Decision,"Prasugrel, Ticagrelor",/apptracker/s/application-public/a102P000008ptyJ,Blood and Blood Forming Organs
a0ROZ000000MEcD2AW,"Prasugrel, Ticagrelor",A-00601,,"Prasugrel, Ticagrelor",Clinician,Amending access post-ACS in clopidogrel non-responders using CYP2C19 genotyping,Decision,"Prasugrel, Ticagrelor",/apptracker/s/application-public/a102P000008ptyk,Blood and Blood Forming Organs
a0ROZ000009KbJB2A0,"Pre-thickened fluids, pudding-thick (extremely thick)",A-00288,,"Pre-thickened fluids, pudding-thick (extremely thick)",Clinician,Dysphagia (hospital),Decision,"Pre-thickened fluids, pudding-thick (extremely thick)",/apptracker/s/application-public/a102P000008pu2I,Special Foods
a0ROZ000003dpTx2AI,"Pre-thickened fluids: functional juices, milk based beverages, hot beverages",A-00289,,"Pre-thickened fluids: functional juices, milk based beverages, hot beverages",Clinician,Dysphagia (hospital),Options Compared,"Pre-thickened fluids: functional juices, milk based beverages, hot beverages",/apptracker/s/application-public/a102P000008puCR,Special Foods
a0ROZ000003dq532AA,Pre-thickened standard supplement,A-00290,,Pre-thickened standard supplement,Clinician,Dysphagia with malnutrition (hospital),Options Compared,Pre-thickened standard supplement,/apptracker/s/application-public/a102P000008puZY,Special Foods
a0R2P000000LmWUUA0,Prednisolone eye drops 0.1% and 1%,A-01113,,Prednisolone eye drops 0.1% and 1%,Clinician,Ocular inflammation,Decision,Prednisolone eye drops 0.1% and 1%,/apptracker/s/application-public/a102P000008ptwo,Sensory Organs
a0R2P000000Sk61UAC,Prednisone on funded on a Practitioners Supply Order (PSO),A-00669,,Prednisone on funded on a Practitioners Supply Order (PSO),Clinician,Multiple indications,Decision,Prednisone on funded on a Practitioners Supply Order (PSO),/apptracker/s/application-public/a102P000008puAW,Respiratory System and Allergies
a0R2P000000LmiHUAS,Preservative free lubricating eye drops,A-01224,lubricating eye drops,Preservative free lubricating eye drops,Clinician,Dry-eye disease and inflammation - severe secretory,Decision,Preservative free lubricating eye drops (lubricating eye drops),/apptracker/s/application-public/a102P000008puDY,Sensory Organs
a0ROZ000005wpXE2AY,Pretomanid,A-04742,Dovprela,Pretomanid,Clinician,Multi drug-resistant Tuberculosis (MDR-TB) and Extensively drug-resistant Tuberculosis (XDR-TB),Under Assessment,Pretomanid (Dovprela),/apptracker/s/application-public/a10OZ0000000gvJ,Infections - Agents for Systemic Use
a0ROZ0000001tSH2AY,Pristinamycin,A-03948,pyostacine,Pristinamycin,Clinician,"Mycoplasma genitalium infection, proven macrolide and quinolone resistance",Seeking Clinical Advice,Pristinamycin (pyostacine),/apptracker/s/application-public/a102P00000BVIFA,Infections - Agents for Systemic Use
a0ROZ000004CWmb2AG,Quinacrine,A-03228,Mepacrine,Quinacrine,Clinician,Systemic Lupus Erythematosus (SLE),Decision,Quinacrine (Mepacrine),/apptracker/s/application-public/a102P00000A2Uiq,Dermatologicals
a0R2P000000NNDgUAO,Raltitrexed,A-00726 A-00802,Tomudex,Raltitrexed,Clinician,"Colorectal cancer, intolerant or contraindicated to fluoropyrimidine due to cardiac toxicity",Options Compared,Raltitrexed (Tomudex),/apptracker/s/application-public/a102P000008pua2,Oncology Agents and Immunosuppressants
a0ROZ000002yO372AE,Renilon 4.0,A-04761,,Renilon 4.0,Clinician,"Nutritional management of chronic kidney disease, adults",Under Assessment,Renilon 4.0,/apptracker/s/application-public/a10OZ000000N9sD,
a0ROZ000002yNbh2AE,Renilon 4.0,A-04761,,Renilon 4.0,Clinician,"Nutritional management of chronic kidney disease, children",Under Assessment,Renilon 4.0,/apptracker/s/application-public/a10OZ00000018A2,
a0ROZ0000011Fm12AE,Ribavirin,A-00357,,Ribavirin,Clinician,"RSV infection, recipients of lung or allogeneic stem cell transplants",Under Assessment,Ribavirin,/apptracker/s/application-public/a102P000008pu1P,Infections - Agents for Systemic Use
a0ROZ00000AQkoC2AT,Ribavirin,A-00357,,Ribavirin,Clinician,"Measles, complicated",Options Compared,Ribavirin,/apptracker/s/application-public/a10OZ0000002AHp,Infections - Agents for Systemic Use
a0R2P000000gcWrUAI,Riboflavin,A-03453,riboflavin,Riboflavin,Clinician,Perioperative use (cystoscopy),Options Compared,Riboflavin (riboflavin),/apptracker/s/application-public/a102P00000Au6e0,Genito-Urinary System
a0R2P000000SVhjUAG,Riboflavin (vitamin B2),A-03070,Solgar,Riboflavin (vitamin B2),Clinician,"Treatment (while awaiting diagnostic results) of relevant riboflavin responsive metabolic conditions: Brown Vialetto van Laere, Multiple acyl-CoA dehydrogenase deificiency (MADD), lipid storage myopathy",Decision,Riboflavin (vitamin B2) (Solgar),/apptracker/s/application-public/a102P00000ACs5c,
a0ROZ00000AqQQa2AN,Rifampicin/Isoniazid/Pyrazinamide/Ethambutol - fixed dose combinations,A-00805,,Rifampicin/Isoniazid/Pyrazinamide/Ethambutol - fixed dose combinations,Clinician,Tuberculosis,Options Compared,Rifampicin/Isoniazid/Pyrazinamide/Ethambutol - fixed dose combinations,/apptracker/s/application-public/a102P000008puVC,Infections - Agents for Systemic Use
a0ROZ000005OJkz2AG,Ring pessary,A-03509,Not applicable- brand to be determined later,Ring pessary,Clinician,"Treatment for pelvic prolapse, vaginal or rectal in women",Options Compared,Ring pessary (Not applicable- brand to be determined later),/apptracker/s/application-public/a102P00000Au6xl,Genito-Urinary System
a0ROZ00000Dms532AB,Riociguat,A-05544,ADEMPAS,Riociguat,Clinician,Chronic Thromboembolic Pulmonary Hypertension (CTEPH),Seeking Clinical Advice,Riociguat (ADEMPAS),/apptracker/s/application-public/a10OZ000007nf61,
a0R2P000000LmgPUAS,Rituximab,A-00938,MabThera,Rituximab,Clinician,Retreatment of indolent Non-Hodgkins Lymphoma (NHL),Decision,Rituximab (MabThera),/apptracker/s/application-public/a102P000008ptox,Oncology Agents and Immunosuppressants
a0R2P000000LmZtUAK,Rituximab,A-00404,Mabthera,Rituximab,Clinician,Hairy cell leukaemia,Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008pua3,Oncology Agents and Immunosuppressants
a0R2P000000X1MTUA0,Rituximab,A-03363,,Rituximab,Clinician,Pemphigus (all types),Decision,Rituximab,/apptracker/s/application-public/a102P00000ACTqk,Oncology Agents and Immunosuppressants
a0R2P000000T8exUAC,Rituximab,A-00670,,Rituximab,Clinician,Precursor B-cell Acute lymphoblastic leukaemia (adults),Decision,Rituximab,/apptracker/s/application-public/a102P000008pu0p,Oncology Agents and Immunosuppressants
a0ROZ000000966D2AQ,Rituximab,A-00931,MabThera,Rituximab,Clinician,Large cell lymphoma pts who have relapsed following prior rituximab therapy,Decision,Rituximab (MabThera),/apptracker/s/application-public/a102P000008pu30,Oncology Agents and Immunosuppressants
a0R2P000000gYsGUAU,Rituximab,A-03648,Riximyo,Rituximab,Clinician,IgG4 disease,Decision,Rituximab (Riximyo),/apptracker/s/application-public/a102P00000AkRTB,
a0R2P000000LmfrUAC,Rituximab,A-01286,Mabthera,Rituximab,Clinician,Refractory systemic lupus erythematosis,Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008pu45,Oncology Agents and Immunosuppressants
a0R2P000000gVXFUA2,Rituximab,A-00450,"Baxter,Mabthera",Rituximab,Clinician,Severe refractory myasthenia gravis (Third-line immunosuppressant),Decision,"Rituximab (Baxter,Mabthera)",/apptracker/s/application-public/a102P000008puNF,Oncology Agents and Immunosuppressants
a0R2P000000NVGfUAO,Rituximab,A-03379,,Rituximab,Clinician,Membranous nephropathy,Decision,Rituximab,/apptracker/s/application-public/a102P00000ACTtL,Oncology Agents and Immunosuppressants
a0R2P000000Lmg1UAC,Rituximab,A-01254,Mabthera,Rituximab,Clinician,Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis,Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008pu4D,Oncology Agents and Immunosuppressants
a0ROZ000006zfhA2AQ,Rituximab,A-04832,Rixiymo,Rituximab,Clinician,"Systemic sclerosis with interstitial lung disease (ILD), not responsive or intolerant to mycophenolate mofetil",Under Assessment,Rituximab (Rixiymo),/apptracker/s/application-public/a10OZ000000TZNO,Oncology Agents and Immunosuppressants
a0ROZ000006qwVt2AI,Rituximab,A-04832,Rixiymo,Rituximab,Clinician,"Connective tissue disease (CTD)-related interstitial lung disease (ILD), second-line treatment",Under Assessment,Rituximab (Rixiymo),/apptracker/s/application-public/a10OZ000003NboL,
a0R2P000000LmTrUAK,Rituximab,A-00694,"Baxter,Mabthera",Rituximab,Clinician,Severe refractory myasthenia gravis (last-line immunosuppressant),Decision,"Rituximab (Baxter,Mabthera)",/apptracker/s/application-public/a102P000008puPk,Oncology Agents and Immunosuppressants
a0R2P000000LmXwUAK,Rituximab,A-00917,Mabthera,Rituximab,Clinician,Large cell lymphoma patients who have relapsed following prior non rituximab therapy,Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008pu0W,Oncology Agents and Immunosuppressants
a0R2P000000LmqRUAS,Rituximab,A-00336,Mabthera,Rituximab,Clinician,"MPO-ANCA positive vasculitis, remove requirement to try mycophenolate mofetil",Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008puCJ,Oncology Agents and Immunosuppressants
a0ROZ000009J3kz2AC,Rituximab,A-04558,Riximyo,Rituximab,Clinician,For use in the treatment of people with Class IV(a) lupus nephritis as part of the induction phase of therapy (expanded SA indication),Decision,Rituximab (Riximyo),/apptracker/s/application-public/a102P00000BYOiJ,Genito-Urinary System
a0R2P000000anYVUAY,Rituximab,A-00210,Mabthera,Rituximab,Clinician,Polyarticular juvenile idiopathic arthritis,Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008pu9u,Oncology Agents and Immunosuppressants
a0R2P000000Lmj4UAC,Rituximab,A-00332,Mabthera,Rituximab,Clinician,"Nephrotic syndrome: idiopathic or resistant, pediatric",Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008puDs,Oncology Agents and Immunosuppressants
a0ROZ000009SF6z2AG,Rituximab,A-04809 A-05274,Riximyo,Rituximab,"Clinician, Consumer",Maintenance therapy of ANCA vasculitis,Under Assessment,Rituximab (Riximyo),/apptracker/s/application-public/a10OZ000001ye3d,Oncology Agents and Immunosuppressants
a0ROZ000009QmAH2A0,Ruxolitinib,A-04685,Jakavi,Ruxolitinib,Clinician,"Graft-versus-host disease, acute, corticosteroid refractory",Under Assessment,Ruxolitinib (Jakavi),/apptracker/s/application-public/a10OZ000000wbGw,Blood and Blood Forming Organs
a0ROZ000008xyWb2AI,Ruxolitinib,A-04685,Jakavi,Ruxolitinib,Clinician,"Graft-versus-host disease, chronic, corticosteroid refractory",Under Assessment,Ruxolitinib (Jakavi),/apptracker/s/application-public/a10OZ0000012ERJ,Blood and Blood Forming Organs
a0ROZ00000Chvov2AB,Ruxolitinib,A-05342,,Ruxolitinib,Clinician,VEXAS syndrome,Under Assessment,Ruxolitinib,/apptracker/s/application-public/a10OZ000003vxkn,Oncology Agents and Immunosuppressants
a0ROZ00000ApE812AF,Sacituzumab govitecan,A-04634 A-05364,trodelvy,Sacituzumab govitecan,"Gilead Sciences Pty Ltd, Clinician","Breast Cancer,  Triple-Negative,Locally Advanced or Metastatic",Options Compared,Sacituzumab govitecan (trodelvy),/apptracker/s/application-public/a10OZ0000000O2L,Oncology Agents and Immunosuppressants
a0ROZ00000DKzXj2AL,Salbutamol dry powder inhaler,A-04132,ventolin accuhaler,Salbutamol dry powder inhaler,Clinician,COPD and asthma,Seeking Clinical Advice,Salbutamol dry powder inhaler (ventolin accuhaler),/apptracker/s/application-public/a102P00000BYrtH,Respiratory System and Allergies
a0ROZ000009J16U2AS,Secura Extra Protective Cream,A-00042,Secura Extra,Secura Extra Protective Cream,Clinician,"Pressure injury prevention, incontinence",Decision,Secura Extra Protective Cream (Secura Extra),/apptracker/s/application-public/a102P000008puZU,Dermatologicals
a0ROZ000003doo12AA,Selenium and copper chloride,A-03148 A-03293,Clinicians,Selenium and copper chloride,Clinician,Patient is admitted to hospital with burns.,Decision,Selenium and copper chloride (Clinicians),/apptracker/s/application-public/a102P000009lJWU,Dermatologicals
a0ROZ000008OWoX2AW,Selpercatinib,A-05079,Retevmo,Selpercatinib,Clinician,"Advanced or metastatic medullary thyroid cancer, germline or somatic mutation in the RET gene",Seeking Clinical Advice,Selpercatinib (Retevmo),/apptracker/s/application-public/a10OZ000004Aprm,
a0ROZ0000077hQn2AI,Sildenafil,A-04964,PDE5 inhibitors,Sildenafil,Clinician,sildenafil for erectile dysfunction,Under Assessment,Sildenafil (PDE5 inhibitors),/apptracker/s/application-public/a10OZ000000wZQP,
a0ROZ00000CJE8Q2AX,Silver diamine fluoride,A-04476,,Silver diamine fluoride,Clinician,Dental caries,Decision,Silver diamine fluoride,/apptracker/s/application-public/a102P00000BYJtQ,Various
a0R2P000000QNEsUAO,Sirolimus,A-00734,,Sirolimus,Clinician,Angiomyolipoma associated with tuberous sclerosis complex,Decision,Sirolimus,/apptracker/s/application-public/a102P00000AAqMY,Oncology Agents and Immunosuppressants
a0R2P000000TbHJUA0,Sirolimus,A-00739,,Sirolimus,Clinician,Widening access to include lymphovascular malformations,Decision,Sirolimus,/apptracker/s/application-public/a102P000008ptwV,Oncology Agents and Immunosuppressants
a0R2P000000QN4zUAG,Sirolimus,A-03065,,Sirolimus,Clinician,Refractory epilepsy associated with tuberous sclerosis complex,Decision,Sirolimus,/apptracker/s/application-public/a102P00000AAq3k,Oncology Agents and Immunosuppressants
a0ROZ00000BV82z2AD,SMA treatments,A-04568,nusinersen/Spinraza and risdiplam/Evrysdi,SMA treatments,Clinician,People with SMA type IV (aged 19 years and over at symptom onset),Reviewing Consultation Feedback,SMA treatments (nusinersen/Spinraza and risdiplam/Evrysdi),/apptracker/s/application-public/a10OZ0000000uVF,
a0ROZ000003Noty2AC,SMA treatments,A-04568,nusinersen/Spinraza and risdiplam/Evrysdi,SMA treatments,Clinician,"People with SMA types IIIb, IIIc and undefined III aged 18 years and under (symptomatic after 3 years of age)",Options Compared,SMA treatments (nusinersen/Spinraza and risdiplam/Evrysdi),/apptracker/s/application-public/a10OZ0000000uQP,
a0ROZ00000DKzXk2AL,Sodium chloride oral liquid 2mmol/mL,A-04907,Biomed,Sodium chloride oral liquid 2mmol/mL,Clinician,"Sodium replacement, neonates and children",Seeking Clinical Advice,Sodium chloride oral liquid 2mmol/mL (Biomed),/apptracker/s/application-public/a10OZ000000fkGb,Blood and Blood Forming Organs
a0R2P000000OceQUAS,Sodium chloride prefilled syringes sterile pack,A-00391,"PosiFlush, PosiFlushXS",Sodium chloride prefilled syringes sterile pack,Clinician,Flushing in-situ vascular access devices,Decision,"Sodium chloride prefilled syringes sterile pack (PosiFlush, PosiFlushXS)",/apptracker/s/application-public/a102P000008ptrm,Blood and Blood Forming Organs
a0ROZ000000PXiM2AW,"Sodium hypochlorite, 5% diluted",A-00037,,"Sodium hypochlorite, 5% diluted",Clinician,"Eczema, secondary bacterial infection",Options Compared,"Sodium hypochlorite, 5% diluted",/apptracker/s/application-public/a102P000008pu0U,Dermatologicals
a0ROZ000009MFeL2AW,Sofosbuvir,A-04793,,Sofosbuvir,Clinician,"Hepatitis C, second-line treatment in combination with glecaprevir and pibrentasvir after prior direct-acting antiviral treatment",Options Compared,Sofosbuvir,/apptracker/s/application-public/a10OZ0000001Quv,
a0ROZ000002rTif2AE,Sofosbuvir with velpatasvir and voxilaprevir,A-04793,,Sofosbuvir with velpatasvir and voxilaprevir,Clinician,"Hepatitis C, second-line after prior direct-acting antiviral treatment",Options Compared,Sofosbuvir with velpatasvir and voxilaprevir,/apptracker/s/application-public/a10OZ0000001QtJ,
a0ROZ0000012WEY2A2,Sofosbuvir/velpatasvir,A-03594,Epclusa,Sofosbuvir/velpatasvir,Clinician,Treatment of individuals with decompensated cirrhosis,Under Assessment,Sofosbuvir/velpatasvir (Epclusa),/apptracker/s/application-public/a102P00000AlhAQ,Infections - Agents for Systemic Use
a0R2P000000LmXfUAK,"Standard Supplements, liquid oral feeds",A-00285,,"Standard Supplements, liquid oral feeds",Clinician,EEN (6-8 weeks) to induce remission in children up to the age of 18 with Crohn's disease,Decision,"Standard Supplements, liquid oral feeds",/apptracker/s/application-public/a102P000008puXG,Special Foods
a0ROZ0000012Uj02AE,"Sunitinib, pazopanib",A-03507,,"Sunitinib, pazopanib",Clinician,"Renal cell carcinoma (RCC), advanced or metastatic, 2nd line after prior TKI treatment",Options Compared,"Sunitinib, pazopanib",/apptracker/s/application-public/a102P00000AUfIW,Oncology Agents and Immunosuppressants
a0R2P000000TEmGUAW,Tacrolimus,A-00212,Tacrolimus Sandoz,Tacrolimus,Clinician,"Nephrotic syndrome, steroid-resistant and refractory/intolerant to ciclosporin",Decision,Tacrolimus (Tacrolimus Sandoz),/apptracker/s/application-public/a102P000008pu3J,Oncology Agents and Immunosuppressants
a0R2P000000OKcdUAG,Tacrolimus ointment,A-00551,,Tacrolimus ointment,Clinician,Atopic dermatitis in children and adults,Decision,Tacrolimus ointment,/apptracker/s/application-public/a102P000008puGj,Dermatologicals
a0ROZ000006Ejmj2AC,tacrolimus prolonged - release capsules,A-04489,Advagraf XL,tacrolimus prolonged - release capsules,Clinician,Immunosuppresssion for all adolescents and young adults ( 12 - 30 years) living with solid organ transplants in New Zealand.,Options Compared,tacrolimus prolonged - release capsules (Advagraf XL),/apptracker/s/application-public/a102P00000BXyQv,Oncology Agents and Immunosuppressants
a0ROZ0000077hFV2AY,Tadalafil,A-04964,PDE5 inhibitors,Tadalafil,Clinician,Tadalafil for people experiencing erectile dysfunction,Under Assessment,Tadalafil (PDE5 inhibitors),/apptracker/s/application-public/a10OZ000001jcBp,
a0ROZ00000DKzXq2AL,Tadalafil,A-05501,"Cialis, Adcirca",Tadalafil,Clinician,Pulmonary arterial hypertension (PAH),Seeking Clinical Advice,"Tadalafil (Cialis, Adcirca)",/apptracker/s/application-public/a10OZ000006KQCb,
a0R2P000000VC8dUAG,Taurine,A-03860,Various,Taurine,Clinician,For the treatment of mitochondrial disorders responsive to taurine supplementation,Decision,Taurine (Various),/apptracker/s/application-public/a102P00000BAUIT,
a0ROZ000000AOdl2AG,Taurolidine and citrate,A-00427 A-00426,,Taurolidine and citrate,"Rollex Medical, Clinician",Catheter lock solution,Options Compared,Taurolidine and citrate,/apptracker/s/application-public/a102P000008puSV,Blood and Blood Forming Organs
a0R2P000000LmUrUAK,Temozolomide,A-00227,Temaccord,Temozolomide,Clinician,High grade gliomas - treatment beyond 6 cycles,Decision,Temozolomide (Temaccord),/apptracker/s/application-public/a102P000008puOR,Oncology Agents and Immunosuppressants
a0R2P000000LmkVUAS,Temozolomide,A-00809,Temodal,Temozolomide,Clinician,Glioblastoma multiforme tumours - widening of access,Decision,Temozolomide (Temodal),/apptracker/s/application-public/a102P000008pugX,Oncology Agents and Immunosuppressants
a0ROZ00000096EH2AY,Temozolomide,A-00810,Temodal,Temozolomide,Clinician,Anaplastic astrocytoma - widening of access,Decision,Temozolomide (Temodal),/apptracker/s/application-public/a102P000008puRU,Oncology Agents and Immunosuppressants
a0R2P000000LmjnUAC,Temozolomide,A-01216,,Temozolomide,Clinician,Oligodendroglial tumours - widening access,Decision,Temozolomide,/apptracker/s/application-public/a102P000008pufi,Oncology Agents and Immunosuppressants
a0R2P000000LmkmUAC,Temozolomide,A-00520,Temaccord,Temozolomide,Clinician,"Widening access to high grade gliomas, newly diagnosed without concomitant radiation and relapsed",Decision,Temozolomide (Temaccord),/apptracker/s/application-public/a102P000008pucr,Oncology Agents and Immunosuppressants
a0ROZ000004CXsL2AW,Teniposide,A-01265,Vumon,Teniposide,Clinician,Primary CNS lymphoma,Decision,Teniposide (Vumon),/apptracker/s/application-public/a102P000008ptyP,Oncology Agents and Immunosuppressants
a0ROZ000008y17t2AA,Teriparatide,A-04055,,Teriparatide,Clinician,"Osteoporosis, treatment for clinical vertebral fractures, 1st line",Under Assessment,Teriparatide,/apptracker/s/application-public/a102P00000BLTj9,Musculoskeletal System
a0ROZ00000Bomvx2AB,Ticagrelor,A-04205,BRILINTA,Ticagrelor,Clinician,"Minor stroke or high risk TIA, prevention of atherothrombotic events",Decision,Ticagrelor (BRILINTA),/apptracker/s/application-public/a102P00000BQipo,
a0R2P000000anXSUAY,Tinzaparin Sodium,A-01444,,Tinzaparin Sodium,Clinician,Thrombosis,Decision,Tinzaparin Sodium,/apptracker/s/application-public/a102P000008pu4Z,Blood and Blood Forming Organs
a0R2P000000UUR3UAO,TNF inhibitors - Etanercept,A-00223,Enbrel,TNF inhibitors - Etanercept,Clinician,Undifferentiated spondyloarthritis,Decision,TNF inhibitors - Etanercept (Enbrel),/apptracker/s/application-public/a102P0000094Mmk,Musculoskeletal System
a0R2P000000PbfCUAS,TNF-alpha inhibitors - amendment to JIA criteria,A-00795,,TNF-alpha inhibitors - amendment to JIA criteria,Clinician,juvenile idiopathic arthritis,Decision,TNF-alpha inhibitors - amendment to JIA criteria,/apptracker/s/application-public/a102P000008ptui,Musculoskeletal System
a0ROZ000004CVgs2AG,Tobramycin (TOBI) Podhaler,A-00646,,Tobramycin (TOBI) Podhaler,Clinician,Cystic fibrosis,Decision,Tobramycin (TOBI) Podhaler,/apptracker/s/application-public/a102P000008puEn,Respiratory System and Allergies
a0R2P000000LmbpUAC,Tocilizumab,A-00368,Actemra,Tocilizumab,Clinician,AA amyloidosis,Seeking Clinical Advice,Tocilizumab (Actemra),/apptracker/s/application-public/a102P000008pubH,Oncology Agents and Immunosuppressants
a0R2P000000TFeuUAG,Tocilizumab,A-00305,Actemra,Tocilizumab,Clinician,Idiopathic multicentric Castlemans,Decision,Tocilizumab (Actemra),/apptracker/s/application-public/a102P000008puZG,Oncology Agents and Immunosuppressants
a0ROZ00000Chw0D2AR,Tocilizumab,A-05342,,Tocilizumab,Clinician,VEXAS syndrome,Under Assessment,Tocilizumab,/apptracker/s/application-public/a10OZ000003vxeL,Oncology Agents and Immunosuppressants
a0R2P000000f0BhUAI,Tocilizumab,A-03782,Actemra,Tocilizumab,Clinician,Moderate-severe COVID-19,Decision,Tocilizumab (Actemra),/apptracker/s/application-public/a102P00000B3MZF,
a0R2P000000TGL7UAO,Tocilizumab,A-00410,Actemra,Tocilizumab,Clinician,Rheumatoid arthritis: remove requirement to try rituximab in certain patients,Decision,Tocilizumab (Actemra),/apptracker/s/application-public/a102P000008pu3z,Oncology Agents and Immunosuppressants
a0ROZ000004CPoM2AW,Tocilizumab,A-00513,,Tocilizumab,Clinician,Grade 3 or 4 cytokine release syndrome,Decision,Tocilizumab,/apptracker/s/application-public/a102P000008pu8e,Oncology Agents and Immunosuppressants
a0ROZ000006h54D2AQ,trabectedin,A-05179,yondelis,trabectedin,Clinician,"leiomyosarcoma, unresectable or metastatic, first or second line treatment",Seeking Clinical Advice,trabectedin (yondelis),/apptracker/s/application-public/a10OZ000003IZ5d,
a0ROZ000006h4uX2AQ,trabectedin,A-05179,yondelis,trabectedin,Clinician,"Liposarcoma, unresectable or metastatic, second line",Seeking Clinical Advice,trabectedin (yondelis),/apptracker/s/application-public/a10OZ000003IYfq,
a0ROZ000006t0wn2AA,Trastuzumab,A-04748,Herceptin,Trastuzumab,Clinician,"Endometrial Carcinoma, HER2 amplified,  relapsed",Seeking Clinical Advice,Trastuzumab (Herceptin),/apptracker/s/application-public/a10OZ000000Ad1h,Oncology Agents and Immunosuppressants
a0ROZ000003KrjB2AS,Trastuzumab,A-00961,Herceptin,Trastuzumab,Clinician,Breast cancer-treatment beyond disease progression,Options Compared,Trastuzumab (Herceptin),/apptracker/s/application-public/a102P000008ptzX,Oncology Agents and Immunosuppressants
a0R2P000000LmXGUA0,Trastuzumab,A-01036,Herceptin,Trastuzumab,Clinician,Breast cancer-Metastatic. Retreatment following previous trastuzumab adjuvant treatment,Decision,Trastuzumab (Herceptin),/apptracker/s/application-public/a102P000008ptx4,Oncology Agents and Immunosuppressants
a0ROZ000006JPDl2AO,Trastuzumab deruxtecan (T-DXd),A-04340 A-04479,Enhertu,Trastuzumab deruxtecan (T-DXd),"ASTRAZENECA LIMITED, Clinician","Breast cancer, 2nd line after HER2 therapy in metastatic setting, or 1st line if progression within 6 months of HER2 treatment in adjuvant setting",Decision,Trastuzumab deruxtecan (T-DXd) (Enhertu),/apptracker/s/application-public/a102P00000BYEh7,
a0R2P000000LmekUAC,Triamcinolone hexacetonide,A-00868,,Triamcinolone hexacetonide,Clinician,Patients with Juvenile Idiopathic Arthritis who Require an Intra-articular Injection,Decision,Triamcinolone hexacetonide,/apptracker/s/application-public/a102P000008ptq9,Musculoskeletal System
a0ROZ0000064KHd2AM,Udderly Smooth,A-00041,Udderly Smooth,Udderly Smooth,Clinician,Palmar-plantar erythrodysesthesia,Reviewing Consultation Feedback,Udderly Smooth (Udderly Smooth),/apptracker/s/application-public/a102P000008puSi,Dermatologicals
a0ROZ000000PXih2AG,Ustekinumab,A-01049,,Ustekinumab,Clinician,"Psoriasis, chronic plaque, 2nd line",Options Compared,Ustekinumab,/apptracker/s/application-public/a10OZ000000H0lC,
a0ROZ000000OQm92AG,Ustekinumab,A-01049 A-01048 A-01050,,Ustekinumab,"Janssen, Clinician","Psoriasis, chronic plaque, 1st line",Options Compared,Ustekinumab,/apptracker/s/application-public/a102P000008pucX,Dermatologicals
a0ROZ00000DqVYB2A3,Valganciclovir oral solution,A-04473,,Valganciclovir oral solution,Clinician,Cytomegalovirus,Options Compared,Valganciclovir oral solution,/apptracker/s/application-public/a10OZ0000000xJR,Infections - Agents for Systemic Use
a0R2P000000LmV1UAK,Valganciclovir tablet,A-01059,,Valganciclovir tablet,Clinician,Stem cell transplant,Decision,Valganciclovir tablet,/apptracker/s/application-public/a102P000008ptyn,Infections - Agents for Systemic Use
a0ROZ000009J3uf2AC,Vancomycin,A-00638,,Vancomycin,Clinician,infected arthroplasty,Decision,Vancomycin,/apptracker/s/application-public/a102P000008puM9,Infections - Agents for Systemic Use
a0ROZ000009MIh32AG,Vancomycin oral capsule,A-05327,,Vancomycin oral capsule,Clinician,For treatment of clostridium difficile diarrhoea,Seeking Clinical Advice,Vancomycin oral capsule,/apptracker/s/application-public/a10OZ000004eaaL,
a0R2P000000g6eLUAQ,Vedolizumab,A-00485,Takeda,Vedolizumab,Clinician,"Ulcerative colitis, moderate to severe, 2nd line after infliximab",Decision,Vedolizumab (Takeda),/apptracker/s/application-public/a102P000008pu67,Oncology Agents and Immunosuppressants
a0R2P000000g6brUAA,Vedolizumab,A-00485,Takeda,Vedolizumab,Clinician,"Ulcerative colitis, moderate to severe, 1st line",Decision,Vedolizumab (Takeda),/apptracker/s/application-public/a102P00000Am9px,Oncology Agents and Immunosuppressants
a0R2P000000g6cKUAQ,Vedolizumab,A-00741,,Vedolizumab,Clinician application,"Crohn's disease, severe, 1st line",Decision,Vedolizumab,/apptracker/s/application-public/a102P00000AmA9O,Oncology Agents and Immunosuppressants
a0ROZ000005E9eu2AC,Venetoclax (with rituximab),A-04622,Venclexta,Venetoclax (with rituximab),Clinician,"CLL without TP53 mutation, retreatment at relapse following prior treatment with venetoclax plus rituximab (venR) (third line)",Under Assessment,Venetoclax (with rituximab) (Venclexta),/apptracker/s/application-public/a102P00000BZUPC,Oncology Agents and Immunosuppressants
a0ROZ000008Z22L2AS,Venetoclax & Ibrutinib,A-04610,Venclexta & Imbruvica,Venetoclax & Ibrutinib,Clinician,"CLL, Widen access for late relapse",Decision,Venetoclax & Ibrutinib (Venclexta & Imbruvica),/apptracker/s/application-public/a102P00000BZCKU,Oncology Agents and Immunosuppressants
a0R2P000000LmjGUAS,Vinorelbine,A-01267,Navelbine,Vinorelbine,Clinician,Adjuvant non-small cell lung cancer (for use with cisplatin),Decision,Vinorelbine (Navelbine),/apptracker/s/application-public/a102P000008puFD,Oncology Agents and Immunosuppressants
a0ROZ000000ewGb2AI,Vitamin and Trace elements,A-04657,vitamin E and vitamin A,Vitamin and Trace elements,Clinician,DSM5 criteria for ASD with ARFID,Seeking Clinical Advice,Vitamin and Trace elements (vitamin E and vitamin A),/apptracker/s/application-public/a10OZ0000000hPx,
a0ROZ000004oeXp2AI,Voriconazole,A-03921,"Vfend liquid, Vttack tablets, Neo Health Injection",Voriconazole,Clinician,"Prophylaxis of invasive fungal infections in people with high risk malignancies, lung and liver transplant recipients",Decision,"Voriconazole (Vfend liquid, Vttack tablets, Neo Health Injection)",/apptracker/s/application-public/a102P00000BRbIA,Infections - Agents for Systemic Use
a0ROZ00000AQko12AD,Ziv Aflibercept  (Aflibercept),A-04271,Zaltrap,Ziv Aflibercept  (Aflibercept),Clinician,Ocular neovascularisation,Options Compared,Ziv Aflibercept  (Aflibercept) (Zaltrap),/apptracker/s/application-public/a102P00000BQki1,
a0R2P000000X1VVUA0,Zoledronic acid,A-03340,Aclasta,Zoledronic acid,Clinician,Prevention of bone loss post spinal cord injury,Decision,Zoledronic acid (Aclasta),/apptracker/s/application-public/a102P00000AAwb6,Musculoskeletal System
a0ROZ0000009Xb32AE,Zoledronic acid,A-00362,Zometa,Zoledronic acid,Clinician,"Breast cancer, early, in postmenopausal women",Decision,Zoledronic acid (Zometa),/apptracker/s/application-public/a102P000008puRX,Oncology Agents and Immunosuppressants
a0ROZ00000CO6wb2AD,"atuzumab vedotin (with rituximab, cyclophosphamide, doxorubicin, and prednisone)",A-05108,POLIVY,"Polatuzumab vedotin (with rituximab, cyclophosphamide, doxorubicin, and prednisone)",ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Diffuse large B-cell lymphoma (DLBCL), 1st line",Seeking Clinical Advice,"Polatuzumab vedotin (with rituximab, cyclophosphamide, doxorubicin, and prednisone) (POLIVY)",/apptracker/s/application-public/a10OZ000001oeJR,Oncology Agents and Immunosuppressants
a0ROZ0000052ORw2AM,Bruton tyrosine kinase inhibitor (BTKi),A-00407 A-03526 A-04644,Imbruvica,Bruton tyrosine kinase inhibitor (BTKi),"Janssen, ASTRAZENECA LIMITED, BEIGENE NZ UNLIMITED","Chronic lymphocytic leukaemia, (CLL) without TP53 mutation, relapsed or refractory or experienced intolerable side effects to venetoclax plus rituximab",Options Compared,Bruton tyrosine kinase inhibitor (BTKi) (Imbruvica),/apptracker/s/application-public/a10OZ000000LvBN,
a0ROZ000004CW3S2AW,Ibritumomab tiuexetan,A-01094,Zevalin,Ibritumomab tiuexetan,Schering,Patients with CD20 positive indolent B-cell non-Hodgkin's lymphoma who have failed rituximab therapy,Decision,Ibritumomab tiuexetan (Zevalin),/apptracker/s/application-public/a102P000008pu55,Oncology Agents and Immunosuppressants
a0R2P000000ZwWcUAK,Obinutuzumab,A-00651,,Obinutuzumab,Roche,Indolent Non-Hodgkins lymphoma (relapsed after or refractory to rituximab),Decision,Obinutuzumab,/apptracker/s/application-public/a102P000008puWf,Oncology Agents and Immunosuppressants
a0R2P000000LmhNUAS,Rituximab,A-01321,MabThera,Rituximab,Roche,First line low grade non-Hodgkins Lymphoma,Decision,Rituximab (MabThera),/apptracker/s/application-public/a102P000008puE1,Oncology Agents and Immunosuppressants
a0R2P000000N6i1UAC,Rituximab,A-00968,Mabthera,Rituximab,Roche,Relapsed chronic lymphocytic leukaemia (rituximab naive),Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008ptxj,Oncology Agents and Immunosuppressants
a0R2P000000N6i7UAC,Rituximab,A-00952,Mabthera,Rituximab,Roche,First line treatment of Chronic Lymphocytic Leukaemia (CLL),Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008puWq,Oncology Agents and Immunosuppressants
a0R2P000000N6idUAC,Rituximab,A-00973,Mabthera,Rituximab,Roche,"Chronic lymphocytic leukaemia, relapsed",Decision,Rituximab (Mabthera),/apptracker/s/application-public/a102P000008pu2z,Oncology Agents and Immunosuppressants
a0ROZ0000006gEH2AY,Rituximab,A-01051,,Rituximab,Roche,"Follicular non-Hodgkin's lymphoma, relapsed/refractory maintenance therapy",Decision,Rituximab,/apptracker/s/application-public/a102P000008ptrV,Oncology Agents and Immunosuppressants
a0R2P000000LmaAUAS,Rituximab,A-00364,MabThera,Rituximab,Roche,Second line rheumatoid arthritis (patients in whom TNF inhibitors have failed or are contraindicated,Decision,Rituximab (MabThera),/apptracker/s/application-public/a102P000008puZZ,Oncology Agents and Immunosuppressants
a0ROZ000004CQHN2A4,Rituximab Biosimilar,A-03249 A-00747,,Rituximab Biosimilar,"Celltrion Healthcare New Zealand Limited, Celltrion Healthcare New Zealand Limited",Multiple indications,Decision,Rituximab Biosimilar,/apptracker/s/application-public/a102P000009mmMv,Oncology Agents and Immunosuppressants
a0R2P000000anYzUAI,"Rituximab, subcutaneous",A-00414,,"Rituximab, subcutaneous",Roche,Non-Hodgkin lymphoma,Decision,"Rituximab, subcutaneous",/apptracker/s/application-public/a102P000008puDB,Oncology Agents and Immunosuppressants
a0ROZ0000006fjf2AA,Venetoclax (in combination with rituximab),A-00745,,Venetoclax (in combination with rituximab),AbbVie,Relapsed or refractory CLL,Decision,Venetoclax (in combination with rituximab),/apptracker/s/application-public/a102P000008ptqi,Oncology Agents and Immunosuppressants
a0ROZ00000DKzXl2AL,Abemaciclib,A-05051,VERZENIO®,Abemaciclib,ELI LILLY AND COMPANY (NZ) LIMITED,"Metastatic breast cancer, HR positive, HER2 negative",Seeking Clinical Advice,Abemaciclib (VERZENIO®),/apptracker/s/application-public/a10OZ000001SWyr,Oncology Agents and Immunosuppressants
a0R2P000000Ui7VUAS,Abiraterone,A-01356,Zytiga,Abiraterone,Janssen,"Prostate cancer, metastatic, castrate-resistant",Decision,Abiraterone (Zytiga),/apptracker/s/application-public/a102P000008puhW,Oncology Agents and Immunosuppressants
a0R2P000000cJCZUA2,Abiraterone Acetate,A-00716,,Abiraterone Acetate,Janssen,"Prostate Cancer, metastatic, naive/hormone sensitive",Options Compared,Abiraterone Acetate,/apptracker/s/application-public/a102P000008puQ9,Oncology Agents and Immunosuppressants
a0ROZ000004nOoe2AE,Acalabrutinib,A-03526,CALQUENCE®,Acalabrutinib,ASTRAZENECA LIMITED,Treatment-naïve CLL with 17p or TP53 mutation (class recommendation received),Options Compared,Acalabrutinib (CALQUENCE®),/apptracker/s/application-public/a102P00000BYQ0K,Oncology Agents and Immunosuppressants
a0ROZ000004hs7h2AA,Acalabrutinib,A-03526,CALQUENCE®,Acalabrutinib,ASTRAZENECA LIMITED,"Chronic lymphocytic leukaemia (CLL), as subsequent line of therapy to venetoclax regimens for those relapsed or refractory within 36 months or have intolerable side effects with venetoclax",Options Compared,Acalabrutinib (CALQUENCE®),/apptracker/s/application-public/a102P00000BLLor,Oncology Agents and Immunosuppressants
a0R2P000000Uw3cUAC,Adalimumab,A-01358,"Humira,Humirapen",Adalimumab,Subcommittee recommendation,"Crohn's disease, severe, rescue therapy",Decision,"Adalimumab (Humira,Humirapen)",/apptracker/s/application-public/a102P000008puj4,Oncology Agents and Immunosuppressants
a0R2P000000LmknUAC,Adalimumab,A-00273,"Humira,Humirapen",Adalimumab,Abbott,Crohn's disease,Decision,"Adalimumab (Humira,Humirapen)",/apptracker/s/application-public/a102P000008pucs,Oncology Agents and Immunosuppressants
a0R2P000000Uw33UAC,Adalimumab,A-01433,"Humira,Humirapen",Adalimumab,Abbott,"Ulcerative colitis, moderately to severely active, 1st line",Decision,"Adalimumab (Humira,Humirapen)",/apptracker/s/application-public/a102P000008ptxI,Oncology Agents and Immunosuppressants
a0R2P000000LmVAUA0,Adalimumab,A-00846,,Adalimumab,Abbott,Severe chronic plaque psoriasis,Decision,Adalimumab,/apptracker/s/application-public/a102P000008pty3,Oncology Agents and Immunosuppressants
a0R2P000000Uw3IUAS,Adalimumab,A-00680,"Humira,Humirapen",Adalimumab,Abbott,"Ulcerative colitis, moderate to severe, 2nd line after infliximab",Decision,"Adalimumab (Humira,Humirapen)",/apptracker/s/application-public/a102P000008puNa,Oncology Agents and Immunosuppressants
a0R2P000000N6i9UAC,Adalimumab,A-01007,Humira,Adalimumab,Abbott,Juvenile idiopathic arthritis,Decision,Adalimumab (Humira),/apptracker/s/application-public/a102P000008puVF,Oncology Agents and Immunosuppressants
a0ROZ00000AGoj32AD,Adalimumab,A-00508 A-03102,Humira,Adalimumab,"AbbVie, Consumer",Citrate free formulation,Decision,Adalimumab (Humira),/apptracker/s/application-public/a102P000008pu6N,Oncology Agents and Immunosuppressants
a0R2P000000LmkRUAS,Adalimumab,A-01052,Humira,Adalimumab,Abbott,Ankylosing spondylitis,Decision,Adalimumab (Humira),/apptracker/s/application-public/a102P000008pucb,Oncology Agents and Immunosuppressants
a0ROZ0000076P312AE,Adalimumab/etanercept,A-03200,Humira,Adalimumab/etanercept,ABBVIE LIMITED,Rheumatoid arthritis - remove SA criteria relating to CRP,Options Compared,Adalimumab/etanercept (Humira),/apptracker/s/application-public/a102P000009lJ04,Oncology Agents and Immunosuppressants
a0R2P000000Uw3rUAC,Adalimumab/etanercept,A-03200,Humira,Adalimumab/etanercept,ABBVIE LIMITED,Rheumatoid arthritis - amendment to SA criteria to reduce joint counts,Decision,Adalimumab/etanercept (Humira),/apptracker/s/application-public/a102P000009lJ0n,Oncology Agents and Immunosuppressants
a0R2P000000SddgUAC,Adalimumab/etanercept,A-03200,Humira,Adalimumab/etanercept,ABBVIE LIMITED,"Rheumatoid arthritis, reduce number of prior DMARDs from 3 to 2",Under Assessment,Adalimumab/etanercept (Humira),/apptracker/s/application-public/a102P000009lJ0Y,Oncology Agents and Immunosuppressants
a0R2P000000M5aNUAS,Alectinib,A-00690,,Alectinib,Roche,"Non-small cell lung cancer, advanced, anaplastic lymphoma kinase-positive, first-line",Decision,Alectinib,/apptracker/s/application-public/a102P000008pty7,Oncology Agents and Immunosuppressants
a0ROZ000000As5Z2AS,Alemtuzumab,A-00444,Mabcampath,Alemtuzumab,Bayer,Chronic lymphocytic leukaemia (CLL) (3rd-line treatment),Options Compared,Alemtuzumab (Mabcampath),/apptracker/s/application-public/a102P000008puRJ,Oncology Agents and Immunosuppressants
a0R2P000000LmaWUAS,Anastrozole,A-01172,Arimidex,Anastrozole,AstraZeneca,Early breast cancer after two years of tamoxifen treatment,Decision,Anastrozole (Arimidex),/apptracker/s/application-public/a102P000008puRG,Oncology Agents and Immunosuppressants
a0R2P000000LmqWUAS,Anastrozole,A-01169,Arimidex,Anastrozole,AstraZeneca,Third line treatment of advanced breast cancer,Decision,Anastrozole (Arimidex),/apptracker/s/application-public/a102P000008puCL,Oncology Agents and Immunosuppressants
a0R2P000000LmVZUA0,Anastrozole,A-01171,Arimidex,Anastrozole,AstraZeneca,Widening of access for second line treatment of advanced breast cancer,Decision,Anastrozole (Arimidex),/apptracker/s/application-public/a102P000008ptvv,Oncology Agents and Immunosuppressants
a0R2P000000LmbzUAC,Anastrozole,A-01170,Arimidex,Anastrozole,AstraZeneca,Widening of access for first line treatment of advanced breast cancer,Decision,Anastrozole (Arimidex),/apptracker/s/application-public/a102P000008puAY,Oncology Agents and Immunosuppressants
a0ROZ00000BP6Bz2AL,Anifrolumab,A-05255,SAPHNELO®,Anifrolumab,ASTRAZENECA LIMITED,"Systemic Lupus Erythematosus (SLE), severe, high disease activity despite triple therapy",Seeking Clinical Advice,Anifrolumab (SAPHNELO®),/apptracker/s/application-public/a10OZ0000058lmr,Oncology Agents and Immunosuppressants
a0R2P000000fjVDUAY,Apalutamide,A-00790 A-04078,,Apalutamide,"Janssen, JANSSEN NZ LIMITED","Prostate cancer ,  non-metastatic, castration-resistant, high risk",Options Compared,Apalutamide,/apptracker/s/application-public/a102P000008pttm,Oncology Agents and Immunosuppressants
a0ROZ000004nOok2AE,Apalutamide,A-04236 A-04653,ERLYAND®,Apalutamide,"JANSSEN NZ LIMITED, Consumer",For the treatment of men with: metastatic hormone-sensitive prostate cancer (mHSPC) / metastatic castrate-sensitive prostate cancer (mHSPC).,Options Compared,Apalutamide (ERLYAND®),/apptracker/s/application-public/a10OZ000000BBbF,Oncology Agents and Immunosuppressants
a0ROZ000003Za8X2AS,Atezolizumab,A-00564,,Atezolizumab,Roche,"Non-small cell lung cancer , locally advanced or metastatic, 2nd line",Decision,Atezolizumab,/apptracker/s/application-public/a102P000008ptuw,Oncology Agents and Immunosuppressants
a0ROZ00000BV7gP2AT,Atezolizumab,A-00622,,Atezolizumab,Roche,"Urothelial carcinoma, locally advanced or metastatic, 2nd line",Reviewing Consultation Feedback,Atezolizumab,/apptracker/s/application-public/a102P000008pufQ,Oncology Agents and Immunosuppressants
a0ROZ000009J4h32AC,Atezolizumab,A-03158,Tecentriq,Atezolizumab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Non-small cell lung cancer, locally advanced or metastatic, high (>50%) PD-L1 expression, 1st line monotherapy",Decision,Atezolizumab (Tecentriq),/apptracker/s/application-public/a102P000009rmyy,Oncology Agents and Immunosuppressants
a0ROZ00000Cn1x32AB,Atezolizumab,A-04488,Tecentriq,Atezolizumab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Non-Small Cell Lung Cancer (NSCLC), PD-L1 positive, Adjuvant treatment",Options Compared,Atezolizumab (Tecentriq),/apptracker/s/application-public/a102P00000BaPb0,Oncology Agents and Immunosuppressants
a0ROZ000007h5Mz2AI,Axitinib,A-01431,Inlyta,Axitinib,Pfizer,"Renal cell carcinoma, metastatic, clear cell, 2nd line",Decision,Axitinib (Inlyta),/apptracker/s/application-public/a102P000008pu4I,Oncology Agents and Immunosuppressants
a0R2P000000N6i8UAC,Azacitidine,A-00970,Vidaza,Azacitidine,Celgene,Myelodysplastic syndromes - Int-2 high risk,Decision,Azacitidine (Vidaza),/apptracker/s/application-public/a102P000008puX5,Oncology Agents and Immunosuppressants
a0ROZ00000BTW9V2AX,Belantamab mafodotin,A-05480,Blenrep®,Belantamab mafodotin,GLAXOSMITHKLINE NZ LIMITED,"Multiple myeloma, relapsed or refractory, 2nd line or later",Seeking Clinical Advice,Belantamab mafodotin (Blenrep®),/apptracker/s/application-public/a10OZ000005MlAH,Oncology Agents and Immunosuppressants
a0R2P000000TGQlUAO,Bendamustine,A-00301,RIBOMUSTIN [S.29],Bendamustine,Janssen,"Chronic lymphocytic leukemia, first-line, unable to tolerate FCR",Decision,Bendamustine (RIBOMUSTIN [S.29]),/apptracker/s/application-public/a102P000008puB9,Oncology Agents and Immunosuppressants
a0R2P000000WOWVUA4,Bendamustine,A-00434,Ribomustin,Bendamustine,Janssen,"Non-Hodgkin lymphoma, indolent, relapsed or refractory",Decision,Bendamustine (Ribomustin),/apptracker/s/application-public/a102P000008puZH,Oncology Agents and Immunosuppressants
a0R2P000000TGTpUAO,Bendamustine,A-00418,Ribomustin,Bendamustine,Janssen,"Non-Hodgkin lymphoma, indolent, first-line",Decision,Bendamustine (Ribomustin),/apptracker/s/application-public/a102P000008pucO,Oncology Agents and Immunosuppressants
a0ROZ00000AqQQd2AN,Benralizumab,A-00791,,Benralizumab,AstraZeneca,"Eosinophilic asthma, ACT and >300 cells/ul eosinophil count criteria (widening access)",Options Compared,Benralizumab,/apptracker/s/application-public/a102P00000BNz5p,Oncology Agents and Immunosuppressants
a0R2P000000WpwIUAS,Benralizumab,A-00791,,Benralizumab,AstraZeneca,Severe eosinophilic asthma - (eosinophilia 500 cells/ul),Decision,Benralizumab,/apptracker/s/application-public/a102P000008puEH,Oncology Agents and Immunosuppressants
a0R2P000000anIcUAI,Bevacizumab,A-00885,Avastin,Bevacizumab,Roche,Metastatic colorectal cancer - first and second-line treatment,Decision,Bevacizumab (Avastin),/apptracker/s/application-public/a102P000008ptpk,Oncology Agents and Immunosuppressants
a0ROZ00000Daa3t2AB,Bevacizumab,A-00422,,Bevacizumab,Consumer,"Glioblastoma multiforme, relapsed or recurrent",Options Compared,Bevacizumab,/apptracker/s/application-public/a102P000008ptvh,Oncology Agents and Immunosuppressants
a0ROZ00000AxLU52AN,Bevacizumab,A-00209,Avastin,Bevacizumab,Roche,Second-line treatment of high-risk advanced ovarian cancer,Seeking Clinical Advice,Bevacizumab (Avastin),/apptracker/s/application-public/a102P00000BTk6R,Oncology Agents and Immunosuppressants
a0ROZ000008xxlp2AA,Bevacizumab,A-00942,Avastin,Bevacizumab,Roche,"Metastatic colorectal cancer , neoadjuvant treatment for metastatic disease confined to the liver",Seeking Clinical Advice,Bevacizumab (Avastin),/apptracker/s/application-public/a102P000008ptpo,Oncology Agents and Immunosuppressants
a0ROZ0000078hbd2AA,Bevacizumab,A-00209,Avastin,Bevacizumab,Roche,"Ovarian cancer, advanced, 1st line",Decision,Bevacizumab (Avastin),/apptracker/s/application-public/a102P000008pufP,Oncology Agents and Immunosuppressants
a0ROZ000008LYrH2AW,Bevacizumab with lomustine,A-00591,,Bevacizumab with lomustine,Consumer,"High-grade glioma, relapsed or recurrent",Seeking Clinical Advice,Bevacizumab with lomustine,/apptracker/s/application-public/a102P000008puCg,Oncology Agents and Immunosuppressants
a0R2P000000LmlMUAS,Bicalutamide,A-00263,Bicalox,Bicalutamide,Douglas Pharmaceuticals Ltd,Advanced Prostate Cancer,Decision,Bicalutamide (Bicalox),/apptracker/s/application-public/a102P000008pukX,Oncology Agents and Immunosuppressants
a0ROZ000004CMlf2AG,Biosimilar Etanercept,A-00747,,Biosimilar Etanercept,Celltrion Healthcare New Zealand Limited,Multiple Indications,Decision,Biosimilar Etanercept,/apptracker/s/application-public/a102P000008pugG,Oncology Agents and Immunosuppressants
a0R2P000000LmkwUAC,Biosimilar Etanercept,A-00688,,Biosimilar Etanercept,Merck Sharp & Dohme,Multiple Indications,Options Compared,Biosimilar Etanercept,/apptracker/s/application-public/a102P000008pues,Oncology Agents and Immunosuppressants
a0R2P000000Lma6UAC,Bortezomib,A-01257,Velcade,Bortezomib,Janssen,Relapsed refractory multiple myeloma - second line,Decision,Bortezomib (Velcade),/apptracker/s/application-public/a102P000008puYJ,Oncology Agents and Immunosuppressants
a0ROZ0000006giv2AA,Bortezomib,A-01313,,Bortezomib,Janssen,Multiple myeloma - widened access,Decision,Bortezomib,/apptracker/s/application-public/a102P000008ptsA,Oncology Agents and Immunosuppressants
a0ROZ00000E5tlN2AR,Brentuximab vedotin,A-04512,ADCETRIS®,Brentuximab vedotin,TAKEDA NEW ZEALAND LIMITED,Previously untreated systemic anaplastic large-cell lymphoma (sALCL),Under Consultation,Brentuximab vedotin (ADCETRIS®),/apptracker/s/application-public/a10OZ0000000hzR,Oncology Agents and Immunosuppressants
a0ROZ00000BQEvR2AX,Bruton tyrosine kinase inhibitor (BTKi),A-00686,,Bruton tyrosine kinase inhibitor (BTKi),Janssen,"Chronic lymphocytic leukaemia (CLL), first-line, without TP53 mutation",Options Compared,Bruton tyrosine kinase inhibitor (BTKi),/apptracker/s/application-public/a10OZ000000LuNN,Oncology Agents and Immunosuppressants
a0ROZ00000B4IG92AN,Bruton tyrosine kinase inhibitor (BTKi),A-04642 A-00686 A-03526,,Bruton tyrosine kinase inhibitor (BTKi),"BeOne Medicines NZ Unlimited, Janssen, ASTRAZENECA LIMITED","Chronic lymphocytic leukaemia (CLL), first-line, with TP53 mutation",Options Compared,Bruton tyrosine kinase inhibitor (BTKi),/apptracker/s/application-public/a10OZ000000LuVR,Oncology Agents and Immunosuppressants
a0R2P000000LmWnUAK,Capecitabine,A-01201,Xeloda,Capecitabine,Roche,Locally advanced or metastatic breast cancer after failure of two prior chemotherapeutic regimes,Decision,Capecitabine (Xeloda),/apptracker/s/application-public/a102P000008ptwx,Oncology Agents and Immunosuppressants
a0ROZ000009TgUv2AK,Carfilzomib,A-00722,,Carfilzomib,Amgen,"Multiple myeloma, relapsed or refractory, 2nd line",Under Assessment,Carfilzomib,/apptracker/s/application-public/a102P00000BIsC8,Oncology Agents and Immunosuppressants
a0ROZ000009qeiX2AQ,Carfilzomib,A-00722,,Carfilzomib,Amgen,Relapsed or refractory multiple myeloma,Under Assessment,Carfilzomib,/apptracker/s/application-public/a102P000008pug4,Oncology Agents and Immunosuppressants
a0R2P000000aoyfUAA,Carfilzomib,A-00722,,Carfilzomib,Amgen,(once-weekly) for the third-line treatment of relapsed or refractory multiple myeloma,Under Assessment,Carfilzomib,/apptracker/s/application-public/a102P00000BIsCD,Oncology Agents and Immunosuppressants
a0ROZ000009J4kH2AS,Certolizumab pegol,A-01149,Cimzia,Certolizumab pegol,UCB Pharma,Rheumatoid athritis,Decision,Certolizumab pegol (Cimzia),/apptracker/s/application-public/a102P000008puDN,Oncology Agents and Immunosuppressants
a0R2P000000anQbUAI,Cetuximab,A-00308 A-00309,Erbitux,Cetuximab,"Merck Serono, Roche","Colorectal cancer, K-RAS wild-type metastatic, metastases limited to liver, with irinotecan",Decision,Cetuximab (Erbitux),/apptracker/s/application-public/a102P000008ptuD,Oncology Agents and Immunosuppressants
a0R2P000000TElmUAG,Cetuximab,A-01331,Erbitux,Cetuximab,Merck Serono,"Squamous cell carcinomas of the head and neck, locally advanced",Decision,Cetuximab (Erbitux),/apptracker/s/application-public/a102P000008pu0J,Oncology Agents and Immunosuppressants
a0ROZ000005fxnd2AA,Cetuximab,A-00693,Erbitux,Cetuximab,Merck Serono,"Colorectal cancer, metastatic, RAS wild-type, left-sided, 1st line",Decision,Cetuximab (Erbitux),/apptracker/s/application-public/a102P000008puV2,Oncology Agents and Immunosuppressants
a0R2P000000anSYUAY,Cetuximab,A-01330,,Cetuximab,Merck Serono,"Colorectal cancer, K-RAS wild-type metastatic, first-line neoadjuvant, metastases limited to liver",Decision,Cetuximab,/apptracker/s/application-public/a102P000008ptyE,Oncology Agents and Immunosuppressants
a0ROZ00000BGaUE2A1,Crisantaspase (Erwinia L-asparaginase),A-01412,,Crisantaspase (Erwinia L-asparaginase),Subcommittee recommendation,"Acute lymphoblastic leukemia, allergic to L-asparaginase",Options Compared,Crisantaspase (Erwinia L-asparaginase),/apptracker/s/application-public/a102P000008puKX,Oncology Agents and Immunosuppressants
a0R2P000000anQWUAY,Crizotinib,A-00406,Xalkori,Crizotinib,Pfizer,"Non-small cell lung cancer, advanced, anaplastic lymphoma kinase-positive",Decision,Crizotinib (Xalkori),/apptracker/s/application-public/a102P000008pttk,Oncology Agents and Immunosuppressants
a0ROZ000002BrKu2AK,"Daratumumab (in combination with bortezomib, cyclophosphamide and dexamethasone)",A-03768 A-04539 A-04540 A-04931,Darzalex® SC (AL-A),"Daratumumab (in combination with bortezomib, cyclophosphamide and dexamethasone)","JANSSEN NZ LIMITED, JANSSEN NZ LIMITED, Consumer","AL amyloidosis, 1L",Options Compared,"Daratumumab (in combination with bortezomib, cyclophosphamide and dexamethasone) (Darzalex® SC (AL-A))",/apptracker/s/application-public/a102P00000BD1Sr,Oncology Agents and Immunosuppressants
a0R2P000000hE9TUAU,Daratumumab IV (with bortezomib and dexamethasone),A-00628,,Daratumumab IV (with bortezomib and dexamethasone),Janssen,"Multiple myeloma, relapsed or refractory, 2nd line",Options Compared,Daratumumab IV (with bortezomib and dexamethasone),/apptracker/s/application-public/a102P000008ptxu,Oncology Agents and Immunosuppressants
a0ROZ00000AQknw2AD,Daratumumab subcutaneous,A-03764,Darzalex® SC,Daratumumab subcutaneous,JANSSEN NZ LIMITED,"Multiple myeloma, received one prior line of myeloma therapy (1PL).",Options Compared,Daratumumab subcutaneous (Darzalex® SC),/apptracker/s/application-public/a102P00000BD0yw,Oncology Agents and Immunosuppressants
a0R2P000000LmiCUAS,Dasatinib,A-00225,Sprycel,Dasatinib,Bristol-Myers Squibb,CML - resistant or intolerant to Imatinib,Decision,Dasatinib (Sprycel),/apptracker/s/application-public/a102P000008pucL,Oncology Agents and Immunosuppressants
a0R2P000000Lmo3UAC,Dasatinib,A-00807,Spyracel,Dasatinib,Bristol-Myers Squibb,Bridge to allogeneic transplant - patients with a defined donor,Decision,Dasatinib (Spyracel),/apptracker/s/application-public/a102P000008ptrb,Oncology Agents and Immunosuppressants
a0R2P000000Lmm1UAC,Docetaxel,A-01106,Taxotere,Docetaxel,Aventis,Adjuvant treatment in breast cancer,Decision,Docetaxel (Taxotere),/apptracker/s/application-public/a102P000008pujg,Oncology Agents and Immunosuppressants
a0ROZ00000Cn1x82AB,Dostarlimab,A-04910,Jemperli,Dostarlimab,GLAXOSMITHKLINE NZ LIMITED,"Endometrial cancer, advanced or recurrent, with deficient mismatch repair (dMMR) status, first line",Options Compared,Dostarlimab (Jemperli),/apptracker/s/application-public/a10OZ000000e2xZ,Oncology Agents and Immunosuppressants
a0ROZ00000DaZe52AF,Dostarlimab,A-04910,Jemperli,Dostarlimab,GLAXOSMITHKLINE NZ LIMITED,"Endometrial cancer, treatment of advanced or recurrent, irrespective of dMMR status, first line",Options Compared,Dostarlimab (Jemperli),/apptracker/s/application-public/a10OZ000002WKNR,Oncology Agents and Immunosuppressants
a0ROZ000006GRdV2AW,Durvalumab,A-05156,IMFINZI®,Durvalumab,ASTRAZENECA LIMITED,"small cell lung cancer, limited-stage, not progressed following platinum-based chemoradiation therapy (CRT).",Seeking Clinical Advice,Durvalumab (IMFINZI®),/apptracker/s/application-public/a10OZ0000035Q3N,Oncology Agents and Immunosuppressants
a0R2P000000WvRaUAK,Durvalumab,A-03155,Imfinzi,Durvalumab,ASTRAZENECA LIMITED,"Adult patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy.",Decision,Durvalumab (Imfinzi),/apptracker/s/application-public/a102P000009kZDh,Oncology Agents and Immunosuppressants
a0ROZ00000AiRRn2AN,Durvalumab,A-05218,IMFINZI®,Durvalumab,ASTRAZENECA LIMITED,combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).,Seeking Clinical Advice,Durvalumab (IMFINZI®),/apptracker/s/application-public/a10OZ0000038EnF,Oncology Agents and Immunosuppressants
a0ROZ00000CHhkn2AD,Entrectinib,A-03476,Rozlytrek,Entrectinib,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Non-small cell lung cancer (NSCLC) - adult patients with ROS1-positive, locally advanced or metastatic",Decision,Entrectinib (Rozlytrek),/apptracker/s/application-public/a102P00000ASxy1,Oncology Agents and Immunosuppressants
a0ROZ000004CTjv2AG,Enzalutamide,A-00506,Xtandi,Enzalutamide,Seqirus,"Prostate cancer, metastatic, castration resistant",Decision,Enzalutamide (Xtandi),/apptracker/s/application-public/a102P000008ptvd,Oncology Agents and Immunosuppressants
a0ROZ000000PXiW2AW,Enzalutamide,A-00506,Xtandi,Enzalutamide,Seqirus,"Prostate cancer, metastatic, castration resistant, contraindicated to abiraterone",Options Compared,Enzalutamide (Xtandi),/apptracker/s/application-public/a102P00000BKbSL,Oncology Agents and Immunosuppressants
a0R2P000000LmjaUAC,Erlotinib,A-01208,Tarceva,Erlotinib,Roche,Non-small cell lung cancer (NSCLC) with EGFR-activating mutation - 1st line,Decision,Erlotinib (Tarceva),/apptracker/s/application-public/a102P000008puho,Oncology Agents and Immunosuppressants
a0ROZ00000096Cf2AI,Erlotinib,A-00880,Tarceva,Erlotinib,Roche,Platinum refractory  NSCLC - second line,Decision,Erlotinib (Tarceva),/apptracker/s/application-public/a102P000008puFE,Oncology Agents and Immunosuppressants
a0ROZ0000006KyX2AU,Etanercept,A-00989,Enbrel,Etanercept,Wyeth,Juvenile idiopathic arthritis (JIA),Decision,Etanercept (Enbrel),/apptracker/s/application-public/a102P000008pu4F,Oncology Agents and Immunosuppressants
a0R2P000000LmahUAC,Etanercept,A-00381,Enbrel,Etanercept,Wyeth,Psoriatic arthritis,Decision,Etanercept (Enbrel),/apptracker/s/application-public/a102P000008puZA,Oncology Agents and Immunosuppressants
a0R2P000000LmWCUA0,Etanercept,A-01115,Enbrel,Etanercept,Wyeth,Adult rheumatoid arthritis,Decision,Etanercept (Enbrel),/apptracker/s/application-public/a102P000008ptxh,Oncology Agents and Immunosuppressants
a0ROZ000004DLM62AO,Everolimus,A-00707,,Everolimus,Consumer,"Breast cancer, advanced, hormone receptor positive, HER-2 negative",Seeking Clinical Advice,Everolimus,/apptracker/s/application-public/a102P000008pu1O,Oncology Agents and Immunosuppressants
a0ROZ00000095zl2AA,Exemestane,A-00333,Aromastin,Exemestane,Pfizer,Widening of access for breast cancer,Decision,Exemestane (Aromastin),/apptracker/s/application-public/a102P000008puhq,Oncology Agents and Immunosuppressants
a0ROZ00000BGaUF2A1,Fixed duration venetoclax with obinutuzumab,A-03216,,Fixed duration venetoclax with obinutuzumab,ABBVIE LIMITED,"Chronic lymphocytic leukaemia (CLL),  previously untreated",Options Compared,Fixed duration venetoclax with obinutuzumab,/apptracker/s/application-public/a102P000009sDbV,Oncology Agents and Immunosuppressants
a0ROZ00000AqQQg2AN,Fixed-duration ibrutinib plus venetoclax,A-04574,IMBRUVICA,Fixed-duration ibrutinib plus venetoclax,JANSSEN NZ LIMITED,"Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Leukaemia (SLL), previously untreated, without TP53 mutation",Options Compared,Fixed-duration ibrutinib plus venetoclax (IMBRUVICA),/apptracker/s/application-public/a102P00000BYfHQ,Oncology Agents and Immunosuppressants
a0ROZ00000BQWSY2A5,Fulvestrant,A-00779,Faslodex,Fulvestrant,AstraZeneca,Breast cancer - locally advanced or metastatic breast cancer (1st line treatment),Decision,Fulvestrant (Faslodex),/apptracker/s/application-public/a102P000008puWJ,Oncology Agents and Immunosuppressants
a0ROZ00000BQWHF2A5,Fulvestrant,A-01279,Faslodex,Fulvestrant,AstraZeneca,"Breast cancer, locally advanced or metastatic, second-line or later treatment",Decision,Fulvestrant (Faslodex),/apptracker/s/application-public/a102P000008puMf,Oncology Agents and Immunosuppressants
a0R2P000000anX8UAI,Gefitinib,A-00919,Iressa,Gefitinib,AstraZeneca,"Non-Small Cell Lung Cancer (NSCLC). second-line, locally advanced or metastatic",Decision,Gefitinib (Iressa),/apptracker/s/application-public/a102P000008pu4Y,Oncology Agents and Immunosuppressants
a0ROZ00000081lJ2AQ,Gemcitabine,A-01119,Gemzar,Gemcitabine,Eli Lilly,Advanced bladder cancer,Decision,Gemcitabine (Gemzar),/apptracker/s/application-public/a102P000008pttr,Oncology Agents and Immunosuppressants
a0ROZ0000002drh2AA,"Gemcitabine Hydrochloride, Oxaliplatin",A-01297,,"Gemcitabine Hydrochloride, Oxaliplatin",NPPA,Germ cell cancer of the testis,Decision,"Gemcitabine Hydrochloride, Oxaliplatin",/apptracker/s/application-public/a102P000008ptzV,Oncology Agents and Immunosuppressants
a0R2P000000dM4sUAE,Hexylaminolevulinate hydrochloride,A-00522,,Hexylaminolevulinate hydrochloride,Juno Pharmaceuticals,Diagnostic detection of bladder cancer under blue flourescent light,Seeking Clinical Advice,Hexylaminolevulinate hydrochloride,/apptracker/s/application-public/a102P000008pu6O,Oncology Agents and Immunosuppressants
a0R2P000000euDXUAY,Ibrutinib,A-00686,Imbruvica,Ibrutinib,Janssen,"Waldenström macroglobulinemia, relapsed/refractory",Under Assessment,Ibrutinib (Imbruvica),/apptracker/s/application-public/a102P00000BQ7KI,Oncology Agents and Immunosuppressants
a0ROZ000003Nn6L2AS,Ibrutinib,A-00430 A-04914,Imbruvica,Ibrutinib,"Janssen, JANSSEN NZ LIMITED",Relapsed or refractory mantle cell lymphoma (R/R MCL),Options Compared,Ibrutinib (Imbruvica),/apptracker/s/application-public/a102P000008puXu,Oncology Agents and Immunosuppressants
a0ROZ000009J4sL2AS,Ibrutinib,A-00407,Imbruvica,Ibrutinib,Janssen,"Chronic lymphocytic leukaemia (CLL),  previously untreated patients (17p deletion) and relapsed/refractory patients for whom ibrutinib is a more appropriate option (alternate)",Decision,Ibrutinib (Imbruvica),/apptracker/s/application-public/a102P000008pu4v,Oncology Agents and Immunosuppressants
a0ROZ00000BQHN32AP,Ibrutinib,A-00686,Imbruvica,Ibrutinib,Janssen,"Chronic lymphocytic leukemia (CLL), previously untreated, chemoimmunotherapy is inappropriate (BTKi class recommendation received)",Options Compared,Ibrutinib (Imbruvica),/apptracker/s/application-public/a102P000008pu1K,Oncology Agents and Immunosuppressants
a0R2P000000bPw4UAE,Ibrutinib,A-00407,Imbruvica,Ibrutinib,Janssen,"Chronic lymphocytic leukaemia, who progress during or relapse after venetoclax treatment or are intolerant of venetoclax (subsequent line)",Decision,Ibrutinib (Imbruvica),/apptracker/s/application-public/a102P00000AaVRQ,Oncology Agents and Immunosuppressants
a0ROZ00000AELQD2A5,Inavolisib,A-05426,ITOVEBI®,Inavolisib,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Breast cancer, locally advanced or metastatic, PIK3CA-mutated, HR-positive, HER2-negative, following recurrence on/after adjuvant therapy",Seeking Clinical Advice,Inavolisib (ITOVEBI®),/apptracker/s/application-public/a10OZ0000054jRu,Oncology Agents and Immunosuppressants
a0R2P000000LmclUAC,Infliximab,A-00339,Remicade,Infliximab,Subcommittee recommendation,"Ulcerative colitis in children, defined with PUCAI scores",Decision,Infliximab (Remicade),/apptracker/s/application-public/a102P000008puaA,Oncology Agents and Immunosuppressants
a0R2P000000LmkEUAS,Infliximab,A-01187,Remicade,Infliximab,Schering-Plough,Rheumatoid arthritis - last-line treatment,Decision,Infliximab (Remicade),/apptracker/s/application-public/a102P000008pueF,Oncology Agents and Immunosuppressants
a0ROZ000004CVnL2AW,Ipilimumab,A-01255,Yervoy,Ipilimumab,Bristol-Myers Squibb,Melanoma - previously treated unresectable stage IIIC or IV,Decision,Ipilimumab (Yervoy),/apptracker/s/application-public/a102P000008pu2m,Oncology Agents and Immunosuppressants
a0ROZ0000002dy92AA,Irinotecan,A-01299,,Irinotecan,NPPA,Adenocarcinoma,Decision,Irinotecan,/apptracker/s/application-public/a102P000008pu1Z,Oncology Agents and Immunosuppressants
a0ROZ00000BQWnV2AX,Lanreotide acetate,A-00627,somatuline autogel,Lanreotide acetate,Ipsen,"Gastroenteropancreatic neuroendocrine tumours, non-functional",Options Compared,Lanreotide acetate (somatuline autogel),/apptracker/s/application-public/a102P000008puZP,Oncology Agents and Immunosuppressants
a0R2P000000LmWaUAK,Lapatinib,A-01032,tykerb,Lapatinib,GlaxoSmithKline,Breast cancer - first line metastatic HER2 positive breast cancer,Decision,Lapatinib (tykerb),/apptracker/s/application-public/a102P000008ptzW,Oncology Agents and Immunosuppressants
a0R2P000000THoyUAG,Lenalidomide,A-00904,Revlimid,Lenalidomide,Celgene,"Multiple myeloma - relapsed or refractory, 2nd line",Decision,Lenalidomide (Revlimid),/apptracker/s/application-public/a102P000008ptpU,Oncology Agents and Immunosuppressants
a0R2P000000TEraUAG,Lenalidomide,A-00230,Revlimid,Lenalidomide,Celgene,"Multiple myeloma - relapsed/refractory, 3rd line",Decision,Lenalidomide (Revlimid),/apptracker/s/application-public/a102P000008puSU,Oncology Agents and Immunosuppressants
a0ROZ000003yfcr2AA,Lenalidomide (with dexamethasone +/- bortezomib),A-00499,Revlimid,Lenalidomide (with dexamethasone +/- bortezomib),Celgene,"Multiple myeloma, transplant ineligible, 1st line",Decision,Lenalidomide (with dexamethasone +/- bortezomib) (Revlimid),/apptracker/s/application-public/a102P000008pua9,Oncology Agents and Immunosuppressants
a0ROZ000005gXhR2AU,Lenvatinib and everolimus,A-03359,LENVIMA®,Lenvatinib and everolimus,EISAI NEW ZEALAND LIMITED,"Renal cell carcinoma, metastatic, clear cell, 2nd line",Decision,Lenvatinib and everolimus (LENVIMA®),/apptracker/s/application-public/a102P00000ANEVb,Oncology Agents and Immunosuppressants
a0ROZ000005ga2b2AA,Lenvatinib mesilate,A-03353,LENVIMA®,Lenvatinib mesilate,EISAI NEW ZEALAND LIMITED,"Unresectable hepatocellular carcinoma, 1st line",Decision,Lenvatinib mesilate (LENVIMA®),/apptracker/s/application-public/a102P00000ANEX8,Oncology Agents and Immunosuppressants
a0ROZ000005gZhe2AE,Lenvatinib mesilate,A-03348,LENVIMA®,Lenvatinib mesilate,EISAI NEW ZEALAND LIMITED,"Thyroid cancer, locally advanced or metastatic, differentiated, refractory to radioactive iodine",Decision,Lenvatinib mesilate (LENVIMA®),/apptracker/s/application-public/a102P00000ANEXc,Oncology Agents and Immunosuppressants
a0ROZ00000AqQQc2AN,Mepolizumab,A-03546,Nucala,Mepolizumab,GLAXOSMITHKLINE NZ LIMITED,"Eosinophilic asthma, remove requirement for Asthma Control Test (ACT)",Options Compared,Mepolizumab (Nucala),/apptracker/s/application-public/a102P00000AnQL4,Oncology Agents and Immunosuppressants
a0ROZ000009SCAl2AO,Mepolizumab,A-03546,Nucala,Mepolizumab,GLAXOSMITHKLINE NZ LIMITED,"Eosinophilic asthma, lowering minimum blood eosinophil count to 300 cells per microlitre",Options Compared,Mepolizumab (Nucala),/apptracker/s/application-public/a102P00000AYn1O,Oncology Agents and Immunosuppressants
a0ROZ0000007jA52AI,Mercaptopurine oral solution,A-00608,,Mercaptopurine oral solution,Link Pharmaceuticals,acute lymphoblastic leukaemia,Decision,Mercaptopurine oral solution,/apptracker/s/application-public/a102P000008puC7,Oncology Agents and Immunosuppressants
a0ROZ000004CXif2AG,Methyl 5-Aminolevulinate Hydrochloride,A-01105,Metvix,Methyl 5-Aminolevulinate Hydrochloride,Galderma,Actinic keratoses and basal cell carcinoma,Decision,Methyl 5-Aminolevulinate Hydrochloride (Metvix),/apptracker/s/application-public/a102P000008puFM,Oncology Agents and Immunosuppressants
a0ROZ00000C4WGv2AN,Mirvetuximab Soravtansine-gynx,A-05443,ELAHERE®,Mirvetuximab Soravtansine-gynx,ABBVIE LIMITED,"epithelial ovarian, fallopian tube, or primary peritoneal cancer, FRα high, platinum-resistant, 2nd Line",Seeking Clinical Advice,Mirvetuximab Soravtansine-gynx (ELAHERE®),/apptracker/s/application-public/a10OZ000005GcG9,Oncology Agents and Immunosuppressants
a0ROZ000000W68k2AC,Mitotane,A-01235,,Mitotane,NPPA,Adrenocortical carcinoma,Decision,Mitotane,/apptracker/s/application-public/a102P000008ptsc,Oncology Agents and Immunosuppressants
a0R2P000000LmgQUAS,Mycophenolate mofetil,A-01195,Cellcept,Mycophenolate mofetil,Roche,Prophylaxis of kidney allograft rejection,Decision,Mycophenolate mofetil (Cellcept),/apptracker/s/application-public/a102P000008ptoy,Oncology Agents and Immunosuppressants
a0ROZ000003dpYn2AI,Mycophenolate mofetil,A-01110,Cellcept,Mycophenolate mofetil,Roche,removal of 12 month restriction on Special Authority approvals for renal transplant recpients,Decision,Mycophenolate mofetil (Cellcept),/apptracker/s/application-public/a102P000008puO0,Oncology Agents and Immunosuppressants
a0R2P000000LmchUAC,Mycophenolate mofetil,A-01111,Cellcept,Mycophenolate mofetil,Roche,widening of access to include heart transplant recipients,Decision,Mycophenolate mofetil (Cellcept),/apptracker/s/application-public/a102P000008pu7G,Oncology Agents and Immunosuppressants
a0R2P000000TFVYUA4,Nab-paclitaxel,A-00338,Abraxane,Nab-paclitaxel,Specialised Therapeutics Ltd,"Pancreatic cancer, metastatic, first-line",Options Compared,Nab-paclitaxel (Abraxane),/apptracker/s/application-public/a102P000008pu1I,Oncology Agents and Immunosuppressants
a0ROZ000001SS8r2AG,Nab-paclitaxel,A-01009,Abraxane,Nab-paclitaxel,Specialised Therapeutics Ltd,"Metastatic breast cancer , following grade 3+ hypersensitivity reaction on paclitaxel",Options Compared,Nab-paclitaxel (Abraxane),/apptracker/s/application-public/a102P00000BX13e,Oncology Agents and Immunosuppressants
a0ROZ000009J4vZ2AS,Nivolumab,A-00455,,Nivolumab,Bristol-Myers Squibb,"Non-small cell lung cancer, locally advanced or metastatic, 2nd line",Decision,Nivolumab,/apptracker/s/application-public/a102P000008puDw,Oncology Agents and Immunosuppressants
a0R2P000000XgKYUA0,Nivolumab,A-00456,,Nivolumab,Bristol-Myers Squibb,"Melanoma, unresectable or metastatic",Decision,Nivolumab,/apptracker/s/application-public/a102P000008puFZ,Oncology Agents and Immunosuppressants
a0ROZ000009Fcqz2AC,Nivolumab (monotherapy),A-05298,Opdivo®,Nivolumab (monotherapy),BRISTOL-MYERS SQUIBB (NZ) LIMITED,"Oesophageal squamous cell carcinoma, advanced, 2nd line",Seeking Clinical Advice,Nivolumab (monotherapy) (Opdivo®),/apptracker/s/application-public/a10OZ000004a3ec,Oncology Agents and Immunosuppressants
a0ROZ000009SFuz2AG,Nivolumab Ipilimumab,A-05058,Opdivo Yervoy,Nivolumab Ipilimumab,BRISTOL-MYERS SQUIBB (NZ) LIMITED,"Mesothelioma, unresectable, malignant (sarcomatoid or biphasic subtypes)",Under Assessment,Nivolumab Ipilimumab (Opdivo Yervoy),/apptracker/s/application-public/a10OZ000004Qm6j,Oncology Agents and Immunosuppressants
a0ROZ00000DKzXn2AL,Nivolumab Ipilimumab,A-05058,Opdivo Yervoy,Nivolumab Ipilimumab,BRISTOL-MYERS SQUIBB (NZ) LIMITED,"Mesothelioma, unresectable, malignant",Seeking Clinical Advice,Nivolumab Ipilimumab (Opdivo Yervoy),/apptracker/s/application-public/a10OZ000002ERaH,Oncology Agents and Immunosuppressants
a0ROZ000008NyGb2AK,Nivolumab with ipilimumab,A-00481,,Nivolumab with ipilimumab,Bristol-Myers Squibb,"Melanoma, unresectable or metastatic",Under Assessment,Nivolumab with ipilimumab,/apptracker/s/application-public/a102P000008puXS,Oncology Agents and Immunosuppressants
a0ROZ000004CYd82AG,Obinutuzumab,A-00658,,Obinutuzumab,Roche,"Follicular lymphoma, 1st line",Decision,Obinutuzumab,/apptracker/s/application-public/a102P000008puZn,Oncology Agents and Immunosuppressants
a0R2P000000XgIwUAK,Obinutuzumab,A-00343,,Obinutuzumab,Roche,Chronic lymphocytic leukaemia,Decision,Obinutuzumab,/apptracker/s/application-public/a102P000008ptyu,Oncology Agents and Immunosuppressants
a0R2P000000SCZfUAO,Octreotide LAR (somatostatin analogue),A-00292,,Octreotide LAR (somatostatin analogue),Subcommittee recommendation,Acromegaly pre-operatively in preparation for pituitary surgery,Decision,Octreotide LAR (somatostatin analogue),/apptracker/s/application-public/a102P000008ptsF,Oncology Agents and Immunosuppressants
a0R2P000000WvQXUA0,Olaparib,A-03156,LYNPARZA®,Olaparib,ASTRAZENECA LIMITED,"Ovarian, fallopian tube or primary peritoneal cancer, newly diagnosed, BRCA-mutated, platinum sensitive - maintenance",Decision,Olaparib (LYNPARZA®),/apptracker/s/application-public/a102P00000AHK3i,Oncology Agents and Immunosuppressants
a0ROZ0000006gvp2AA,Olaparib,A-00548,Lynparza,Olaparib,AstraZeneca,"Ovarian cancer, relapsed, BRCA-mutated, platinum sensitive",Decision,Olaparib (Lynparza),/apptracker/s/application-public/a102P000008pufS,Oncology Agents and Immunosuppressants
a0ROZ00000BQLti2AH,Osimertinib,A-00617,,Osimertinib,AstraZeneca,"Non-small cell lung cancer, locally advanced or metatastic, EGFR T790M positive, 2nd line",Decision,Osimertinib,/apptracker/s/application-public/a102P000008ptxm,Oncology Agents and Immunosuppressants
a0ROZ00000BQQJv2AP,Palbociclib,A-00654,Ibrance,Palbociclib,Pfizer,"Breast cancer, locally advanced/metastatic, HER2negative, HRpositive, first-line endocrine treatment",Decision,Palbociclib (Ibrance),/apptracker/s/application-public/a102P000008puQd,Oncology Agents and Immunosuppressants
a0ROZ00000BQWxB2AX,Palbociclib,A-00748,Ibrance,Palbociclib,Consumer,"Breast cancer, locally advanced/metastatic, HER2negative, HRpositive, second-line endocrine treatment",Decision,Palbociclib (Ibrance),/apptracker/s/application-public/a102P000008puev,Oncology Agents and Immunosuppressants
a0R2P000000LmoQUAS,Pazopanib,A-01055,Votrient),Pazopanib,GlaxoSmithKline,"Renal cell carcinoma, advanced or metastatic - first-line or intolerant to sunitinib",Decision,Pazopanib (Votrient)),/apptracker/s/application-public/a102P000008pu18,Oncology Agents and Immunosuppressants
a0ROZ000009A8qT2AS,Pegylated liposomal doxorubicin,A-01285,Caelyx,Pegylated liposomal doxorubicin,Schering-Plough,Advanced epithelial ovarian cancer (3rd-line treatment) - platinum resistant,Options Compared,Pegylated liposomal doxorubicin (Caelyx),/apptracker/s/application-public/a102P000008ptxY,Oncology Agents and Immunosuppressants
a0R2P000000fjXYUAY,Pembrolizumab,A-00547,Keytruda,Pembrolizumab,Merck Sharp & Dohme,"Non small cell lung cancer, PDL1-positive, 1st line, monotherapy",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008pu56,Oncology Agents and Immunosuppressants
a0R2P000000UTlNUAW,Pembrolizumab,A-00401,Keytruda,Pembrolizumab,Merck Sharp & Dohme,Metastatic melanoma,Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008puLx,Oncology Agents and Immunosuppressants
a0R2P000000OizCUAS,Pembrolizumab,A-00556,Keytruda,Pembrolizumab,Merck Sharp & Dohme,"Metastatic melanoma, amendment to access criteria",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008puUm,Oncology Agents and Immunosuppressants
a0R2P000000anYHUAY,Pembrolizumab,A-00647,Keytruda,Pembrolizumab,Merck Sharp & Dohme,"Urothelial carcinoma, locally advanced/metastatic, first-line, not eligible for cisplatin",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008puFJ,Oncology Agents and Immunosuppressants
a0ROZ000000Bhkn2AC,Pembrolizumab,A-03350 A-03473,Keytruda,Pembrolizumab,Consumer,Unresectable or metastatic cancers with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) that have progressed after receiving previous treatment,Seeking Clinical Advice,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P00000ANEXw,Oncology Agents and Immunosuppressants
a0ROZ000001QcXJ2A0,Pembrolizumab,A-04138,KEYTRUDA - for first-line esophageal cancer,Pembrolizumab,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,"Esophagus or gastroesophageal junction cancer, PD-L1 CPS≥10, locally advanced unresectable or metastatic, 1st line",Seeking Clinical Advice,Pembrolizumab (KEYTRUDA - for first-line esophageal cancer),/apptracker/s/application-public/a102P00000BNzRH,Oncology Agents and Immunosuppressants
a0ROZ000003Krcj2AC,Pembrolizumab,A-04435,Keytruda,Pembrolizumab,Consumer,"Pancreatic adenocarcinoma, metastatic MMR deficient, Stage 4",Seeking Clinical Advice,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P00000BW4LK,Oncology Agents and Immunosuppressants
a0ROZ00000BQXjZ2AX,Pembrolizumab,A-00615,,Pembrolizumab,Merck Sharp & Dohme,"Hodgkin's lymphoma, relapsed or refractory, post-auto transplantation",Decision,Pembrolizumab,/apptracker/s/application-public/a102P00000BLKJv,Oncology Agents and Immunosuppressants
a0ROZ000004obuv2AA,Pembrolizumab,A-00616 A-04436,Keytruda,Pembrolizumab,"Merck Sharp & Dohme, Consumer","Urothelial carcinoma, locally advanced or metastatic, 2nd line",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008pu1w,Oncology Agents and Immunosuppressants
a0ROZ00000BQXej2AH,Pembrolizumab,A-00615,,Pembrolizumab,Merck Sharp & Dohme,"Hodgkin's lymphoma, relapsed or refractory, ASCT ineligible patients",Decision,Pembrolizumab,/apptracker/s/application-public/a102P00000BLKJl,Oncology Agents and Immunosuppressants
a0ROZ000006xFvd2AE,Pembrolizumab,A-03548,KEYTRUDA,Pembrolizumab,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,"Unresectable or metastatic colorectal cancer, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), 1st line",Decision,Pembrolizumab (KEYTRUDA),/apptracker/s/application-public/a102P00000B08gX,Oncology Agents and Immunosuppressants
a0ROZ000006xGEz2AM,Pembrolizumab,A-03548,KEYTRUDA - MSI-H CRC,Pembrolizumab,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,"Unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (second line)",Decision,Pembrolizumab (KEYTRUDA - MSI-H CRC),/apptracker/s/application-public/a10OZ000002AWK1,Oncology Agents and Immunosuppressants
a0ROZ000008fdK92AI,Pembrolizumab,A-00757,Keytruda,Pembrolizumab,Merck Sharp & Dohme,"Melanoma, Resected Stage III, Adjuvant treatment",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008ptx2,Oncology Agents and Immunosuppressants
a0ROZ000008gK7N2AU,Pembrolizumab,A-04617 A-05087,Keytruda,Pembrolizumab,"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Consumer",Biliary tract cancer,Options Compared,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P00000BajR0,Oncology Agents and Immunosuppressants
a0ROZ000009J4yn2AC,Pembrolizumab,A-00504,Keytruda,Pembrolizumab,Merck Sharp & Dohme,"Non small cell lung cancer, locally advanced or metastatic, PD-L1 positive, 2nd line",Decision,Pembrolizumab (Keytruda),/apptracker/s/application-public/a102P000008puZ2,Oncology Agents and Immunosuppressants
a0ROZ00000AcPPR2A3,pembrolizumab,A-05258,Keytruda,pembrolizumab,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,advanced or recurrent endometrial cancer,Seeking Clinical Advice,pembrolizumab (Keytruda),/apptracker/s/application-public/a10OZ000005FVmz,Oncology Agents and Immunosuppressants
a0ROZ00000BP6C22AL,Pembrolizumab (subcutaneous),A-05483,KEYTRUDA SC,Pembrolizumab (subcutaneous),MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,All funded IV indications.,Seeking Clinical Advice,Pembrolizumab (subcutaneous) (KEYTRUDA SC),/apptracker/s/application-public/a10OZ000005TUe9,Oncology Agents and Immunosuppressants
a0ROZ000009A8qm2AC,Pembrolizumab Lenvatinib,A-04771 A-04983,Keytruda Lenvima,Pembrolizumab Lenvatinib,"MERCK SHARP & DOHME (NEW ZEALAND) LIMITED, Consumer","advanced clear cell renal cell carcinoma, first line",Options Compared,Pembrolizumab Lenvatinib (Keytruda Lenvima),/apptracker/s/application-public/a10OZ000000Ac41,Oncology Agents and Immunosuppressants
a0R2P000000LmegUAC,Pemetrexed Disodium,A-01107,Ailimta,Pemetrexed Disodium,Eli Lilly,"Malignant pleural mesothelioma, first line",Decision,Pemetrexed Disodium (Ailimta),/apptracker/s/application-public/a102P000008pttH,Oncology Agents and Immunosuppressants
a0R2P000000THmxUAG,Pertuzumab,A-00208,Perjeta,Pertuzumab,Roche,"Breast cancer; HER2 positive, metastatic, treatment naive",Decision,Pertuzumab (Perjeta),/apptracker/s/application-public/a102P000008ptrl,Oncology Agents and Immunosuppressants
a0ROZ00000BQLLp2AP,Pertuzumab (IV form),A-00623 A-05368,,Pertuzumab (IV form),"Roche, Consumer","Breast cancer, HER2-positive, locally advanced, inflammatory or early-stage, neoadjuvant treatment",Options Compared,Pertuzumab (IV form),/apptracker/s/application-public/a102P000008ptqk,Oncology Agents and Immunosuppressants
a0ROZ000003NweH2AS,"Pertuzumab and trastuzumab (SC, as PHESGO)",A-04334,PHESGO,"Pertuzumab and trastuzumab (SC, as PHESGO)",ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Breast cancer, HER2-positive, locally advanced, inflammatory or early-stage, neoadjuvant treatment",Options Compared,"Pertuzumab and trastuzumab (SC, as PHESGO) (PHESGO)",/apptracker/s/application-public/a102P00000BSgcX,Oncology Agents and Immunosuppressants
a0ROZ00000CHhhZ2AT,"Pertuzumab and trastuzumab (SC, as PHESGO)",A-04334,PHESGO,"Pertuzumab and trastuzumab (SC, as PHESGO)",ROCHE PRODUCTS (NEW ZEALAND) LIMITED,HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with docetaxel,Decision,"Pertuzumab and trastuzumab (SC, as PHESGO) (PHESGO)",/apptracker/s/application-public/a102P00000BZPBk,Oncology Agents and Immunosuppressants
a0ROZ000004F3Uj2AK,Pomalidomide,A-00423,,Pomalidomide,Celgene,"Multiple myeloma, relapsed or refractory (4th line)",Decision,Pomalidomide,/apptracker/s/application-public/a102P000008puU1,Oncology Agents and Immunosuppressants
a0ROZ000004EtDj2AK,Pomalidomide,A-00423,,Pomalidomide,Celgene,"multiple myeloma, relapsed or refractory, 3rd line with bortezomib and dexamethasone",Decision,Pomalidomide,/apptracker/s/application-public/a102P00000BIsCX,Oncology Agents and Immunosuppressants
a0ROZ000004F3L32AK,Pomalidomide,A-00423,,Pomalidomide,Celgene,"multiple myeloma, relapsed or refractory, 3rd line with dexamethasone",Decision,Pomalidomide,/apptracker/s/application-public/a102P00000BIsCh,Oncology Agents and Immunosuppressants
a0ROZ000000B2Hp2AK,Ripretinib,A-04080,QINLOCK®,Ripretinib,SPECIALISED THERAPEUTICS LIMITED,For people with advanced metastatic or unresectable GIST who have experienced disease progression following treatment with imatinib and sunitinib,Options Compared,Ripretinib (QINLOCK®),/apptracker/s/application-public/a102P00000BNzPa,Oncology Agents and Immunosuppressants
a0R2P000000LmbsUAC,Siltuximab,A-00474,,Siltuximab,Janssen,HHV-8 negative Multicentric Castleman's disease,Decision,Siltuximab,/apptracker/s/application-public/a102P000008pu6o,Oncology Agents and Immunosuppressants
a0ROZ000000962z2AA,Sirolimus,A-01300,Rapamune,Sirolimus,Wyeth,Prophylaxis of renal transplant rejection,Decision,Sirolimus (Rapamune),/apptracker/s/application-public/a102P000008pudW,Oncology Agents and Immunosuppressants
a0ROZ000004CLZV2A4,Sorafenib,A-00905,Nexavar,Sorafenib,Bayer,"Hepatocellular carcinoma, advanced",Decision,Sorafenib (Nexavar),/apptracker/s/application-public/a102P000008pu69,Oncology Agents and Immunosuppressants
a0ROZ000004CXlt2AG,Sorafenib,A-00568,Nexavar,Sorafenib,Bayer,Renal Cell Carcinoma,Decision,Sorafenib (Nexavar),/apptracker/s/application-public/a102P000008puFg,Oncology Agents and Immunosuppressants
a0R2P000000anYQUAY,Sunitinib,A-00342,,Sunitinib,Pfizer,Pancreatic neuroendocrine tumour,Decision,Sunitinib,/apptracker/s/application-public/a102P000008pu6B,Oncology Agents and Immunosuppressants
a0R2P000000LmUUUA0,Sunitinib Malate,A-01328,Sutent,Sunitinib Malate,Pfizer,Metastatic Gastrointestinal Stromal Tumour (GIST) after failure of imatinib,Decision,Sunitinib Malate (Sutent),/apptracker/s/application-public/a102P000008puQc,Oncology Agents and Immunosuppressants
a0R2P000000LmeVUAS,Sunitinib Malate,A-01339,Sutent,Sunitinib Malate,Pfizer,Metastatic Renal Cell Carcinoma - poor and intermediate prognosis,Decision,Sunitinib Malate (Sutent),/apptracker/s/application-public/a102P000008ptt6,Oncology Agents and Immunosuppressants
a0ROZ0000007Xs52AE,Tacrolimus,A-01324,Tacrolimus Sandoz,Tacrolimus,Subcommittee recommendation,"Non-transplant patients requiring immunosuppression, after ciclosporin",Decision,Tacrolimus (Tacrolimus Sandoz),/apptracker/s/application-public/a102P000008puWh,Oncology Agents and Immunosuppressants
a0ROZ00000081i52AA,Temozolomide,A-01092,Temodal,Temozolomide,Schering-Plough,glioblastoma multiforme,Decision,Temozolomide (Temodal),/apptracker/s/application-public/a102P000008puZR,Oncology Agents and Immunosuppressants
a0R2P000000TFbWUAW,Temozolomide,A-00363,Temaccord,Temozolomide,Subcommittee recommendation,Neuroendocrine tumours,Decision,Temozolomide (Temaccord),/apptracker/s/application-public/a102P000008puG6,Oncology Agents and Immunosuppressants
a0R2P000000LmoVUAS,Thalidomide,A-00908,Thalidomide Pharmion,Thalidomide,Celgene,"Multiple myeloma, stem cell transplant eligible",Decision,Thalidomide (Thalidomide Pharmion),/apptracker/s/application-public/a102P000008ptrn,Oncology Agents and Immunosuppressants
a0R2P000000LmcGUAS,Thalidomide,A-00922,Thalidomide Pharmion,Thalidomide,Celgene,"First line Multiple myeloma, Stem cell transplant ineligible",Decision,Thalidomide (Thalidomide Pharmion),/apptracker/s/application-public/a102P000008pu7x,Oncology Agents and Immunosuppressants
a0ROZ00000C4Wbt2AF,Tislelizumab,A-05477,TEVIMBRA,Tislelizumab,BeOne Medicines NZ Unlimited,"Gastric/gastro-oesophageal junction adenocarcinoma, advanced or metastatic, HER2-negative, PD-L1 expression ≥5%, 1st line",Seeking Clinical Advice,Tislelizumab (TEVIMBRA),/apptracker/s/application-public/a10OZ000005Mosv,Oncology Agents and Immunosuppressants
a0ROZ0000003ph72AA,Tocilizumab,A-04466,Actemra,Tocilizumab,Consumer,polymyalgia rheumatica,Seeking Clinical Advice,Tocilizumab (Actemra),/apptracker/s/application-public/a102P00000BXHJR,Oncology Agents and Immunosuppressants
a0ROZ0000013VRh2AM,Tocilizumab SC,A-04619,Actemra,Tocilizumab SC,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,giant cell arteritis (GCA) in adult patients.,Seeking Clinical Advice,Tocilizumab SC (Actemra),/apptracker/s/application-public/a102P00000BZUx7,Oncology Agents and Immunosuppressants
a0R2P000000Lmm7UAC,Trastuzumab,A-01228,Herceptin,Trastuzumab,Roche,early HER-2 positive breast cancer - 12 month regimen,Decision,Trastuzumab (Herceptin),/apptracker/s/application-public/a102P000008pujz,Oncology Agents and Immunosuppressants
a0ROZ0000006L092AE,Trastuzumab,A-01031,,Trastuzumab,Roche,"Gastric cancer, locally advanced or metastatic, HER2 positive",Decision,Trastuzumab,/apptracker/s/application-public/a102P000008ptrO,Oncology Agents and Immunosuppressants
a0ROZ0000001Knt2AE,Trastuzumab Biosimilar,A-00788,,Trastuzumab Biosimilar,Celltrion Healthcare New Zealand Limited,Multiple Indications,Decision,Trastuzumab Biosimilar,/apptracker/s/application-public/a102P000008ptrL,Oncology Agents and Immunosuppressants
a0ROZ00000BGaUN2A1,Trastuzumab deruxtecan,A-04789,Enhertu,Trastuzumab deruxtecan,ASTRAZENECA LIMITED,"breast cancer, unresectable or metastatic, HER2 low (IHC 1+ or IHC 2+ or ISH negative)",Options Compared,Trastuzumab deruxtecan (Enhertu),/apptracker/s/application-public/a10OZ000001A07q,Oncology Agents and Immunosuppressants
a0R2P000000YUgzUAG,Trastuzumab emtansine,A-03159,Kadcyla,Trastuzumab emtansine,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Adjuvant treatment of patients with HER2- positive early breast cancer who have residual disease after pre-operative systemic treatment that included HER2-targeted therapy. ,Decision,Trastuzumab emtansine (Kadcyla),/apptracker/s/application-public/a102P000009rn2n,Oncology Agents and Immunosuppressants
a0ROZ00000BQVg92AH,Trastuzumab emtansine,A-00600,,Trastuzumab emtansine,Roche,HER2+ metastatic breast cancer after prior trastuzumab and a taxane,Decision,Trastuzumab emtansine,/apptracker/s/application-public/a102P000008ptzl,Oncology Agents and Immunosuppressants
a0R2P000000Lmf1UAC,"Trastuzumab, subcutaneous",A-00328,Herceptin,"Trastuzumab, subcutaneous",Roche,"Breast cancer, same indication as IV trastuzumab",Options Compared,"Trastuzumab, subcutaneous (Herceptin)",/apptracker/s/application-public/a102P000008ptpR,Oncology Agents and Immunosuppressants
a0R2P000000ezAiUAI,Upadacitinib,A-00789,,Upadacitinib,AbbVie,"Rheumatoid arthritis, moderate to severe,1st line biologic",Under Assessment,Upadacitinib,/apptracker/s/application-public/a102P000008puia,Oncology Agents and Immunosuppressants
a0ROZ000006BuYD2A0,Upadacitinib,A-04146,RINVOQ®,Upadacitinib,ABBVIE LIMITED,"Psoriatic arthritis, 2nd line biologic",Options Compared,Upadacitinib (RINVOQ®),/apptracker/s/application-public/a102P00000BNnhH,Oncology Agents and Immunosuppressants
a0ROZ000000IGcb2AG,Upadacitinib,A-04146,RINVOQ®,Upadacitinib,ABBVIE LIMITED,"Psoriatic arthritis (PsA), 3rd line biologic",Options Compared,Upadacitinib (RINVOQ®),/apptracker/s/application-public/a102P00000BR3Xe,Oncology Agents and Immunosuppressants
a0ROZ000000D2f72AC,Upadacitinib,A-04255,RINVOQ®,Upadacitinib,ABBVIE LIMITED,"Ankylosing spondylitis, 2nd line biologic",Under Assessment,Upadacitinib (RINVOQ®),/apptracker/s/application-public/a102P00000BQ2Gk,Oncology Agents and Immunosuppressants
a0ROZ0000003pij2AA,Upadacitinib,A-04255,RINVOQ®,Upadacitinib,ABBVIE LIMITED,"Ankylosing spondylitis, 3rd line biologic",Under Assessment,Upadacitinib (RINVOQ®),/apptracker/s/application-public/a102P00000BR3Xk,Oncology Agents and Immunosuppressants
a0R2P000000ezEuUAI,Upadacitinib,A-00789,,Upadacitinib,AbbVie,"Rheumatoid arthritis, moderate to severe , 2nd line biologic",Under Assessment,Upadacitinib,/apptracker/s/application-public/a102P00000BX0wJ,Oncology Agents and Immunosuppressants
a0R2P000000g5BSUAY,Ustekinumab,A-00565,Stelara,Ustekinumab,Janssen,"Crohn's disease, severe, 2nd line after infliximab and/or adalimumab",Decision,Ustekinumab (Stelara),/apptracker/s/application-public/a102P000008pu4N,Oncology Agents and Immunosuppressants
a0ROZ00000BV7q52AD,Vemurafenib,A-01150,Zelboraf,Vemurafenib,Roche,"Melanoma, Stage IIIC/IV with BRAF V600 mutation",Reviewing Consultation Feedback,Vemurafenib (Zelboraf),/apptracker/s/application-public/a102P000008puJX,Oncology Agents and Immunosuppressants
a0ROZ000009A8qY2AS,Vemurafenib and cobimetinib,A-00562,,Vemurafenib and cobimetinib,Roche,"Melanoma, stage III/IV with BRAF V600 mutation",Options Compared,Vemurafenib and cobimetinib,/apptracker/s/application-public/a102P000008pu9e,Oncology Agents and Immunosuppressants
a0ROZ00000BQRxX2AX,Venetoclax (monotherapy),A-00619,,Venetoclax (monotherapy),AbbVie,adults relapsed or refractory CLL with 17p deletion,Decision,Venetoclax (monotherapy),/apptracker/s/application-public/a102P000008pty4,Oncology Agents and Immunosuppressants
a0ROZ00000BQU2X2AX,Venetoclax (monotherapy),A-00620,,Venetoclax (monotherapy),AbbVie,previously untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,Decision,Venetoclax (monotherapy),/apptracker/s/application-public/a102P000008pttF,Oncology Agents and Immunosuppressants
a0R2P000000cQdXUAU,Vinorelbine (oral),A-00787,Oral Navelbine,Vinorelbine (oral),Pierre Fabre,Non-small cell lung cancer,Decision,Vinorelbine (oral) (Oral Navelbine),/apptracker/s/application-public/a102P000008puCe,Oncology Agents and Immunosuppressants
a0R2P000000anJGUAY,Vismodegib,A-00376,ERIVEDGE,Vismodegib,Roche,Basal cell carcinoma in patients with Gorlin syndrome,Decision,Vismodegib (ERIVEDGE),/apptracker/s/application-public/a102P000008ptrd,Oncology Agents and Immunosuppressants
a0R2P000000QP0rUAG,Vismodegib,A-00624,,Vismodegib,Roche,"Basal cell carcinoma, locally advanced or metatastic",Options Compared,Vismodegib,/apptracker/s/application-public/a102P000008puDo,Oncology Agents and Immunosuppressants
a0ROZ000009qedh2AA,Zanubrutinib,A-04641,BRUKINSA (for R/R WM),Zanubrutinib,BEIGENE NZ UNLIMITED,"Waldenström macroglobulinaemia, relapsed or refractory",Under Assessment,Zanubrutinib (BRUKINSA (for R/R WM)),/apptracker/s/application-public/a102P00000BaLcj,Oncology Agents and Immunosuppressants
a0ROZ000003Notv2AC,Zanubrutinib,A-04639,BRUKINSA (for R/R MCL),Zanubrutinib,BEIGENE NZ UNLIMITED,Relapsed or refractory mantle cell lymphoma (R/R MCL),Options Compared,Zanubrutinib (BRUKINSA (for R/R MCL)),/apptracker/s/application-public/a102P00000BaaQE,Oncology Agents and Immunosuppressants
a0ROZ000007hqPD2AY,Zanubrutinib,A-04644,BRUKINSA,Zanubrutinib,BEIGENE NZ UNLIMITED,"CLL or SLL , relapsed or refractory, second line",Options Compared,Zanubrutinib (BRUKINSA),/apptracker/s/application-public/a102P00000Babqi,Oncology Agents and Immunosuppressants
a0ROZ000009qcoq2AA,Zanubrutinib,A-04640,BRUKINSA (for 1L WM),Zanubrutinib,BEIGENE NZ UNLIMITED,Waldenström macroglobulinaemia 1L  treatment for patients unsuitable or unable to receive chemoimmunotherapy,Under Assessment,Zanubrutinib (BRUKINSA (for 1L WM)),/apptracker/s/application-public/a102P00000BaZ6c,Oncology Agents and Immunosuppressants
a0ROZ000003RVKY2A4,Apixaban,A-01399,Eliquis,Apixaban,Pfizer,End stage renal disease (ESRD) or intolerable side effects from dabigatran and rivaroxaban,Under Assessment,Apixaban (Eliquis),/apptracker/s/application-public/a10OZ0000000XAT,Blood and Blood Forming Organs
a0R2P000000LmTxUAK,Dabigatran,A-00863,Pradaxa,Dabigatran,Boehringer Ingelheim,Prevention of venous thromboembolism following orthopaedic surgery,Decision,Dabigatran (Pradaxa),/apptracker/s/application-public/a102P000008puN0,Blood and Blood Forming Organs
a0R2P000000N6iSUAS,Dabigatran,A-00978,Pradaxa,Dabigatran,Boehringer Ingelheim,Prevention of stroke and systemic embolism in atrial fibrillation,Decision,Dabigatran (Pradaxa),/apptracker/s/application-public/a102P000008puip,Blood and Blood Forming Organs
a0R2P000000LmW4UAK,Idarucizumab,A-00408,,Idarucizumab,Boehringer Ingelheim,Antidote for dabigatran,Decision,Idarucizumab,/apptracker/s/application-public/a102P000008ptxg,Blood and Blood Forming Organs
a0R2P000000TgRJUA0,Apixaban,A-01399,Eliquis,Apixaban,Pfizer,Stroke prevention in atrial fibrillation,Options Compared,Apixaban (Eliquis),/apptracker/s/application-public/a102P000008puNw,Blood and Blood Forming Organs
a0R2P000000THnHUAW,Apixaban,A-01400,Eliquis,Apixaban,Pfizer,Prevention of venous thromboembolic events following major orthopaedic surgery,Decision,Apixaban (Eliquis),/apptracker/s/application-public/a102P000008pu9t,Blood and Blood Forming Organs
a0ROZ000000969R2AQ,Atorvastatin and ezetimibe,A-00981,"Ezetrol,Lorstat",Atorvastatin and ezetimibe,Merck Sharp & Dohme,"Hyperlipidemia (widen access, combination therapy)",Decision,"Atorvastatin and ezetimibe (Ezetrol,Lorstat)",/apptracker/s/application-public/a102P000008pu1Y,Blood and Blood Forming Organs
a0R2P000000LmpXUAS,Darbepoetin alfa,A-01192,Aranesp,Darbepoetin alfa,Amgen,Anaemia associated with chronic renal failure,Decision,Darbepoetin alfa (Aranesp),/apptracker/s/application-public/a102P000008puCV,Blood and Blood Forming Organs
a0R2P000000LmgfUAC,Deferiprone,A-00893 A-00894,Ferriprox,Deferiprone,"Orphan, Healthcare Logistics",Patients with transfusional iron overload secondary to congenital anaemia and contraindicated to DFO,Decision,Deferiprone (Ferriprox),/apptracker/s/application-public/a102P000008ptut,Blood and Blood Forming Organs
a0R2P000000LmlyUAC,Deferiprone,A-00743 A-00744,Ferriprox,Deferiprone,"Orphan, Healthcare Logistics","Transfusional iron overload secondary to congenital anaemia, intolerant to desferrioxamine",Decision,Deferiprone (Ferriprox),/apptracker/s/application-public/a102P000008puiY,Blood and Blood Forming Organs
a0ROZ00000AiKA92AN,Diflunisal,A-03276 A-03377,,Diflunisal,Consumer,ATTRwt induced cardiomyopathy,Options Compared,Diflunisal,/apptracker/s/application-public/a102P00000ABk8y,Blood and Blood Forming Organs
a0R2P000000LmjpUAC,Dipyridamole,A-00815,Persantin,Dipyridamole,Boehringer Ingelheim,Aspirin intolerant patients,Decision,Dipyridamole (Persantin),/apptracker/s/application-public/a102P000008pudX,Blood and Blood Forming Organs
a0R2P000000MTcaUAG,Dipyridamole 200mg,A-00150,,Dipyridamole 200mg,Boehringer Ingelheim,Stroke prophylaxis,Decision,Dipyridamole 200mg,/apptracker/s/application-public/a102P000008puhV,Blood and Blood Forming Organs
a0R2P000000MTcuUAG,Dipyridamole 200mg + aspirin,A-00161,Asasantin,Dipyridamole 200mg + aspirin,Boehringer Ingelheim,Stroke prophylaxis,Decision,Dipyridamole 200mg + aspirin (Asasantin),/apptracker/s/application-public/a102P000008puUh,Blood and Blood Forming Organs
a0R2P000000LmghUAC,Dipyridamole widening of access,A-00814,Persantin,Dipyridamole widening of access,Boehringer Ingelheim,Removal of Special Authority criteria,Decision,Dipyridamole widening of access (Persantin),/apptracker/s/application-public/a102P000008ptuv,Blood and Blood Forming Organs
a0R2P000000SXvQUAW,Eculizumab,A-01151,Soliris,Eculizumab,Alexion,Paroxysmal nocturnal haemoglobinuria (PNH),Decision,Eculizumab (Soliris),/apptracker/s/application-public/a102P000008puVZ,Blood and Blood Forming Organs
a0R2P000000NMhrUAG,Eltrombopag Olamine,A-01152,Revolade,Eltrombopag Olamine,GlaxoSmithKline,Idiopathic thrombocytopenic purpura (ITP),Decision,Eltrombopag Olamine (Revolade),/apptracker/s/application-public/a102P000008pu3U,Blood and Blood Forming Organs
a0R2P000000XXLCUA4,Emicizumab,A-00689,Hemlibra,Emicizumab,Roche,Patients with haemophilia A (congenital factor VIII deficiency) with factor VIII  inhibitors,Decision,Emicizumab (Hemlibra),/apptracker/s/application-public/a102P000008pucK,Blood and Blood Forming Organs
a0R2P000000Wkk9UAC,Erythropoietin,A-00953,,Erythropoietin,Consumer,Anaemia in cancer patients,Decision,Erythropoietin,/apptracker/s/application-public/a102P000008pu06,Blood and Blood Forming Organs
a0R2P000000LmnCUAS,Gemfibrozil,A-00194,,Gemfibrozil,Subcommittee recommendation,Open listing (including hypercholestorolemia patients intolerant of statins),Decision,Gemfibrozil,/apptracker/s/application-public/a102P000008ptrQ,Blood and Blood Forming Organs
a0R2P000000gVVOUA2,"Long acting heamophilia treatments - Efmoroctocog alfa, Eftrenonacog alfa",A-00493,"Alprolix,Eloctate","Long acting heamophilia treatments - Efmoroctocog alfa, Eftrenonacog alfa",Biogen,Haemophilia A and Haemophilia B,Decision,"Long acting heamophilia treatments - Efmoroctocog alfa, Eftrenonacog alfa (Alprolix,Eloctate)",/apptracker/s/application-public/a102P000008puEo,Blood and Blood Forming Organs
a0R2P000000MTczUAG,Niacin + laropiprant (extended release),A-00862,Tredaptive,Niacin + laropiprant (extended release),Merck Sharp & Dohme,Hypercholesterolaemia and mixed dyslipidaemia,Decision,Niacin + laropiprant (extended release) (Tredaptive),/apptracker/s/application-public/a102P000008pu77,Blood and Blood Forming Organs
a0R2P000000anOzUAI,Prasugrel,A-01043,Effient,Prasugrel,Eli Lilly,Percutaneous coronary intervention (PCI) for patients with reduced function of CYP2C19 enzyme,Decision,Prasugrel (Effient),/apptracker/s/application-public/a102P000008ptt8,Blood and Blood Forming Organs
a0R2P000000LmZ9UAK,Prasugrel,A-01039,Effient,Prasugrel,Eli Lilly,Stent thrombosis - prevention of recurrence in PCI patients who are on clopidogrel,Decision,Prasugrel (Effient),/apptracker/s/application-public/a102P000008puX4,Blood and Blood Forming Organs
a0R2P000000LmXbUAK,Prasugrel,A-01040,Effient,Prasugrel,Eli Lilly,Percutaneous coronary intervention (PCI) - use for patients with a clopidogrel allergy,Decision,Prasugrel (Effient),/apptracker/s/application-public/a102P000008pu0L,Blood and Blood Forming Organs
a0ROZ000004COSV2A4,Prasugrel,A-00941,Effient,Prasugrel,Eli Lilly,Percutaneous coronary intervention - immediate PCI for STEMI patients,Decision,Prasugrel (Effient),/apptracker/s/application-public/a102P000008pu6p,Blood and Blood Forming Organs
a0R2P000000MTd4UAG,Prasugrel,A-01041,Effient,Prasugrel,Eli Lilly,Percutaneous coronary intervention (PCI) - use in procedure for patients with diabetes,Decision,Prasugrel (Effient),/apptracker/s/application-public/a102P000008pubt,Blood and Blood Forming Organs
a0R2P000000LmffUAC,Propranolol oral liquid,A-01282,,Propranolol oral liquid,NPPA,Patients unable to take propranolol tablets,Decision,Propranolol oral liquid,/apptracker/s/application-public/a102P000008pu4R,Blood and Blood Forming Organs
a0R2P000000LmpsUAC,Recombinant Pegylated Factor VIII - rurioctocog alfa pegol,A-00597,,Recombinant Pegylated Factor VIII - rurioctocog alfa pegol,Shire,Haemophilia A,Decision,Recombinant Pegylated Factor VIII - rurioctocog alfa pegol,/apptracker/s/application-public/a102P000008puBt,Blood and Blood Forming Organs
a0R2P000000TEq3UAG,Rivaroxaban,A-01259,Xarelto,Rivaroxaban,Bayer,Stroke prevention in atrial fibrillation,Decision,Rivaroxaban (Xarelto),/apptracker/s/application-public/a102P000008puBv,Blood and Blood Forming Organs
a0R2P000000TEn4UAG,Rivaroxaban,A-01260,Xarelto,Rivaroxaban,Bayer,Venous thromboembolism (VTE): treatment and prevention,Decision,Rivaroxaban (Xarelto),/apptracker/s/application-public/a102P000008pu3O,Blood and Blood Forming Organs
a0R2P000000LmgeUAC,Rivaroxaban,A-00921,Xarelto,Rivaroxaban,Bayer,Prevention of venous thromboembolism following orthopaedic surgery,Decision,Rivaroxaban (Xarelto),/apptracker/s/application-public/a102P000008ptql,Blood and Blood Forming Organs
a0R2P000000LmacUAC,Rosuvastatin,A-01122,Crestor,Rosuvastatin,AstraZeneca,Hypercholesterolemia and Hyperlipidemia,Decision,Rosuvastatin (Crestor),/apptracker/s/application-public/a102P000008puSv,Blood and Blood Forming Organs
a0R2P000000Lmk9UAC,Ticagrelor,A-01068,Brilinta,Ticagrelor,AstraZeneca,Acute coronary syndrome,Decision,Ticagrelor (Brilinta),/apptracker/s/application-public/a102P000008pug5,Blood and Blood Forming Organs
a0R2P000000aneiUAA,Ticagrelor,A-00425,Brilinta,Ticagrelor,AstraZeneca,Removal of Special Authority,Decision,Ticagrelor (Brilinta),/apptracker/s/application-public/a102P000008pubg,Blood and Blood Forming Organs
a0R2P000000anZUUAY,Ticagrelor 60 mg,A-00576,,Ticagrelor 60 mg,AstraZeneca,High risk patients commencing 1 -3 years post-ACS event,Decision,Ticagrelor 60 mg,/apptracker/s/application-public/a102P000008puGk,Blood and Blood Forming Organs
a0ROZ000000W2mf2AC,Meloxicam,A-01189,Mobic,Meloxicam,Boehringer Ingelheim,Osteoarthritis and rheumatoid arthritis,Decision,Meloxicam (Mobic),/apptracker/s/application-public/a102P000008puU0,Musculoskeletal System
a0ROZ0000007Xor2AE,Nintedanib,A-00429,,Nintedanib,Boehringer Ingelheim,Idiopathic pulmonary fibrosis,Decision,Nintedanib,/apptracker/s/application-public/a102P000008puay,Respiratory System and Allergies
a0R2P000000andkUAA,Tiotropium bromide,A-00525,,Tiotropium bromide,Boehringer Ingelheim,Severe uncontrolled asthma,Decision,Tiotropium bromide,/apptracker/s/application-public/a102P000008puNx,Respiratory System and Allergies
a0ROZ0000007fJN2AY,Tiotropium bromide,A-00829,Spiriva,Tiotropium bromide,Boehringer Ingelheim,Maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) (2002),Decision,Tiotropium bromide (Spiriva),/apptracker/s/application-public/a102P000008ptsK,Respiratory System and Allergies
a0R2P000000LmZdUAK,Tiotropium bromide,A-01100,Spiriva,Tiotropium bromide,Boehringer Ingelheim,COPD widening of access - include patients whose FEV1 < 60% of predicted,Decision,Tiotropium bromide (Spiriva),/apptracker/s/application-public/a102P000008puZo,Respiratory System and Allergies
a0R2P000000LmogUAC,Tiotropium bromide,A-01053,Spiriva,Tiotropium bromide,Boehringer Ingelheim,COPD widening of access - amending Special Authority,Decision,Tiotropium bromide (Spiriva),/apptracker/s/application-public/a102P000008ptrv,Respiratory System and Allergies
a0R2P000000LmXVUA0,Tiotropium bromide with olodaterol,A-00399,,Tiotropium bromide with olodaterol,Boehringer Ingelheim,Chronic obstructive pulmonary disease,Decision,Tiotropium bromide with olodaterol,/apptracker/s/application-public/a102P000008puW8,Respiratory System and Allergies
a0R2P000000bfyhUAA,Emtricitabine with tenofovir disoproxil - HIV pre-exposure prophylaxis (PrEP),A-00806,,Emtricitabine with tenofovir disoproxil - HIV pre-exposure prophylaxis (PrEP),Consumer,Widening Access Prescriber Type,Decision,Emtricitabine with tenofovir disoproxil - HIV pre-exposure prophylaxis (PrEP),/apptracker/s/application-public/a102P000008puVM,Infections - Agents for Systemic Use
a0R2P000000ZKQrUAO,ine with tenofovir disoproxil - Widening Access (PrEP) - removal of Restrictions,A-00806,,Emtricitabine with tenofovir disoproxil - Widening Access (PrEP) - removal of Restrictions,Consumer,HIV pre-exposure prophylaxis,Decision,Emtricitabine with tenofovir disoproxil - Widening Access (PrEP) - removal of Restrictions,/apptracker/s/application-public/a102P00000BE0nj,Infections - Agents for Systemic Use
a0R2P000000LmU5UAK,PreOp,A-01414,,PreOp,Nutricia,Major abdominal surgery as part of ERAS,Decision,PreOp,/apptracker/s/application-public/a102P000008puN2,Special Foods
a0ROZ00000083Tl2AI,Preoperative carbohydrate feed 0.5 kcal per mL,A-04543,DEX,Preoperative carbohydrate feed 0.5 kcal per mL,Medical Symbiosis Pty Ltd,Dietary management before major elective surgery,Seeking Clinical Advice,Preoperative carbohydrate feed 0.5 kcal per mL (DEX),/apptracker/s/application-public/a10OZ0000001Wyj,
a0ROZ0000014rBd2AI,acropeptide formula with docosahexaenoic acid and low phenylalanine (PKU Sphere),A-03349,PKU Sphere,Glycomacropeptide formula with docosahexaenoic acid and low phenylalanine (PKU Sphere),Vitaflo,Phenylketonuria (PKU).,Decision,Glycomacropeptide formula with docosahexaenoic acid and low phenylalanine (PKU Sphere) (PKU Sphere),/apptracker/s/application-public/a102P00000Adtsc,Special Foods
a0ROZ000004CT0m2AG,Adult enteral feed with fibre and increased protein - Promote,A-01087,Promote,Adult enteral feed with fibre and increased protein - Promote,Abbott,Adult enteral feed with fibre 1Kcal/ml and increased protein,Decision,Adult enteral feed with fibre and increased protein - Promote (Promote),/apptracker/s/application-public/a102P000008puVk,Special Foods
a0R2P000000dfj6UAA,AdVital (special food product),A-00723,,AdVital (special food product),Flavour Creations,"Malnutrition, peri-surgery, tube feeding, and similar",Options Compared,AdVital (special food product),/apptracker/s/application-public/a102P000008puWi,Special Foods
a0ROZ000007hqP72AI,AdVital (special food product),A-00448,,AdVital (special food product),Flavour Creations,Malnutrition with taste fatigue,Options Compared,AdVital (special food product),/apptracker/s/application-public/a102P000008ptpj,Special Foods
a0R2P000000N6ieUAC,Aminio acid Formula without phenylalanine - PKU Anamix Junior LQ,A-01014,PKU Anamix Junior LQ,Aminio acid Formula without phenylalanine - PKU Anamix Junior LQ,Nutricia,Phenylketonuria (PKU),Decision,Aminio acid Formula without phenylalanine - PKU Anamix Junior LQ (PKU Anamix Junior LQ),/apptracker/s/application-public/a102P000008puCd,Special Foods
a0ROZ0000006gZF2AY,Amino Acid Based Formula - Alfamino,A-00589,,Amino Acid Based Formula - Alfamino,Nestle,Multiple food intolerance and protein allergy,Decision,Amino Acid Based Formula - Alfamino,/apptracker/s/application-public/a102P000008puRr,Special Foods
a0R2P000000LmdwUAC,Amino Acid Formula without phenylalanine - PKU Lophlex Sensation 20,A-01458,,Amino Acid Formula without phenylalanine - PKU Lophlex Sensation 20,Nutricia,Dietary management of proven phenylketonuria (protein substitute for PKU),Decision,Amino Acid Formula without phenylalanine - PKU Lophlex Sensation 20,/apptracker/s/application-public/a102P000008pttT,Special Foods
a0ROZ000004CZnk2AG,"Amino Acid plus carbs,vits, mins - PKU Synergy",A-00582,,"Amino Acid plus carbs,vits, mins - PKU Synergy",Nutricia,Phenylketonuria (PKU),Decision,"Amino Acid plus carbs,vits, mins - PKU Synergy",/apptracker/s/application-public/a102P000008puTX,Special Foods
a0ROZ0000006zdV2AQ,Amino Acid plus vitamins and minerals  - PKU Anamix 1st Spoon,A-00586,,Amino Acid plus vitamins and minerals  - PKU Anamix 1st Spoon,Nutricia,Phenylketonuria (PKU),Options Compared,Amino Acid plus vitamins and minerals  - PKU Anamix 1st Spoon,/apptracker/s/application-public/a102P000008ptpT,Special Foods
a0R2P000000Oj2GUAS,Amino Acid Supplement - Neocate Syneo,A-00585,,Amino Acid Supplement - Neocate Syneo,Nutricia,Multiple food intolerance and protein allergy,Decision,Amino Acid Supplement - Neocate Syneo,/apptracker/s/application-public/a102P000008pu0g,Special Foods
a0R2P000000LmoBUAS,Diabetic Oral Supplement 1Kcal/ml - Glucerna,A-01090,Glucerna SR,Diabetic Oral Supplement 1Kcal/ml - Glucerna,Abbott,Diabetic oral supplement 1 Kcal/ml,Decision,Diabetic Oral Supplement 1Kcal/ml - Glucerna (Glucerna SR),/apptracker/s/application-public/a102P000008pu1L,Special Foods
a0R2P000000LmUSUA0,Diasip,A-01143,Diasip,Diasip,Nutricia,Oral supplement/complete diet,Decision,Diasip (Diasip),/apptracker/s/application-public/a102P000008puNV,Special Foods
a0R2P000000LmZDUA0,Diason,A-01146,Diason,Diason,Nutricia,Oral supplement/complete diet for diabetic patients,Decision,Diason (Diason),/apptracker/s/application-public/a102P000008puVg,Special Foods
a0ROZ000009J4fS2AS,Elemental Formula - Alfare,A-00997,Alfare,Elemental Formula - Alfare,Nestle,"Cow's milk protein allergy, food intolerance and hypersensitivity",Decision,Elemental Formula - Alfare (Alfare),/apptracker/s/application-public/a102P000008puNz,Special Foods
a0R2P000000LmdaUAC,Elemental Formulas,A-01086,Elecare,Elemental Formulas,Abbott,Food hypersensitivity - various,Decision,Elemental Formulas (Elecare),/apptracker/s/application-public/a102P000008pu9f,Special Foods
a0R2P000000OciIUAS,Extensively hydrolised Infant Formula (Pepticate),A-00584,,Extensively hydrolised Infant Formula (Pepticate),Nutricia,Protein allergy,Decision,Extensively hydrolised Infant Formula (Pepticate),/apptracker/s/application-public/a102P000008puGl,Special Foods
a0R2P000000LmZWUA0,Forticreme,A-01144,Forticreme,Forticreme,Nutricia,Oral supplement/complete diet,Decision,Forticreme (Forticreme),/apptracker/s/application-public/a102P000008puTW,Special Foods
a0R2P000000aZuxUAE,Fortini and Fortini Multi-fibre,A-01139 A-03652,"Fortini, Fortini Multi-fibre",Fortini and Fortini Multi-fibre,"Nutricia, NUTRICIA LIMITED",Oral Supplement/complete diet,Decision,"Fortini and Fortini Multi-fibre (Fortini, Fortini Multi-fibre)",/apptracker/s/application-public/a102P000008puFF,Special Foods
a0ROZ00000DKzXp2AL,Fortisip PlantBased,A-05114,Fortisip PlantBased,Fortisip PlantBased,NUTRICIA LIMITED,"Oral nutrition support, vegan option",Seeking Clinical Advice,Fortisip PlantBased (Fortisip PlantBased),/apptracker/s/application-public/a10OZ000004o8Eb,Special Foods
a0R2P000000LmjbUAC,Gluten free Gluten,A-01018,Orgran,Gluten free Gluten,Crombie and Price,Coeliac disease,Decision,Gluten free Gluten (Orgran),/apptracker/s/application-public/a102P000008puhp,Special Foods
a0R2P000000N6i0UAC,Gluten Free Multi-seed bread mix - Bakels,A-01019,,Gluten Free Multi-seed bread mix - Bakels,Bakels Ltd,Coeliac disease,Decision,Gluten Free Multi-seed bread mix - Bakels,/apptracker/s/application-public/a102P000008ptxb,Special Foods
a0ROZ0000014qIn2AI,Glycomacropeptide,A-00645,,Glycomacropeptide,CORTEX Health,PKU phenylketonuria,Decision,Glycomacropeptide,/apptracker/s/application-public/a102P000008ptxc,Special Foods
a0ROZ0000006zdq2AA,HCU LOPHLEX POWDER,A-03366,HCU LOPHLEX POWDER,HCU LOPHLEX POWDER,NUTRICIA LIMITED,Homocystinuria,Options Compared,HCU LOPHLEX POWDER (HCU LOPHLEX POWDER),/apptracker/s/application-public/a102P00000ATdn0,Special Foods
a0ROZ000003dpgr2AA,Homocystinuria (HCU) Cooler,A-00871,,Homocystinuria (HCU) Cooler,Vitaflo,Homocystinuria (HCU),Options Compared,Homocystinuria (HCU) Cooler,/apptracker/s/application-public/a102P000008puTM,Special Foods
a0R2P000000d7ftUAA,Hydrolised Whey Protein (Nutrini Peptisorb Energy),A-00583,,Hydrolised Whey Protein (Nutrini Peptisorb Energy),Nutricia,Enteral Feed 1.5 kcal/ml RTH (1-14 yrs) Impaired gastrointestinal tolerance,Decision,Hydrolised Whey Protein (Nutrini Peptisorb Energy),/apptracker/s/application-public/a102P000008puMz,Special Foods
a0R2P000000anZEUAY,Hydrolysed Rice Protein Formula - Risolac,A-00998,Risolac,Hydrolysed Rice Protein Formula - Risolac,Heinz,Cow's milk protein or soy protein allergy,Decision,Hydrolysed Rice Protein Formula - Risolac (Risolac),/apptracker/s/application-public/a102P000008puDl,Special Foods
a0ROZ000004nOob2AE,KetoCal 4:1 LQ,A-03370,KETOCAL 4:1 LQ,KetoCal 4:1 LQ,NUTRICIA LIMITED,"Epilepsy treated with ketogenic diet and other conditions, requiring appropriate nutrition",Options Compared,KetoCal 4:1 LQ (KETOCAL 4:1 LQ),/apptracker/s/application-public/a102P00000ATdft,Special Foods
a0R2P000000N6i5UAC,Ketogenic diet formula - Ketocal,A-01001,Ketocal,Ketogenic diet formula - Ketocal,Nutricia,Epilepsy - chronic intractable epilepsy,Decision,Ketogenic diet formula - Ketocal (Ketocal),/apptracker/s/application-public/a102P000008pu0X,Special Foods
a0R2P000000MywDUAS,Liquid Peptide (nutrini peptisorb),A-00587,,Liquid Peptide (nutrini peptisorb),Nutricia,Enteral Feed 1 kcal/ml RTH (1-6 yrs) Impaired gastrointestinal tolerance,Decision,Liquid Peptide (nutrini peptisorb),/apptracker/s/application-public/a102P000008puDn,Special Foods
a0ROZ0000006L4z2AE,Loprofin,A-01138,Loprofin,Loprofin,Nutricia,Oral supplement,Decision,Loprofin (Loprofin),/apptracker/s/application-public/a102P000008puY4,Special Foods
a0R2P000000OchyUAC,"Lorenzo's Oil - Glycerol Trierucate Oil, Glycerol Trioleate",A-01243,,"Lorenzo's Oil - Glycerol Trierucate Oil, Glycerol Trioleate",NPPA,Adrenoleukodystrophy,Decision,"Lorenzo's Oil - Glycerol Trierucate Oil, Glycerol Trioleate",/apptracker/s/application-public/a102P000008ptuk,Special Foods
a0ROZ000000B2kr2AC,Low Protein Foods,A-00645,,Low Protein Foods,CORTEX Health,PKU phenylketonuria,Options Compared,Low Protein Foods,/apptracker/s/application-public/a102P000009LHTR,Special Foods
a0R2P000000LmZmUAK,Maltodextrin with xanthan gum and potato starch - Altrix - Community Listing,A-00462,,Maltodextrin with xanthan gum and potato starch - Altrix - Community Listing,Douglas Pharmaceuticals Ltd,Dysphagia,Options Compared,Maltodextrin with xanthan gum and potato starch - Altrix - Community Listing,/apptracker/s/application-public/a102P000008puZq,Special Foods
a0R2P000000N6iFUAS,Milk substitute formula - S-26 Gold,A-00939,S-26 Gold Premgro,Milk substitute formula - S-26 Gold,Wyeth,Nutrition in premature infants post discharge,Decision,Milk substitute formula - S-26 Gold (S-26 Gold Premgro),/apptracker/s/application-public/a102P000008pu7F,Special Foods
a0R2P000000LmfdUAC,Minaphlex,A-01142,Minaphlex,Minaphlex,Nutricia,Protein supplement,Decision,Minaphlex (Minaphlex),/apptracker/s/application-public/a102P000008ptpb,Special Foods
a0R2P000000Oci3UAC,Modulen IBD,A-00995,Modulen IBD,Modulen IBD,Nestle,Crohn's Disease,Decision,Modulen IBD (Modulen IBD),/apptracker/s/application-public/a102P000008puZa,Special Foods
a0ROZ0000006zdr2AA,MSUD LOPHLEX POWDER,A-03367,MSUD LOPHLEX POWDER,MSUD LOPHLEX POWDER,NUTRICIA LIMITED,Maple Syrup Urine Disease,Options Compared,MSUD LOPHLEX POWDER (MSUD LOPHLEX POWDER),/apptracker/s/application-public/a102P00000ATdqi,Special Foods
a0R2P000000Wlo2UAC,Oral Feed - Calogen Extra,A-01457,,Oral Feed - Calogen Extra,Nutricia,Oral nutrition support for malnutrition and those at risk of malnutrition,Decision,Oral Feed - Calogen Extra,/apptracker/s/application-public/a102P000008pudY,Special Foods
a0R2P000000ane4UAA,Oral Feed 1.25 kcal/ml - Cubitan,A-01440,Cubitan,Oral Feed 1.25 kcal/ml - Cubitan,Nutricia,Pressure ulcers,Decision,Oral Feed 1.25 kcal/ml - Cubitan (Cubitan),/apptracker/s/application-public/a102P000008puPs,Special Foods
a0ROZ0000001Lf72AE,Oral Feed 1.5Kcal/ml - Fortijuce,A-01024,Fortijuce,Oral Feed 1.5Kcal/ml - Fortijuce,Nutricia,Malnutrition,Options Compared,Oral Feed 1.5Kcal/ml - Fortijuce (Fortijuce),/apptracker/s/application-public/a102P000008ptz9,Special Foods
a0R2P000000OciDUAS,Oral feed 2.4 Kcal/ml - Fortisip Compact,A-01002,Fortisip Compact,Oral feed 2.4 Kcal/ml - Fortisip Compact,Nutricia,Oral nutrition support,Decision,Oral feed 2.4 Kcal/ml - Fortisip Compact (Fortisip Compact),/apptracker/s/application-public/a102P000008pucR,Special Foods
a0ROZ000004Camz2AC,Oral Supplement - Prosure,A-01089,ProSure,Oral Supplement - Prosure,Abbott,Oral supplementation for use in cancer,Decision,Oral Supplement - Prosure (ProSure),/apptracker/s/application-public/a102P000008pubi,Special Foods
a0ROZ000004CaYT2A0,Oral supplement 1 Kcal/ml - Complan,A-00996,Complan,Oral supplement 1 Kcal/ml - Complan,Heinz,Nutrition supplementation,Decision,Oral supplement 1 Kcal/ml - Complan (Complan),/apptracker/s/application-public/a102P000008puXv,Special Foods
a0R2P000000N6iEUAS,Oral supplement 1 Kcal/ml to 2 Kcal/ml - Enprocal,A-00940,Enprocal,Oral supplement 1 Kcal/ml to 2 Kcal/ml - Enprocal,Warrnabrool,Nutrition supplementation,Decision,Oral supplement 1 Kcal/ml to 2 Kcal/ml - Enprocal (Enprocal),/apptracker/s/application-public/a102P000008pubh,Special Foods
a0R2P000000LmVQUA0,Osmolite HN,A-01133,,Osmolite HN,Abbott,Oral supplement,Decision,Osmolite HN,/apptracker/s/application-public/a102P000008ptvu,Special Foods
a0R2P000000OvcVUAS,Paediatric enteral feed 1.5 kcal with fibre RTH  -Nutrini Energy Multi Fibre,A-01016,Nutrini Energy Multi Fibre,Paediatric enteral feed 1.5 kcal with fibre RTH  -Nutrini Energy Multi Fibre,Nutricia,Nutritional supplement,Decision,Paediatric enteral feed 1.5 kcal with fibre RTH  -Nutrini Energy Multi Fibre (Nutrini Energy Multi Fibre),/apptracker/s/application-public/a102P000008ptso,Special Foods
a0R2P000000Ovc6UAC,Paediatric enteral feed 1.5 kcal with fibre RTH  -Nutrini Energy RTH,A-01140,Nutrini Extra,Paediatric enteral feed 1.5 kcal with fibre RTH  -Nutrini Energy RTH,Nutricia,Nutritional supplement,Decision,Paediatric enteral feed 1.5 kcal with fibre RTH  -Nutrini Energy RTH (Nutrini Extra),/apptracker/s/application-public/a102P000008puBd,Special Foods
a0R2P000000LmXAUA0,Paediatric feed -  Pediasure,A-01085,Paediasure,Paediatric feed -  Pediasure,Abbott,"Paediatric enteral feed, enteral feed with fibre, oral feed, oral feed with fibre",Decision,Paediatric feed -  Pediasure (Paediasure),/apptracker/s/application-public/a102P000008ptxx,Special Foods
a0R2P000000N6iPUAS,Paediatric Oral Feed - Neocate Nutra,A-00999,Neocate Nutra,Paediatric Oral Feed - Neocate Nutra,Nutricia,Food allergies,Decision,Paediatric Oral Feed - Neocate Nutra (Neocate Nutra),/apptracker/s/application-public/a102P000008pudQ,Special Foods
a0R2P000000Oci8UAC,Paediatric Oral Feed - NutriniDrink,A-00044,,Paediatric Oral Feed - NutriniDrink,Nutricia,Special food,Decision,Paediatric Oral Feed - NutriniDrink,/apptracker/s/application-public/a102P000008puQE,Special Foods
a0ROZ000001rFbR2AU,Paediatric oral feed 1kcal/ml in 100ml Ready to Feed bottle - Infatrini,A-01015,Infatrini,Paediatric oral feed 1kcal/ml in 100ml Ready to Feed bottle - Infatrini,Nutricia,Nutritional supplement for infants with increased nutritional requirements,Decision,Paediatric oral feed 1kcal/ml in 100ml Ready to Feed bottle - Infatrini (Infatrini),/apptracker/s/application-public/a102P000008puVN,Special Foods
a0ROZ000004Cb372AC,"PKU cooler protein drink (10mg, 15mg, 20mg)",A-00853,,"PKU cooler protein drink (10mg, 15mg, 20mg)",Vitaflo,Phenylketonuria,Decision,"PKU cooler protein drink (10mg, 15mg, 20mg)",/apptracker/s/application-public/a102P000008pueE,Special Foods
a0ROZ000004Cb6L2AS,PKU Gel,A-00870,PKU Gel,PKU Gel,Vitaflo,Phenylketonuria (PKU),Decision,PKU Gel (PKU Gel),/apptracker/s/application-public/a102P000008ptrD,Special Foods
a0ROZ000004CbBB2A0,PKU Supplementation (Add-ins),A-00994,,PKU Supplementation (Add-ins),Nutricia,Phenylketonuria (PKU),Decision,PKU Supplementation (Add-ins),/apptracker/s/application-public/a102P000008pu7t,Special Foods
a0ROZ000003dsEv2AI,Protein drink MSUD,A-00854,,Protein drink MSUD,Vitaflo,Maple Syrup Urine Disease,Options Compared,Protein drink MSUD,/apptracker/s/application-public/a102P000008puac,Special Foods
a0R2P000000anf7UAA,protein enteral feed with fibre 1.28 kcal/ml (Nutrison Protein Plus Multi Fibre),A-00394,,High protein enteral feed with fibre 1.28 kcal/ml (Nutrison Protein Plus Multi Fibre),Nutricia,"Increased protein requirements due to mild and moderate metabolic stress, requiring enteral feed",Decision,High protein enteral feed with fibre 1.28 kcal/ml (Nutrison Protein Plus Multi Fibre),/apptracker/s/application-public/a102P000008pueY,Special Foods
a0ROZ0000007fWH2AY,Renilon 7.5,A-01141,Renilon 7.5,Renilon 7.5,Nutricia,Oral supplement,Decision,Renilon 7.5 (Renilon 7.5),/apptracker/s/application-public/a102P000008puDV,Special Foods
a0R2P000000N6iWUAS,ric enteral feed - 0.75 kcal/ml with fibre RTH  - Nutrini Low Energy Multi Fibre,A-01017,Nutrini Low Energy Multi Fibre,Paediatric enteral feed - 0.75 kcal/ml with fibre RTH  - Nutrini Low Energy Multi Fibre,Nutricia,Nutritional supplement where low energy feed is required,Decision,Paediatric enteral feed - 0.75 kcal/ml with fibre RTH  - Nutrini Low Energy Multi Fibre (Nutrini Low Energy Multi Fibre),/apptracker/s/application-public/a102P000008ptrF,Special Foods
a0ROZ000007543l2AA,Scandishake,A-01084,Scandishake,Scandishake,Nutricia,Complete oral nutrition for cystic fibrosis patients,Decision,Scandishake (Scandishake),/apptracker/s/application-public/a102P000008puRp,Special Foods
a0R2P000000LmrbUAC,"Special Foods, Paediatric Products",A-00284,,"Special Foods, Paediatric Products",Subcommittee recommendation,"Patients who have, or are expected to, eat little or nothing for 3 days",Decision,"Special Foods, Paediatric Products",/apptracker/s/application-public/a102P000008puG8,Special Foods
a0R2P000000akFhUAI,"TYR Cooler, tyrosine and phenylalanine free protein substitute",A-00872,TYR Cooler,"TYR Cooler, tyrosine and phenylalanine free protein substitute",Vitaflo,Tyrosinaemia,Options Compared,"TYR Cooler, tyrosine and phenylalanine free protein substitute (TYR Cooler)",/apptracker/s/application-public/a102P000008ptyt,Special Foods
a0ROZ0000006zdp2AA,TYR LOPHLEX POWDER,A-03360,TYR LOPHLEX POWDER,TYR LOPHLEX POWDER,NUTRICIA LIMITED,For use from 3 years of age and adults for the dietary management of Tyrosinaemia (TYR).,Options Compared,TYR LOPHLEX POWDER (TYR LOPHLEX POWDER),/apptracker/s/application-public/a102P00000ATdkf,Special Foods
a0R2P000000LmaDUAS,"ult enteral feed with fibre (1, 1.2 and 1.5 Kcal/ml) - Jevity Plus, Jevity HiCal",A-01088,"Jevity, Jevity Plus, Jevity HiCal","Adult enteral feed with fibre (1, 1.2 and 1.5 Kcal/ml) - Jevity Plus, Jevity HiCal",Abbott,Adult enteral feed with fibre,Decision,"Adult enteral feed with fibre (1, 1.2 and 1.5 Kcal/ml) - Jevity Plus, Jevity HiCal (Jevity, Jevity Plus, Jevity HiCal)",/apptracker/s/application-public/a102P000008puYL,Special Foods
a0ROZ00000DKzXo2AL,Whey Protein Concentrate (Unflavoured),A-04831,McLeod Nutrition,Whey Protein Concentrate (Unflavoured),MCLEOD NUTRITION LIMITED,"Protein supplement for protein losing enteropathy, high protein needs, or use as a component in a modular formula",Seeking Clinical Advice,Whey Protein Concentrate (Unflavoured) (McLeod Nutrition),/apptracker/s/application-public/a10OZ000002Q3Ir,Special Foods
a0R2P000000OcfJUAS,Carbetocin,A-01308,Duratocin,Carbetocin,Pharmaco (NZ) Ltd,Uterine atony and excessive bleeding following caesarean,Decision,Carbetocin (Duratocin),/apptracker/s/application-public/a102P000008puir,Genito-Urinary System
a0ROZ000007Sgmf2AC,Desogestrel,A-00215 A-04991,Cerazette,Desogestrel,"Pharmaco (NZ) Ltd, Consumer",Contraception,Decision,Desogestrel (Cerazette),/apptracker/s/application-public/a102P000008pukI,Genito-Urinary System
a0R2P000000OcfdUAC,Cefuroxime axetil,A-00269,,Cefuroxime axetil,GlaxoSmithKline,Open listing,Decision,Cefuroxime axetil,/apptracker/s/application-public/a102P000008ptxe,Infections - Agents for Systemic Use
a0ROZ0000008Za52AE,Montelukast,A-00634,Singulair,Montelukast,Subcommittee recommendation,Open listing,Decision,Montelukast (Singulair),/apptracker/s/application-public/a102P000008pueH,Respiratory System and Allergies
a0R2P000000TGPOUA4,"Nitrofurantoin, modified-release capsules",A-00445,,"Nitrofurantoin, modified-release capsules",Subcommittee recommendation,Open listing (anti-infective),Decision,"Nitrofurantoin, modified-release capsules",/apptracker/s/application-public/a102P000008pu2G,Infections - Agents for Systemic Use
a0R2P000000LmVpUAK,Roxithromycin dispersible tablets,A-00358,,Roxithromycin dispersible tablets,Subcommittee recommendation,"Anti-infective, open listing",Decision,Roxithromycin dispersible tablets,/apptracker/s/application-public/a102P000008ptzr,Infections - Agents for Systemic Use
a0ROZ000004CIdG2AW,Adalimumab/etanercept,A-03200,Humira,Adalimumab/etanercept,ABBVIE LIMITED,Rheumatoid arthritis - amendment to SA criteria to include patient-reported outcomes,Decision,Adalimumab/etanercept (Humira),/apptracker/s/application-public/a102P000009lJ0i,Musculoskeletal System
a0ROZ0000006eik2AA,Adalimumab,A-00509,Humirapen,Adalimumab,AbbVie,Moderate to severe hidradenitis suppurativa,Decision,Adalimumab (Humirapen),/apptracker/s/application-public/a102P000008puAZ,Dermatologicals
a0R2P000000Lmh3UAC,Adapalene,A-01062,Differin,Adapalene,Galderma,Acne (first line treatment),Decision,Adapalene (Differin),/apptracker/s/application-public/a102P000008ptpx,Dermatologicals
a0ROZ00000DqVY92AN,Alitretinoin,A-04127,Zematane,Alitretinoin,DOUGLAS PHARMACEUTICALS LIMITED,Severe chronic hand eczema in adults unresponsive to potent topical corticosteroids,Options Compared,Alitretinoin (Zematane),/apptracker/s/application-public/a102P00000BPyuG,Dermatologicals
a0ROZ000004CNZe2AO,Aluminium hydrochloride 35% suspension,A-00262,,Aluminium hydrochloride 35% suspension,Subcommittee recommendation,Compounding ingredient,Decision,Aluminium hydrochloride 35% suspension,/apptracker/s/application-public/a102P000008ptrU,Dermatologicals
a0R2P000000LmeiUAC,Calcipotriol and betamethasone dipropionate,A-00844,Daivobet,Calcipotriol and betamethasone dipropionate,CSL,Psoriasis,Decision,Calcipotriol and betamethasone dipropionate (Daivobet),/apptracker/s/application-public/a102P000008pttJ,Dermatologicals
a0ROZ0000006TCD2A2,Calcipotriol and betamethasone foam spray,A-00618,,Calcipotriol and betamethasone foam spray,Leo Pharmaceuticals,psoriasis,Decision,Calcipotriol and betamethasone foam spray,/apptracker/s/application-public/a102P000008pubW,Dermatologicals
a0R2P000000Lmj6UAC,Capsaicin 0.075%,A-01174,Zostrix HP cream,Capsaicin 0.075%,AFT Pharmaceuticals,Post herpetic neuralgia and relief of diabetic peripheral polyneuropathy,Decision,Capsaicin 0.075% (Zostrix HP cream),/apptracker/s/application-public/a102P000008puF9,Dermatologicals
a0ROZ000009KiSj2AK,Cavilon barrier cream,A-01488,Cavilon,Cavilon barrier cream,3M Pharmaceuticals,Skin integrity,Decision,Cavilon barrier cream (Cavilon),/apptracker/s/application-public/a102P000008puBc,Dermatologicals
a0R2P000000anV7UAI,"Clindamycin phosphate, topical",A-01155,"Dalacin T, Clinac, Topicil","Clindamycin phosphate, topical",Pharmacia,Acne,Decision,"Clindamycin phosphate, topical (Dalacin T, Clinac, Topicil)",/apptracker/s/application-public/a102P000008pu0V,Dermatologicals
a0R2P000000LmZnUAK,"Coal tar 12%, sulphur 4% and salicylic acid 2%",A-01206,Cocois,"Coal tar 12%, sulphur 4% and salicylic acid 2%",AFT Pharmaceuticals,"Scalp psoriasis, eczema and seborrhoeic dermatitis",Decision,"Coal tar 12%, sulphur 4% and salicylic acid 2% (Cocois)",/apptracker/s/application-public/a102P000008puZr,Dermatologicals
a0R2P000000LmetUAC,"Dimethicone cream 4%, gel or lotion",A-00438,,"Dimethicone cream 4%, gel or lotion",Subcommittee recommendation,Dermatology,Decision,"Dimethicone cream 4%, gel or lotion",/apptracker/s/application-public/a102P000008ptvL,Dermatologicals
a0ROZ000000VUrR2AW,Dithranol powder,A-00265,,Dithranol powder,Subcommittee recommendation,Dermatology,Decision,Dithranol powder,/apptracker/s/application-public/a102P000008puUj,Dermatologicals
a0ROZ000000VVU92AO,Doxycycline (low-dose),A-00491,Any,Doxycycline (low-dose),Subcommittee recommendation,Dermatological indications,Decision,Doxycycline (low-dose) (Any),/apptracker/s/application-public/a102P000008ptvs,Dermatologicals
a0R2P000000LmfoUAC,Etanercept,A-01013,Enbrel,Etanercept,Wyeth,Severe chronic plaque psoriasis,Decision,Etanercept (Enbrel),/apptracker/s/application-public/a102P000008pu4S,Dermatologicals
a0ROZ000003doUf2AI,Guselkumab,A-04579,,Guselkumab,"JANSSEN NZ LIMITED, Consumer","Plaque psoriasis, moderate to severe, 2nd line biologic",Options Compared,Guselkumab,/apptracker/s/application-public/a102P00000BaNat,Dermatologicals
a0ROZ000009CkMr2AK,Guselkumab,A-04579 A-05282,TREMFYA,Guselkumab,"JANSSEN NZ LIMITED, Consumer","Plaque psoriasis, moderate to severe, 1st line biologic",Options Compared,Guselkumab (TREMFYA),/apptracker/s/application-public/a102P00000Ba2XE,Dermatologicals
a0ROZ000000VWd72AG,Hydrocortisone ointment 1%,A-00261,,Hydrocortisone ointment 1%,Subcommittee recommendation,Dermatology,Decision,Hydrocortisone ointment 1%,/apptracker/s/application-public/a102P000008puPj,Dermatologicals
a0ROZ00000081er2AA,Hydrogen peroxide cream,A-01132,Crystacide,Hydrogen peroxide cream,AFT Pharmaceuticals,Impetigo,Decision,Hydrogen peroxide cream (Crystacide),/apptracker/s/application-public/a102P000008pu1B,Dermatologicals
a0ROZ000004KhWL2A0,Ichthammol powder,A-00264,Egoderm,Ichthammol powder,Subcommittee recommendation,Dermatology,Seeking Clinical Advice,Ichthammol powder (Egoderm),/apptracker/s/application-public/a102P000008pttA,Dermatologicals
a0R2P000000LmhlUAC,Imiquimod,A-01082,,Imiquimod,3M Pharmaceuticals,Basal cell carcinoma - first line treatment,Decision,Imiquimod,/apptracker/s/application-public/a102P000008puFW,Dermatologicals
a0R2P000000LmofUAC,Imiquimod,A-00322,Aldara,Imiquimod,3M Pharmaceuticals,Basal cell carcinoma (GP surgery contraindicated),Decision,Imiquimod (Aldara),/apptracker/s/application-public/a102P000008ptrp,Dermatologicals
a0R2P000000LmciUAC,Imiquimod,A-01091,Aldara,Imiquimod,3M Pharmaceuticals,Genital warts,Decision,Imiquimod (Aldara),/apptracker/s/application-public/a102P000008pu8b,Dermatologicals
a0R2P000000LmbAUAS,Imiquimod,A-00943,Aldara,Imiquimod,Douglas Pharmaceuticals Ltd,Actinic keratosis,Decision,Imiquimod (Aldara),/apptracker/s/application-public/a102P000008puTL,Dermatologicals
a0R2P000000Ocf4UAC,Ingenol mebutate,A-00277,Picato,Ingenol mebutate,Seqirus,Solar (actinic) keratoses lesions,Decision,Ingenol mebutate (Picato),/apptracker/s/application-public/a102P000008puEc,Dermatologicals
a0ROZ000009J22X2AS,Ixekizumab,A-04726,Taltz,Ixekizumab,Consumer,Inflammatory conditions,Decision,Ixekizumab (Taltz),/apptracker/s/application-public/a10OZ00000017Dx,Dermatologicals
a0ROZ000000VVIr2AO,Lassar's paste,A-00267,,Lassar's paste,Subcommittee recommendation,Dermatology,Decision,Lassar's paste,/apptracker/s/application-public/a102P000008pu4l,Dermatologicals
a0ROZ00000Cn1wy2AB,Leptospermum - Active 100% (16+UMF MGO Manuka Honey),A-04141,MANUKApli,Leptospermum - Active 100% (16+UMF MGO Manuka Honey),MANUKAMED LIMITED PARTNERSHIP,"1st and 2nd degree burns, pressure ulcers, wounds, and diabetic ulcers",Options Compared,Leptospermum - Active 100% (16+UMF MGO Manuka Honey) (MANUKApli),/apptracker/s/application-public/a102P00000BP6tQ,Dermatologicals
a0ROZ000005Bajd2AC,Metronidazole,A-00260,,Metronidazole,Subcommittee recommendation,Fungating wounds,Options Compared,Metronidazole,/apptracker/s/application-public/a102P000008puDF,Dermatologicals
a0ROZ0000006h5V2AQ,"Paraffin, liquid with white soft paraffin",A-01341,Duoleum,"Paraffin, liquid with white soft paraffin",Subcommittee recommendation,Atopic eczema in children,Decision,"Paraffin, liquid with white soft paraffin (Duoleum)",/apptracker/s/application-public/a102P000008puPw,Dermatologicals
a0R2P000000MzHHUA0,Pimecrolimus 1% cream,A-00137 A-00136,Elidel,Pimecrolimus 1% cream,"Mylan New Zealand Ltd, Radiant Health",Atopic dermatitis,Decision,Pimecrolimus 1% cream (Elidel),/apptracker/s/application-public/a102P000008ptsJ,Dermatologicals
a0R2P000000UANdUAO,Risankizumab,A-00713,,Risankizumab,AbbVie,Moderate to severe plaque psoriasis - first line biologic,Options Compared,Risankizumab,/apptracker/s/application-public/a102P000008puXW,Dermatologicals
a0ROZ000004COYw2AO,Sirolimus ointment,A-00415,Sirolimus,Sirolimus ointment,NPPA,Facial angiofibromas secondary to tuberous sclerosis complex,Decision,Sirolimus ointment (Sirolimus),/apptracker/s/application-public/a102P000008ptsg,Dermatologicals
a0R2P000000anaRUAQ,Super Oxidising Solution,A-00439,,Super Oxidising Solution,Te Arai Biofarma,Various dermatological indications,Decision,Super Oxidising Solution,/apptracker/s/application-public/a102P000008puGn,Dermatologicals
a0ROZ000007tfwD2AQ,Tacrolimus ointment 0.1%,A-05220,ZEMATOP,Tacrolimus ointment 0.1%,DOUGLAS PHARMACEUTICALS LIMITED,"Atopic dermatitis, moderate to severe, not adequately responsive/intolerant to conventional therapies (flare treatment and maintenance treatment)",Seeking Clinical Advice,Tacrolimus ointment 0.1% (ZEMATOP),/apptracker/s/application-public/a10OZ000003xSzR,Dermatologicals
a0R2P000000Lmf9UAC,"Topical Retinoids - Adapalene, Tretinoin",A-00983,,"Topical Retinoids - Adapalene, Tretinoin",Valeant,Acne,Decision,"Topical Retinoids - Adapalene, Tretinoin",/apptracker/s/application-public/a102P000008ptpS,Dermatologicals
a0ROZ000008BUEH2A4,Upadacitinib,A-03997,RINVOQ®,Upadacitinib,ABBVIE LIMITED,Treatment of moderate to severe atopic dermatitis,Decision,Upadacitinib (RINVOQ®),/apptracker/s/application-public/a102P00000BLJLJ,Dermatologicals
a0ROZ000009M5Or2AK,Upadacitinib,A-03997,RINVOQ,Upadacitinib,ABBVIE LIMITED,Very severe Atopic Dermatitis,Decision,Upadacitinib (RINVOQ),/apptracker/s/application-public/a10OZ0000004HIP,Dermatologicals
a0ROZ000004KhT72AK,Zinc paste,A-00266,,Zinc paste,Subcommittee recommendation,Dermatological conditions,Seeking Clinical Advice,Zinc paste,/apptracker/s/application-public/a102P000008puCq,Dermatologicals
a0R2P000000LmUOUA0,Icatibant,A-00395,Firazyr,Icatibant,Shire,Hereditary angioedema,Decision,Icatibant (Firazyr),/apptracker/s/application-public/a102P000008puM5,Respiratory System and Allergies
a0R2P000000OchPUAS,Aclidinium Bromide,A-00398,Bretaris Genuair,Aclidinium Bromide,Te Arai Biofarma,Chronic obstructive pulmonary disease,Decision,Aclidinium Bromide (Bretaris Genuair),/apptracker/s/application-public/a102P000008ptzp,Respiratory System and Allergies
a0R2P000000anZsUAI,Allergen Pollen Extract Of 5 Grasses,A-00451,Oralair,Allergen Pollen Extract Of 5 Grasses,Stallergenes,Allergic rhinitis,Decision,Allergen Pollen Extract Of 5 Grasses (Oralair),/apptracker/s/application-public/a102P000008puEZ,Respiratory System and Allergies
a0ROZ000009SHC12AO,Benralizumab,A-05157,FASENRA PEN,Benralizumab,ASTRAZENECA LIMITED,"Eosinophilic granulomatosis with polyangiitis (EGPA) - widening access, 1st line",Under Assessment,Benralizumab (FASENRA PEN),/apptracker/s/application-public/a10OZ000002wYeT,Respiratory System and Allergies
a0ROZ000009SH7B2AW,Benralizumab,A-05157,FASENRA PEN,Benralizumab,ASTRAZENECA LIMITED,"Eosinophilic granulomatosis with polyangiitis (EGPA) - widening access, 2nd line",Under Assessment,Benralizumab (FASENRA PEN),/apptracker/s/application-public/a10OZ000004QmwL,Respiratory System and Allergies
a0R2P000000MTkHUAW,Bovine lipid extract surfactant,A-01289,BLES,Bovine lipid extract surfactant,Rex Medical,Pulmonary distress,Decision,Bovine lipid extract surfactant (BLES),/apptracker/s/application-public/a102P000008ptyY,Respiratory System and Allergies
a0ROZ000000827t2AA,Budesonide with eformoterol,A-01202,Symbicort,Budesonide with eformoterol,AstraZeneca,Regular treatment of asthma where use of a combination is appropriate (second line),Decision,Budesonide with eformoterol (Symbicort),/apptracker/s/application-public/a102P000008ptvg,Respiratory System and Allergies
a0R2P000000LmZcUAK,Budesonide with eformoterol,A-01117,Symbicort,Budesonide with eformoterol,AstraZeneca,Widening of access for asthma,Decision,Budesonide with eformoterol (Symbicort),/apptracker/s/application-public/a102P000008puTm,Respiratory System and Allergies
a0R2P000000Lma5UAC,Budesonide with eformoterol,A-00937,Symbicort,Budesonide with eformoterol,AstraZeneca,Removal of Special Authority (asthma - maintenance and reliever),Decision,Budesonide with eformoterol (Symbicort),/apptracker/s/application-public/a102P000008puQA,Respiratory System and Allergies
a0R2P000000LmbSUAS,Budesonide with eformoterol,A-01116,Symbicort,Budesonide with eformoterol,AstraZeneca,Chronic obstructive pulmonary disease (COPD),Decision,Budesonide with eformoterol (Symbicort),/apptracker/s/application-public/a102P000008puTP,Respiratory System and Allergies
a0ROZ000006JP5h2AG,"Budesonide, Glycopyrronium and Formoterol (eformoterol)",A-04600,"Breztri Aerosphere Aerosol inhaler, metered dose","Budesonide, Glycopyrronium and Formoterol (eformoterol)",ASTRAZENECA LIMITED,Moderate to very severe COPD in adults,Decision,"Budesonide, Glycopyrronium and Formoterol (eformoterol) (Breztri Aerosphere Aerosol inhaler, metered dose)",/apptracker/s/application-public/a102P00000BaW9P,Respiratory System and Allergies
a0ROZ00000DSZpl2AH,Dupilumab,A-04060,DUPIXENT,Dupilumab,Consumer,"Chronic rhinosinusitis with nasal polyposis (CRSwNP), maintenance treatment of uncontrolled disease",Options Compared,Dupilumab (DUPIXENT),/apptracker/s/application-public/a102P00000BMh6q,Respiratory System and Allergies
a0ROZ00000E6SRN2A3,Elexacaftor/tezacaftor/ivacaftor and ivacaftor,A-04929,Trikafta,Elexacaftor/tezacaftor/ivacaftor and ivacaftor,Vertex Pharmaceuticals (Australia) Pty Ltd,"Cystic fibrosis, aged 2-5 years, with F508del mutation(s) in the CFTR gene, G551D mutation or other mutation responsive in vitro to Trikafta",Reviewing Consultation Feedback,Elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta),/apptracker/s/application-public/a10OZ000000hRHt,Respiratory System and Allergies
a0R2P000000cSE5UAM,Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA),A-03998,Trikafta®,Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA),Vertex Pharmaceuticals,"Cystic fibrosis, aged 12 years and older, with F508del mutation(s) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene",Decision,Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA) (Trikafta®),/apptracker/s/application-public/a102P00000BP7zG,Respiratory System and Allergies
a0R2P000000cSDHUA2,Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA),A-03998,Trikafta®,Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA),Vertex Pharmaceuticals,"Cystic fibrosis, aged 6 years and older, with F508del mutation(s) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene",Decision,Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA) (Trikafta®),/apptracker/s/application-public/a102P00000BJo9L,Respiratory System and Allergies
a0ROZ000002Z6m92AC,Fluticasone furoate with umeclidinium bromide and vilanterol trifenatate,A-00715,,Fluticasone furoate with umeclidinium bromide and vilanterol trifenatate,GlaxoSmithKline,COPD,Decision,Fluticasone furoate with umeclidinium bromide and vilanterol trifenatate,/apptracker/s/application-public/a102P000008ptsE,Respiratory System and Allergies
a0R2P000000LmaxUAC,"Fluticasone furoate with vilanterol, 100/25 mcg",A-00304,Breo Ellipta,"Fluticasone furoate with vilanterol, 100/25 mcg",GlaxoSmithKline,Asthma and chronic obstructive pulmonary disease,Decision,"Fluticasone furoate with vilanterol, 100/25 mcg (Breo Ellipta)",/apptracker/s/application-public/a102P000008puZE,Respiratory System and Allergies
a0R2P000000N6i4UAC,Fluticasone with Salmeterol,A-01027,Seretide,Fluticasone with Salmeterol,GlaxoSmithKline,Asthma - removal of the three month trial period,Decision,Fluticasone with Salmeterol (Seretide),/apptracker/s/application-public/a102P000008puXV,Respiratory System and Allergies
a0ROZ000009J5Bh2AK,"Fluticasone with salmeterol, high dose",A-00355,"Seretide,Seretide Accuhaler","Fluticasone with salmeterol, high dose",GlaxoSmithKline,Asthma and chronic obstructive pulmonary disease,Decision,"Fluticasone with salmeterol, high dose (Seretide,Seretide Accuhaler)",/apptracker/s/application-public/a102P000008ptpV,Respiratory System and Allergies
a0ROZ00000DqVY62AN,"Fluticasone with Vilanterol, 200/25, high dose, severe asthma",A-00346 A-03547,Breo Ellipta,"Fluticasone with Vilanterol, 200/25, high dose, severe asthma","GlaxoSmithKline, GLAXOSMITHKLINE NZ LIMITED",Asthma,Options Compared,"Fluticasone with Vilanterol, 200/25, high dose, severe asthma (Breo Ellipta)",/apptracker/s/application-public/a102P000008pu6h,Respiratory System and Allergies
a0ROZ00000Degqf2AB,Ivacaftor,A-04063,Kalydeco,Ivacaftor,Consumer,"Cystic fibrosis, mutations responsive to ivacaftor",Reviewing Consultation Feedback,Ivacaftor (Kalydeco),/apptracker/s/application-public/a102P00000BMh7U,Respiratory System and Allergies
a0R2P000000SogwUAC,Ivacaftor,A-00224,Kalydeco,Ivacaftor,Vertex,"Cystic fibrosis, G551D mutation",Decision,Ivacaftor (Kalydeco),/apptracker/s/application-public/a102P000008pu76,Respiratory System and Allergies
a0ROZ00000Cn1x62AB,Lanadelumab,A-04721,TAKHZYRO®,Lanadelumab,TAKEDA NEW ZEALAND LIMITED,Routine prevention of recurrent attacks of hereditary angioedema,Options Compared,Lanadelumab (TAKHZYRO®),/apptracker/s/application-public/a10OZ000000MfFp,Respiratory System and Allergies
a0ROZ00000DL1uT2AT,Mepolizumab,A-05540,Nucala,Mepolizumab,GLAXOSMITHKLINE NZ LIMITED,Inadequately controlled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype,Seeking Clinical Advice,Mepolizumab (Nucala),/apptracker/s/application-public/a10OZ000007O5H3,Respiratory System and Allergies
a0ROZ0000006L3P2AU,Mepolizumab,A-00553,,Mepolizumab,GlaxoSmithKline,Severe refractory eosinophilic asthma,Decision,Mepolizumab,/apptracker/s/application-public/a102P000008puUH,Respiratory System and Allergies
a0ROZ000006zguw2AA,Mepolizumab,A-05052,NUCALA,Mepolizumab,GLAXOSMITHKLINE NZ LIMITED,"Chronic rhinosinusitis with nasal polyps (CRSwNP), after one nasal polyp surgery",Under Assessment,Mepolizumab (NUCALA),/apptracker/s/application-public/a10OZ000001Mo8r,Respiratory System and Allergies
a0R2P000000N6hyUAC,Montelukast,A-00891,Singulair,Montelukast,Merck Sharp & Dohme,Asthma - exercise induced (EIA),Decision,Montelukast (Singulair),/apptracker/s/application-public/a102P000008puPt,Respiratory System and Allergies
a0R2P000000LmhsUAC,Montelukast,A-00244,Singulair,Montelukast,Subcommittee recommendation,Amending access around inhaler use and asthma desensitisation,Decision,Montelukast (Singulair),/apptracker/s/application-public/a102P000008puEU,Respiratory System and Allergies
a0ROZ0000008Zbh2AE,Montelukast,A-00884,Singulair,Montelukast,Merck Sharp & Dohme,Asthma - ICS intolerant,Decision,Montelukast (Singulair),/apptracker/s/application-public/a102P000008ptst,Respiratory System and Allergies
a0R2P000000N6ifUAC,Montelukast Sodium,A-00990,Singulair,Montelukast Sodium,Merck Sharp & Dohme,Asthma - preschool wheeze,Decision,Montelukast Sodium (Singulair),/apptracker/s/application-public/a102P000008puDH,Respiratory System and Allergies
a0ROZ0000007XiP2AU,Omalizumab,A-00366,Xolair,Omalizumab,Subcommittee recommendation,Minor widening of access and SA amendments,Decision,Omalizumab (Xolair),/apptracker/s/application-public/a102P000008puGf,Respiratory System and Allergies
a0R2P000000TgQzUAK,Pirfenidone,A-00678,,Pirfenidone,Subcommittee recommendation,Widening access - multiple changes,Decision,Pirfenidone,/apptracker/s/application-public/a102P000008puG5,Respiratory System and Allergies
a0ROZ0000052ORk2AM,SYMBICORT® RAPIHALER® 100/3; metered aerosol inhaler,A-03508,SYMBICORT® RAPIHALER® 100/3; metered aerosol inhaler,SYMBICORT® RAPIHALER® 100/3; metered aerosol inhaler,ASTRAZENECA LIMITED,Asthma,Options Compared,SYMBICORT® RAPIHALER® 100/3; metered aerosol inhaler (SYMBICORT® RAPIHALER® 100/3; metered aerosol inhaler),/apptracker/s/application-public/a102P00000AYn0Z,Respiratory System and Allergies
a0ROZ000008X3qX2AS,Tezepelumab,A-05025,Tezspire,Tezepelumab,ASTRAZENECA LIMITED,Severe asthma irrespective of phenotype,Under Assessment,Tezepelumab (Tezspire),/apptracker/s/application-public/a10OZ000002EOcP,Respiratory System and Allergies
a0R2P000000LmokUAC,Umeclidinium,A-00397,,Umeclidinium,GlaxoSmithKline,Chronic obstructive pulmonary disease,Decision,Umeclidinium,/apptracker/s/application-public/a102P000008pu35,Respiratory System and Allergies
a0R2P000000LmUxUAK,Umeclidinium with vilanterol,A-00303,Anoro Ellipta,Umeclidinium with vilanterol,GlaxoSmithKline,Chronic obstructive pulmonary disease,Decision,Umeclidinium with vilanterol (Anoro Ellipta),/apptracker/s/application-public/a102P000008ptx9,Respiratory System and Allergies
a0ROZ00000DbPPl2AN,Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek),A-05231,ALYFTREK,Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek),Vertex Pharmaceuticals (Australia) Pty Ltd,"Cystic fibrosis, aged 6 years and older, with F508del mutation(s) or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, eligible for elexacaftor/tezacaftor/ivacaftor and ivacaftor",Reviewing Consultation Feedback,Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek) (ALYFTREK),/apptracker/s/application-public/a10OZ000003lLVW,Respiratory System and Allergies
a0ROZ000003dsAB2AY,Teduglutide,A-00733,,Teduglutide,Takeda (Shire),Short bowel syndrome intestinal failure for children,Options Compared,Teduglutide,/apptracker/s/application-public/a10OZ0000000uTd,
a0ROZ00000D1QaT2AV,Garadacimab,A-05102,Andembry,Garadacimab,CSL Behring (Australia) Pty Ltd,Hereditary angioedema (HAE),Options Compared,Garadacimab (Andembry),/apptracker/s/application-public/a10OZ0000049FYb,
a0R2P000000UfBNUA0,Latanoprost with timolol acetate,A-01102,Xalacom,Latanoprost with timolol acetate,Pfizer,Glaucoma,Decision,Latanoprost with timolol acetate (Xalacom),/apptracker/s/application-public/a102P000008puGm,Sensory Organs
a0ROZ000003nnNe2AI,Tofacitinib,A-00611,,Tofacitinib,Pfizer,Rheumatoid arthritis,Under Assessment,Tofacitinib,/apptracker/s/application-public/a102P000008ptuO,Musculoskeletal System
a0ROZ0000046vcP2AQ,"Tozinameran, Riltozinameran, Famtozinameran, Raxtozinameran",A-04838,COMIRNATY,"Tozinameran, Riltozinameran, Famtozinameran, Raxtozinameran",PFIZER NEW ZEALAND LIMITED,prevention of COVID-19,Under Assessment,"Tozinameran, Riltozinameran, Famtozinameran, Raxtozinameran (COMIRNATY)",/apptracker/s/application-public/a10OZ000000N05l,
a0ROZ00000085H32AI,Abacavir/lamivudine,A-01434,Kivexa,Abacavir/lamivudine,GlaxoSmithKline,HIV infection,Decision,Abacavir/lamivudine (Kivexa),/apptracker/s/application-public/a102P000008pttx,Infections - Agents for Systemic Use
a0ROZ000003PT6j2AG,Belimumab,A-04562,Benlysta™,Belimumab,GLAXOSMITHKLINE NZ LIMITED,Lupus nephritis in adult patients as an add-on therapy to standard of care,Under Assessment,Belimumab (Benlysta™),/apptracker/s/application-public/a102P00000BYSFH,Genito-Urinary System
a0R2P000000Lmo4UAC,Dolutegravir,A-00279,,Dolutegravir,GlaxoSmithKline,HIV,Decision,Dolutegravir,/apptracker/s/application-public/a102P000008ptrc,Infections - Agents for Systemic Use
a0ROZ000002VUtV2AW,Dolutegravir/lamivudine (DTG/3TC),A-04147,Dovato®,Dolutegravir/lamivudine (DTG/3TC),GLAXOSMITHKLINE NZ LIMITED,Human Immunodeficiency Virus (HIV-1) infection,Decision,Dolutegravir/lamivudine (DTG/3TC) (Dovato®),/apptracker/s/application-public/a102P00000BO9h3,Infections - Agents for Systemic Use
a0ROZ000009A8qo2AC,Dostarlimab-gxly,A-04910,Jemperli,Dostarlimab-gxly,GLAXOSMITHKLINE NZ LIMITED,"endometrial cancer, treatment of advanced or recurrent, irrespective of dMMR status, second line",Options Compared,Dostarlimab-gxly (Jemperli),/apptracker/s/application-public/a10OZ000002WKQf,
a0ROZ0000077hAf2AI,Dostarlimab-gxly,A-04910,Jemperli,Dostarlimab-gxly,GLAXOSMITHKLINE NZ LIMITED,"endometrial cancer, treatment of advanced or recurrent, dMMR deficient, second line",Under Assessment,Dostarlimab-gxly (Jemperli),/apptracker/s/application-public/a10OZ000002WKP3,
a0R2P000000OcfOUAS,Dutasteride,A-01148,Avodart,Dutasteride,GlaxoSmithKline,Benign prostatic hyperplasia,Decision,Dutasteride (Avodart),/apptracker/s/application-public/a102P000008ptrf,Genito-Urinary System
a0R2P000000LmWMUA0,Lamivudine,A-01200,Zeffix,Lamivudine,GlaxoSmithKline,Hepatitis B infection,Decision,Lamivudine (Zeffix),/apptracker/s/application-public/a102P000008ptwm,Infections - Agents for Systemic Use
a0ROZ00000ApJsa2AF,Momelotinib,A-05245 A-04995,Omjjara,Momelotinib,"GLAXOSMITHKLINE NZ LIMITED, Consumer","Primary myelofibrosis (MF), post-polycythaemia vera MF or post-essential thrombocythaemia MF, intermediate or high-risk, with moderate to severe anaemia, 1L (JAKi naive)",Seeking Clinical Advice,Momelotinib (Omjjara),/apptracker/s/application-public/a10OZ0000059XDB,
a0ROZ00000AODft2AH,Momelotinib,A-05245 A-04995,Omjjara,Momelotinib,"GLAXOSMITHKLINE NZ LIMITED, Consumer","Primary myelofibrosis (MF), post-polycythaemia vera MF or post-essential thrombocythaemia MF, intermediate or high-risk, with moderate to severe anaemia, 2L (JAKi experienced)",Seeking Clinical Advice,Momelotinib (Omjjara),/apptracker/s/application-public/a10OZ000003OMIb,
a0ROZ000002UT6f2AG,Niraparib,A-03725,ZEJULA®,Niraparib,GLAXOSMITHKLINE NZ LIMITED,"Ovarian, fallopian tube and peritoneal cancer, homologous recombination deficient, 2nd line maintenance",Decision,Niraparib (ZEJULA®),/apptracker/s/application-public/a102P00000BJ5iw,
a0ROZ000002UJby2AG,Niraparib,A-03725,ZEJULA®,Niraparib,GLAXOSMITHKLINE NZ LIMITED,"Ovarian, fallopian tube and peritoneal cancer, all-comers, 2nd line maintenance",Decision,Niraparib (ZEJULA®),/apptracker/s/application-public/a102P00000BNfqu,
a0ROZ000002VUn32AG,Niraparib,A-03725,ZEJULA®,Niraparib,GLAXOSMITHKLINE NZ LIMITED,"Ovarian, fallopian tube and peritoneal cancer, all-comers, 1st line maintenance",Decision,Niraparib (ZEJULA®),/apptracker/s/application-public/a102P00000BNfqf,
a0ROZ000002UJ482AG,Niraparib,A-03725,ZEJULA®,Niraparib,GLAXOSMITHKLINE NZ LIMITED,"Ovarian, fallopian tube and peritoneal cancer, BRCA-mutated, 2nd line maintenance",Decision,Niraparib (ZEJULA®),/apptracker/s/application-public/a102P00000BJ5S1,
a0ROZ000002UObe2AG,Niraparib,A-03725,ZEJULA®,Niraparib,GLAXOSMITHKLINE NZ LIMITED,"Ovarian, fallopian tube and peritoneal cancer, homologous recombination deficient, 1st line maintenance",Decision,Niraparib (ZEJULA®),/apptracker/s/application-public/a102P00000BJ5Rw,
a0ROZ000002UPsg2AG,Niraparib,A-03725,ZEJULA®,Niraparib,GLAXOSMITHKLINE NZ LIMITED,"Ovarian, fallopian tube and peritoneal cancer, BRCA-mutated, 1st line maintenance",Decision,Niraparib (ZEJULA®),/apptracker/s/application-public/a102P00000AtoKg,
a0ROZ000008BedR2AS,Insulin degludec and insulin aspart,A-04472,Ryzodeg 70-30 Penfill,Insulin degludec and insulin aspart,NOVO NORDISK PHARMACEUTICALS LIMITED,Diabetes mellitus (Type 1 or Type 2),Decision,Insulin degludec and insulin aspart (Ryzodeg 70-30 Penfill),/apptracker/s/application-public/a102P00000BYxPv,
a0ROZ00000CHho12AD,Semaglutide,A-05396,Wegovy,Semaglutide,NOVO NORDISK PHARMACEUTICALS LIMITED,"Established cardiovascular disease, Body Mass Index (BMI) ≥27 kg/m2",Seeking Clinical Advice,Semaglutide (Wegovy),/apptracker/s/application-public/a10OZ000006O73K,
a0ROZ00000DLI2T2AX,Semaglutide,A-05395 A-05397,Ozempic®,Semaglutide,"NOVO NORDISK PHARMACEUTICALS LIMITED, NOVO NORDISK PHARMACEUTICALS LIMITED","Type II diabetes mellitus, insufficiently controlled",Seeking Clinical Advice,Semaglutide (Ozempic®),/apptracker/s/application-public/a10OZ000005R33l,
a0R2P000000LmUdUAK,Teriparatide,A-00956,Forteo,Teriparatide,Eli Lilly,Osteoporosis (second-line following bisphosphonates),Decision,Teriparatide (Forteo),/apptracker/s/application-public/a102P000008puNZ,Musculoskeletal System
a0R2P000000OcgHUAS,Abatacept,A-00869,Orencia,Abatacept,Bristol-Myers Squibb,Rheumatoid arthritis,Decision,Abatacept (Orencia),/apptracker/s/application-public/a102P000008puDj,Musculoskeletal System
a0R2P000000LmgDUAS,Adalimumab,A-01042,Humira,Adalimumab,Abbott,Psoriatic arthritis,Decision,Adalimumab (Humira),/apptracker/s/application-public/a102P000008ptop,Musculoskeletal System
a0ROZ0000002e1N2AQ,Alendronate sodium with cholecalciferol 2800 iu,A-01184,Fosamax Plus,Alendronate sodium with cholecalciferol 2800 iu,Merck Sharp & Dohme,Osteoporosis,Decision,Alendronate sodium with cholecalciferol 2800 iu (Fosamax Plus),/apptracker/s/application-public/a102P000008puTk,Musculoskeletal System
a0R2P000000TFdhUAG,"Benzbromarone, Febuxostat",A-00348,"Adenuric,Benzbromaron Al 100","Benzbromarone, Febuxostat",Te Arai Biofarma,Amendment of criteria,Decision,"Benzbromarone, Febuxostat (Adenuric,Benzbromaron Al 100)",/apptracker/s/application-public/a102P000008puRY,Musculoskeletal System
a0R2P000000LmhkUAC,Capsaicin 0.025%,A-01211,Zostrix,Capsaicin 0.025%,AFT Pharmaceuticals,Osteoarthritis,Decision,Capsaicin 0.025% (Zostrix),/apptracker/s/application-public/a102P000008puFQ,Musculoskeletal System
a0R2P000000LmVfUAK,Celecoxib,A-01188,Celebrex,Celecoxib,Searle,Osteoarthritis and rheumatoid arthritis,Decision,Celecoxib (Celebrex),/apptracker/s/application-public/a102P000008ptzn,Musculoskeletal System
a0ROZ000009J4E12AK,Collagenase clostridium histolyticum,A-00575,Xiaflex,Collagenase clostridium histolyticum,Actelion,Dupuytren's contracture,Decision,Collagenase clostridium histolyticum (Xiaflex),/apptracker/s/application-public/a102P000008ptpi,Musculoskeletal System
a0ROZ000004CRRy2AO,Denosumab,A-00740,Prolia,Denosumab,Amgen,"Osteoporosis, removing definition of contraindicated to zoledronic acid",Decision,Denosumab (Prolia),/apptracker/s/application-public/a102P000008puCW,Musculoskeletal System
a0ROZ0000074L0D2AU,Denosumab,A-00687,Prolia,Denosumab,Amgen,"Osteoporosis, contraindicated to or unable to tolerate bisphosphonates",Decision,Denosumab (Prolia),/apptracker/s/application-public/a102P000008pu0f,Musculoskeletal System
a0ROZ0000074FCq2AM,Denosumab,A-00687,Prolia,Denosumab,Amgen,"Osteoporosis, contraindicated to bisphosphonates",Decision,Denosumab (Prolia),/apptracker/s/application-public/a102P00000BKJ7c,Musculoskeletal System
a0ROZ0000007jBh2AI,Denosumab,A-01212,Prolia,Denosumab,Amgen,Osteoporosis in patients contraindicated to zoledronic acid,Decision,Denosumab (Prolia),/apptracker/s/application-public/a102P000008puXq,Musculoskeletal System
a0ROZ00000096ar2AA,Etanercept,A-01023,Enbrel,Etanercept,Wyeth,Ankylosing spondylitis,Decision,Etanercept (Enbrel),/apptracker/s/application-public/a102P000008puQb,Musculoskeletal System
a0ROZ000004CWt32AG,Etoricoxib,A-01126,Arcoxia,Etoricoxib,Merck Sharp & Dohme,Osteoarthritis and rheumatoid arthritis,Decision,Etoricoxib (Arcoxia),/apptracker/s/application-public/a102P000008pugW,Musculoskeletal System
a0ROZ00000BVkJb2AL,Fampridine,A-00313,,Fampridine,Biogen,Symptomatic walking improvement for people with MS,Reviewing Consultation Feedback,Fampridine,/apptracker/s/application-public/a102P000008puL3,Musculoskeletal System
a0R2P000000TGOLUA4,Febuxostat,A-00386,Adenuric,Febuxostat,Te Arai Biofarma,Gout: widening current access criteria,Options Compared,Febuxostat (Adenuric),/apptracker/s/application-public/a102P000008ptr6,Musculoskeletal System
a0R2P000000TEzDUAW,Febuxostat,A-01332,Adenuric,Febuxostat,Te Arai Biofarma,Severe gout,Decision,Febuxostat (Adenuric),/apptracker/s/application-public/a102P000008puiy,Musculoskeletal System
a0R2P000000MTfnUAG,Golimumab,A-00966,Simponi,Golimumab,Merck Sharp & Dohme,Psoriatic arthritis - second-line TNF inhibitor,Decision,Golimumab (Simponi),/apptracker/s/application-public/a102P000008puEb,Musculoskeletal System
a0R2P000000OcgMUAS,Golimumab,A-00950,Simponi,Golimumab,Merck Sharp & Dohme,Rheumatoid arthritis - second-line TNF inhibitor,Decision,Golimumab (Simponi),/apptracker/s/application-public/a102P000008puin,Musculoskeletal System
a0R2P000000MTeWUAW,Golimumab,A-01025,Simponi,Golimumab,Merck Sharp & Dohme,Ankylosing spondylitis - second-line TNF inhibitor,Decision,Golimumab (Simponi),/apptracker/s/application-public/a102P000008pu6M,Musculoskeletal System
a0ROZ000000x8cf2AA,Hydroxychloroquine,A-03739,Plaquenil,Hydroxychloroquine,Consumer,"Histiocytic intervillositis, chronic",Decision,Hydroxychloroquine (Plaquenil),/apptracker/s/application-public/a102P00000BVvDh,Musculoskeletal System
a0R2P000000OcgRUAS,Ibandronate,A-00293,,Ibandronate,Subcommittee recommendation,Osteoporosis,Decision,Ibandronate,/apptracker/s/application-public/a102P000008ptuu,Musculoskeletal System
a0R2P000000LmmpUAC,Leflunomide,A-01182,Arava,Leflunomide,Aventis,Rheumatoid arthritis,Decision,Leflunomide (Arava),/apptracker/s/application-public/a102P000008pu1v,Musculoskeletal System
a0R2P000000Wlm1UAC,Mefenamic acid,A-00297,Ponstan,Mefenamic acid,Subcommittee recommendation,"Full funding for primary dysmenorrhoea, dysfunctional uterine bleeding and pain or menorrhagia",Decision,Mefenamic acid (Ponstan),/apptracker/s/application-public/a102P000008puW9,Musculoskeletal System
a0R2P000000LmXjUAK,Raloxifene Hydrochloride,A-01173,Evista,Raloxifene Hydrochloride,Eli Lilly,Osteoporosis,Decision,Raloxifene Hydrochloride (Evista),/apptracker/s/application-public/a102P000008puWH,Musculoskeletal System
a0R2P000000Lmj0UAC,Risedronate,A-00886,Actonel,Risedronate,Aventis,Osteoporosis,Decision,Risedronate (Actonel),/apptracker/s/application-public/a102P000008puF7,Musculoskeletal System
a0R2P000000Lmm2UAC,Risedronate,A-00969,,Risedronate,Aventis,Paget's disease,Decision,Risedronate,/apptracker/s/application-public/a102P000008pujw,Musculoskeletal System
a0R2P000000LmZZUA0,Rofecoxib,A-00881,Vioxx,Rofecoxib,Merck Sharp & Dohme,"Osteoarthritis, pain relief, primary dysmenorrhoea and rheumatoid arthritis",Decision,Rofecoxib (Vioxx),/apptracker/s/application-public/a102P000008puSJ,Musculoskeletal System
a0R2P000000LmjKUAS,Tocilizumab,A-01432,Actemra,Tocilizumab,Roche,"Rheumatoid arthritis - monotherapy, methotrexate intolerance",Decision,Tocilizumab (Actemra),/apptracker/s/application-public/a102P000008pufA,Musculoskeletal System
a0R2P000000LmoOUAS,Tocilizumab,A-01074,Actemra,Tocilizumab,Roche,Systemic juvenile idiopathic arthritis (sJIA),Decision,Tocilizumab (Actemra),/apptracker/s/application-public/a102P000008ptsd,Musculoskeletal System
a0R2P000000LmjTUAS,Tocilizumab,A-00388,Actemra,Tocilizumab,Roche,Polyarticular juvenile idiopathic arthritis,Decision,Tocilizumab (Actemra),/apptracker/s/application-public/a102P000008pufD,Musculoskeletal System
a0R2P000000LmZgUAK,Tocilizumab,A-01069,Actemra,Tocilizumab,Roche,"Rheumatoid arthritis (last line, patient can take methotrexate)",Decision,Tocilizumab (Actemra),/apptracker/s/application-public/a102P000008puTf,Musculoskeletal System
a0R2P000000TGLCUA4,"Tocilizumab, subcutaneous",A-00389,,"Tocilizumab, subcutaneous",Roche,Rheumatoid arthritis,Under Assessment,"Tocilizumab, subcutaneous",/apptracker/s/application-public/a102P000008ptpE,Musculoskeletal System
a0ROZ00000DGeA52AL,Upadacitinib,A-05543,Rinvoq,Upadacitinib,ABBVIE LIMITED,"Giant cell ateritis (GCA), glucocorticoid tapering, 1st or later line",Seeking Clinical Advice,Upadacitinib (Rinvoq),/apptracker/s/application-public/a10OZ000007JUXp,Musculoskeletal System
a0R2P000000LmZ7UAK,Antiretrovirals,A-01318,,Antiretrovirals,NPPA,Post-exposure prophylaxis following non-consensual intercourse,Decision,Antiretrovirals,/apptracker/s/application-public/a102P000008puVa,Infections - Agents for Systemic Use
a0R2P000000dNRxUAM,Ciclosporin eye preparation,A-00555 A-01239,,Ciclosporin eye preparation,"NPPA, NPPA","Severe keratoconjunctivitis sicca, severe atopic keratoconjunctivitis and severe vernal keratoconjunctivitis",Options Compared,Ciclosporin eye preparation,/apptracker/s/application-public/a102P000008pu7u,Sensory Organs
a0R2P000000Lme8UAC,Cycloserine,A-01244,,Cycloserine,NPPA,"Tuberculosis , multi-drug resistant (MDR)",Decision,Cycloserine,/apptracker/s/application-public/a102P000008pttl,Infections - Agents for Systemic Use
a0ROZ000009J3xt2AC,Fosfomycin,A-01263,,Fosfomycin,NPPA,Extended spectrum beta lactamase infections,Decision,Fosfomycin,/apptracker/s/application-public/a102P000008puim,Infections - Agents for Systemic Use
a0R2P000000LmhSUAS,Moxifloxacin,A-01284,,Moxifloxacin,NPPA,Mycoplasma genitalium infection -  refractory,Decision,Moxifloxacin,/apptracker/s/application-public/a102P000008pu5s,Infections - Agents for Systemic Use
a0R2P000000LmjOUAS,Moxifloxacin,A-01338,,Moxifloxacin,NPPA,Prophylaxis of endophthalmitis following penetrating eye injuries,Decision,Moxifloxacin,/apptracker/s/application-public/a102P000008pud8,Sensory Organs
a0R2P000000LmhcUAC,Nitazoxanide,A-01241,Alinia,Nitazoxanide,NPPA,Protozoan infections,Decision,Nitazoxanide (Alinia),/apptracker/s/application-public/a102P000008puEG,Infections - Agents for Systemic Use
a0R2P000000LmmRUAS,Para-amino salicylic acid,A-01261,,Para-amino salicylic acid,NPPA,Tuberculosis,Decision,Para-amino salicylic acid,/apptracker/s/application-public/a102P000008ptrE,Infections - Agents for Systemic Use
a0R2P000000LmaFUAS,Progesterone,A-01246,,Progesterone,NPPA,Preterm birth - prevention in women with short cervices or a history of preterm birth,Decision,Progesterone,/apptracker/s/application-public/a102P000008puYN,Genito-Urinary System
a0R2P000000LmYsUAK,Prothionamide,A-01245,,Prothionamide,NPPA,Tuberculosis,Decision,Prothionamide,/apptracker/s/application-public/a102P000008puVP,Infections - Agents for Systemic Use
a0R2P000000LmiFUAS,Quinacrine,A-01236,,Quinacrine,NPPA,Giardiasis,Seeking Clinical Advice,Quinacrine,/apptracker/s/application-public/a102P000008pu4u,Infections - Agents for Systemic Use
a0R2P000000LmpMUAS,Valaciclovir,A-01295,,Valaciclovir,NPPA,Herpes zoster (shingles) - in immunocompromised patients,Decision,Valaciclovir,/apptracker/s/application-public/a102P000008puB5,Infections - Agents for Systemic Use
a0ROZ00000081mv2AA,Adefovir dipivoxil,A-01104,Hepsera,Adefovir dipivoxil,Gilead Sciences,Chronic Hepatitis B Infection,Decision,Adefovir dipivoxil (Hepsera),/apptracker/s/application-public/a102P000008puX3,Infections - Agents for Systemic Use
a0ROZ000004CPjX2AW,Albendazole,A-00684,,Albendazole,Te Arai Biofarma,Giardiasis,Seeking Clinical Advice,Albendazole,/apptracker/s/application-public/a102P000008pu8s,Infections - Agents for Systemic Use
a0R2P000000TGU9UAO,Antiretrovirals,A-00271,,Antiretrovirals,Subcommittee recommendation,HIV - removal of severity criteria,Decision,Antiretrovirals,/apptracker/s/application-public/a102P000008puga,Infections - Agents for Systemic Use
a0R2P000000TGRFUA4,"aritaprevir, ritonavir and ombitasvir with dasabuvir (with or without ribavirin)",A-00384,"Viekira Pak,Viekira Pak - Rbv 200Mg","Paritaprevir, ritonavir and ombitasvir with dasabuvir (with or without ribavirin)",AbbVie,"Chronic hepatitis C, genotype 1, lower-risk groups",Decision,"Paritaprevir, ritonavir and ombitasvir with dasabuvir (with or without ribavirin) (Viekira Pak,Viekira Pak - Rbv 200Mg)",/apptracker/s/application-public/a102P000008puDP,Infections - Agents for Systemic Use
a0ROZ00000082fl2AA,Atazanavir sulfate,A-01101,Reyataz,Atazanavir sulfate,Bristol-Myers Squibb,HIV infection,Decision,Atazanavir sulfate (Reyataz),/apptracker/s/application-public/a102P000008ptoj,Infections - Agents for Systemic Use
a0R2P000000LmYzUAK,Azithromycin,A-00419,"Apo-Azithromycin,Zithromax",Azithromycin,Subcommittee recommendation,"Bronchiectasis - non-cystic fibrosis, in children with high exacerbation or hospitalisation rates",Decision,"Azithromycin (Apo-Azithromycin,Zithromax)",/apptracker/s/application-public/a102P000008puVX,Infections - Agents for Systemic Use
a0R2P000000MaOyUAK,Bedaquiline,A-00473,,Bedaquiline,Janssen,Extensively drug-resistant tuberculosis (XDR-TB),Decision,Bedaquiline,/apptracker/s/application-public/a102P000008ptrC,Infections - Agents for Systemic Use
a0ROZ000009A8qe2AC,Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir alafenamide 25 mg,A-03114,BIKTARVY® tablets,Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir alafenamide 25 mg,GILEAD SCIENCES (NZ),HIV-1 infection in adults,Options Compared,Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir alafenamide 25 mg (BIKTARVY® tablets),/apptracker/s/application-public/a102P00000AW9pI,Infections - Agents for Systemic Use
a0R2P000000LmgxUAC,Boceprevir,A-01363,Victrelis,Boceprevir,Merck Sharp & Dohme,"Removal of Special Authority (hepatitis C, genotype 1)",Application Received,Boceprevir (Victrelis),/apptracker/s/application-public/a102P000008ptuM,Infections - Agents for Systemic Use
a0R2P000000LmapUAC,Boceprevir,A-01210,Victrelis,Boceprevir,Merck Sharp & Dohme,"Hepatitis C Virus - genotype 1, non-CC allele",Decision,Boceprevir (Victrelis),/apptracker/s/application-public/a102P000008puZC,Infections - Agents for Systemic Use
a0R2P000000LmZeUAK,Ceftaroline fosamil,A-00214,Zinforo,Ceftaroline fosamil,AstraZeneca,Multi-drug-resistant infections,Decision,Ceftaroline fosamil (Zinforo),/apptracker/s/application-public/a102P000008puZp,Infections - Agents for Systemic Use
a0ROZ000004vZgH2AU,Ceftolozane and tazobactam,A-00521,,Ceftolozane and tazobactam,Merck Sharp & Dohme,"Complicated intra -abdominal infections, complicated urinary tract infections",Decision,Ceftolozane and tazobactam,/apptracker/s/application-public/a102P000008puBa,Infections - Agents for Systemic Use
a0ROZ0000006zde2AA,D-mannose,A-00524,UroFem,D-mannose,Te Arai Biofarma,"Cystitis, uncomplicated during pregnancy or associated neurogenic bladder",Options Compared,D-mannose (UroFem),/apptracker/s/application-public/a102P000008puQG,Infections - Agents for Systemic Use
a0R2P000000LminUAC,Darunavir,A-00402,Prezista,Darunavir,Janssen,HIV infection (patients who have failed at least 3 antiretroviral regimens),Decision,Darunavir (Prezista),/apptracker/s/application-public/a102P000008pu53,Infections - Agents for Systemic Use
a0ROZ000000Ba092AC,Darunavir (400mg tablets),A-00960,Prezista,Darunavir (400mg tablets),Janssen,Human Imminodeficiency Virus (HIV),Decision,Darunavir (400mg tablets) (Prezista),/apptracker/s/application-public/a102P000008pufE,Infections - Agents for Systemic Use
a0ROZ000004CQXV2A4,Elbasvir with grazoprevir,A-00516,,Elbasvir with grazoprevir,Merck Sharp & Dohme,"Chronic hepatitis C, genotype 1",Decision,Elbasvir with grazoprevir,/apptracker/s/application-public/a102P000008pu6n,Infections - Agents for Systemic Use
a0R2P000000LmnrUAC,Emtricitabine,A-01427,Emtiva,Emtricitabine,Gilead Sciences,HIV infection (list with tenofovir),Decision,Emtricitabine (Emtiva),/apptracker/s/application-public/a102P000008pu28,Infections - Agents for Systemic Use
a0R2P000000LmktUAC,Emtricitabine - tenofovir alafenamide,A-00692,,Emtricitabine - tenofovir alafenamide,Gilead Sciences,HIV 1,Options Compared,Emtricitabine - tenofovir alafenamide,/apptracker/s/application-public/a102P000008pucu,Infections - Agents for Systemic Use
a0ROZ00000081rl2AA,Enfuvirtide,A-01099,Fuzeon,Enfuvirtide,Roche,HIV/AIDS,Decision,Enfuvirtide (Fuzeon),/apptracker/s/application-public/a102P000008puil,Infections - Agents for Systemic Use
a0R2P000000Lmq0UAC,Entecavir,A-01445,Baraclude,Entecavir,Bristol-Myers Squibb,Chronic Hepatitis B (treatment naive patients),Decision,Entecavir (Baraclude),/apptracker/s/application-public/a102P000008puCt,Infections - Agents for Systemic Use
a0R2P000000LmoGUAS,Etravirine,A-00920,Intelence,Etravirine,Janssen,treatment of HIV/AIDS,Decision,Etravirine (Intelence),/apptracker/s/application-public/a102P000008ptsa,Infections - Agents for Systemic Use
a0ROZ0000051is92AA,Fosfomycin,A-00697,,Fosfomycin,Te Arai Biofarma,Urinary Tract Infection,Decision,Fosfomycin,/apptracker/s/application-public/a102P000008ptsM,Infections - Agents for Systemic Use
a0ROZ0000007XqT2AU,Glecaprevir with pibrentasvir,A-00558,Maviret,Glecaprevir with pibrentasvir,AbbVie,"Chronic hepatitis C, compensated patients",Decision,Glecaprevir with pibrentasvir (Maviret),/apptracker/s/application-public/a102P000008ptzq,Infections - Agents for Systemic Use
a0ROZ0000006LMj2AM,Interferon alpha-2b,A-00896,Pegintron,Interferon alpha-2b,Merck Sharp & Dohme,Hepatitis C,Decision,Interferon alpha-2b (Pegintron),/apptracker/s/application-public/a102P000008puRs,Infections - Agents for Systemic Use
a0ROZ0000045m4v2AA,Ivermectin,A-04073,Stromectol,Ivermectin,Consumer,For the prevention and or treatment of Covid-19,Decision,Ivermectin (Stromectol),/apptracker/s/application-public/a10OZ0000005GvN,Infections - Agents for Systemic Use
a0R2P000000LmneUAC,Lamivudine,A-00360,Zeffix,Lamivudine,Subcommittee recommendation,Hepatitis B (HBV)  - amendment of renewal criteria,Decision,Lamivudine (Zeffix),/apptracker/s/application-public/a102P000008ptsR,Infections - Agents for Systemic Use
a0R2P000000LmfuUAC,Ledipasvir with sofosbuvir,A-00559,,Ledipasvir with sofosbuvir,Gilead Sciences,"Chronic hepatitis C, decompensated cirrhosis, removing MELD score criteria (<12)",Decision,Ledipasvir with sofosbuvir,/apptracker/s/application-public/a102P000008ptok,Infections - Agents for Systemic Use
a0R2P000000LmWOUA0,Ledipasvir with sofosbuvir,A-00375,Harvoni,Ledipasvir with sofosbuvir,Gilead Sciences,"Chronic hepatitis C, advanced disease",Decision,Ledipasvir with sofosbuvir (Harvoni),/apptracker/s/application-public/a102P000008ptxl,Infections - Agents for Systemic Use
a0ROZ000004COqg2AG,Ledipasvir with sofosbuvir,A-00497,,Ledipasvir with sofosbuvir,Gilead Sciences,"Chronic hepatitis C, lower-risk groups, genotype 1",Decision,Ledipasvir with sofosbuvir,/apptracker/s/application-public/a102P000008puH4,Infections - Agents for Systemic Use
a0R2P000000Lmp4UAC,Ledipasvir with sofosbuvir,A-00494,,Ledipasvir with sofosbuvir,Gilead Sciences,"Chronic hepatitis C, decompensated cirrhosis, MELD score 12-14",Decision,Ledipasvir with sofosbuvir,/apptracker/s/application-public/a102P000008pu2l,Infections - Agents for Systemic Use
a0ROZ0000052ORe2AM,Letermovir,A-00803,,Letermovir,Merck Sharp & Dohme,"Cytomegalovirus infection prophylaxis, stem cell transplant patients",Options Compared,Letermovir,/apptracker/s/application-public/a102P000008puFK,Infections - Agents for Systemic Use
a0ROZ0000006L1l2AE,Lopinavir/ritonavir,A-01467,Kaletra,Lopinavir/ritonavir,Abbott,HIV infection (salvage treatment only),Decision,Lopinavir/ritonavir (Kaletra),/apptracker/s/application-public/a102P000008puT9,Infections - Agents for Systemic Use
a0R2P000000OcfiUAC,Micafungin,A-00306,Mycamine,Micafungin,Seqirus,Invasive candidiasis and other indications,Decision,Micafungin (Mycamine),/apptracker/s/application-public/a102P000008puDJ,Infections - Agents for Systemic Use
a0R2P000000dOrSUAU,Moxifloxacin,A-00443,"Avelox,Avelox Iv 400",Moxifloxacin,Subcommittee recommendation,"Post-splenectomy, confirmed allergy to penicillin",Decision,"Moxifloxacin (Avelox,Avelox Iv 400)",/apptracker/s/application-public/a102P000008ptzm,Infections - Agents for Systemic Use
a0ROZ0000045lIX2AY,Palivizumab,A-00875,Syngis,Palivizumab,Abbott,Respiratory syncytial virus (RSV) - prevention of infection in high risk infants,Decision,Palivizumab (Syngis),/apptracker/s/application-public/a102P000008pu58,Infections - Agents for Systemic Use
a0R2P000000LmeKUAS,Paromomycin,A-01316,Humatin,Paromomycin,Subcommittee recommendation,Entamoeba histolytica intestinal colonisation,Decision,Paromomycin (Humatin),/apptracker/s/application-public/a102P000008pttQ,Infections - Agents for Systemic Use
a0ROZ0000006KP32AM,Pegylated interferon alpha 2a with ribavirin,A-01097,Pegasys RBV,Pegylated interferon alpha 2a with ribavirin,Roche,Hepatitis C,Decision,Pegylated interferon alpha 2a with ribavirin (Pegasys RBV),/apptracker/s/application-public/a102P000008ptrw,Infections - Agents for Systemic Use
a0R2P000000LmhmUAC,Pegylated interferon alpha-2a,A-01098,Pegasys,Pegylated interferon alpha-2a,Roche,Hepatitis B in treatment naive patients,Decision,Pegylated interferon alpha-2a (Pegasys),/apptracker/s/application-public/a102P000008pu4h,Infections - Agents for Systemic Use
a0R2P000000LmhKUAS,Pegylated interferon alpha-2A,A-01378,,Pegylated interferon alpha-2A,Roche,Hepatitis B (treatment naive patients),Decision,Pegylated interferon alpha-2A,/apptracker/s/application-public/a102P000008pu5f,Infections - Agents for Systemic Use
a0R2P000000LmnwUAC,Pegylated interferon alpha-2b with ribavirin,A-01095,Pegatron,Pegylated interferon alpha-2b with ribavirin,Merck Sharp & Dohme,Hepatitis C,Decision,Pegylated interferon alpha-2b with ribavirin (Pegatron),/apptracker/s/application-public/a102P000008ptsV,Infections - Agents for Systemic Use
a0R2P000000LmhnUAC,Primaquine phosphate,A-00359,,Primaquine phosphate,Subcommittee recommendation,"Malaria, vivax or ovale, addition of renewal criteria",Decision,Primaquine phosphate,/apptracker/s/application-public/a102P000008pu4i,Infections - Agents for Systemic Use
a0R2P000000LmVgUAK,Raltegravir,A-00864,ISENTRESS,Raltegravir,Merck Sharp & Dohme,Antiretroviral therapy for HIV,Decision,Raltegravir (ISENTRESS),/apptracker/s/application-public/a102P000008ptzo,Infections - Agents for Systemic Use
a0R2P000000Lme3UAC,Raltegravir 600 mg,A-00750,,Raltegravir 600 mg,Merck Sharp & Dohme,HIV,Decision,Raltegravir 600 mg,/apptracker/s/application-public/a102P000008pttj,Infections - Agents for Systemic Use
a0R2P000000OcfnUAC,Rilpivirine,A-01311,Edurant,Rilpivirine,Janssen,HIV/AIDS,Decision,Rilpivirine (Edurant),/apptracker/s/application-public/a102P000008ptxq,Infections - Agents for Systemic Use
a0R2P000000TGRjUAO,Simeprevir,A-00396,,Simeprevir,Janssen,"Chronic hepatitis C, genotype 1",Decision,Simeprevir,/apptracker/s/application-public/a102P000008puHc,Infections - Agents for Systemic Use
a0R2P000000Ocg2UAC,Sofosbuvir,A-00298,Sovaldi,Sofosbuvir,Gilead Sciences,"Chronic hepatitis C, advanced disease",Decision,Sofosbuvir (Sovaldi),/apptracker/s/application-public/a102P000008pu4z,Infections - Agents for Systemic Use
a0R2P000000N7FEUA0,Sofosbuvir,A-00280,Sovaldi,Sofosbuvir,Gilead Sciences,"Chronic hepatitis C, lower-risk groups, genotype 1",Decision,Sofosbuvir (Sovaldi),/apptracker/s/application-public/a102P000008puFG,Infections - Agents for Systemic Use
a0R2P000000OcfxUAC,Sofosbuvir,A-00495,Sovaldi,Sofosbuvir,Gilead Sciences,"Chronic hepatitis C, decompensated cirrhosis MELD score <15",Decision,Sofosbuvir (Sovaldi),/apptracker/s/application-public/a102P000008puFP,Infections - Agents for Systemic Use
a0R2P000000Ocg7UAC,Sofosbuvir and velpatasvir,A-03565,Epclusa,Sofosbuvir and velpatasvir,GILEAD SCIENCES (NZ),Chronic Hepatitis C Virus Infection,Decision,Sofosbuvir and velpatasvir (Epclusa),/apptracker/s/application-public/a102P00000Ac8Y4,Infections - Agents for Systemic Use
a0ROZ000009MFb72AG,Sofosbuvir with velpatasvir and voxilaprevir,A-00742,Vosevi,Sofosbuvir with velpatasvir and voxilaprevir,Gilead Sciences,"Hepatitis C, second-line after prior direct-acting antiviral treatment, NS5A resistance",Options Compared,Sofosbuvir with velpatasvir and voxilaprevir (Vosevi),/apptracker/s/application-public/a102P000008pu4P,Infections - Agents for Systemic Use
a0R2P000000anSIUAY,Telaprevir,A-01217,Incivo,Telaprevir,Janssen,"Chronic hepatitis C, genotype 1",Decision,Telaprevir (Incivo),/apptracker/s/application-public/a102P000008ptvD,Infections - Agents for Systemic Use
a0R2P000000LmgBUAS,Tenofivir with emtricitabine,A-00948,Truvada,Tenofivir with emtricitabine,Gilead Sciences,HIV Infection,Decision,Tenofivir with emtricitabine (Truvada),/apptracker/s/application-public/a102P000008pu4G,Infections - Agents for Systemic Use
a0ROZ00000085Lt2AI,Tenofovir,A-01406,Viread,Tenofovir,Gilead Sciences,HIV infection - treatment experienced,Decision,Tenofovir (Viread),/apptracker/s/application-public/a102P000008puOT,Infections - Agents for Systemic Use
a0R2P000000LmnfUAC,Tenofovir,A-00861,Viread,Tenofovir,Gilead Sciences,"Widening of access - patients with chronic, treatment resistant Hepatitis B infection",Decision,Tenofovir (Viread),/apptracker/s/application-public/a102P000008pu0m,Infections - Agents for Systemic Use
a0R2P000000LmocUAC,Tenofovir,A-00243,Viread,Tenofovir,Subcommittee recommendation,Hepatitis B - women of childbearing potential,Decision,Tenofovir (Viread),/apptracker/s/application-public/a102P000008ptr2,Infections - Agents for Systemic Use
a0R2P000000LmpUUAS,Tenofovir,A-00928,Viread,Tenofovir,Gilead Sciences,Post liver transplant in Hepatitis B,Decision,Tenofovir (Viread),/apptracker/s/application-public/a102P000008puB8,Infections - Agents for Systemic Use
a0R2P000000LmcsUAC,Tenofovir,A-01424,Viread,Tenofovir,Gilead Sciences,HIV infection - HIV/Hep B co-infection,Decision,Tenofovir (Viread),/apptracker/s/application-public/a102P000008pu8p,Infections - Agents for Systemic Use
a0R2P000000Lml3UAC,Tenofovir,A-01417,Viread,Tenofovir,Gilead Sciences,HIV infection - treatment naive,Decision,Tenofovir (Viread),/apptracker/s/application-public/a102P000008puii,Infections - Agents for Systemic Use
a0ROZ000004CIJr2AO,Tenofovir Alafenamide,A-00691,,Tenofovir Alafenamide,Gilead Sciences,Chronic Hepatitis B adults,Decision,Tenofovir Alafenamide,/apptracker/s/application-public/a102P000008pu4w,Infections - Agents for Systemic Use
a0R2P000000LmbVUAS,"Tenofovir, emtricitabine, efavirenz",A-00949,Atripla,"Tenofovir, emtricitabine, efavirenz",Gilead Sciences,HIV Infection,Decision,"Tenofovir, emtricitabine, efavirenz (Atripla)",/apptracker/s/application-public/a102P000008puS2,Infections - Agents for Systemic Use
a0R2P000000OcgCUAS,"Tenofovir, emtricitabine, elvitegravir, and coicistat combination",A-00239,,"Tenofovir, emtricitabine, elvitegravir, and coicistat combination",Gilead Sciences,HIV,Decision,"Tenofovir, emtricitabine, elvitegravir, and coicistat combination",/apptracker/s/application-public/a102P000008puHY,Infections - Agents for Systemic Use
a0R2P000000anJkUAI,Tobramycin ampoules,A-00259,Dbl Tobramycin,Tobramycin ampoules,Subcommittee recommendation,Non-cystic fibrosis patients with bronchiectasis,Decision,Tobramycin ampoules (Dbl Tobramycin),/apptracker/s/application-public/a102P000008ptsr,Infections - Agents for Systemic Use
a0R2P000000TbDqUAK,Valganciclovir,A-01230,Valcyte,Valganciclovir,Subcommittee recommendation,Widening access - extended use after lung transplant and methylprednisolone,Decision,Valganciclovir (Valcyte),/apptracker/s/application-public/a102P000008puQy,Infections - Agents for Systemic Use
a0R2P000000Sk3WUAS,Adalimumab,A-00566,"Humira,Humirapen",Adalimumab,AbbVie,Severe and chronic ocular inflammation (uveitis),Decision,"Adalimumab (Humira,Humirapen)",/apptracker/s/application-public/a102P000008puik,Sensory Organs
a0ROZ0000076Lyb2AE,Belzutifan,A-04945,WELIREG,Belzutifan,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,VHL disease,Seeking Clinical Advice,Belzutifan (WELIREG),/apptracker/s/application-public/a10OZ000000q7VF,
a0ROZ00000DKizt2AD,pembrolizumab,A-05472,KEYTRUDA,pembrolizumab,MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,"Squamous Cell Carcinoma of the Head and Neck, Resectable, Locally Advanced",Seeking Clinical Advice,pembrolizumab (KEYTRUDA),/apptracker/s/application-public/a10OZ000007NtEH,
a0ROZ00000BV7Wj2AL,Esketamine,A-04651,SPRAVATO,Esketamine,JANSSEN NZ LIMITED,"treatment resistant depression, post augmentation",Reviewing Consultation Feedback,Esketamine (SPRAVATO),/apptracker/s/application-public/a10OZ0000001EDp,
a0ROZ000002BrKo2AK,Fomepizole,A-00350,,Fomepizole,AFT Pharmaceuticals,Methanol poisoning,Options Compared,Fomepizole,/apptracker/s/application-public/a102P000008ptyT,Various
a0ROZ0000012ZcD2AU,Sirolimus (Rapamycin),A-04501,Pascomer,Sirolimus (Rapamycin),AFT PHARMACEUTICALS LIMITED,Facial angiofibromas associated with Tuberous Sclerosis Complex,Options Compared,Sirolimus (Rapamycin) (Pascomer),/apptracker/s/application-public/a102P00000BYYkJ,
a0ROZ000000OSPl2AO,Osimertinib,A-03818,Tagrisso,Osimertinib,ASTRAZENECA LIMITED,"EGFR-mutated NSCLC, adjuvant treatment after tumour resection",Seeking Clinical Advice,Osimertinib (Tagrisso),/apptracker/s/application-public/a102P00000BIJrJ,
a0ROZ000006JP0r2AG,Osimertinib,A-03147,Tagrisso,Osimertinib,ASTRAZENECA LIMITED,"Non-small-cell lung carcinoma, epidermal growth factor receptor mutation, locally advanced or metastatic, 1st line",Decision,Osimertinib (Tagrisso),/apptracker/s/application-public/a102P000009sG55,
a0ROZ00000BP6C02AL,Tezepelumab,A-05428,TEZSPIRE,Tezepelumab,ASTRAZENECA LIMITED,Chronic rhinosinusitis with nasal polyps (CRSwNP),Seeking Clinical Advice,Tezepelumab (TEZSPIRE),/apptracker/s/application-public/a10OZ000005MAlp,
a0R2P000000V18PUAS,BAK-free/ Preservative-free glaucoma drops,A-00352,,BAK-free/ Preservative-free glaucoma drops,Subcommittee recommendation,Glaucoma,Decision,BAK-free/ Preservative-free glaucoma drops,/apptracker/s/application-public/a102P000008ptvM,Sensory Organs
a0R2P000000LmlOUAS,"Prednisolone eye drops, preservative-free",A-01305,,"Prednisolone eye drops, preservative-free",Subcommittee recommendation,Eye inflammation - severe,Decision,"Prednisolone eye drops, preservative-free",/apptracker/s/application-public/a102P000008puit,Sensory Organs
a0R2P000000LmVeUAK,Brinzolamide,A-01190,Azopt,Brinzolamide,Pacific Pharmaceuticals,Ocular hypertension or open angle glaucoma,Decision,Brinzolamide (Azopt),/apptracker/s/application-public/a102P000008ptyH,Sensory Organs
a0R2P000000anY7UAI,Aflibercept,A-00409,Eylea,Aflibercept,Bayer,"Diabetic macular oedema, first-line of anti-VEGF",Decision,Aflibercept (Eylea),/apptracker/s/application-public/a102P000008puEX,Sensory Organs
a0ROZ0000007Uvr2AE,Aflibercept,A-00437,Eylea,Aflibercept,Bayer,"Diabetic macular oedema, second-line anti-VEGF",Decision,Aflibercept (Eylea),/apptracker/s/application-public/a102P000008puQv,Sensory Organs
a0ROZ0000007fRR2AY,Bimatoprost,A-01178,Lumigan,Bimatoprost,Allergan,Elevated intraocular pressure in glaucoma or ocular hypertension,Decision,Bimatoprost (Lumigan),/apptracker/s/application-public/a102P000008puVD,Sensory Organs
a0R2P000000OchUUAS,Bimatoprost 0.03% and timolol maleate 0.5%,A-00816,Ganfort,Bimatoprost 0.03% and timolol maleate 0.5%,Allergan,Open-angle glaucmoma (OAG) or ocular hypertension (OHT),Decision,Bimatoprost 0.03% and timolol maleate 0.5% (Ganfort),/apptracker/s/application-public/a102P000008puEW,Sensory Organs
a0R2P000000LmnvUAC,Brimonidine tartrate and timolol maleate,A-01103,Combigan,Brimonidine tartrate and timolol maleate,Allergan,Glaucoma,Decision,Brimonidine tartrate and timolol maleate (Combigan),/apptracker/s/application-public/a102P000008ptsU,Sensory Organs
a0R2P000000OchZUAS,Brimonidine tartrate eye drops 0.15%,A-00606,,Brimonidine tartrate eye drops 0.15%,Allergan,Glaucoma,Decision,Brimonidine tartrate eye drops 0.15%,/apptracker/s/application-public/a102P000008puem,Sensory Organs
a0R2P000000LmcxUAC,Carboxymethylcellulose sodium solution,A-01130,TheraTears,Carboxymethylcellulose sodium solution,Corneal Lens Corporation,Dry eyes,Decision,Carboxymethylcellulose sodium solution (TheraTears),/apptracker/s/application-public/a102P000008pucJ,Sensory Organs
a0R2P000000anGgUAI,Cysteamine/mercaptamine (eye drops),A-00804,Recordati,Cysteamine/mercaptamine (eye drops),Recordati Rare Diseases Australia,Cystinosis,Decision,Cysteamine/mercaptamine (eye drops) (Recordati),/apptracker/s/application-public/a102P000008ptps,Sensory Organs
a0ROZ000004CWY82AO,Dexamethasone implant,A-00442,,Dexamethasone implant,Allergan,"Diabetic macular oedema, first-line",Decision,Dexamethasone implant,/apptracker/s/application-public/a102P000008ptur,Sensory Organs
a0ROZ000000Ba1l2AC,Dexamethasone implant,A-00479,,Dexamethasone implant,Allergan,"Diabetic macular oedema, second line, in pregnant women",Decision,Dexamethasone implant,/apptracker/s/application-public/a102P000008puXr,Sensory Organs
a0R2P000000LmalUAC,Dexamethasone implant,A-00477,,Dexamethasone implant,Allergan,"Diabetic macular oedema, second line, post-surgery",Decision,Dexamethasone implant,/apptracker/s/application-public/a102P000008puRV,Sensory Organs
a0ROZ000004CZxN2AW,Isopropyl alcohol 95% and anhydrous glycerin 5%,A-00946,Ear Clear,Isopropyl alcohol 95% and anhydrous glycerin 5%,Wilson Consumer Products,Swimmer's ear,Decision,Isopropyl alcohol 95% and anhydrous glycerin 5% (Ear Clear),/apptracker/s/application-public/a102P000008puiZ,Sensory Organs
a0ROZ0000006Jkl2AE,Travoprost,A-01191,Travatan,Travoprost,Pacific Pharmaceuticals,Open angle glaucoma and ocular hypertension as monotherapy or adjunctive therapy,Decision,Travoprost (Travatan),/apptracker/s/application-public/a102P000008puWd,Sensory Organs
a0R2P000000OcheUAC,Travoprost and timolol,A-00879,Duotrav,Travoprost and timolol,Alcon,Glaucoma,Decision,Travoprost and timolol (Duotrav),/apptracker/s/application-public/a102P000008pu0q,Sensory Organs
a0ROZ000004pDfF2AU,Alectinib,A-05147,Alecensa,Alectinib,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Non-Small Cell Lung Cancer, Adjuvant Treatment, Resected, ALK positive",Seeking Clinical Advice,Alectinib (Alecensa),/apptracker/s/application-public/a10OZ000002C9Pm,
a0ROZ0000052ORx2AM,Atezolizumab,A-04939,Tecentriq,Atezolizumab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Subcutaneous formulation, NSCLC, and all other IV atezolizumab indications",Options Compared,Atezolizumab (Tecentriq),/apptracker/s/application-public/a10OZ000000ohY1,
a0ROZ00000DabXp2AJ,Crovalimab,A-05333,,Crovalimab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Paroxysmal nocturnal haemoglobinuria (PNH),Under Assessment,Crovalimab,/apptracker/s/application-public/a10OZ000004CDaH,
a0ROZ0000006HSn2AM,Emicizumab,A-03777,Hemlibra®,Emicizumab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Haemophilia A without FVIII inhibitors. ,Decision,Emicizumab (Hemlibra®),/apptracker/s/application-public/a102P00000B0eUI,
a0ROZ00000CHi492AD,Faricimab,A-04779,Vabysmo,Faricimab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Vabysmo (faricimab) for the second-line treatment of patients with neovascular (wet) age-related macular degeneration,Decision,Faricimab (Vabysmo),/apptracker/s/application-public/a10OZ0000001GxB,
a0ROZ00000CHhfx2AD,Faricimab,A-04782,Vabysmo,Faricimab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,Vabysmo (faricimab) for the second-line treatment of patients with diabetic macular oedema (DMO).,Decision,Faricimab (Vabysmo),/apptracker/s/application-public/a10OZ0000001Gyn,
a0ROZ00000ApJsW2AV,Glofitamab,A-05243,COLUMVI,Glofitamab,ROCHE PRODUCTS (NEW ZEALAND) LIMITED,"Diffuse large B-cell lymphoma, relapsed/refractory, transplant ineligible, 2nd line or later (with gemcitabine and oxaliplatin)",Seeking Clinical Advice,Glofitamab (COLUMVI),/apptracker/s/application-public/a10OZ000003OUpd,
a0ROZ0000046sD82AI,ARCT-154,A-04862,Kostaive,ARCT-154,Seqirus,"Prevent COVID-19 caused by SARS-CoV-2,  in individuals 18 years of age and older",Seeking Clinical Advice,ARCT-154 (Kostaive),/apptracker/s/application-public/a10OZ000000N1hl,
a0ROZ00000AQko52AD,"za virus haemagglutinin, surface antigen, inactivated, prepared in cell cultures",A-04379,Flucelvax® Quad,"Quadrivalent Influenza virus haemagglutinin, surface antigen, inactivated, prepared in cell cultures",Seqirus,Prevention of influenza caused by Influenza Virus Types A and B,Options Compared,"Quadrivalent Influenza virus haemagglutinin, surface antigen, inactivated, prepared in cell cultures (Flucelvax® Quad)",/apptracker/s/application-public/a102P00000BUjqp,
a0ROZ00000AqQQk2AN,Macitentan,A-00312,Opsumit,Macitentan,Actelion,Portopulmonary hypertension,Options Compared,Macitentan (Opsumit),/apptracker/s/application-public/a10OZ000001jcWn,
a0ROZ00000Cn1xC2AR,Nivolumab,A-05060,OPDIVO,Nivolumab,BRISTOL-MYERS SQUIBB (NZ) LIMITED,"resected melanoma (Stage IIIB, IIIC, IIID or Stage IV), adjuvant to complete surgical resection.",Options Compared,Nivolumab (OPDIVO),/apptracker/s/application-public/a10OZ000002EQr7,
a0R2P000000LmdNUAS,Metronidazole,A-00951,Zidoval Gel,Metronidazole,Douglas Pharmaceuticals Ltd,Bacterial vaginosis,Options Compared,Metronidazole (Zidoval Gel),/apptracker/s/application-public/a102P000008puaY,Genito-Urinary System
a0ROZ00000DaaBx2AJ,Daratumumab (with bortezomib and dexamethasone),A-03764,Darzalex® SC,Daratumumab (with bortezomib and dexamethasone),JANSSEN NZ LIMITED,"Multiple myeloma, 3rd line",Under Assessment,Daratumumab (with bortezomib and dexamethasone) (Darzalex® SC),/apptracker/s/application-public/a102P00000BQDzw,
a0ROZ0000051zuc2AA,Fixed duration Ibrutinib plus venetoclax,A-04574,IMBRUVICA,Fixed duration Ibrutinib plus venetoclax,JANSSEN NZ LIMITED,previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Leukaemia (SLL) patients without TP53 mutation,Under Assessment,Fixed duration Ibrutinib plus venetoclax (IMBRUVICA),/apptracker/s/application-public/a10OZ0000000aOT,
a0ROZ00000BVWbt2AH,Guselkumab,A-04710,TREMFYA,Guselkumab,JANSSEN NZ LIMITED,"First-line biologic, psoriatic arthritis where DMARDs are not effective",Reviewing Consultation Feedback,Guselkumab (TREMFYA),/apptracker/s/application-public/a10OZ0000001PUD,
a0ROZ000007hqPJ2AY,Guselkumab,A-04710,TREMFYA,Guselkumab,JANSSEN NZ LIMITED,"Psoriatic arthritis, 2nd line biologic",Options Compared,Guselkumab (TREMFYA),/apptracker/s/application-public/a10OZ000000uZcc,
a0ROZ000004CYBh2AO,Ibrutinib,A-00407,Imbruvica,Ibrutinib,Janssen,"Chronic lymphocytic leukaemia, relapsed/refractory Del 11q",Decision,Ibrutinib (Imbruvica),/apptracker/s/application-public/a102P00000AaVR6,
a0ROZ000002dS3J2AU,Pomalidomide (with dexamethasone +/- bortezomib),A-00423,,Pomalidomide (with dexamethasone +/- bortezomib),Celgene,"Multiple myeloma, relapsed or refractory, 2nd line",Decision,Pomalidomide (with dexamethasone +/- bortezomib),/apptracker/s/application-public/a102P00000B0S1s,
a0ROZ00000DabpZ2AR,3 mg Drospirenone and 20mcg Ethinylestradiol (betadex clathrate) (YAZ),A-04923 A-05294 A-04994,Yasmin - AUST R 226238,3 mg Drospirenone and 20mcg Ethinylestradiol (betadex clathrate) (YAZ),"BAYER NEW ZEALAND LIMITED, Consumer",Contraception,Under Assessment,3 mg Drospirenone and 20mcg Ethinylestradiol (betadex clathrate) (YAZ) (Yasmin - AUST R 226238),/apptracker/s/application-public/a10OZ00000187rl,Genito-Urinary System
a0ROZ00000Dabsn2AB,3mg Drospirenone and 30 mcg Ethinylestradiol (Yasmin),A-04923 A-05294,Yasmin - AUST R 226238,3mg Drospirenone and 30 mcg Ethinylestradiol (Yasmin),"BAYER NEW ZEALAND LIMITED, Consumer",Contraception,Under Assessment,3mg Drospirenone and 30 mcg Ethinylestradiol (Yasmin) (Yasmin - AUST R 226238),/apptracker/s/application-public/a10OZ00000187TZ,Genito-Urinary System
a0ROZ000001joxl2AA,Eculizumab,A-04554,Soliris,Eculizumab,Alexion Pharmaceuticals Australasia,atypical Haemolytic Uraemic Syndrome (aHUS),Under Assessment,Eculizumab (Soliris),/apptracker/s/application-public/a102P00000BYMq8,Genito-Urinary System
a0ROZ000005Q1td2AC,Female/internal condoms,A-01204,,Female/internal condoms,Meridian,Sexually transmitted infection (STI) prevention and contraception,Options Compared,Female/internal condoms,/apptracker/s/application-public/a102P000008pugE,Genito-Urinary System
a0R2P000000d7nOUAQ,Lactic acid and thymol gel,A-00512,Lactigel,Lactic acid and thymol gel,Te Arai Biofarma,Bacterial vaginosis,Decision,Lactic acid and thymol gel (Lactigel),/apptracker/s/application-public/a102P000008ptzt,Genito-Urinary System
a0ROZ000000Ba3N2AS,Menstrual Cups,A-00604,,Menstrual Cups,Consumer,Menstruation,Decision,Menstrual Cups,/apptracker/s/application-public/a102P000008pu1J,Genito-Urinary System
a0ROZ000005VPX72AO,Non-latex condoms,A-00915,Ultima,Non-latex condoms,Meridian,Sexually transmitted infection (STI) prevention and contraception in patients with latex allergies,Options Compared,Non-latex condoms (Ultima),/apptracker/s/application-public/a102P000008puaC,Genito-Urinary System
a0R2P000000OcfTUAS,Oxybutynin patches (transdermal),A-00845,Oxytrol,Oxybutynin patches (transdermal),Hospira,Urinary incontinence,Decision,Oxybutynin patches (transdermal) (Oxytrol),/apptracker/s/application-public/a102P000008puY2,Genito-Urinary System
a0R2P000000SFjNUAW,Sanitary products,A-00550,,Sanitary products,Consumer,Menstruation,Decision,Sanitary products,/apptracker/s/application-public/a102P000008ptyR,Genito-Urinary System
a0R2P000000anXmUAI,Sodium hyaluronate and sodium chondroitin sulphate prefilled syringe,A-00523,,Sodium hyaluronate and sodium chondroitin sulphate prefilled syringe,Juno Pharmaceuticals,Painful bladder syndrome and interstitial cystitis,Decision,Sodium hyaluronate and sodium chondroitin sulphate prefilled syringe,/apptracker/s/application-public/a102P000008pujc,Genito-Urinary System
a0R2P000000LmrCUAS,Solifenacin,A-01435,Vesicare,Solifenacin,CSL,Urinary incontinence,Decision,Solifenacin (Vesicare),/apptracker/s/application-public/a102P000008puIX,Genito-Urinary System
a0R2P000000LmnJUAS,Tamsulosin hydrochloride,A-01203,Tamsulosin-Rex,Tamsulosin hydrochloride,CSL,"Benign prostatic hyperplasia (BPH), intolerant of alpha-blockers",Decision,Tamsulosin hydrochloride (Tamsulosin-Rex),/apptracker/s/application-public/a102P000008pu25,Genito-Urinary System
a0ROZ000006c84L2AQ,β-hCG low-sensitivity urine test kit,A-04120,CheckToP®,β-hCG low-sensitivity urine test kit,ISTAR LIMITED,Confirmation of termination of pregnancy,Decision,β-hCG low-sensitivity urine test kit (CheckToP®),/apptracker/s/application-public/a102P00000BS6Mz,Genito-Urinary System
a0ROZ000007FKDk2AO,Dexamethasone Implant (Ozurdex),A-04830,Ozurdex,Dexamethasone Implant (Ozurdex),ABBVIE LIMITED,treatment of macular oedema due to retinal vein occlusion (RVO),Under Assessment,Dexamethasone Implant (Ozurdex) (Ozurdex),/apptracker/s/application-public/a10OZ000000DD5t,
a0ROZ00000DzAuD2AV,AEON Protect,A-04591,AEON,AEON Protect,MEDIX 21 LIMITED,Dry Eye Disease,Under Assessment,AEON Protect (AEON),/apptracker/s/application-public/a102P00000BZ6SG,
a0ROZ00000DzAuF2AV,AEON Protect Plus,A-04654,AEON,AEON Protect Plus,MEDIX 21 LIMITED,Dry Eye Disease,Under Assessment,AEON Protect Plus (AEON),/apptracker/s/application-public/a102P00000Baui2,
a0ROZ00000DzAuE2AV,AEON Repair,A-04655,AEON,AEON Repair,MEDIX 21 LIMITED,Dry Eye Disease,Under Assessment,AEON Repair (AEON),/apptracker/s/application-public/a102P00000Bauhx,
a0ROZ00000Cn1x52AB,Atogepant,A-04773,AQUIPTA,Atogepant,ABBVIE LIMITED,Episodic migraine prevention,Options Compared,Atogepant (AQUIPTA),/apptracker/s/application-public/a10OZ00000019E9,
a0ROZ00000Cn1x42AB,Erenumab,A-03753,Aimovig,Erenumab,Consumer,Episodic migraine prevention,Options Compared,Erenumab (Aimovig),/apptracker/s/application-public/a10OZ0000000zI1,
a0R2P000000UBGQUA4,Risankizumab,A-00713,,Risankizumab,AbbVie,Moderate to severe plaque psoriasis - second line biologic,Options Compared,Risankizumab,/apptracker/s/application-public/a102P00000B1Jf9,
a0ROZ00000Cn1wz2AB,Naloxone nasal spray,A-04460,Nyxoid®,Naloxone nasal spray,Consumer,"Reversal of opioid overdose, use by emergency medical service personnel",Options Compared,Naloxone nasal spray (Nyxoid®),/apptracker/s/application-public/a102P00000BWuid,Various
a0ROZ000000PXib2AG,Darolutamide,A-04335,NUBEQA,Darolutamide,BAYER NEW ZEALAND LIMITED,for patients with high risk non-metastatic-castration resistant prostate cancer (nmCRPC).,Options Compared,Darolutamide (NUBEQA),/apptracker/s/application-public/a102P00000BSUIe,
a0R2P000000av9VUAQ,MiniMed 780G System,A-04041,MiniMed 780G System,MiniMed 780G System,INTERMED MEDICAL LIMITED,"Type 1 diabetes mellitus, individuals aged 7-80 years, whose total daily dose of insulin is 8 units per day or more.",Options Compared,MiniMed 780G System (MiniMed 780G System),/apptracker/s/application-public/a102P00000BL1eN,
a0ROZ00000ApJsV2AV,Epcoritamab,A-05253,EPKINLY,Epcoritamab,ABBVIE LIMITED,"Diffuse large B-cell lymphoma (DLBCL), relapsed/refractory (R/R), 3rd line or later",Seeking Clinical Advice,Epcoritamab (EPKINLY),/apptracker/s/application-public/a10OZ000003OSr3,
a0ROZ000002nsqw2AA,Zanubrutinib,A-04645,BRUKINSA,Zanubrutinib,BEIGENE NZ UNLIMITED,"Relapsed or refractory Chronic lymphocytic leukemia (CLL) or Small lymphocytic lymphoma (SLL)﻿, third line",Options Compared,Zanubrutinib (BRUKINSA),/apptracker/s/application-public/a102P00000BahwZ,
a0ROZ0000052ORu2AM,Zanubrutinib,A-04643,BRUKINSA,Zanubrutinib,BEIGENE NZ UNLIMITED,"Relapsed or refractory Chronic lymphocytic leukemia (CLL) or Small lymphocytic lymphoma (SLL) , 17p deletion or TP53 mutation disease, second line",Options Compared,Zanubrutinib (BRUKINSA),/apptracker/s/application-public/a102P00000BahNf,
a0ROZ000001QdI52AK,Elosulfase alfa,A-00728,,Elosulfase alfa,BioMarin Pharmaceutical Australia Ltd,MPS IVA for children under the age of two years,Under Assessment,Elosulfase alfa,/apptracker/s/application-public/a10OZ0000000uLZ,
a0ROZ000002O6uN2AS,Netupitant/palonosetron,A-04708,Akynzeo,Netupitant/palonosetron,JUNIPER BIOLOGICS PTY LTD,Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic anti-cancer treatments.,Under Assessment,Netupitant/palonosetron (Akynzeo),/apptracker/s/application-public/a10OZ000000umef,
a0ROZ00000BV8Cf2AL,Netupitant/palonosetron,A-04708,Akynzeo,Netupitant/palonosetron,JUNIPER BIOLOGICS PTY LTD,Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic anti-cancer treatments.,Reviewing Consultation Feedback,Netupitant/palonosetron (Akynzeo),/apptracker/s/application-public/a10OZ0000000WPh,
a0ROZ00000AiTIH2A3,Etonogestrel,A-05293,IMPLANON NXT etonogestrel 68mg subcutaneous implant,Etonogestrel,Organon Pharma Pty Ltd,Contraception,Seeking Clinical Advice,Etonogestrel (IMPLANON NXT etonogestrel 68mg subcutaneous implant),/apptracker/s/application-public/a10OZ000003kaLJ,
a0ROZ000000W5pU2AS,lumacaftor/ivacaftor,A-03055,ORKAMBI,lumacaftor/ivacaftor,Consumer,"Cystic Fibrosis, F508del gene mutations",Decision,lumacaftor/ivacaftor (ORKAMBI),/apptracker/s/application-public/a102P00000ABukK,
a0ROZ00000E6SZR2A3,Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek),A-05231,ALYFTREK,Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek),Vertex Pharmaceuticals (Australia) Pty Ltd,"Cystic fibrosis in people aged 6 years and older with F508del mutation(s) or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CTFR) gene, ineligible for elexacaftor/tezacaftor/ivacaftor and ivacaftor",Reviewing Consultation Feedback,Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek) (ALYFTREK),/apptracker/s/application-public/a10OZ000004nC7O,
a0R2P000000fSQfUAM,Ruxolitinib,A-04570,Opzelura,Ruxolitinib,Consumer,Vitiligo,Seeking Clinical Advice,Ruxolitinib (Opzelura),/apptracker/s/application-public/a102P00000BYYgW,
a0ROZ00000CISrl2AH,Continuous Glucose Monitor,A-05129 A-05168 A-05168 A-05442,Dexcom ONE+,Continuous Glucose Monitor,"NEW ZEALAND MEDICAL AND SCIENTIFIC LIMITED, Consumer","Type 2 diabetes, intensive insulin, suboptimal glycaemic profile.",Seeking Clinical Advice,Continuous Glucose Monitor (Dexcom ONE+),/apptracker/s/application-public/a10OZ000002CAH0,
a0ROZ000003ny9N2AQ,Burosumab,A-04497 A-05080,CRYSVITA,Burosumab,Consumer,X linked hypophosphatemia,Seeking Clinical Advice,Burosumab (CRYSVITA),/apptracker/s/application-public/a10OZ000001cfMX,
a0ROZ000007aSrN2AU,Desogestrel,A-05041,Cerazette,Desogestrel,Consumer,Premenstrual Dysphoric Disorder,Decision,Desogestrel (Cerazette),/apptracker/s/application-public/a10OZ000001nuTV,
a0ROZ00000Cn1x92AB,Naloxone hydrochloride dihydrate,A-04460,Nyxoid®,Naloxone hydrochloride dihydrate,Consumer,"Reversal of opioid overdose, as part of a 'take-home naloxone' program",Options Compared,Naloxone hydrochloride dihydrate (Nyxoid®),/apptracker/s/application-public/a10OZ0000015Wpu,
a0ROZ00000Cn1xA2AR,Naloxone hydrochloride dihydrate nasal spray,A-04460,Nyxoid®,Naloxone hydrochloride dihydrate nasal spray,Consumer,"Reversal of opioid overdose, use by non-paramedic first responders (ie fire service, police)",Options Compared,Naloxone hydrochloride dihydrate nasal spray (Nyxoid®),/apptracker/s/application-public/a10OZ0000015bb3,
a0ROZ000002crGf2AI,Sirolimus ointment (Pascomer),A-04870,Rapamune,Sirolimus ointment (Pascomer),Consumer,"Hyperkeritinization disorders  (keratosis pilaris rubra faciei, atrophoderma vermicualta and ulerythema ophryogenes)",Seeking Clinical Advice,Sirolimus ointment (Pascomer) (Rapamune),/apptracker/s/application-public/a10OZ0000018ACv,
a0ROZ000005fxpF2AQ,Cetuximab,A-00693,Erbitux,Cetuximab,Merck Serono,"Colorectal cancer, metastatic, RAS wild-type, left-sided, second-line",Decision,Cetuximab (Erbitux),/apptracker/s/application-public/a10OZ000002Qg5h,
a0ROZ0000006zdx2AA,Abiraterone,A-03932,Yonsa,Abiraterone,Health Outcomes Associates Ltd,"Prostate cancer, same indications as for originator",Options Compared,Abiraterone (Yonsa),/apptracker/s/application-public/a102P00000BIGVA,
a0ROZ000004nOof2AE,Zanubrutinib,A-04642,BRUKINSA,Zanubrutinib,BEIGENE NZ UNLIMITED,"Chronic lymphocytic leukemia (CLL) or Small lymphocytic lymphoma (SLL) , 17p deletion or TP53 mutation disease, first line (class recommendation received)",Options Compared,Zanubrutinib (BRUKINSA),/apptracker/s/application-public/a102P00000Bacdp,
a0ROZ00000C4WX32AN,Tislelizumab,A-05479,TEVIMBRA,Tislelizumab,BeOne Medicines NZ Unlimited,"Oesophageal squamous cell carcinoma, advanced or metastatic, PD-L1  ≥1%, 1st line",Seeking Clinical Advice,Tislelizumab (TEVIMBRA),/apptracker/s/application-public/a10OZ000005Mql3,
a0ROZ00000C4WYf2AN,Tislelizumab,A-05479,TEVIMBRA,Tislelizumab,BeOne Medicines NZ Unlimited,"Oesophageal squamous cell carcinoma, advanced or metastatic, 2nd line",Seeking Clinical Advice,Tislelizumab (TEVIMBRA),/apptracker/s/application-public/a10OZ000005MqoH,
a0ROZ000005s1gz2AA,Osilodrostat,A-05142,Isturisa,Osilodrostat,RECORDATI RARE DISEASES AUSTRALIA PTY LTD,"Treatment of endogenous Cushing’s syndrome, in adults, who cannot have surgery or  surgery was not curative and metyrapone is intolerable or unsuitable",Seeking Clinical Advice,Osilodrostat (Isturisa),/apptracker/s/application-public/a10OZ000002pohZ,
a0ROZ00000DkBU12AN,Tolvaptan,A-04988,JINARC,Tolvaptan,Otsuka Australia Pharmaceutical Pty Ltd,"ADPKD, rapidly progressing Mayo 1D-E disease and likely rapidly progressing Mayo 1C disease - widening access",Under Assessment,Tolvaptan (JINARC),/apptracker/s/application-public/a10OZ000001Cozl,
a0ROZ000009J56r2AC,Tislelizumab,A-04346,Tevimbra,Tislelizumab,BEIGENE NZ UNLIMITED,"Advanced non-small cell lung cancer, 2nd line monotherapy irrespective of PDL-1 status",Decision,Tislelizumab (Tevimbra),/apptracker/s/application-public/a102P00000BTxbA,
a0ROZ0000003yin2AA,Polyethylene glycol 3350 with electrolytes (Plenvu),A-04412,Plenvu,Polyethylene glycol 3350 with electrolytes (Plenvu),Norgine Pty Ltd,Bowel cleansing prior to procedures,Decision,Polyethylene glycol 3350 with electrolytes (Plenvu) (Plenvu),/apptracker/s/application-public/a10OZ00000010yr,
a0ROZ00000DKzXm2AL,Testosterone cream,A-05106,AndroFeme 1,Testosterone cream,ALCHEMY HEALTH LIMITED,Hypoactive sexual desire dysfunction (HSDD) in postmenopausal women,Seeking Clinical Advice,Testosterone cream (AndroFeme 1),/apptracker/s/application-public/a10OZ000001rAez,
a0ROZ00000083aG2AQ,AEON Sodium Chloride 5 Percent,A-04432,AEON,AEON Sodium Chloride 5 Percent,MEDIX 21 LIMITED,Corneal oedema relief,Seeking Clinical Advice,AEON Sodium Chloride 5 Percent (AEON),/apptracker/s/application-public/a102P00000BZ6SB,
a0ROZ00000DqVYD2A3,Pegunigalsidase alfa-iwxj,A-05325,ELFABRIO,Pegunigalsidase alfa-iwxj,CHIESI NEW ZEALAND LIMITED,Fabry Disease,Options Compared,Pegunigalsidase alfa-iwxj (ELFABRIO),/apptracker/s/application-public/a10OZ00000466q1,
a0ROZ000003nufF2AQ,Elemental Food (Elemental Gold),A-04296,It is not a pharmaceutical. The brand name is ElementGold Plus which is an elemental food plus added protein.,Elemental Food (Elemental Gold),ENDOTHERAPEUTICS NZ LIMITED,Currently funded indications,Seeking Clinical Advice,Elemental Food (Elemental Gold) (It is not a pharmaceutical. The brand name is ElementGold Plus which is an elemental food plus added protein.),/apptracker/s/application-public/a10OZ000001dzUU,
a0ROZ00000AQkoE2AT,SARS-CoV-2 rS (Omicron XBB.1.5),A-04785,NUVAXOVID XBB.1.5,SARS-CoV-2 rS (Omicron XBB.1.5),BIOCELECT NEW ZEALAND LIMITED,prevention of COVID-19,Options Compared,SARS-CoV-2 rS (Omicron XBB.1.5) (NUVAXOVID XBB.1.5),/apptracker/s/application-public/a10OZ000000N49N,
a0ROZ0000070NGj2AM,"Elasomeran, Elasomeran and Davesomeran, Andusomeran",A-04863,SPIKEVAX,"Elasomeran, Elasomeran and Davesomeran, Andusomeran",Moderna Australia Pty Ltd,active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2﻿,Under Assessment,"Elasomeran, Elasomeran and Davesomeran, Andusomeran (SPIKEVAX)",/apptracker/s/application-public/a10OZ000000N8Cz,
